


AUSTRALIAN NSP SURVEY NATIONAL DATA REPORT 2019 - 2023

Prevalence of HIV, HCV and injecting and sexual behaviour among NSP attendees



© Kirby Institute, UNSW Sydney

ISSN 1448-5915

This publication is available at: <http://www.kirby.unsw.edu.au>

Kirby Institute
UNSW Sydney
Sydney NSW 2052
Australia

Telephone: **02 9385 0900** Facsimile: **02 6100 2860** International prefix: **612** Email: info@kirby.unsw.edu.au

AUSTRALIAN NSP SURVEY
Prevalence of HIV, HCV and injecting and
sexual behaviour among NSP attendees

NATIONAL DATA REPORT
2019 - 2023

Report prepared by
Sue Heard and Lisa Maher

Kirby Institute
UNSW Sydney
Sydney NSW 2052
Australia

July 2024

Any presentation of these data should include acknowledgement of the Australian Needle Syringe Program Survey, Kirby Institute, UNSW Sydney.

Citation: Heard, S & Maher, L. (2024). Australian Needle Syringe Program Survey National Data Report 2019-2023: Prevalence of HIV, HCV and injecting and sexual behaviour among NSP attendees. Sydney: Kirby Institute, UNSW Sydney.

The Australian Needle Syringe Program Survey is funded by the Australian Government Department of Health and Aged Care. Kirby Institute, Faculty of Medicine & Health, UNSW Sydney.

ACKNOWLEDGEMENTS

We would like to acknowledge the many people who assist each year in the development and implementation of the Australian Needle Syringe Program Survey (ANSPS), particularly the clients, staff and managers at participating Needle Syringe Program (NSP) services. We also appreciate the dedication and vision of the founding members of the project and the late Dr Margaret MacDonald who was responsible for the initiation and conduct of the ANSPS from 1995 until 2003.

Ethical approvals for the survey are obtained from institutional ethics committees associated with the investigators and participating NSP sites. The Australian Needle Syringe Program Survey is funded by the Australian Government Department of Health and Aged Care.

Special thanks go to Associate Professor Philip Cunningham OAM, Chief Operating Officer and Deputy Director of Research, Mr Mitchell Starr, Senior Hospital Scientist, Mr Andrew Kelly, Research Assistant and Ms Shannen Butterly, Research Assistant at the NSW State Reference Laboratory for HIV at St Vincent's Hospital and St Vincent's Centre for Applied Medical Research. We also appreciate the assistance provided by Ms Rachel McCleave from the Kirby Institute.

In 2023, the project received support and input from the following members of the ANSPS National Advisory Group: Mr Phillip Hull (ACT); Ms Kate Patten (NSW); Mr David Decolongon (NT); Ms Kate Kelly (SA); Ms Myf Briggs (TAS); Mr Gary Morris (VIC); Mr Robert Kemp (QLD); Mr Adrian Gorringer and Ms Ele Morrison (Australian Injecting and Illicit Drug Users League); and Ms Sue Heard, Dr Farzaneh Zolala and Professor Lisa Maher (Kirby Institute). We would particularly like to thank Ms Jude Bevan (WA) for chairing the National Advisory Group.

In this report, we also wish to acknowledge and thank Mr Robert Kemp (QLD) for his contribution to the ANSPS National Advisory Group since it was formed in 2004, and as chairperson for the past 12 years until 2023. Robert's experience and expertise over two decades were highly valued and sincerely appreciated.

ABBREVIATIONS

ACT	Australian Capital Territory
ANSPS	Australian Needle Syringe Program Survey
COVID-19	Coronavirus disease 2019
DAA	Direct acting antiviral
DBS	Dried blood spot
HCV	Hepatitis C virus
HIV	Human immunodeficiency virus
NSP	Needle syringe program
NSW	New South Wales
NT	Northern Territory
OAT	Opioid agonist therapy
PIEDs	Performance and image-enhancing drugs
PWID	People who inject drugs
PBS	Pharmaceutical Benefits Scheme
QLD	Queensland
RNA	Ribonucleic acid
SA	South Australia
SARS-CoV-2	Severe Acute Respiratory Syndrome - Corona Virus 2
TAS	Tasmania
VIC	Victoria
WA	Western Australia

TABLE OF CONTENTS

Summary

Key Findings	i
Introduction	1
COVID-19	1
Demographic characteristics	2
Injection behaviour	3
Sexual behaviour.....	5
Drug treatment	5
HIV and HCV diagnostic testing	6
HIV antibody prevalence	6
HCV antibody prevalence.....	8
HCV RNA prevalence.....	9
HCV treatment	11
References.....	13

Tables

1. National	14
2. Australian Capital Territory	42
3. New South Wales.....	62
4. Northern Territory	90
5. Queensland	110
6. South Australia.....	138
7. Tasmania	158
8. Victoria	178
9. Western Australia	206

Appendix

A. Participating NSP services.....	234
B. Methodological notes	236
C. List of tables	238

KEY FINDINGS

- The Australian NSP Survey (ANSPS) functions as a strategic early-warning system designed to monitor blood borne viral infections and injecting and sexual risk behaviour among people who inject drugs.
- In 2023, 55 Needle Syringe Programs (NSPs) throughout Australia participated in the ANSPS and 1,991 NSP attendees completed the survey. The response rate was 37%.
- The number of respondents in 2020, 2021 and 2022 was lower than in previous years due to the ongoing impacts of the COVID-19 pandemic and public health measures designed to reduce community transmission during ANSPS data collection periods.

COVID-19

- As a sentinel surveillance system with the capacity to respond to emerging issues, the 2020 to 2023 surveys included a module about COVID-19-related impacts, including vaccination uptake and, in 2022 and 2023, questions designed to assess barriers to vaccine uptake.
- In 2023, the majority (58%) of respondents reported they had been tested for COVID-19 in the previous 12 months. One fifth (19%) of those reporting ever being tested for COVID-19 reported a positive result in the past 12 months and one quarter (26%) reported a positive result more than a year ago.
- All respondents were eligible for COVID-19 vaccination (two primary doses plus booster) at the time of survey completion in October 2023, and the majority (80%) reported receiving at least one dose of a COVID-19 vaccine. This includes 48% reporting three or more doses and 26% reporting two doses.
- Among participants who reported having no doses of a COVID-19 vaccine (unvaccinated), one third (34%) indicated hesitancy due to concerns about vaccine safety or not believing they were at risk of serious illness. Among participants who reported having one or two doses of a COVID-19 vaccine, one-third (35%) reported the reason for not completing vaccination was that they hadn't got around to it yet.

Demographic characteristics

- Over the period 2019 to 2023, the median age of survey respondents was stable (range 42 to 45 years), with a decline in the proportion of young injectors (aged <25 years) from 4% in 2019 to 2% in 2023.
- The median time since first injection remained stable between 2019 and 2023 (range 22 to 24 years), and the proportion of new initiates (those injecting for less than three years) was also stable between 2019 and 2023 (range 4% to 6%).
- The proportion of respondents from an Aboriginal and Torres Strait Islander background increased significantly, from 22% in 2019 to 29% in 2023.
- The proportion of respondents reporting incarceration in the 12 months prior to survey completion decreased from 13% in 2019 to 11% in 2023.
- The proportion of respondents reporting sex work in the month prior to the survey remained low and stable at 5% to 6% over the last five years. Condom use at last paid sex was also stable over the five-year period 2019 to 2023 (range 44% to 70%).

Injection behaviour

- Daily or more frequent injecting in the month prior to the survey was reported by approximately half of respondents in all survey years between 2019 and 2023.
- The proportion of respondents reporting methamphetamine as the last drug injected increased from 49% in 2019 to 53% in 2023. Methamphetamine was the most commonly reported drug last injected nationally in all years between 2019 and 2023.

- The proportion of respondents reporting heroin as the last drug injected was stable between 2019 and 2023 (range 20% to 27%), while prevalence of pharmaceutical opioid injection declined from 6% in 2019 to 3% in 2023.
- The proportion of respondents who reported performance and image enhancing drugs (PIEDs) as the last drug injected increased from 4% in 2019 to 5% in 2023.
- The proportion of respondents reporting receptive sharing of syringes increased from 16% in 2019 to 19% in 2023.
- The prevalence of receptive sharing of drug preparation equipment (range 25% to 32%) and re-use of syringes (range 23% to 26%) were both stable over the past five years 2019 to 2023.
- The prevalence of self-reported drug overdose in the previous 12 months declined from 17% in 2019 to 13% in 2023.

Drug treatment

- Engagement with drug treatment services remained high, with two thirds (67%) of respondents in 2023 reporting a lifetime history of drug treatment.
- The proportion of respondents who reported current engagement in opioid agonist therapy (OAT) between 2019 and 2023 was stable (range 25% to 32%), and engagement in OAT remained stable among respondents who reported last injecting an opioid (range 44% to 55%).

HIV antibody prevalence

- HIV antibody prevalence remained low and stable nationally, ranging from 1.5% to 2.5% over the five-year period 2019 to 2023.
- In all years 2019 to 2023 HIV antibody prevalence was higher among homosexual men, compared to bisexual or heterosexual men, and compared to women.

HCV antibody prevalence

- Hepatitis C virus (HCV) antibody prevalence declined nationally from 45.5% in 2019 to 44.8% in 2023. This is the seventh consecutive year that less than half of respondents had this marker indicating exposure to HCV, following two decades of HCV antibody prevalence $\geq 50\%$ (all years 1999 to 2016).
- Across all survey years 2019 to 2023, prevalence of HCV antibody was higher among older than among younger respondents and among those with longer injection histories.

HCV RNA prevalence

- The proportion of respondents with detectable HCV RNA (active infection) declined from 18% in 2019 to 12% in 2023. HCV RNA prevalence declined among both males (19% in 2019 to 13% in 2023) and females (16% in 2019 to 10% in 2023).

HCV treatment uptake

- Among respondents assessed as eligible for HCV treatment, the proportion who reported a lifetime history of HCV treatment increased over the five-year period, from 64% in 2019 to 75% in 2023.
- However, among respondents assessed as eligible for HCV treatment, the proportion who reported recent (last 12 months) treatment decreased between 2019 (44%) and 2023 (38%).
- There was also a decline in the last five years in the proportion of respondents who reported a recent HCV diagnostic test from 2019 (54%) to 2023 (47%).

INTRODUCTION

The Australian Needle Syringe Program Survey (ANSPS) provides serial point prevalence estimates of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) antibody prevalence, HCV ribonucleic acid (RNA) prevalence and sexual and injecting risk behaviour among people who inject drugs (PWID) in Australia. Conducted annually over a one-two week period in October, all clients attending participating Needle Syringe Program (NSP) services are invited to complete a brief, anonymous questionnaire and to provide a capillary blood sample for HIV and HCV testing (see methodological notes [Appendix B] for further details on the ANSPS design and implementation). Commencing in 2015, HCV RNA testing has also been conducted among respondents with sufficient dried blood spot (DBS) samples. This report presents national and state/territory results for the period 2019 to 2023.

COVID-19

In Australia, a range of public health measures have been implemented since COVID-19 was declared a global pandemic by the World Health Organisation in March 2020. As a sentinel surveillance system with the capacity to respond to emerging issues, the 2020, 2021, 2022 and 2023 ANSPS included a module about the impacts of COVID-19¹.

Following several years of reduced participation by a number of NSP services due to impacts of the COVID-19 pandemic, 55 sites participated in the 2023 ANSPS. In the 2023 ANSPS the sample size was 1,991 participants which is an increase compared to 2020 (n=1,324), 2021 (n=1,474) and 2022 (n=1,781), however participation remained lower than in pre-COVID years (n=2,609 in 2019). The annual response rate over the past five years ranged from 34% to 45% (Table 1.1.1). Of the 1,991 ANSPS respondents in 2023, the majority (68%) were recruited from NSP services (n=28) that participated in the ANSPS in each of the past five years (2019 to 2023). Appendix A provides details of participating NSP services over the period 2019 to 2023.

Among the overall 1,991 ANSPS respondents in 2023, 1,906 (96%) completed at least one question in the COVID-19 module. The following analysis excludes ANSPS respondents who did not report responses to individual 2023 COVID-19 module questions.

Almost three fifths of respondents (58%, n=1,093) reported that they had a COVID-19 test in the last 12 months and one third (30%, n=560) reported having a COVID-19 test more than 12 months ago. Of those who reported ever having a COVID-19 test (n=1,653), 744 respondents (37%) reported a positive COVID-19 test result, with 57% (n=423) of these more than 12 months ago (Table 1.1.7).

In 2023, 80% of respondents (n=1,491) reported having at least one dose of a COVID-19 vaccine. This includes 48% (n=894) reporting three or more doses, 26% (n=477) reporting two doses and 6% (n=120) of participants reporting having received one dose of a COVID-19 vaccine.

Among respondents reporting at least one dose of COVID-19 vaccine, two fifths (42%, n=661) of participants received their last COVID-19 vaccination at a GP or medical centre, one fifth (21%, n=324) at a pharmacy and one eighth at a vaccine hub (13%, n=210). A minority of participants

received their last vaccination in prison (9%, n=137), at an NSP (3%, n=51) or at an opioid treatment clinic (1%, n=21).

The 2022 and 2023 ANSPS COVID-19 modules also included questions on barriers to COVID-19 vaccine uptake and vaccine hesitancy. Among participants who reported not having any doses of a COVID-19 vaccine (n=375, 19%) and excluding those who did not report a reason, the main reasons given were concerns about vaccine safety (n=57, 17%), not perceived at risk of serious illness (n=57, 17%), concerns about vaccine side effects (n=45, 14%), hadn't got around to it yet (n=36, 11%), personal choice (n=21, 6%) and n=21 (6%) who reported that they didn't believe in the vaccine or thought that COVID-19 was a hoax or conspiracy.

Of the participants who reported having one or two doses of a COVID-19 vaccine (n=597, 30%) and excluding those who did not report a reason, the main reasons provided for not receiving three or more doses of a COVID vaccine were that they hadn't got around to it yet (n=187, 35%), did not perceive themselves as being at risk of serious illness (n=96, 18%), or had concerns about vaccine side effects (n=85, 16%). A minority of participants reported concerns about vaccine safety (n=51, 9%), personal choice (n=17, 3%) and difficulty getting an appointment (n=13, 2%) as barriers to not being fully vaccinated.

Demographic characteristics

Approximately two thirds of ANSPS respondents were male across all years 2019 to 2023. In 2023, the majority (79%) of respondents identified as heterosexual, while 10% identified as bisexual and 4% as homosexual (Table 1.1.1). Women were significantly more likely to identify as bisexual than men in each of the past five years (19% vs 6% respectively in 2023, $p < 0.001$).

Over the period 2019 to 2023 the proportion of respondents from an Aboriginal and Torres Strait Islander background increased significantly from 22% to 29% (χ^2 trend $p < 0.001$)^{2,3}. In all years 2019 to 2023, the majority of respondents were born in Australia (range 86% to 89%), with the United Kingdom/Ireland (3%) and New Zealand (3%) the predominant countries of birth outside Australia in 2023. Most respondents also reported that their parents spoke English at home (range 94% to 95%) over the period 2019 to 2023.

Over the period 2019 to 2023, the median age at survey completion ranged from 42 to 45 years while the proportion of respondents aged <25 years (2% in 2023) decreased significantly (χ^2 trend $p = 0.008$, Table 1.1.1). The median time since first injection ranged from 22 to 24 years and the proportion of new initiates (those injecting for less than 3 years) was stable across the period 2019 to 2023, (range 4% to 6%, χ^2 trend $p = 0.292$). The median age at first drug injection was stable across the period 2019 to 2023, (19 years of age in all years). Among new initiates to injection drug use, the median age at first drug injection remained stable (range 29 to 34 years).

The proportion of respondents reporting incarceration in the 12 months prior to survey completion decreased significantly, from 13% to 11% over the five-year period 2019 to 2023 (χ^2 trend $p = 0.003$). Among respondents with a history of recent incarceration, approximately one in three reported injecting while in prison and this proportion was stable over the period 2019 to 2023 (χ^2 trend $p = 0.824$, Table 1.1.1).

Injection behaviour


Methamphetamine was the most commonly reported drug last injected nationally in all years 2019 to 2023 (Table 1.1.2), with a significant increase in prevalence observed between 2019 and 2023 (49% to 53%, χ^2 trend $p=0.026$, Figure 1). Heroin was the second most commonly reported drug last injected nationally in 2023, with reports of heroin as the last drug injected stable over the five-year period (range 20% to 27%, χ^2 trend $p=0.096$).

The third most commonly reported drug last injected nationally was performance and image enhancing drugs (PIEDs) which increased significantly over the five-year period, from 4% in 2019 to 5% in 2023 (χ^2 trend $p=0.005$, Figure 2). A significant increase in reports of PIEDs as the last drug injected was also observed in NSW from 10% in 2019 to 15% in 2023 (χ^2 trend $p=0.010$), while prevalence remained stable at between 5% and 9% in QLD (χ^2 trend $p=0.105$). The proportion of respondents who reported last injecting PIEDs was <5% in all other jurisdictions in 2023.

The prevalence of pharmaceutical opioids^{4,5} as the last drug injected (3% in 2023, including morphine, oxycodone and fentanyl) decreased over the period 2019 to 2023 (χ^2 trend $p<0.001$, Figure 2).

Methadone was reported as the last drug injected by less than ten percent of ANSPS respondents in all years 2019 to 2023 (range 6% to 4%) and prevalence remained stable over this period (χ^2 trend $p=0.321$). Buprenorphine and buprenorphine-naloxone injection were reported by a minority of survey respondents. The prevalence of both buprenorphine-naloxone injection (1% to 2%, χ^2 trend $p=0.468$), and buprenorphine injection (2% to 4%, χ^2 trend $p=0.973$) were stable over the period 2019 to 2023.


Figure 1. Proportion of respondents (%) reporting last injecting heroin, methamphetamine, and all other drugs, 2019–2023



A minority of survey respondents (1% across all of the last five survey years) reported cocaine as the last drug injected.

In all years 2019 to 2023 except 2022, methamphetamine was the most commonly reported last drug injected among new initiates (less than 3 years since first injection), and prevalence was stable over this period (range 38% to 63%, χ^2 trend $p=0.090$). In 2023 PIEDs was the second most commonly reported drug last injected among new initiates (less than 3 years since first injection) with a significant increase observed between 2019 (18%) and 2023 (26%, χ^2 trend $p=0.005$).


Figure 2. Proportion of respondents (%) reporting last injecting pharmaceutical opioids, methadone, and performance and image enhancing drugs (PIEDs), 2019–2023



Daily or more frequent injection was reported by approximately half of respondents in each of the past five years (Table 1.1.2). Prevalence of at least one public injection (injection in a car, beach, park, street or squat) in the month prior to survey completion was stable between 2019 and 2023 (range 42% to 48%, χ^2 trend $p=0.338$, Table 1.1.3). In 2023, 13% of respondents reported they had experienced a drug overdose in the previous 12 months ($n=266$, Table 1.1.2), and reports of overdose declined significantly (χ^2 trend $p<0.001$) over the period 2019 (17%) to 2023 (13%)⁶.

As shown in Figure 3, there was a significant increase in one of the three key injecting risk behaviours with reports of receptive sharing of needles and syringes in the month prior to survey completion increasing significantly from 16% in 2019 to 19% in 2023 (χ^2 trend $p=0.007$). The proportion of respondents who reported reuse of needles and syringes (including one’s own) in the month preceding the survey was stable over the past 5 years (range 23% to 26%, χ^2 trend $p=0.102$). as were reports of receptive sharing of ancillary equipment (range 25% to 32%, χ^2 trend $p=0.099$). As in previous years, spoons and water were the most commonly identified receptively shared ancillary items in 2023 (Table 1.1.3).

Figure 3. Proportion of respondents (%) reporting reuse and receptive sharing of needles and syringes and receptive sharing of ancillary equipment in the last month, 2019–2023



Sexual behaviour

In all years 2019 to 2023 just under half of respondents reported sex with a regular partner in the month prior to survey completion (range 44% to 43%, Table 1.1.6). Of these, the majority (72% to 78%) reported that they never use condoms with their regular sex partner. A smaller proportion of respondents (14% to 16%) reported sex with other partners in the month preceding survey participation. Condom use was higher among this group, with 21% reporting always using condoms and 21% reporting some condom use with non-regular sex partners in 2023. The proportion of respondents reporting sex work in the month prior to the survey remained low and stable at 5% to 6% over the last five years (χ^2 trend $p=0.362$), and condom use at last paid sex was also stable, (range 44% to 70%, χ^2 trend $p=0.096$, Table 1.1.6). Of the respondents who reported sex work in the previous month in 2023 ($n=109$), 53% were men, 40% were women, and 5% identified as other.

Drug treatment

Engagement with drug treatment services was high (Table 1.1.4) with two thirds (67%) of respondents in 2023 reporting a lifetime history of drug treatment. The proportion of respondents reporting current OAT was stable between 2019 to 2023 (range 25% to 32%, χ^2 trend $p=0.066$). This may reflect the high proportion of respondents reporting methamphetamine as the last drug injected over this period (~50% in all years), with OAT not indicated for methamphetamine dependence. Among respondents who reported last injecting opioids, current OAT remained stable over the period 2019 to 2023 (range 44% to 55%, χ^2 trend $p=0.459$). In 2023, current methadone treatment was reported by 16% of respondents, with current buprenorphine treatment reported by 7% of respondents, current depot buprenorphine treatment reported by 7% of respondents and current buprenorphine-naloxone treatment by 6% of respondents⁷.

HIV and HCV diagnostic testing

Prevalence of HIV diagnostic screening among ANSPS respondents over the period 2019 to 2023 was high, with 75% to 81% reporting a lifetime history of HIV diagnostic testing (Table 1.1.5). In 2023, 42% of respondents reported an HIV diagnostic test in the previous 12 months. Among the n=30 respondents who tested HIV antibody positive, the majority (77%, n=23) were aware of their HIV positive status. A minority (10%, n=3) of respondents who tested HIV positive reported that they were HIV negative, and 7% (n=2) did not report their HIV status.

Respondents also reported high prevalence of lifetime HCV diagnostic screening over the period 2019 to 2023 (range 78% to 82%). In 2023, 47% of respondents reported an HCV diagnostic test in the previous 12 months, however a significant decline in recent (last 12 months) HCV diagnostic testing was observed over the period 2019 (54%) to 2023 (47%, χ^2 trend $p < 0.001$).

HIV antibody prevalence

HIV antibody prevalence was low and stable nationally over the period 2019 to 2023 (range 1.5% to 2.5%, χ^2 trend $p = 0.189$, Table 1.2.1). HIV prevalence was low and stable in all jurisdictions (Figure 4). No women in the Australian Capital Territory, South Australia or Tasmania tested positive to HIV antibodies in any of the five years 2019 to 2023.

Nationally, HIV antibody prevalence was consistently higher among homosexual male respondents than among bisexual and heterosexual male or female respondents in all years, (Table 1.2.2 and Figure 5)⁸. In 2023, the median age of respondents living with HIV was 50 years (range 29 to 64 years) and the median time since first injection was 28 years (range 2 to 48 years). In 2023, comparable to previous years, 77% of respondents living with HIV reported they were on HIV antiretroviral treatment.

Figure 4. HIV antibody prevalence (%) by jurisdiction, 2019–2023





Figure 5. HIV antibody prevalence (%) by gender and sexual identity, 2019–2023



Although respondents from an Aboriginal and Torres Strait Islander background were significantly more likely to test HIV antibody positive than respondents who were not from an Aboriginal and Torres Strait Islander background in 2019 and 2023 ($p < 0.05$), this difference was not statistically significant in 2020, 2021 or 2022 (Table 1.2.11). Further, prevalence of HIV infection among Aboriginal and Torres Strait Islander respondents remained stable between 2019 (3.6%) and 2023 (3.2%, χ^2 trend $p = 0.490$). Of the 15 Aboriginal and Torres Strait Islander respondents who tested HIV antibody positive in 2023, two-fifths ($n = 6$) identified as heterosexual, one-third ($n = 5$) identified as homosexual, one-fifth ($n = 3$) identified as bisexual and $n = 1$ did not report their sexual orientation.

HCV antibody prevalence

HCV antibody prevalence nationally declined significantly from 45.5% in 2019 to 44.8% in 2023 (χ^2 trend $p < 0.001$, Table 1.3.1). Over the five-year period 2019 to 2023, HCV antibody prevalence declined among men (from 47% in 2019 to 45% in 2023, χ^2 trend $p < 0.001$) but remained stable among women (range 34% to 45%, χ^2 trend $p = 0.485$). In 2023, changes to the assays used for HCV antibody testing resulted in an increase in HCV antibody prevalence from 32% in 2022, however HCV antibody prevalence in 2023 remained lower than in the pre-DAA era (Appendix B: Methodological notes for detailed explanation of changes to laboratory testing methods in 2023).

Figure 6. HCV antibody prevalence (%) by jurisdiction, 2019–2023






Figure 7. HCV antibody prevalence (%) by time since first injection, 2023



At the jurisdictional level (Figure 6), a decline in HCV antibody prevalence was observed in Queensland and Victoria, however HCV antibody prevalence was stable in all other jurisdictions over the past five years from 2019 to 2023. Across all five years of the survey, HCV antibody prevalence was significantly higher among older respondents and those with longer injection histories (Table 1.3.3 and 1.3.4). Figure 7 illustrates the relationship between exposure to HCV and time since first injection among respondents in 2023.

In all survey years, prevalence of HCV antibody was also higher among respondents reporting heroin or other opioids as the last drug injected, compared to respondents who last injected methamphetamine (Figure 8). HCV antibody prevalence was also consistently higher among respondents who reported imprisonment in the year preceding survey completion compared to those who did not ($p < 0.050$ in all years 2019 to 2023, Table 1.3.8) and among respondents who reported an Aboriginal and Torres Strait Islander background ($p \leq 0.001$ in most years 2019 to 2023, Table 1.3.9).

Figure 8. HCV antibody prevalence (%) by drug last injected and gender, 2019–2023




HCV RNA prevalence

The ANSPS commenced HCV RNA testing in 2015, immediately before HCV direct acting antiviral (DAA) therapies were made available through the Australian Government’s Pharmaceutical Benefits Scheme (PBS) in March 2016⁹. The proportion of the ANSPS sample with sufficient DBS for HCV RNA testing has improved over time, with ~90% of respondents tested for HCV RNA in all years since 2020. In order to adjust for potential sample bias in the RNA tested sub-sample in previous years (2019 and earlier), weights were applied to adjust for gender (given higher rates of spontaneous clearance among women)¹⁰ and HCV antibody status. HCV RNA results with small sample sizes, particularly at the jurisdictional level, should be interpreted with caution.

As previously stated, over the last five years HCV antibody prevalence declined significantly from 45.5% in 2019 to 44.8% in 2023 (χ^2 trend $p < 0.001$, Table 1.3.1). Lifetime HCV treatment increased


significantly (from 64% in 2019 to 75% in 2023, χ^2 trend $p < 0.001$) and the proportion of respondents with detectable HCV RNA decreased significantly, from 18% in 2019 to 12% in 2023 (χ^2 trend $p < 0.001$). As shown in Figure 9, HCV RNA prevalence declined significantly among both males (19% in 2019 to 13% in 2023, χ^2 trend $p < 0.001$) and females (16% in 2019 to 10% in 2023, χ^2 trend $p < 0.001$).

Figure 9. Proportion of respondents (%) with detectable HCV RNA* by gender and survey year




* Weighted for gender and HCV antibody status in 2019

Figure 10. HCV viraemic status (%) by survey year



Results of HCV antibody and HCV RNA testing can be combined to provide an estimate of viraemic prevalence among respondents¹¹. As shown in Figure 10, the proportion of respondents with cleared infection (HCV antibody positive and HCV RNA negative) remained relatively stable (range 33% in 2023 to 20% in 2021 and 2022), while the proportion of respondents with no evidence of exposure to HCV (HCV antibody negative) increased from 55% in 2019 to 68% in 2022. The decline in the proportion of participants with no evidence of exposure (55%) observed in 2023 is likely due to the changes in the antibody testing methodology described in Appendix B: Methodological Notes. Over the five-year period, 2019 to 2023, the proportion of respondents with active HCV infection declined by one-third (33%).


Figure 11. HCV viraemic status (%) nationally and by jurisdiction in 2023



HCV treatment


Among respondents who tested HCV antibody positive, and after excluding those who reported spontaneous HCV clearance, the proportion who reported a lifetime history of HCV treatment increased significantly from 64% in 2019 to 75% in 2023 (χ^2 trend $p=0.001$)^{11,12}. This trend in lifetime treatment uptake was observed among both men and women. Conversely, among respondents who tested HCV antibody positive, and after excluding those who reported spontaneous or treatment-induced clearance more than 12 months previously, the proportion who reported recent (last 12 months) HCV treatment declined significantly between 2019 (44%) and 2023 (38%, χ^2 trend $p<0.001$, Figure 12). The significant decline in recent treatment uptake between 2019 to 2023 was observed in men, however the trend for women was stable¹³.

Figure 12. Proportion of respondents (%) reporting lifetime and recent* HCV treatment among HCV antibody positive respondents who did not report spontaneous clearance by survey year



* The denominator for recent HCV treatment excludes those who reported prior HCV treatment induced clearance

Figure 13. Lifetime history of HCV treatment (%) nationally and by jurisdiction, 2019-2023



References

1. Iversen J, Wand H, Kemp R, Bevan J, Briggs M, Patten K, Heard S, Maher L. Uptake of COVID-19 vaccination among people who inject drugs. *Harm Reduction Journal* 2022;19 (59).
2. Doyle M, Maher L, Graham S, Wand H, Iversen J. Hepatitis C virus prevalence and associated risk factors among Indigenous Australians who inject drugs. *Australia New Zealand Journal of Public Health* 2018;42(1):52-6.
3. Graham S, Maher L, Wand H, Doyle M, Iversen J. Trends in hepatitis C antibody prevalence among Aboriginal and Torres Strait Islander people attending Australian Needle and Syringe Programs, 1996-2015. *International Journal of Drug Policy* 2017;47:69-76.
4. Iversen J, Dertadian G, Geddes L, Maher L. High risk injecting behaviour among people who inject pharmaceutical opioids in Australia. *International Journal of Drug Policy* 2017;42:1-6.
5. Geddes L, Iversen J, Memedovic S, Maher L. Intravenous fentanyl use among people who inject drugs in Australia. *Drug and Alcohol Review* 2018;37 Suppl 1:S314-S22.
6. Geddes L, Iversen J, Darke S, Dietze P, Maher L. Prevalence and correlates of multiple non-fatal opioid overdoses among people who inject drugs who utilise needle syringe programs in Australia. *International Journal of Drug Policy* 2021;96:103245
7. Geddes L, Iversen J, Wand H, Maher L. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia. *Addiction* 2021;116(3):525-535.
8. Iversen J, Wand H, Topp L, Kaldor J, Maher L. Extremely low and sustained HIV incidence among people who inject drugs in a setting of harm reduction. *AIDS* 2014;28(2):275-8.
9. Iversen J, Dore G, Starr M, Catlett B, Cunningham P, Geddes L, Maher L. Estimating the Consensus Hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy. *International Journal of Drug Policy* 2020;83:102837.
10. Geddes L, Iversen J, Wand H, Esmaeili A, Tsui J, Hellard M, Dore G, Grebely J, Dietze P, Prins M, Morris M, Shoukry N, Lloyd A, Lauer G, Cox A, Page K, Maher L. Sex discrepancies in the protective effect of opioid agonist therapy on incident hepatitis C infection. *Clinical Infectious Diseases* 2020;70(1):123-131.
11. Iversen J, Dore G, Catlett B, Cunningham P, Grebely J, Maher L. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia. *Journal of Hepatology* 2019;70(1):33-39.
12. Iversen J, Wand H, McManus H, Dore G, Maher L. Incidence of primary hepatitis C virus infection among people who inject drugs in Australia pre- and post-unrestricted availability of direct acting antiviral therapies. *Addiction* 2023;118(5):901-911.
13. Iversen J, Wand H, Chan PL, Le LV, Maher L. Systematic review of hepatitis C virus prevalence in the WHO Western Pacific Region. *Viruses* 2022;14(7):1548.

National

Table 1.1.1 Number (percentage) of respondents by demographic characteristics and survey year

National	2019	2020*	2021*	2022	2023
Number of sites	54	38	37	53	55
N° surveyed	N=2609	N=1324	N=1474	N=1781	N=1991
Response rate (%)	45%	35%	45%	34%	37%
Gender (%)					
Male	1722 (66)	902 (68)	933 (63)	1156 (65)	1276 (64)
Female	861 (33)	413 (31)	520 (35)	586 (33)	679 (34)
Other	18 (1)	8 (1)	19 (1)	35 (2)	30 (2)
Not reported	8 (<1)	1 (<1)	2 (<1)	4 (<1)	6 (<1)
Sexual identity (%)					
Heterosexual	1969 (75)	1045 (79)	1204 (82)	1409 (79)	1579 (79)
Bisexual	262 (10)	128 (10)	149 (10)	178 (10)	207 (10)
Gay/Lesbian	119 (5)	50 (4)	65 (4)	87 (5)	86 (4)
Other	-- --	35 (3)	45 (3)	93 (5)	99 (5)
Not reported	259 (10)	66 (5)	11 (1)	14 (1)	20 (1)
Aboriginal and Torres Strait Islander origin (%)					
No	1994 (76)	982 (74)	1031 (70)	1312 (74)	1383 (69)
Yes	568 (22)	290 (22)	373 (25)	438 (25)	581 (29)
Not reported	47 (2)	52 (4)	70 (5)	31 (2)	27 (1)
Region/country of birth (%)					
Australia	2302 (88)	1142 (86)	1274 (86)	1541 (87)	1776 (89)
Other Oceania	67 (3)	42 (3)	43 (3)	50 (3)	62 (3)
Asia	26 (1)	18 (1)	12 (1)	26 (1)	18 (1)
UK & Ireland	87 (3)	52 (4)	57 (4)	58 (3)	55 (3)
Other	102 (4)	49 (4)	48 (3)	72 (4)	57 (3)
Not reported	25 (1)	21 (2)	40 (3)	34 (2)	23 (1)
Main language spoken at home by parents (%)					
English	2465 (94)	1253 (95)	1406 (95)	1669 (94)	1876 (94)
Non-English	128 (5)	59 (4)	51 (3)	93 (5)	100 (5)
Not reported	16 (1)	12 (1)	17 (1)	19 (1)	15 (1)
Age and time since first injection (years)					
<i>Median age</i>	42	43	44	45	45
<i>Age range</i>	15-73	18-74	16-78	16-73	18-77
Age group (%)					
<25 years	95 (4)	44 (3)	34 (2)	52 (3)	48 (2)
25+ years	2502 (96)	1279 (97)	1431 (97)	1711 (96)	1926 (97)
Not reported	12 (<1)	1 (<1)	9 (1)	18 (1)	17 (1)
Median age first injection					
<i>Median age first injection</i>	19	19	19	19	19
<i>Age range</i>	10-67	10-60	10-85	10-72	10-72
<i>N° not reported</i>	135	33	49	99	73
Median yrs since first injection					
<i>Median yrs since first injection</i>	22	22	23	24	24
<i>Range</i>	<1-59	<1-53	<1-62	<1-56	<1-56
Years since first injection					
<3 years	149 (6)	82 (6)	65 (4)	97 (5)	103 (5)
3+ years	2321 (89)	1208 (91)	1353 (92)	1584 (89)	1812 (91)
Not reported	139 (5)	34 (3)	56 (4)	100 (6)	76 (4)
Imprisonment last year (%)					
No	2106 (81)	1095 (83)	1230 (83)	1508 (85)	1637 (82)
Yes	350 (13)	158 (12)	157 (11)	198 (11)	213 (11)
Not reported	153 (6)	71 (5)	87 (6)	75 (4)	141 (7)
N° in prison					
<i>N° in prison</i>	N=350	N=158	N=157	N=198	N=213
Injected in prison	111 (32)	48 (30)	54 (34)	66 (33)	67 (31)

* Implementation of the 2020 and 2021 ANSPS was impacted by the COVID-19 pandemic, see page 1 for more information

Table 1.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

National	2019	2020	2021	2022	2023
N° surveyed	N=2609	N=1324	N=1474	N=1781	N=1991
Drug last injected (%)					
Cocaine	20 (1)	7 (1)	8 (1)	14 (1)	15 (1)
Methamphetamine	1269 (49)	619 (47)	750 (51)	840 (47)	1048 (53)
Heroin	707 (27)	286 (22)	299 (20)	451 (25)	478 (24)
Pharm. opioids	153 (6)	109 (8)	110 (7)	87 (5)	65 (3)
Methadone	124 (5)	77 (6)	70 (5)	75 (4)	91 (5)
Buprenorphine	43 (2)	39 (3)	53 (4)	40 (2)	34 (2)
Buprenorphine/naloxone	23 (1)	17 (1)	33 (2)	23 (1)	21 (1)
PIEDs	93 (4)	84 (6)	52 (4)	118 (7)	101 (5)
More than one	119 (5)	64 (5)	77 (5)	98 (6)	105 (5)
Other	37 (1)	5 (<1)	11 (1)	17 (1)	19 (1)
Not reported	21 (1)	17 (1)	11 (1)	18 (1)	14 (1)
Ever injected opioids					
No	603 (23)	377 (28)	434 (29)	472 (27)	559 (28)
Yes	1989 (76)	946 (71)	1030 (70)	1302 (73)	1422 (71)
Not reported	17 (1)	1 (<1)	10 (1)	7 (<1)	10 (1)
Frequency of injection last month (%)					
Not last month	235 (9)	138 (10)	186 (13)	165 (9)	202 (10)
Less than weekly	371 (14)	228 (17)	293 (20)	286 (16)	301 (15)
Weekly not daily	586 (22)	300 (23)	312 (21)	393 (22)	426 (21)
Daily or more	1376 (53)	645 (49)	654 (44)	902 (51)	1021 (51)
Not reported	41 (2)	13 (1)	29 (2)	35 (2)	41 (2)
Present when someone injected for the first time in the last 12 months (%)					
No	2056 (79)	1088 (82)	1207 (82)	1459 (82)	1603 (81)
Yes	448 (17)	206 (16)	234 (16)	286 (16)	297 (15)
Not reported	105 (4)	30 (2)	33 (2)	36 (2)	91 (5)
Overdosed in last 12 months					
No	2060 (79)	1120 (85)	1265 (86)	1525 (86)	1631 (82)
Yes	438 (17)	171 (13)	166 (11)	220 (12)	266 (13)
Not reported	111 (4)	33 (2)	43 (3)	36 (2)	94 (5)

Table 1.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

National	2019	2020	2021	2022	2023
N° injected last month	N=2333	N=1173	N=1259	N=1581	N=1748
Places injected last month (%)					
All private	1214 (52)	673 (57)	694 (55)	841 (53)	896 (51)
Any public	1105 (47)	496 (42)	559 (44)	734 (46)	843 (48)
Not reported	14 (1)	4 (<1)	6 (<1)	6 (<1)	9 (1)
Use of new and sterile needles and syringes last month (%)					
All injections	1746 (75)	891 (76)	941 (75)	1179 (75)	1275 (73)
Most of the time	449 (19)	220 (19)	244 (19)	312 (20)	354 (20)
Half of the time	53 (2)	23 (2)	27 (2)	39 (2)	55 (3)
Some of the time	39 (2)	19 (2)	28 (2)	23 (1)	31 (2)
Not last month	13 (1)	4 (<1)	10 (1)	9 (1)	13 (1)
Not reported	33 (1)	16 (1)	9 (1)	19 (1)	20 (1)
Re-used someone else's used needle & syringe last month (%)					
None	1924 (82)	980 (84)	1030 (82)	1269 (80)	1396 (80)
Once	126 (5)	66 (6)	61 (5)	93 (6)	102 (6)
Twice	113 (5)	40 (3)	61 (5)	95 (6)	103 (6)
3-5 times	82 (4)	51 (4)	44 (3)	61 (4)	73 (4)
>5 times	57 (2)	28 (2)	54 (4)	56 (4)	54 (3)
Not reported	31 (1)	8 (1)	9 (1)	7 (<1)	20 (1)
Number of people needle & syringe was re-used after last month (%)					
None	1924 (82)	980 (84)	1029 (82)	1269 (80)	1396 (80)
One	168 (7)	73 (6)	94 (7)	125 (8)	136 (8)
Two	38 (2)	20 (2)	30 (2)	38 (2)	35 (2)
Three to five	27 (1)	14 (1)	14 (1)	21 (1)	22 (1)
More than five	17 (1)	10 (1)	14 (1)	19 (1)	16 (1)
Don't know	79 (3)	46 (4)	50 (4)	54 (3)	78 (4)
Not reported	80 (3)	30 (3)	28 (2)	55 (3)	65 (4)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	147 (6)	73 (6)	77 (6)	111 (7)	101 (6)
Casual sex partner	18 (1)	14 (1)	12 (1)	13 (1)	21 (1)
Close friend	82 (4)	48 (4)	67 (5)	86 (5)	92 (5)
Acquaintance	58 (2)	30 (3)	42 (3)	40 (3)	58 (3)
Other	47 (2)	19 (2)	17 (1)	28 (2)	19 (1)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	482 (21)	182 (16)	252 (20)	292 (18)	334 (19)
Water	451 (19)	191 (16)	284 (23)	288 (18)	403 (23)
Filter	221 (9)	71 (6)	123 (10)	122 (8)	174 (10)
Drug mix	234 (10)	89 (8)	127 (10)	149 (9)	199 (11)
None	1555 (67)	836 (71)	834 (66)	1071 (68)	1148 (66)
Injected by someone after that person injected themselves or others last month (%)					
No	1939 (83)	1005 (86)	1030 (82)	1276 (81)	1429 (82)
Yes	369 (16)	159 (14)	219 (17)	288 (18)	306 (18)
Not reported	25 (1)	9 (1)	10 (1)	17 (1)	13 (1)
Source of needle acquisition					
Needle Syringe Program	2032 (87)	1001 (85)	1071 (85)	1341 (85)	1459 (83)
Chemist/Pharmacy	572 (25)	319 (27)	327 (26)	339 (21)	341 (20)
Personal sources	325 (14)	130 (11)	143 (11)	190 (12)	204 (12)
Dispensing/Vending Machine	441 (19)	172 (15)	134 (11)	234 (15)	266 (15)
Other sources	69 (3)	37 (3)	27 (2)	43 (3)	13 (1)

Table 1.1.4 Number (percentage) of respondents by treatment for drug use and survey year

National	2019	2020	2021	2022	2023
N° surveyed	N=2609	N=1324	N=1474	N=1781	N=1991
Ever any treatment/therapy for drug use (%)					
No	809 (31)	454 (34)	534 (36)	574 (32)	654 (33)
Yes	1789 (69)	868 (66)	939 (64)	1204 (68)	1336 (67)
Not reported	11 (<1)	2 (<1)	1 (<1)	3 (<1)	1 (<1)
History of methadone maintenance treatment (%)					
Currently	634 (24)	235 (18)	219 (15)	345 (19)	316 (16)
Previously	522 (20)	236 (18)	281 (19)	399 (22)	464 (23)
Never	1395 (53)	809 (61)	921 (62)	990 (56)	1116 (56)
Not reported	58 (2)	44 (3)	53 (4)	47 (3)	95 (5)
History of buprenorphine (Subutex®) treatment (%)					
Currently	169 (6)	105 (8)	119 (8)	139 (8)	147 (7)
Previously	640 (25)	278 (21)	310 (21)	422 (24)	471 (24)
Never	1759 (67)	903 (68)	1001 (68)	1175 (66)	1280 (64)
Not reported	41 (2)	38 (3)	44 (3)	45 (3)	93 (5)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	173 (7)	70 (5)	105 (7)	101 (6)	118 (6)
Previously	596 (23)	258 (19)	298 (20)	422 (24)	443 (22)
Never	1795 (69)	987 (75)	1053 (71)	1242 (70)	1415 (71)
Not reported	45 (2)	9 (1)	18 (1)	16 (1)	15 (1)
History of depot buprenorphine treatment (%)					
Currently	-- --	57 (4)	59 (4)	116 (7)	130 (7)
Previously	-- --	79 (6)	92 (6)	181 (10)	183 (9)
Never	-- --	693 (52)	1280 (87)	1439 (81)	1583 (80)
Not reported	-- --	495 (37)	43 (3)	45 (3)	95 (5)

Table 1.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

National	2019	2020	2021	2022	2023
N° surveyed	N=2609	N=1324	N=1474	N=1781	N=1991
Previous HIV test (%)					
Yes, ever	2105 (81)	1042 (79)	1116 (76)	1360 (76)	1484 (75)
Yes, last year	1271 (49)	601 (45)	557 (38)	768 (43)	839 (42)
>1 year ago	834 (32)	441 (33)	559 (38)	592 (33)	645 (32)
Never tested	381 (15)	232 (18)	296 (20)	357 (20)	399 (20)
Not reported	123 (5)	50 (4)	62 (4)	64 (4)	108 (5)
Previous HCV test (%)					
Yes, ever	2101 (81)	1087 (82)	1147 (78)	1417 (80)	1561 (78)
Yes, last year	1409 (54)	631 (48)	686 (47)	875 (49)	943 (47)
>1 year ago	692 (27)	456 (34)	462 (31)	542 (30)	618 (31)
Never tested	257 (10)	128 (10)	194 (13)	212 (12)	235 (12)
Not reported	251 (10)	109 (8)	132 (9)	152 (9)	195 (10)
Lifetime treatment for HCV (%)#					
N° self-reported HCV diagnosis	N=667	N=289	N=309	N=334	N=403
Antiviral treatment	428 (64)	180 (62)	191 (62)	226 (68)	301 (75)
No antiviral treatment	237 (36)	107 (37)	116 (38)	107 (32)	100 (25)
Not reported	2 (<1)	2 (1)	2 (1)	1 (<1)	2 (1)
Treatment for HCV in past 12 months (%)**					
N° self-reported HCV diagnosis	N=502	N=196	N=200	N=199	N=224
Antiviral treatment	222 (44)	62 (32)	56 (28)	68 (34)	85 (38)
No antiviral treatment	278 (55)	132 (67)	142 (71)	130 (65)	137 (61)
Not reported	2 (<1)	2 (1)	2 (1)	1 (1)	2 (1)

among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

Table 1.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

National	2019	2020	2021	2022	2023
N° surveyed	N=2609	N=1324	N=1474	N=1781	N=1991
Sex with a regular partner last month (%)					
No	1345 (52)	684 (52)	758 (51)	933 (52)	1032 (52)
Yes	1124 (43)	584 (44)	631 (43)	774 (43)	849 (43)
Not reported	140 (5)	56 (4)	85 (6)	74 (4)	110 (6)
Condom used with regular partner last month (%)					
N° surveyed	N=1124	N=584	N=631	N=774	N=849
Never	808 (72)	450 (77)	479 (76)	604 (78)	653 (77)
Sometimes	150 (13)	55 (9)	68 (11)	74 (10)	90 (11)
Every time	110 (10)	51 (9)	52 (8)	61 (8)	61 (7)
Not reported	56 (5)	28 (5)	32 (5)	35 (5)	45 (5)
Sex with other partner(s) last month (%)					
No	2040 (78)	1063 (80)	1154 (78)	1409 (79)	1538 (77)
Yes	399 (15)	190 (14)	213 (14)	283 (16)	311 (16)
Not reported	170 (7)	71 (5)	107 (7)	89 (5)	142 (7)
Condom used with other partner(s) last month (%)					
N° surveyed	N=399	N=190	N=213	N=283	N=311
Never	184 (46)	90 (47)	104 (49)	152 (54)	174 (56)
Sometimes	100 (25)	54 (28)	47 (22)	70 (25)	66 (21)
Every time	89 (22)	41 (22)	48 (23)	52 (18)	65 (21)
Not reported	26 (7)	5 (3)	14 (7)	9 (3)	6 (2)
Sex work last month (%)					
No	2276 (87)	1190 (90)	1292 (88)	1579 (89)	1741 (87)
Yes	134 (5)	61 (5)	76 (5)	100 (6)	109 (5)
Not reported	199 (8)	73 (6)	106 (7)	102 (6)	141 (7)
Condom used at last sex work (%)					
Yes	78 (58)	27 (44)	43 (57)	70 (70)	67 (61)

Table 1.1.7 Number (percentage) of respondents by COVID-19 related impacts, 2020-2023

National	2020	2021	2022	2023
N° surveyed	N=1324	N=1474	N=1781	N=1991
COVID-19 test				
Yes	337 (25)	450 (31)	1521 (85)	1653 (83)
No	802 (61)	680 (46)	213 (12)	237 (12)
Don't know	60 (5)	63 (4)	-- --	-- --
Not reported	125 (9)	281 (19)	47 (3)	101 (5)
Self-reported positive COVID-19 test result				
Yes	4 (<1)	16 (1)	642 (42)	733 (44)
Yes, last 12 months	-- --	-- --	546 (36)	316 (19)
Yes, more than a year ago	-- --	-- --	96 (6)	417 (25)
COVID-19 vaccine uptake				
≥1 dose	-- --	599 (41)	1409 (79)	1491 (75)
COVID-19 vaccine doses				
One dose	-- --	232 (16)	126 (7)	120 (6)
Two doses	-- --	367 (25)	496 (28)	477 (24)
Three or more doses	-- --	-- --	787 (44)	894 (45)
No doses	-- --	635 (43)	304 (17)	375 (19)
Not reported	-- --	240 (16)	68 (4)	125 (6)
Vaccine type *			N=1409	
Astra Zeneca	-- --	139 (9)	415 (29)	-- --
Pfizer	-- --	310 (21)	913 (65)	-- --
Don't know	-- --	104 (7)	197 (14)	-- --
Other	-- --	-- --	121 (9)	-- --
Not reported	-- --	921 (62)	-- --	-- --
* 2021 only one response permitted, 2022 multiple responses permitted				
Last vaccine location			N=1781	N=1991
GP or medical centre	-- --	-- --	565 (32)	661 (33)
Pharmacy/ chemist	-- --	-- --	304 (17)	324 (16)
Vaccine hub	-- --	-- --	256 (14)	210 (11)
Opioid treatment/ methadone clinic	-- --	-- --	30 (2)	21 (1)
NSP	-- --	-- --	52 (3)	51 (3)
Prison	-- --	-- --	91 (5)	137 (7)
Multiple response	-- --	-- --	40 (2)	33 (2)
Other	-- --	-- --	114 (6)	122 (6)
Not reported	-- --	-- --	329 (18)	432 (22)
Vaccine hesitancy - if not had three or more doses				
Haven't got around to it	-- --	-- --	344 (19)	262 (13)
Difficulty booking appointment	-- --	-- --	37 (2)	20 (1)
Concerns about side effects	-- --	-- --	97 (5)	147 (7)
Concerns about vaccine safety	-- --	-- --	92 (5)	122 (6)
Not at risk of serious illness	-- --	-- --	129 (7)	208 (10)
Other	-- --	-- --	195 (11)	211 (11)
Multiple response	-- --	-- --	85 (5)	80 (4)
Not reported	-- --	-- --	802 (45)	941 (47)

HIV antibody prevalence

Table 1.2.1 HIV antibody prevalence by gender and survey year

National Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019	1675	51 (3.0)	841	6 (0.7)	2542	59 (2.3)
2020	877	27 (3.1)	406	3 (0.7)	1292	32 (2.5)
2021	902	16 (1.8)	514	3 (0.6)	1435	21 (1.5)
2022	1132	28 (2.5)	583	6 (1.0)	1752	37 (2.1)
2023	1049	26 (2.5)	583	4 (0.7)	1662	30 (1.8)
X ² p trend		0.206		0.826		0.189

Table 1.2.2 HIV antibody prevalence by sexual identity, gender and survey year

National Sexual identity	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
Heterosexual	1355	13 (1.0)	560	5 (0.9)	1919	18 (0.9)
Bisexual	92	13 (14.1)	148	0 (0.0)	253	14 (5.5)
Homosexual	79	25 (31.7)	36	0 (0.0)	117	26 (22.2)
p value		<0.001		0.680		<0.001
2020						
Heterosexual	746	5 (0.7)	276	3 (1.1)	1023	8 (0.8)
Bisexual	43	4 (9.3)	72	0 (0.0)	120	5 (4.2)
Homosexual	38	17 (44.7)	10	0 (0.0)	49	18 (36.7)
p value		<0.001		1.000		<0.001
2021						
Heterosexual	793	4 (0.5)	375	2 (0.5)	1172	7 (0.6)
Bisexual	49	0 (0.0)	96	0 (0.0)	148	0 (0.0)
Homosexual	40	11 (27.5)	16	1 (6.3)	61	13 (21.3)
p value		<0.001		0.201		<0.001
2022						
Heterosexual	973	3 (0.3)	407	4 (1.0)	1387	7 (0.5)
Bisexual	61	2 (3.3)	107	1 (0.9)	177	5 (2.8)
Homosexual	58	22 (37.9)	24	0 (0.0)	84	22 (26.2)
p value		<0.001		0.410		<0.001
2023						
Heterosexual	897	5 (0.6)	413	3 (0.7)	1314	8 (0.6)
Bisexual	60	6 (10.0)	116	1 (0.9)	181	7 (3.9)
Homosexual	51	14 (27.5)	15	0 (0.0)	69	14 (20.3)
p value		<0.001		1.000		<0.001

Table 1.2.3 HIV antibody prevalence by age group, gender and survey year

National Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
<25 years	51	0 (0.0)	39	0 (0.0)	91	0 (0.0)
25-34 years	254	8 (3.2)	175	0 (0.0)	436	9 (2.1)
35-44 years	605	11 (1.8)	332	2 (0.6)	943	13 (1.4)
45+ years	757	31 (4.1)	294	4 (1.4)	1062	36 (3.4)
p value		0.062		0.457		0.011
2020						
<25 years	23	0 (0.0)	18	1 (5.6)	42	1 (2.4)
25-34 years	145	4 (2.8)	78	1 (1.3)	225	5 (2.2)
35-44 years	288	6 (2.1)	160	0 (0.0)	449	6 (1.3)
45+ years	420	17 (4.1)	150	1 (0.7)	575	20 (3.5)
p value		0.487		0.054		0.151
2021						
<25 years	21	1 (4.8)	12	0 (0.0)	34	1 (2.9)
25-34 years	122	1 (0.8)	83	0 (0.0)	209	2 (1.0)
35-44 years	306	3 (1.0)	194	2 (1.0)	509	6 (1.2)
45+ years	449	11 (2.5)	221	1 (0.5)	675	12 (1.8)
p value		0.202		0.785		0.483
2022						
<25 years	36	0 (0.0)	12	0 (0.0)	52	0 (0.0)
25-34 years	161	2 (1.2)	84	0 (0.0)	250	2 (0.8)
35-44 years	341	9 (2.6)	213	3 (1.4)	561	13 (2.3)
45+ years	583	16 (2.7)	268	3 (1.1)	871	21 (2.4)
p value		0.720		0.880		0.365
2023						
<25 years	27	0 (0.0)	16	0 (0.0)	43	0 (0.0)
25-34 years	132	2 (1.5)	79	1 (1.3)	218	3 (1.4)
35-44 years	323	8 (2.5)	197	1 (0.5)	526	9 (1.7)
45+ years	561	16 (2.9)	286	2 (0.7)	860	18 (2.1)
p value		0.876		0.664		0.929

Table 1.2.4 HIV antibody prevalence by last drug injected, gender and survey year

National Last drug injected	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
Heroin	429	9 (2.1)	249	2 (0.8)	689	12 (1.7)
Methamphetamine	794	37 (4.7)	427	3 (0.7)	1231	41 (3.3)
Other opioids	241	4 (1.7)	96	0 (0.0)	339	4 (1.2)
PIEDs	88	0 (0.0)	5	0 (0.0)	93	0 (0.0)
Other drugs	114	1 (0.9)	55	1 (1.8)	170	2 (1.2)
p value		0.008		0.565		0.030
2020						
Heroin	191	2 (1.1)	88	1 (1.1)	280	3 (1.1)
Methamphetamine	391	21 (5.4)	207	2 (1.0)	603	24 (4.0)
Other opioids	161	2 (1.2)	78	0 (0.0)	241	2 (0.8)
PIEDs	77	0 (0.0)	3	0 (0.0)	80	0 (0.0)
Other drugs	50	1 (2.0)	27	0 (0.0)	78	2 (2.6)
p value		0.008		1.000		0.013
2021						
Heroin	180	2 (1.1)	106	1 (0.9)	292	4 (1.4)
Methamphetamine	419	11 (2.6)	299	2 (0.7)	725	14 (1.9)
Other opioids	187	2 (1.1)	72	0 (0.0)	263	2 (0.8)
PIEDs	51	0 (0.0)	0	0 (0.0)	51	0 (0.0)
Other drugs	59	0 (0.0)	33	0 (0.0)	93	0 (0.0)
p value		0.515		1.000		0.564
2022						
Heroin	262	1 (0.4)	176	2 (1.1)	443	4 (0.9)
Methamphetamine	497	22 (4.4)	308	4 (1.3)	827	26 (3.1)
Other opioids	163	1 (0.6)	54	0 (0.0)	223	1 (0.5)
PIEDs	113	2 (1.8)	4	0 (0.0)	117	2 (1.7)
Other drugs	90	2 (2.2)	33	0 (0.0)	126	3 (2.4)
p value		0.003		1.000		0.023
2023						
Heroin	223	6 (2.7)	141	2 (1.4)	371	8 (2.2)
Methamphetamine	533	16 (3.0)	344	2 (0.6)	891	18 (2.0)
Other opioids	135	4 (3.0)	55	0 (0.0)	194	4 (2.1)
PIEDs	75	0 (0.0)	4	0 (0.0)	80	0 (0.0)
Other drugs	77	0 (0.0)	38	0 (0.0)	116	0 (0.0)
p value		0.382		0.800		0.458

Table 1.2.5 HIV antibody prevalence by years of injection, gender and survey year

National Years of injection	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
<3 years	97	3 (3.1)	49	0 (0.0)	146	3 (2.1)
3 to 10 years	210	12 (5.7)	145	1 (0.7)	361	14 (3.9)
11+ years	1278	35 (2.7)	608	5 (0.8)	1091	41 (2.2)
p value		0.076		1.000		0.165
2020						
<3 years	56	1 (1.8)	26	0 (0.0)	82	1 (1.2)
3 to 10 years	134	8 (6.0)	61	2 (3.3)	197	10 (5.1)
11+ years	665	18 (2.7)	309	1 (0.3)	981	21 (2.1)
p value		0.131		0.123		0.055
2021						
<3 years	43	0 (0.0)	19	0 (0.0)	64	0 (0.0)
3 to 10 years	108	6 (5.6)	76	0 (0.0)	185	7 (3.8)
11+ years	719	9 (1.3)	397	3 (0.8)	1131	13 (1.2)
p value		0.015		1.000		0.035
2022						
<3 years	69	1 (1.5)	23	0 (0.0)	96	1 (1.0)
3 to 10 years	127	2 (1.6)	77	0 (0.0)	207	2 (1.0)
11+ years	866	23 (2.7)	456	6 (1.3)	1349	32 (2.4)
p value		0.857		0.690		0.478
2023						
<3 years	56	1 (1.8)	29	0 (0.0)	86	1 (1.2)
3 to 10 years	138	4 (2.9)	86	0 (0.0)	229	4 (1.8)
11+ years	818	21 (2.6)	453	4 (0.9)	1287	25 (1.9)
p value		0.921		1.000		1.000

Table 1.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

National Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
No receptive sharing	1235	41 (3.3)	625	3 (0.5)	1877	46 (2.5)
Receptive sharing	247	6 (2.4)	115	2 (1.7)	366	8 (2.2)
p value		0.466		0.174		0.762
2020						
No receptive sharing	663	20 (3.0)	284	3 (1.1)	955	25 (2.6)
Receptive sharing	107	2 (1.9)	75	0 (0.0)	182	2 (1.1)
p value		0.756		0.494		0.293
2021						
No receptive sharing	638	14 (2.2)	355	2 (0.6)	1003	18 (1.8)
Receptive sharing	135	1 (0.7)	75	1 (1.3)	215	2 (0.9)
p value		0.490		0.438		0.555
2022						
No receptive sharing	814	22 (2.7)	408	2 (0.5)	1249	26 (2.1)
Receptive sharing	189	3 (1.6)	107	1 (0.9)	303	4 (1.3)
p value		0.603		0.504		0.491
2023						
No receptive sharing	714	20 (2.8)	414	3 (0.7)	1149	23 (2.0)
Receptive sharing	196	4 (2.0)	87	0 (0.0)	286	4 (1.4)
p value		0.801		1.000		0.631

Table 1.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

National Frequency of injection	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
Less than daily	643	26 (4.0)	291	2 (0.7)	941	28 (3.0)
Daily or more	856	21 (2.5)	461	4 (0.9)	1331	27 (2.0)
Not last month	149	3 (2.0)	78	0 (0.0)	230	3 (1.3)
p value		0.172		1.000		0.204
2020						
Less than daily	350	11 (3.1)	159	2 (1.3)	514	13 (2.5)
Daily or more	425	11 (2.6)	202	1 (0.5)	630	14 (2.2)
Not last month	93	5 (5.4)	42	0 (0.0)	136	5 (3.7)
p value		0.373		0.702		0.615
2021						
Less than daily	373	10 (2.7)	209	0 (0.0)	588	10 (1.7)
Daily or more	402	5 (1.2)	228	3 (1.3)	639	10 (1.6)
Not last month	111	0 (0.0)	67	0 (0.0)	180	0 (0.0)
p value		0.118		0.361		0.199
2022						
Less than daily	438	14 (3.2)	214	1 (0.5)	669	15 (2.2)
Daily or more	570	11 (1.9)	303	2 (0.7)	890	15 (1.7)
Not last month	105	3 (2.9)	51	3 (5.9)	158	6 (3.8)
p value		0.391		0.020		0.220
2023						
Less than daily	408	11 (2.7)	205	2 (1.0)	621	13 (2.1)
Daily or more	516	13 (2.5)	300	1 (0.3)	832	14 (1.7)
Not last month	103	2 (1.9)	66	1 (1.5)	172	3 (1.7)
p value		1.000		0.342		0.864

Table 1.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

National Imprisonment last year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
No imprisonment	1322	43 (3.3)	708	5 (0.7)	2049	50 (2.4)
Imprisonment	250	3 (1.2)	89	1 (1.1)	344	4 (1.2)
p value		0.099		0.510		0.170
2020						
No imprisonment	711	23 (3.2)	349	3 (0.9)	1069	28 (2.6)
Imprisonment	118	4 (3.4)	38	0 (0.0)	156	4 (2.6)
p value		1.000		1.000		0.614
2021						
No imprisonment	733	13 (1.8)	447	3 (0.7)	1196	18 (1.5)
Imprisonment	114	1 (0.9)	39	0 (0.0)	154	1 (0.7)
p value		0.707		1.000		0.714
2022						
No imprisonment	938	28 (3.0)	514	3 (0.6)	1484	34 (2.3)
Imprisonment	147	0 (0.0)	48	2 (4.2)	197	2 (1.0)
p value		0.024		0.060		0.427
2023						
No imprisonment	845	23 (2.7)	498	4 (0.8)	1369	27 (2.0)
Imprisonment	132	2 (1.5)	44	0 (0.0)	177	2 (1.1)
p value		0.562		1.000		0.766

Table 1.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

National Condom use at last sex	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
No condom use	469	18 (3.8)	317	0 (0.0)	790	18 (2.3)
Condom use	159	1 (0.6)	89	3 (3.4)	253	4 (1.6)
p value		0.056		0.010		0.621
2020						
No condom use	278	13 (4.7)	159	1 (0.6)	439	15 (3.4)
Condom use	75	3 (4.0)	29	0 (0.0)	104	3 (2.9)
p value		1.000		1.000		1.000
2021						
No condom use	267	4 (1.5)	200	0 (0.0)	473	4 (0.9)
Condom use	65	0 (0.0)	48	0 (0.0)	116	1 (0.9)
p value		1.000		--		1.000
2022						
No condom use	353	10 (2.8)	235	2 (0.9)	598	13 (2.2)
Condom use	83	1 (1.2)	45	1 (2.2)	133	3 (2.3)
p value		0.698		0.410		1.000
2023						
No condom use	328	8 (2.4)	228	1 (0.4)	564	9 (1.6)
Condom use	68	3 (4.4)	53	0 (0.0)	123	3 (2.4)
p value		0.411		1.000		0.458

Table 1.2.10 HIV antibody prevalence by sex work last month, gender and survey year

National Sex work last month	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
No sex work	1490	44 (3.0)	717	5 (0.7)	2226	51 (2.3)
Sex work	60	4 (6.7)	64	1 (1.6)	129	5 (3.9)
p value		0.111		0.402		0.251
2020						
No sex work	807	23 (2.9)	352	2 (0.6)	1166	26 (2.2)
Sex work	26	4 (15.4)	30	1 (3.3)	58	6 (10.3)
p value		0.008		0.218		<0.001
2021						
No sex work	820	13 (1.6)	425	3 (0.7)	1259	16 (1.3)
Sex work	27	1 (3.7)	44	0 (0.0)	74	3 (4.1)
p value		0.367		1.000		0.084
2022						
No sex work	1018	22 (2.2)	504	6 (1.2)	1553	31 (2.0)
Sex work	44	5 (11.4)	52	0 (0.0)	100	5 (5.0)
p value		<0.001		1.000		0.046
2023						
No sex work	931	21 (2.3)	508	4 (0.8)	1460	25 (1.7)
Sex work	45	3 (6.7)	35	0 (0.0)	86	3 (3.5)
p value		0.094		1.000		0.201

Table 1.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

National Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
Non Indigenous	1314	37 (2.8)	615	1 (0.2)	1947	39 (2.0)
Indigenous	331	14 (4.2)	215	5 (2.3)	552	20 (3.6)
p value		0.185		0.005		0.027
2020						
Non Indigenous	675	20 (3.0)	278	2 (0.7)	958	23 (2.4)
Indigenous	168	6 (3.6)	115	1 (0.9)	285	8 (2.8)
p value		0.683		1.000		0.699
2021						
Non Indigenous	650	13 (2.0)	347	1 (0.3)	1008	15 (1.5)
Indigenous	207	3 (1.5)	145	2 (1.4)	359	6 (1.7)
p value		0.773		0.209		0.804
2022						
Non Indigenous	864	22 (2.6)	399	4 (1.0)	1287	27 (2.1)
Indigenous	248	6 (2.4)	175	2 (1.1)	434	10 (2.3)
p value		0.910		1.000		0.798
2023						
Non Indigenous	759	13 (1.7)	380	2 (0.5)	1161	15 (1.3)
Indigenous	273	13 (4.8)	196	2 (1.0)	476	15 (3.2)
p value		0.006		0.608		0.011

Table 1.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

National Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
English speaking	1566	48 (3.1)	817	5 (0.6)	2405	55 (2.3)
Non-English speaking	100	3 (3.0)	22	1 (4.6)	125	4 (3.2)
p value		1.000		0.148		0.534
2020						
English speaking	824	26 (3.2)	392	3 (0.8)	1225	31 (2.5)
Non-English speaking	48	1 (2.1)	10	0 (0.0)	58	1 (1.7)
p value		1.000		1.000		1.000
2021						
English speaking	856	15 (1.8)	495	3 (0.6)	1368	20 (1.5)
Non-English speaking	35	1 (2.9)	14	0 (0.0)	51	1 (2.0)
p value		0.476		1.000		0.539
2022						
English speaking	1052	26 (2.5)	556	6 (1.1)	1643	35 (2.1)
Non-English speaking	68	2 (2.9)	22	0 (0.0)	91	2 (2.2)
p value		0.685		1.000		1.000
2023						
English speaking	987	26 (2.6)	558	4 (0.7)	1573	30 (1.9)
Non-English speaking	56	0 (0.0)	21	0 (0.0)	78	0 (0.0)
p value		0.393		1.000		0.397

Table 1.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

National Region/country of birth	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
Australia	1467	45 (3.1)	763	6 (0.8)	2248	53 (2.4)
Other Oceania	38	1 (2.6)	23	0 (0.0)	66	1 (1.5)
Asia	22	3 (13.6)	3	0 (0.0)	25	3 (12.0)
UK & Ireland	55	0 (0.0)	28	0 (0.0)	83	0 (0.0)
Other	77	2 (2.6)	22	0 (0.0)	100	2 (2.0)
p value		0.085		1.000		0.055
2020						
Australia	740	22 (3.0)	365	3 (0.8)	1113	26 (2.3)
Other Oceania	33	1 (3.0)	9	0 (0.0)	42	1 (2.4)
Asia	16	1 (6.3)	2	0 (0.0)	18	1 (5.6)
UK & Ireland	34	1 (2.9)	17	0 (0.0)	51	1 (2.0)
Other	39	1 (2.6)	10	0 (0.0)	49	1 (2.0)
p value		0.722		1.000		0.652
2021						
Australia	776	12 (1.6)	449	3 (0.7)	1241	16 (1.3)
Other Oceania	22	0 (0.0)	18	0 (0.0)	43	1 (2.3)
Asia	7	0 (0.0)	5	0 (0.0)	12	0 (0.0)
UK & Ireland	39	0 (0.0)	15	0 (0.0)	54	0 (0.0)
Other	32	3 (9.4)	15	0 (0.0)	47	3 (6.4)
p value		0.080		1.000		0.087
2022						
Australia	968	22 (2.3)	517	6 (1.2)	1518	30 (2.0)
Other Oceania	36	2 (5.6)	13	0 (0.0)	50	2 (4.0)
Asia	12	0 (0.0)	11	0 (0.0)	23	0 (0.0)
UK & Ireland	35	1 (2.9)	22	0 (0.0)	58	1 (1.7)
Other	54	3 (5.6)	14	0 (0.0)	69	3 (4.4)
p value		0.241		1.000		0.352
2023						
Australia	926	25 (2.7)	533	4 (0.8)	1486	29 (2.0)
Other Oceania	28	1 (3.6)	23	0 (0.0)	52	1 (1.9)
Asia	12	0 (0.0)	2	0 (0.0)	14	0 (0.0)
UK & Ireland	33	0 (0.0)	10	0 (0.0)	44	0 (0.0)
Other	37	0 (0.0)	11	0 (0.0)	48	0 (0.0)
p value		0.749		1.000		1.000

HCV antibody prevalence

Table 1.3.1 HCV antibody prevalence by gender and survey year

National Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019	1670	781 (47)	835	360 (43)	2531	1151 (45)
2020	877	342 (39)	405	163 (40)	1291	507 (39)
2021	902	343 (38)	514	173 (34)	1435	522 (36)
2022	1115	350 (31)	573	194 (34)	1724	554 (32)
2023*	1050	473 (45)	583	264 (45)	1663	745 (45)
X ² p trend		<0.001		0.485		<0.001

* Antibody testing assay changed in 2023. See Appendix B: Methodological Notes

Table 1.3.2 HCV antibody prevalence by sexual identity, gender and survey year

National Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
Heterosexual	1351	645 (48)	554	239 (43)	1909	887 (46)
Bisexual	91	38 (42)	149	61 (41)	253	104 (41)
Homosexual	79	15 (19)	36	15 (42)	117	30 (26)
p value		<0.001		0.894		<0.001
2020						
Heterosexual	746	297 (40)	275	106 (39)	1022	404 (40)
Bisexual	43	16 (37)	72	40 (56)	120	56 (47)
Homosexual	38	6 (16)	10	3 (30)	49	9 (18)
p value		0.024		0.027		0.004
2021						
Heterosexual	791	316 (40)	375	118 (31)	1170	436 (37)
Bisexual	49	16 (33)	96	38 (40)	148	54 (36)
Homosexual	42	6 (14)	16	7 (44)	63	13 (21)
p value		0.004		0.216		0.156
2022						
Heterosexual	956	316 (33)	398	141 (35)	1361	463 (34)
Bisexual	60	17 (28)	106	26 (25)	175	43 (25)
Homosexual	59	6 (10)	24	6 (25)	85	13 (15)
p value		0.005		0.018		0.002
2023						
Heterosexual	897	425 (47)	413	189 (46)	1314	614 (47)
Bisexual	61	18 (30)	116	46 (40)	182	65 (36)
Homosexual	51	12 (24)	15	7 (47)	69	19 (28)
p value		0.001		0.309		0.005

Table 1.3.3 HCV antibody prevalence by age group, gender and survey year

National Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
<25 years	51	13 (25)	40	8 (20)	92	21 (23)
25-34 years	254	66 (26)	175	74 (42)	436	141 (32)
35-44 years	601	275 (46)	331	137 (41)	938	416 (44)
45+ years	756	424 (56)	288	141 (49)	1055	569 (54)
p value		<0.001		0.004		<0.001
2020						
<25 years	23	3 (13)	18	7 (39)	42	10 (24)
25-34 years	145	30 (21)	78	26 (33)	225	56 (25)
35-44 years	289	118 (41)	159	70 (44)	449	188 (42)
45+ years	419	190 (45)	150	60 (40)	574	252 (44)
p value		<0.001		0.473		<0.001
2021						
<25 years	21	4 (19)	12	3 (25)	34	7 (21)
25-34 years	122	30 (25)	83	25 (30)	209	56 (27)
35-44 years	307	126 (41)	194	60 (31)	510	189 (37)
45+ years	448	183 (41)	221	83 (38)	674	268 (40)
p value		0.001		0.410		0.002
2022						
<25 years	36	5 (14)	11	2 (18)	50	7 (14)
25-34 years	162	27 (17)	83	19 (23)	250	46 (18)
35-44 years	337	102 (30)	210	67 (32)	554	172 (31)
45+ years	569	212 (37)	263	104 (40)	852	322 (38)
p value		<0.001		0.020		<0.001
2023						
<25 years	27	3 (11)	16	4 (25)	43	7 (16)
25-34 years	132	27 (20)	79	26 (33)	218	54 (25)
35-44 years	324	128 (40)	197	91 (46)	527	220 (42)
45+ years	561	310 (55)	286	139 (49)	860	452 (53)
p value		<0.001		0.031		<0.001

Table 1.3.4 HCV antibody prevalence by years since first injection, gender and survey year

National Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019						
<3 years	96	8 (8)	50	0 (0)	146	8 (5)
3 to 10 years	210	46 (22)	145	48 (33)	361	96 (27)
11+ years	1273	683 (54)	601	294 (49)	1889	982 (52)
p value		<0.001		<0.001		<0.001
2020						
<3 years	56	5 (9)	26	0 (0)	82	5 (6)
3 to 10 years	135	21 (16)	61	22 (36)	198	43 (22)
11+ years	663	305 (46)	308	136 (44)	978	443 (45)
p value		<0.001		<0.001		<0.001
2021						
<3 years	43	2 (5)	19	3 (16)	64	5 (8)
3 to 10 years	108	19 (18)	76	16 (21)	185	35 (19)
11+ years	719	308 (43)	397	147 (37)	1131	460 (41)
p value		<0.001		0.005		<0.001
2022						
<3 years	69	3 (4)	22	1 (5)	94	4 (4)
3 to 10 years	127	16 (13)	76	12 (16)	206	29 (14)
11+ years	850	310 (36)	448	170 (38)	1325	488 (37)
p value		<0.001		<0.001		<0.001
2023						
<3 years	56	3 (5)	29	4 (14)	86	7 (8)
3 to 10 years	138	23 (17)	86	17 (20)	229	40 (17)
11+ years	819	431 (53)	453	235 (52)	1288	670 (52)
p value		<0.001		<0.001		<0.001

Table 1.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

National Receptively shared syringe last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019						
No receptive sharing	113	5 (4)	1683	803 (48)	1870	853 (46)
Receptive sharing	15	1 (7)	318	170 (53)	362	185 (51)
p value		0.534		0.060		0.055
2020						
No receptive sharing	65	4 (6)	872	352 (40)	953	364 (38)
Receptive sharing	5	0 (0)	171	88 (51)	182	93 (51)
p value		1.000		0.007		0.001
2021						
No receptive sharing	44	3 (7)	924	343 (37)	1003	358 (36)
Receptive sharing	5	2 (40)	202	100 (50)	214	106 (50)
p value		0.075		0.001		<0.001
2022						
No receptive sharing	73	2 (3)	1100	347 (32)	1228	370 (30)
Receptive sharing	6	2 (33)	273	121 (44)	299	130 (43)
p value		0.027		<0.001		<0.001
2023						
No receptive sharing	66	2 (3)	1050	482 (46)	1150	503 (44)
Receptive sharing	12	5 (42)	263	156 (59)	286	166 (58)
p value		0.001		<0.001		<0.001

Table 1.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

National Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
Heroin	14	2 (14)	632	415 (66)	677	441 (65)
Methamphetamine	90	4 (4)	1058	385 (36)	1210	415 (34)
Other opioids	7	1 (14)	319	171 (54)	334	178 (53)
PIEDs	27	0 (0)	59	1 (2)	91	1 (1)
Other drugs	5	1 (20)	148	89 (60)	168	97 (58)
p value		0.147		<0.001		<0.001
2020						
Heroin	6	1 (17)	267	160 (60)	278	164 (59)
Methamphetamine	42	4 (10)	546	162 (30)	599	173 (29)
Other opioids	5	0 (0)	230	116 (50)	238	119 (50)
PIEDs	23	0 (0)	49	2 (4)	79	2 (3)
Other drugs	4	0 (0)	69	40 (58)	76	42 (55)
p value		0.404		<0.001		<0.001
2021						
Heroin	4	1 (25)	277	134 (48)	289	139 (48)
Methamphetamine	39	1 (3)	649	184 (28)	710	193 (27)
Other opioids	8	2 (25)	239	119 (50)	257	125 (49)
PIEDs	8	0 (0)	41	4 (10)	51	4 (8)
Other drugs	2	0 (0)	81	42 (52)	91	45 (49)
p value		0.079		<0.001		<0.001
2022						
Heroin	4	0 (0)	406	185 (46)	424	191 (45)
Methamphetamine	35	3 (9)	725	195 (27)	806	216 (27)
Other opioids	7	1 (14)	196	92 (47)	214	97 (45)
PIEDs	43	0 (0)	63	2 (3)	115	3 (3)
Other drugs	2	0 (0)	107	35 (33)	117	36 (31)
p value		0.255		<0.001		<0.001
2023						
Heroin	3	0 (0)	352	224 (64)	363	231 (64)
Methamphetamine	52	5 (10)	802	316 (39)	878	332 (38)
Other opioids	3	0 (0)	182	103 (57)	192	107 (56)
PIEDs	21	0 (0)	52	0 (0)	79	0 (0)
Other drugs	6	2 (33)	95	53 (56)	108	58 (54)
p value		0.109		<0.001		<0.001

Table 1.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

National Frequency of injection last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019						
Less than daily	65	4 (6)	835	365 (44)	935	389 (41)
Daily or more	66	3 (5)	1190	617 (52)	1326	660 (50)
Not last month	15	1 (7)	195	82 (42)	231	86 (37)
p value		0.772		<0.001		<0.001
2020						
Less than daily	38	2 (5)	469	170 (36)	516	176 (34)
Daily or more	32	2 (6)	581	273 (47)	626	284 (45)
Not last month	12	1 (8)	116	38 (33)	137	41 (30)
p value		1.000		<0.001		<0.001
2021						
Less than daily	32	1 (3)	541	160 (30)	589	167 (28)
Daily or more	18	4 (22)	592	286 (48)	637	301 (47)
Not last month	13	0 (0)	160	38 (24)	181	41 (23)
p value		0.041		<0.001		<0.001
2022						
Less than daily	55	1 (2)	575	177 (31)	657	187 (28)
Daily or more	24	3 (13)	802	293 (37)	877	315 (36)
Not last month	13	0 (0)	129	42 (33)	155	44 (28)
p value		0.106		0.079		0.005
2023						
Less than daily	45	3 (7)	562	247 (44)	622	256 (41)
Daily or more	33	4 (12)	769	400 (52)	832	422 (51)
Not last month	7	0 (0)	157	51 (32)	172	52 (30)
p value		0.705		<0.001		<0.001

Table 1.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

National Imprisonment last year	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019						
No imprisonment	129	7 (5)	1815	827 (46)	2041	878 (43)
Imprisonment	12	0 (0)	301	178 (59)	342	194 (57)
p value		1.000		<0.001		<0.001
2020						
No imprisonment	75	4 (5)	969	381 (39)	1068	395 (37)
Imprisonment	7	1 (14)	141	68 (48)	156	75 (48)
p value		0.367		0.044		0.008
2021						
No imprisonment	55	4 (7)	1100	395 (36)	1196	413 (35)
Imprisonment	4	0 (0)	142	66 (46)	154	70 (45)
p value		1.000		0.014		0.008
2022						
No imprisonment	85	2 (2)	1298	424 (33)	1459	450 (31)
Imprisonment	7	2 (29)	171	65 (38)	195	74 (38)
p value		0.028		0.163		0.045
2023						
No imprisonment	71	5 (7)	1254	564 (45)	1370	589 (43)
Imprisonment	9	1 (11)	159	92 (58)	177	98 (55)
p value		0.523		0.002		0.002

Table 1.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

National Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
Non Indigenous	1309	584 (45)	610	253 (41)	1937	844 (44)
Indigenous	331	180 (54)	214	102 (48)	551	284 (52)
p value		0.001		0.116		0.001
2020						
Non Indigenous	676	234 (35)	277	101 (36)	958	337 (35)
Indigenous	167	91 (54)	115	54 (47)	284	145 (51)
p value		<0.001		0.053		<0.001
2021						
Non Indigenous	650	214 (33)	347	108 (31)	1008	324 (32)
Indigenous	207	108 (52)	145	58 (40)	359	169 (47)
p value		<0.001		0.058		<0.001
2022						
Non Indigenous	849	251 (30)	390	130 (33)	1262	387 (31)
Indigenous	246	92 (37)	174	59 (34)	431	154 (36)
p value		0.02		0.894		0.052
2023						
Non Indigenous	760	321 (42)	380	164 (43)	1162	489 (42)
Indigenous	273	145 (53)	196	96 (49)	476	244 (51)
p value		0.002		0.183		0.001

Table 1.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

National Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
English speaking	1561	726 (47)	811	347 (43)	2394	1081 (45)
Non-English speaking	100	53 (53)	22	12 (55)	125	67 (54)
p value		0.207		0.272		0.065
2020						
English speaking	824	319 (39)	391	157 (40)	1224	478 (39)
Non-English speaking	48	22 (46)	10	6 (60)	58	28 (48)
p value		0.326		0.328		0.160
2021						
English speaking	856	326 (38)	495	163 (33)	1368	494 (36)
Non-English speaking	35	14 (40)	14	7 (50)	51	22 (43)
p value		0.819		0.182		0.306
2022						
English speaking	1038	318 (31)	547	188 (34)	1619	516 (32)
Non-English speaking	66	28 (42)	21	5 (24)	88	33 (38)
p value		0.045		0.316		0.271
2023						
English speaking	988	450 (46)	558	250 (45)	1574	707 (45)
Non-English speaking	56	19 (34)	21	12 (57)	78	31 (40)
p value		0.089		0.265		0.370

Table 1.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

National Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
Australia	1463	684 (47)	757	325 (43)	2238	1015 (45)
Other Oceania	38	19 (50)	23	11 (48)	66	32 (48)
Asia	23	7 (30)	3	1 (33)	26	8 (31)
UK & Ireland	55	31 (56)	28	14 (50)	83	45 (54)
Other	75	33 (44)	22	7 (32)	98	40 (41)
p value		0.299		0.741		0.204
2020						
Australia	740	292 (39)	365	149 (41)	1113	443 (40)
Other Oceania	33	10 (30)	9	2 (22)	42	12 (29)
Asia	16	5 (31)	2	1 (50)	18	6 (33)
UK & Ireland	34	10 (29)	16	5 (31)	50	15 (30)
Other	39	22 (56)	10	5 (50)	49	27 (55)
p value		0.102		0.679		0.054
2021						
Australia	775	292 (38)	449	147 (33)	1240	445 (36)
Other Oceania	22	12 (55)	18	8 (44)	43	20 (47)
Asia	7	1 (14)	5	3 (60)	12	4 (33)
UK & Ireland	39	12 (31)	15	3 (20)	54	15 (28)
Other	33	14 (42)	15	7 (47)	48	21 (44)
p value		0.270		0.264		0.293
2022						
Australia	951	293 (31)	508	173 (34)	1491	475 (32)
Other Oceania	36	16 (44)	13	4 (31)	50	21 (42)
Asia	12	2 (17)	11	3 (27)	23	5 (22)
UK & Ireland	35	7 (20)	22	7 (32)	58	14 (24)
Other	54	19 (35)	13	2 (15)	68	21 (31)
p value		0.169		0.739		0.280
2023						
Australia	927	423 (46)	533	232 (44)	1487	662 (45)
Other Oceania	28	11 (39)	23	12 (52)	52	23 (44)
Asia	12	4 (33)	2	0 (0)	14	4 (29)
UK & Ireland	33	18 (55)	10	8 (80)	44	26 (59)
Other	37	10 (27)	11	8 (73)	48	18 (38)
p value		0.122		0.023		0.194

HCV RNA prevalence

Table 1.4.1 HCV RNA prevalence by gender and survey year

National Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*	1412	264 (19)	706	111 (16)	2140	378 (18)
2020	808	136 (17)	361	57 (16)	1175	193 (16)
2021	835	148 (18)	474	62 (13)	1328	214 (16)
2022	1065	137 (13)	552	58 (11)	1653	200 (12)
2023	1038	140 (13)	578	56 (10)	1646	197 (12)
X ² p trend		<0.001		<0.001		<0.001

* 2019: Weighted for gender and HCV antibody status

Totals include respondents where gender was reported as other or not reported

Table 1.4.2 HCV RNA prevalence by sexual identity, gender and survey year

National Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
Heterosexual	1148	215 (19)	460	69 (15)	1611	285 (18)
Bisexual	77	14 (18)	132	20 (15)	220	36 (16)
Homosexual	70	3 (4)	34	6 (18)	106	9 (8)
p value		0.008		0.921		0.043
2020						
Heterosexual	684	117 (17)	244	43 (18)	929	160 (17)
Bisexual	41	7 (17)	65	10 (15)	109	17 (16)
Homosexual	36	2 (6)	10	0 (0)	46	2 (4)
p value		0.191		0.326		0.069
2021						
Heterosexual	736	136 (18)	345	41 (12)	1085	179 (16)
Bisexual	43	8 (19)	90	11 (12)	136	19 (14)
Homosexual	37	1 (3)	16	4 (25)	58	5 (9)
p value		0.049		0.298		0.226
2022						
Heterosexual	914	122 (13)	386	47 (12)	1307	171 (13)
Bisexual	58	7 (12)	100	5 (5)	166	12 (7)
Homosexual	54	3 (6)	21	1 (5)	77	5 (6)
p value		0.314		0.311		0.102
2023						
Heterosexual	887	128 (14)	410	44 (11)	1301	172 (13)
Bisexual	60	8 (13)	115	7 (6)	180	16 (9)
Homosexual	50	3 (6)	14	0 (0)	67	3 (4)
p value		0.327		0.307		0.149

Table 1.4.3 HCV RNA prevalence by age group, gender and survey year

National Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
<25 years	44	5 (11)	39	7 (18)	84	12 (14)
25-34 years	220	27 (12)	146	24 (16)	372	52 (14)
35-44 years	503	102 (20)	277	46 (17)	785	148 (19)
45+ years	639	129 (20)	244	34 (14)	891	165 (19)
p value		0.028		0.773		0.143
2020						
<25 years	20	1 (5)	19	4 (21)	40	5 (13)
25-34 years	129	12 (9)	71	12 (17)	201	24 (12)
35-44 years	271	63 (23)	139	27 (19)	411	90 (22)
45+ years	387	60 (16)	132	14 (11)	522	74 (14)
p value		0.001		0.211		0.003
2021						
<25 years	21	2 (10)	12	2 (17)	34	4 (12)
25-34 years	113	21 (19)	78	10 (13)	195	33 (17)
35-44 years	281	55 (20)	174	18 (10)	464	74 (16)
45+ years	416	70 (17)	206	31 (15)	627	102 (16)
p value		0.593		0.573		0.899
2022						
<25 years	35	3 (9)	12	1 (8)	51	4 (8)
25-34 years	158	14 (9)	79	8 (10)	242	22 (9)
35-44 years	326	39 (12)	201	18 (9)	534	59 (11)
45+ years	535	80 (15)	254	31 (12)	808	114 (14)
p value		0.181		0.731		0.103
2023						
<25 years	27	1 (4)	16	1 (6)	43	2 (5)
25-34 years	132	13 (10)	78	10 (13)	217	24 (11)
35-44 years	320	40 (13)	195	17 (9)	521	57 (11)
45+ years	553	84 (15)	284	27 (10)	850	111 (13)
p value		0.169		0.758		0.306

Table 1.4.4 HCV RNA prevalence by years since first injection, gender and survey year

National Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
<3 years	87	7 (8)	43	1 (2)	130	8 (6)
3 to 10 years	174	22 (13)	126	28 (22)	305	51 (17)
11+ years	1073	220 (21)	509	76 (15)	1594	297 (19)
p value		0.001		0.007		0.001
2020						
<3 years	51	2 (4)	22	0 (0)	73	2 (3)
3 to 10 years	125	12 (10)	57	12 (21)	183	24 (13)
11+ years	610	117 (19)	273	44 (16)	888	161 (18)
p value		0.001		0.071		0.001
2021						
<3 years	42	1 (2)	17	1 (6)	61	2 (3)
3 to 10 years	103	21 (20)	67	9 (13)	171	31 (18)
11+ years	660	122 (18)	368	48 (13)	1043	172 (16)
p value		0.024		0.680		0.018
2022						
<3 years	67	2 (3)	23	0 (0)	94	2 (2)
3 to 10 years	126	12 (10)	75	8 (11)	204	20 (10)
11+ years	807	115 (14)	427	48 (11)	1260	168 (13)
p value		0.009		0.271		0.001
2023						
<3 years	56	0 (0)	29	2 (7)	86	2 (2)
3 to 10 years	137	10 (7)	86	12 (14)	228	22 (10)
11+ years	809	125 (15)	448	40 (9)	1273	166 (13)
p value		<0.001		0.325		0.002

Table 1.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

National Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
No receptive sharing	1055	205 (19)	527	81 (15)	1597	288 (18)
Receptive sharing	196	43 (22)	99	21 (21)	300	65 (22)
p value		0.456		0.169		0.152
2020						
No receptive sharing	610	97 (16)	246	39 (16)	861	136 (16)
Receptive sharing	94	33 (35)	72	14 (19)	166	47 (28)
p value		<0.001		0.472		<0.001
2021						
No receptive sharing	588	101 (17)	325	39 (12)	923	142 (15)
Receptive sharing	124	36 (29)	72	15 (21)	201	52 (26)
p value		0.002		0.048		<0.001
2022						
No receptive sharing	769	95 (12)	385	30 (8)	1180	127 (11)
Receptive sharing	175	34 (19)	101	22 (22)	283	59 (21)
p value		0.014		<0.001		<0.001
2023						
No receptive sharing	707	93 (13)	411	40 (10)	1139	133 (12)
Receptive sharing	193	37 (19)	86	11 (13)	282	49 (17)
p value		0.035		0.395		0.010

Table 1.4.6 HCV RNA prevalence by last drug injected, gender and survey year

National Last drug injected	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
Heroin	364	81 (22)	205	41 (20)	578	122 (21)
Methamphetamine	659	122 (19)	351	46 (13)	1019	171 (17)
Other opioids	202	39 (19)	87	9 (10)	291	49 (17)
PIEDs	73	1 (1)	5	0 (0)	78	1 (1)
Other drugs	90	18 (20)	48	13 (27)	139	30 (22)
p value		0.001		0.019		<0.001
2020						
Heroin	177	34 (19)	85	14 (16)	263	48 (18)
Methamphetamine	354	56 (16)	171	24 (14)	529	80 (15)
Other opioids	145	31 (21)	74	8 (11)	220	39 (18)
PIEDs	71	0 (0)	3	0 (0)	74	0 (0)
Other drugs	46	12 (26)	25	11 (44)	71	23 (32)
p value		<0.001		0.002		<0.001
2021						
Heroin	164	29 (18)	95	14 (15)	265	45 (17)
Methamphetamine	382	72 (19)	267	28 (10)	656	100 (15)
Other opioids	173	32 (18)	67	11 (16)	244	44 (18)
PIEDs	48	3 (6)	0	0 (0)	48	3 (6)
Other drugs	50	7 (14)	32	7 (22)	82	14 (17)
p value		0.264		0.198		0.320
2022						
Heroin	228	28 (12)	158	22 (14)	391	50 (13)
Methamphetamine	470	73 (16)	292	25 (9)	783	100 (13)
Other opioids	158	21 (13)	52	8 (15)	216	32 (15)
PIEDs	111	0 (0)	3	0 (0)	114	0 (0)
Other drugs	77	12 (16)	25	2 (8)	104	14 (13)
p value		<0.001		0.304		0.001
2023						
Heroin	215	33 (15)	136	16 (12)	358	49 (14)
Methamphetamine	521	76 (15)	337	30 (9)	872	107 (12)
Other opioids	132	18 (14)	54	3 (6)	190	21 (11)
PIEDs	74	0 (0)	4	0 (0)	79	0 (0)
Other drugs	70	10 (14)	34	6 (18)	105	16 (15)
p value		0.013		0.305		0.011

Table 1.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year

National Frequency of injection last month	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019*						
Less than daily	559	93 (17)	246	40 (16)	810	133 (16)
Daily or more	706	157 (22)	390	63 (16)	1108	223 (20)
Not last month	131	12 (9)	64	7 (11)	197	19 (10)
p value		<0.001		0.518		<0.001
2020						
Less than daily	326	49 (15)	141	22 (16)	471	71 (15)
Daily or more	383	81 (21)	179	31 (17)	563	112 (20)
Not last month	90	4 (4)	38	4 (11)	129	8 (6)
p value		<0.001		0.578		<0.001
2021						
Less than daily	352	56 (16)	196	20 (10)	554	76 (14)
Daily or more	362	81 (22)	206	35 (17)	577	119 (21)
Not last month	106	6 (6)	62	5 (8)	170	11 (6)
p value		<0.001		0.060		<0.001
2022						
Less than daily	424	47 (11)	206	18 (9)	647	67 (10)
Daily or more	525	82 (16)	281	34 (12)	822	119 (14)
Not last month	100	5 (5)	50	5 (10)	152	10 (7)
p value		0.006		0.487		0.005
2023						
Less than daily	407	47 (12)	205	19 (9)	620	66 (11)
Daily or more	507	85 (17)	296	32 (11)	819	118 (14)
Not last month	103	5 (5)	65	4 (6)	171	9 (5)
p value		0.002		0.558		0.002

Table 1.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year

National Imprisonment last year	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019*						
No imprisonment	1107	186 (17)	594	88 (15)	1718	276 (16)
Imprisonment	215	57 (27)	76	17 (22)	295	75 (25)
p value		<0.001		0.101		<0.001
2020						
No imprisonment	658	102 (16)	309	48 (16)	973	150 (15)
Imprisonment	107	26 (24)	35	7 (20)	142	33 (23)
p value		0.024		0.494		0.019
2021						
No imprisonment	680	110 (16)	412	50 (12)	1108	163 (15)
Imprisonment	107	23 (21)	36	6 (17)	144	29 (20)
p value		0.172		0.431		0.089
2022						
No imprisonment	882	105 (12)	486	50 (10)	1399	160 (11)
Imprisonment	141	24 (17)	46	7 (15)	189	31 (16)
p value		0.089		0.302		0.049
2023						
No imprisonment	834	115 (14)	496	49 (10)	1356	164 (12)
Imprisonment	132	13 (10)	41	2 (5)	174	16 (9)
p value		0.215		0.411		0.264

Table 1.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

National Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
Non Indigenous	1117	185 (17)	514	71 (14)	1646	258 (16)
Indigenous	273	74 (27)	182	39 (21)	461	114 (25)
p value		<0.001		0.020		<0.001
2020						
Non Indigenous	617	90 (15)	241	35 (15)	862	125 (15)
Indigenous	158	38 (24)	108	20 (19)	267	58 (22)
p value		0.004		0.344		0.005
2021						
Non Indigenous	596	81 (14)	315	40 (13)	922	123 (13)
Indigenous	197	55 (28)	140	21 (15)	344	78 (23)
p value		<0.001		0.506		<0.001
2022						
Non Indigenous	809	101 (12)	375	41 (11)	1207	144 (12)
Indigenous	238	34 (14)	168	15 (9)	417	51 (12)
p value		0.466		0.478		0.871
2023						
Non Indigenous	752	91 (12)	377	36 (10)	1151	127 (11)
Indigenous	270	48 (18)	195	20 (10)	472	69 (15)
p value		0.020		0.787		0.044

Table 1.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year

National Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
English speaking	1322	248 (19)	685	105 (15)	2026	355 (18)
Non-English speaking	85	17 (20)	19	6 (32)	107	23 (21)
p value		0.858		0.056		0.242
2020						
English speaking	758	127 (17)	351	54 (15)	1115	181 (16)
Non-English speaking	46	9 (20)	9	3 (33)	55	12 (22)
p value		0.622		0.145		0.276
2021						
English speaking	794	140 (18)	459	56 (12)	1270	199 (16)
Non-English speaking	32	7 (22)	13	4 (31)	47	12 (26)
p value		0.538		0.047		0.070
2022						
English speaking	993	124 (12)	527	55 (10)	1555	184 (12)
Non-English speaking	61	12 (20)	20	2 (10)	81	14 (17)
p value		0.104		1.000		0.143
2023						
English speaking	977	136 (14)	553	50 (9)	1558	187 (12)
Non-English speaking	56	4 (7)	21	6 (29)	78	10 (13)
p value		0.225		0.003		0.829

Table 1.4.11 HCV RNA prevalence by region/country of birth, gender and survey year

National Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
Australia	1244	238 (19)	636	101 (16)	1895	340 (18)
Other Oceania	32	4 (13)	19	4 (21)	55	10 (18)
Asia	16	3 (19)	3	0 (0)	19	3 (16)
UK & Ireland	44	8 (18)	26	4 (15)	70	13 (19)
Other	63	10 (16)	21	1 (5)	85	11 (13)
p value		0.813		0.575		0.782
2020						
Australia	681	109 (16)	328	53 (16)	1015	162 (16)
Other Oceania	31	5 (16)	8	1 (13)	39	6 (15)
Asia	16	0 (0)	2	0 (0)	18	0 (0)
UK & Ireland	29	7 (24)	13	2 (15)	42	9 (21)
Other	37	13 (35)	9	1 (11)	46	14 (30)
p value		0.018		0.976		0.048
2021						
Australia	718	126 (18)	416	52 (13)	1150	181 (16)
Other Oceania	20	7 (35)	15	4 (27)	38	12 (32)
Asia	6	1 (17)	5	2 (40)	11	3 (27)
UK & Ireland	36	6 (17)	14	1 (7)	50	7 (14)
Other	30	5 (17)	14	2 (14)	44	7 (16)
p value		0.391		0.187		0.093
2022						
Australia	912	111 (12)	489	52 (11)	1434	167 (12)
Other Oceania	34	6 (18)	12	1 (8)	47	8 (17)
Asia	12	2 (17)	10	1 (10)	22	3 (14)
UK & Ireland	32	3 (9)	22	2 (9)	55	5 (9)
Other	51	9 (18)	13	1 (8)	64	10 (16)
p value		0.512		1.000		0.559
2023						
Australia	917	124 (14)	528	52 (10)	1472	177 (12)
Other Oceania	28	2 (7)	23	1 (4)	52	3 (6)
Asia	12	1 (8)	2	0 (0)	14	1 (7)
UK & Ireland	32	9 (28)	10	0 (0)	43	9 (21)
Other	37	2 (5)	11	1 (9)	48	3 (6)
p value		0.056		0.870		0.162

Australian Capital Territory

Table 2.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Australian Capital Territory	2019	2020*	2021*	2022	2023
Number of sites	1	1	1	1	1
N° surveyed	N=128	N=104	N=100	N=100	N=109
Response rate (%)	71%	67%	68%	67%	56%
Gender (%)					
Male	86 (67)	70 (67)	68 (68)	67 (67)	68 (62)
Female	42 (33)	33 (32)	32 (32)	32 (32)	38 (35)
Other	0 (0)	1 (1)	0 (0)	1 (1)	3 (3)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	93 (73)	84 (81)	87 (87)	81 (81)	85 (78)
Bisexual	13 (10)	11 (11)	7 (7)	11 (11)	11 (10)
Gay/Lesbian	4 (3)	2 (2)	4 (4)	1 (1)	4 (4)
Other	-- --	3 (3)	1 (1)	7 (7)	9 (8)
Not reported	18 (14)	4 (4)	1 (1)	0 (0)	
Aboriginal and Torres Strait Islander origin (%)					
No	106 (83)	82 (79)	68 (68)	71 (71)	77 (71)
Yes	21 (16)	19 (18)	29 (29)	27 (27)	30 (28)
Not reported	1 (1)	3 (3)	3 (3)	2 (2)	2 (2)
Region/country of birth (%)					
Australia	113 (88)	93 (89)	91 (91)	85 (85)	100 (92)
Other Oceania	6 (5)	3 (3)	2 (2)	5 (5)	1 (1)
Asia	0 (0)	1 (1)	0 (0)	2 (2)	2 (2)
UK & Ireland	4 (3)	3 (3)	3 (3)	4 (4)	1 (1)
Other	5 (4)	2 (2)	4 (4)	1 (1)	3 (3)
Not reported	0 (0)	2 (2)	0 (0)	3 (3)	2 (2)
Main language spoken at home by parents (%)					
English	119 (93)	99 (95)	95 (95)	94 (94)	102 (94)
Non-English	9 (7)	5 (5)	5 (5)	4 (4)	6 (6)
Not reported	0 (0)	0 (0)	0 (0)	2 (2)	1 (1)
Age and time since first injection (years)					
<i>Median age</i>	42	44	42.5	45	46
<i>Age range</i>	18-66	23-63	21-65	25-62	23-68
Age group (%)					
<25 years	5 (4)	1 (1)	2 (2)	0 (0)	1 (1)
25+ years	123 (96)	103 (99)	98 (98)	100 (100)	107 (98)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Median age first injection					
<i>Median age first injection</i>	18	18	19	19	19
<i>Age range</i>	11-43	11-53	12-65	10-60	10-49
<i>N° not reported</i>	3	3	4	3	4
Median yrs since first injection					
<i>Median yrs since first injection</i>	24	24	23	23	25
<i>Range</i>	<1-46	<1-47	<1-43	<1-42	<1-47
Years since first injection					
<3 years	8 (6)	4 (4)	10 (10)	8 (8)	4 (4)
3+ years	117 (91)	97 (93)	86 (86)	89 (89)	101 (93)
Not reported	3 (2)	3 (3)	4 (4)	3 (3)	4 (4)
Imprisonment last year (%)					
No	104 (81)	84 (81)	81 (81)	89 (89)	96 (88)
Yes	19 (15)	15 (14)	12 (12)	9 (9)	8 (7)
Not reported	5 (4)	5 (5)	7 (7)	2 (2)	5 (5)
N° in prison					
<i>N° in prison</i>	N=19	N=15	N=12	N=9	N=8
<i>Injected in prison</i>	5 (26)	3 (20)	8 (67)	3 (33)	5 (63)

* Implementation of the 2020 and 2021 ANSPS was impacted by the COVID-19 pandemic, see page 1 for more information

Table 2.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

Australian Capital Territory	2019	2020	2021	2022	2023
N° surveyed	N=128	N=104	N=100	N=100	N=109
Drug last injected (%)					
Cocaine	0 (0)	2 (2)	1 (1)	0 (0)	1 (1)
Methamphetamine	58 (45)	39 (38)	40 (40)	42 (42)	52 (48)
Heroin	59 (46)	50 (48)	44 (44)	44 (44)	48 (44)
Pharm. opioids	2 (2)	3 (3)	0 (0)	0 (0)	1 (1)
Methadone	5 (4)	4 (4)	6 (6)	2 (2)	2 (2)
Buprenorphine	0 (0)	1 (1)	0 (0)	0 (0)	2 (2)
Buprenorphine/naloxone	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
PIEDs	0 (0)	1 (1)	1 (1)	1 (1)	1 (1)
More than one	4 (3)	3 (3)	7 (7)	7 (7)	2 (2)
Other	0 (0)	0 (0)	0 (0)	3 (3)	0 (0)
Not reported	0 (0)	1 (1)	1 (1)	1 (1)	0 (0)
Ever injected opioids					
No	8 (6)	11 (11)	15 (15)	14 (14)	16 (15)
Yes	120 (94)	93 (89)	84 (84)	86 (86)	91 (83)
Not reported	0 (0)	0 (0)	1 (1)	0 (0)	2 (2)
Frequency of injection last month (%)					
Not last month	10 (8)	7 (7)	7 (7)	3 (3)	6 (6)
Less than weekly	18 (14)	14 (13)	16 (16)	17 (17)	14 (13)
Weekly not daily	32 (25)	24 (23)	17 (17)	24 (24)	28 (26)
Daily or more	66 (52)	59 (57)	58 (58)	54 (54)	58 (53)
Not reported	2 (2)	0 (0)	2 (2)	2 (2)	3 (3)
Present when someone injected for the first time in the last 12 months (%)					
No	111 (87)	89 (86)	83 (83)	90 (90)	93 (85)
Yes	15 (12)	11 (11)	16 (16)	9 (9)	13 (12)
Not reported	2 (2)	4 (4)	1 (1)	1 (1)	3 (3)
Overdosed in last 12 months					
No	101 (79)	77 (74)	79 (79)	80 (80)	88 (81)
Yes	26 (20)	23 (22)	19 (19)	18 (18)	20 (18)
Not reported	1 (1)	4 (4)	2 (2)	2 (2)	1 (1)

Table 2.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

Australian Capital Territory	2019	2020	2021	2022	2023
N° injected last month	N=116	N=97	N=91	N=95	N=100
Places injected last month (%)					
All private	53 (46)	39 (40)	56 (62)	52 (55)	53 (53)
Any public	61 (53)	58 (60)	35 (38)	43 (45)	47 (47)
Not reported	2 (2)	0 (0)	0 (0)	0 (0)	0 (0)
Use of new and sterile needles and syringes last month (%)					
All injections	86 (74)	73 (75)	70 (77)	74 (78)	65 (65)
Most of the time	25 (22)	18 (19)	20 (22)	17 (18)	29 (29)
Half of the time	2 (2)	3 (3)	0 (0)	3 (3)	3 (3)
Some of the time	0 (0)	0 (0)	1 (1)	1 (1)	2 (2)
Not last month	1 (1)	1 (1)	0 (0)	0 (0)	0 (0)
Not reported	2 (2)	2 (2)	0 (0)	0 (0)	1 (1)
Re-used someone else's used needle & syringe last month (%)					
None	99 (85)	79 (81)	71 (78)	80 (84)	74 (74)
Once	7 (6)	8 (8)	4 (4)	1 (1)	11 (11)
Twice	3 (3)	1 (1)	6 (7)	4 (4)	5 (5)
3-5 times	4 (3)	7 (7)	1 (1)	5 (5)	6 (6)
>5 times	2 (2)	1 (1)	8 (9)	5 (5)	4 (4)
Not reported	1 (1)	1 (1)	1 (1)	0 (0)	0 (0)
Number of people needle & syringe was re-used after last month (%)					
None	99 (85)	79 (81)	71 (78)	80 (84)	74 (74)
One	4 (3)	8 (8)	7 (8)	5 (5)	9 (9)
Two	3 (3)	1 (1)	3 (3)	3 (3)	2 (2)
Three to five	1 (1)	0 (0)	0 (0)	2 (2)	1 (1)
More than five	0 (0)	0 (0)	2 (2)	0 (0)	2 (2)
Don't know	5 (4)	8 (8)	6 (7)	3 (3)	11 (11)
Not reported	4 (3)	1 (1)	2 (2)	2 (2)	1 (1)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	5 (4)	3 (3)	8 (9)	7 (7)	7 (7)
Casual sex partner	1 (1)	1 (1)	1 (1)	0 (0)	2 (2)
Close friend	4 (3)	9 (9)	4 (4)	1 (1)	9 (9)
Acquaintance	2 (2)	4 (4)	2 (2)	2 (2)	7 (7)
Other	3 (3)	0 (0)	1 (1)	3 (3)	4 (4)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	27 (23)	24 (25)	29 (32)	29 (31)	23 (23)
Water	14 (12)	12 (12)	21 (23)	14 (15)	17 (17)
Filter	7 (6)	9 (9)	12 (13)	9 (9)	8 (8)
Drug mix	9 (8)	8 (8)	11 (12)	16 (17)	10 (10)
None	79 (68)	65 (67)	58 (64)	63 (66)	69 (69)
Injected by someone after that person injected themselves or others last month (%)					
No	102 (88)	86 (89)	74 (81)	82 (86)	82 (82)
Yes	13 (11)	11 (11)	16 (18)	13 (14)	18 (18)
Not reported	1 (1)	0 (0)	1 (1)	0 (0)	0 (0)
Source of needle acquisition					
Needle Syringe Program	108 (93)	86 (89)	75 (82)	84 (88)	93 (93)
Chemist/Pharmacy	33 (28)	26 (27)	25 (27)	23 (24)	28 (28)
Personal sources	17 (15)	17 (18)	14 (15)	19 (20)	22 (22)
Dispensing/Vending Machine	32 (28)	17 (18)	9 (10)	16 (17)	16 (16)
Other sources	3 (3)	3 (3)	3 (3)	2 (2)	0 (0)

Table 2.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Australian Capital Territory	2019	2020	2021	2022	2023
N° surveyed	N=128	N=104	N=100	N=100	N=109
Ever any treatment/therapy for drug use (%)					
No	26 (20)	21 (20)	20 (20)	26 (26)	17 (16)
Yes	101 (80)	83 (80)	80 (80)	74 (74)	92 (84)
Not reported	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)
History of methadone maintenance treatment (%)					
Currently	49 (38)	33 (32)	39 (39)	37 (37)	25 (23)
Previously	32 (25)	23 (22)	26 (26)	18 (18)	40 (37)
Never	43 (34)	45 (43)	33 (33)	44 (44)	43 (39)
Not reported	4 (3)	3 (3)	2 (2)	1 (1)	1 (1)
History of buprenorphine (Subutex®) treatment (%)					
Currently	5 (4)	7 (7)	5 (5)	9 (9)	12 (11)
Previously	29 (23)	35 (34)	38 (38)	28 (28)	42 (39)
Never	91 (71)	60 (58)	56 (56)	63 (63)	53 (49)
Not reported	3 (2)	2 (2)	1 (1)	0 (0)	2 (2)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	9 (7)	3 (3)	5 (5)	5 (5)	7 (6)
Previously	28 (22)	29 (28)	34 (34)	31 (31)	44 (40)
Never	88 (69)	72 (69)	60 (60)	63 (63)	57 (52)
Not reported	3 (2)	0 (0)	1 (1)	1 (1)	1 (1)
History of depot buprenorphine treatment (%)					
Currently	-- --	5 (5)	9 (9)	16 (16)	16 (15)
Previously	-- --	7 (7)	10 (10)	13 (13)	17 (16)
Never	-- --	52 (50)	80 (80)	71 (71)	74 (68)
Not reported	-- --	40 (38)	1 (1)	0 (0)	2 (2)

Table 2.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

Australian Capital Territory	2019	2020	2021	2022	2023
N° surveyed	N=128	N=104	N=100	N=100	N=109
Previous HIV test (%)					
Yes, ever	113 (88)	85 (82)	82 (82)	83 (83)	93 (85)
Yes, last year	70 (55)	49 (47)	44 (44)	51 (51)	52 (48)
>1 year ago	43 (34)	36 (35)	38 (38)	32 (32)	41 (38)
Never tested	12 (9)	14 (13)	16 (16)	17 (17)	13 (12)
Not reported	3 (2)	5 (5)	2 (2)	0 (0)	3 (3)
Previous HCV test (%)					
Yes, ever	116 (91)	87 (84)	80 (80)	85 (85)	95 (87)
Yes, last year	80 (63)	48 (46)	46 (46)	58 (58)	60 (55)
>1 year ago	36 (28)	39 (38)	34 (34)	27 (27)	35 (32)
Never tested	4 (3)	8 (8)	7 (7)	11 (11)	5 (5)
Not reported	8 (6)	9 (9)	13 (13)	4 (4)	9 (8)
Lifetime treatment for HCV (%)#					
N° self-reported HCV diagnosis	N=50	N=29	N=24	N=23	N=36
Antiviral treatment	33 (66)	16 (55)	11 (46)	16 (70)	27 (75)
No antiviral treatment	17 (34)	12 (41)	13 (54)	7 (30)	9 (25)
Not reported	0 (0)	1 (3)	0 (0)	0 (0)	0 (0)
Treatment for HCV in past 12 months (%)**					
N° self-reported HCV diagnosis	N=37	N=18	N=18	N=15	N=17
Antiviral treatment	17 (46)	2 (11)	4 (22)	6 (40)	4 (24)
No antiviral treatment	20 (54)	15 (83)	14 (78)	9 (60)	13 (76)
Not reported	0 (0)	1 (6)	0 (0)	0 (0)	0 (0)

among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

Table 2.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

Australian Capital Territory	2019	2020	2021	2022	2023
N° surveyed	N=128	N=104	N=100	N=100	N=109
Sex with a regular partner last month (%)					
No	78 (61)	69 (66)	62 (62)	59 (59)	69 (63)
Yes	46 (36)	31 (30)	35 (35)	41 (41)	39 (36)
Not reported	4 (3)	4 (4)	3 (3)	0 (0)	1 (1)
Condom used with regular partner last month (%)					
N° surveyed	N=46	N=31	N=35	N=41	N=39
Never	38 (83)	25 (81)	23 (66)	32 (78)	29 (74)
Sometimes	3 (7)	4 (13)	1 (3)	5 (12)	6 (15)
Every time	3 (7)	1 (3)	6 (17)	3 (7)	3 (8)
Not reported	2 (4)	1 (3)	5 (14)	1 (2)	1 (3)
Sex with other partner(s) last month (%)					
No	115 (90)	95 (91)	86 (86)	91 (91)	97 (89)
Yes	11 (9)	5 (5)	10 (10)	5 (5)	10 (9)
Not reported	2 (2)	4 (4)	4 (4)	4 (4)	2 (2)
Condom used with other partner(s) last month (%)					
N° surveyed	N=11	N=5	N=10	N=5	N=10
Never	7 (64)	2 (40)	5 (50)	3 (60)	5 (50)
Sometimes	1 (9)	3 (60)	2 (20)	0 (0)	4 (40)
Every time	2 (18)	0 (0)	3 (30)	2 (40)	1 (10)
Not reported	1 (9)	0 (0)	0 (0)	0 (0)	0 (0)
Sex work last month (%)					
No	117 (91)	97 (93)	93 (93)	98 (98)	98 (90)
Yes	5 (4)	4 (4)	5 (5)	2 (2)	5 (5)
Not reported	6 (5)	3 (3)	2 (2)	0 (0)	6 (6)
Condom used at last sex work (%)					
Yes	4 (80)	1 (25)	1 (20)	2 (100)	4 (80)

Table 2.1.7 Number (percentage) of respondents by COVID-19 related impacts, 2020-2023

Australian Capital Territory	2020	2021	2022	2023
N° surveyed	N=104	N=100	N=100	N=109
COVID-19 test				
Yes	27 (26)	56 (56)	89 (89)	91 (83)
No	71 (68)	23 (23)	10 (10)	16 (15)
Don't know	5 (5)	5 (5)	-- --	-- --
Not reported	1 (1)	16 (16)	1 (1)	2 (2)
Self-reported positive COVID-19 test result				
Yes	0 (0)	10 (10)	33 (37)	31 (34)
Yes, last 12 months	-- --	-- --	28 (31)	17 (19)
Yes, more than a year ago	-- --	-- --	5 (6)	14 (15)
COVID-19 vaccine uptake				
≥1 dose	-- --	82 (82)	85 (85)	91 (83)
COVID-19 vaccine doses				
One dose	-- --	11 (11)	5 (5)	7 (6)
Two doses	-- --	71 (71)	27 (27)	24 (22)
Three or more doses	-- --	-- --	53 (53)	60 (55)
No doses	-- --	12 (12)	14 (14)	16 (15)
Not reported	-- --	6 (6)	1 (1)	2 (2)
Vaccine type *			N=85	
Astra Zeneca	-- --	17 (17)	30 (35)	-- --
Pfizer	-- --	46 (46)	46 (54)	-- --
Don't know	-- --	4 (4)	16 (19)	-- --
Other	-- --	-- --	14 (16)	-- --
Not reported	-- --	33 (33)	-- --	-- --
* 2021 only one response permitted, 2022 multiple responses permitted				
Last vaccine location			N=100	N=109
GP or medical centre	-- --	-- --	46 (46)	46 (42)
Pharmacy/ chemist	-- --	-- --	14 (14)	16 (15)
Vaccine hub	-- --	-- --	7 (7)	8 (7)
Opioid treatment/ methadone clinic	-- --	-- --	0 (0)	1 (1)
NSP	-- --	-- --	5 (5)	5 (5)
Prison	-- --	-- --	4 (4)	7 (6)
Multiple response	-- --	-- --	4 (4)	3 (3)
Other	-- --	-- --	9 (9)	8 (7)
Not reported	-- --	-- --	11 (11)	15 (14)
Vaccine hesitancy - if not had three or more doses				
Haven't got around to it	-- --	-- --	19 (19)	12 (11)
Difficulty booking appointment	-- --	-- --	2 (2)	3 (3)
Concerns about side effects	-- --	-- --	4 (4)	10 (9)
Concerns about vaccine safety	-- --	-- --	3 (3)	6 (6)
Not at risk of serious illness	-- --	-- --	11 (11)	14 (13)
Other	-- --	-- --	18 (18)	10 (9)
Multiple response	-- --	-- --	4 (4)	2 (2)
Not reported	-- --	-- --	39 (39)	52 (48)

HIV antibody prevalence

Table 2.2.1 HIV antibody prevalence by gender and survey year

Aust. Capital Territory	Male		Female		Total	
Survey year	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2019	84	0 (0.0)	42	0 (0.0)	126	0 (0.0)
2020	69	0 (0.0)	33	0 (0.0)	103	0 (0.0)
2021	67	0 (0.0)	32	0 (0.0)	99	0 (0.0)
2022	66	1 (1.5)	32	0 (0.0)	99	1 (1.0)
2023	65	0 (0.0)	34	0 (0.0)	101	0 (0.0)
X ² p trend		0.437		--		0.446

HCV antibody prevalence

Table 2.3.1 HCV antibody prevalence by gender and survey year

Aust. Capital Territory	Male		Female		Total	
Survey year	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019	84	38 (45)	42	23 (55)	126	61 (48)
2020	69	32 (46)	33	19 (58)	103	51 (50)
2021	67	27 (40)	32	9 (28)	99	36 (36)
2022	67	25 (37)	32	10 (31)	100	35 (35)
2023*	65	45 (69)	34	22 (65)	101	68 (67)
X ² p trend		0.054		0.870		0.163

* Antibody testing assay changed in 2023. See Appendix B: Methodological Notes

Table 2.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Aust. Capital Territory	Male		Female		Total	
Sexual identity	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019						
Heterosexual	64	28 (44)	27	15 (56)	91	43 (47)
Bisexual	5	3 (60)	8	5 (63)	13	8 (62)
Homosexual	3	3 (100)	1	0 (0)	4	3 (75)
p value		0.158		0.495		0.401
2020						
Heterosexual	63	28 (44)	21	12 (57)	84	40 (48)
Bisexual	5	3 (60)	5	3 (60)	10	6 (60)
Homosexual	0	0 (0)	2	1 (50)	2	1 (50)
p value		0.653		0.580		0.381
2021						
Heterosexual	62	25 (40)	24	7 (29)	86	32 (37)
Bisexual	3	2 (67)	4	2 (50)	7	4 (57)
Homosexual	2	0 (0)	2	0 (0)	4	0 (0)
p value		0.490		0.717		0.260
2022						
Heterosexual	60	23 (38)	21	7 (33)	81	30 (37)
Bisexual	3	0 (0)	8	2 (25)	11	2 (18)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.124		0.557		0.187
2023						
Heterosexual	57	40 (70)	22	15 (68)	79	55 (70)
Bisexual	3	1 (33)	8	4 (50)	11	5 (45)
Homosexual	1	1 (100)	2	1 (50)	3	2 (67)
p value		0.396		0.833		0.327

Table 2.3.3 HCV antibody prevalence by age group, gender and survey year

Aust. Capital Territory Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
<25 years	1	0 (0)	4	2 (50)	5	2 (40)
25-34 years	9	1 (11)	10	6 (60)	19	7 (37)
35-44 years	33	16 (48)	14	6 (43)	47	22 (47)
45+ years	41	21 (51)	14	9 (64)	55	30 (55)
p value		0.097		0.777		0.602
2020						
<25 years	0	0 (0)	1	1 (100)	1	1 (100)
25-34 years	9	2 (22)	5	4 (80)	15	6 (40)
35-44 years	23	8 (35)	15	8 (53)	38	16 (42)
45+ years	37	22 (59)	12	6 (50)	49	28 (57)
p value		0.059		0.668		0.298
2021						
<25 years	0	0 (0)	2	1 (50)	2	1 (50)
25-34 years	15	5 (33)	5	1 (20)	20	6 (30)
35-44 years	23	11 (48)	11	4 (36)	34	15 (44)
45+ years	29	11 (38)	14	3 (21)	43	14 (33)
p value		0.634		0.764		0.579
2022						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	8	1 (13)	9	1 (11)	18	2 (11)
35-44 years	23	11 (48)	8	2 (25)	31	13 (42)
45+ years	36	13 (36)	15	7 (47)	51	20 (39)
p value		0.232		0.204		0.053
2023						
<25 years	1	0 (0)	0	0 (0)	1	0 (0)
25-34 years	6	1 (17)	7	6 (86)	14	7 (50)
35-44 years	19	16 (84)	13	8 (62)	32	24 (75)
45+ years	39	28 (72)	14	8 (57)	53	36 (68)
p value		0.006		0.525		0.160

Table 2.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Aust. Capital Territory Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
<3 years	3	0 (0)	5	0 (0)	8	0 (0)
3 to 10 years	6	1 (17)	6	5 (83)	12	6 (50)
11+ years	73	36 (49)	30	17 (57)	103	53 (51)
p value		0.108		0.016		0.014
2020						
<3 years	3	0 (0)	1	0 (0)	4	0 (0)
3 to 10 years	6	1 (17)	2	2 (100)	8	3 (38)
11+ years	59	31 (53)	28	15 (54)	88	46 (52)
p value		0.069		0.337		0.122
2021						
<3 years	5	1 (20)	5	2 (40)	10	3 (30)
3 to 10 years	4	1 (25)	4	1 (25)	8	2 (25)
11+ years	57	24 (42)	20	6 (30)	77	30 (39)
p value		0.649		1.000		0.785
2022						
<3 years	4	0 (0)	4	0 (0)	8	0 (0)
3 to 10 years	6	0 (0)	6	3 (50)	12	3 (25)
11+ years	57	25 (44)	20	6 (30)	77	31 (40)
p value		0.031		0.344		0.046
2023						
<3 years	2	1 (50)	1	0 (0)	3	1 (33)
3 to 10 years	6	3 (50)	5	3 (60)	11	6 (55)
11+ years	56	40 (71)	28	19 (68)	84	59 (70)
p value		0.328		0.565		0.228

Table 2.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Aust. Capital Territory Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
No receptive sharing	8	0 (0)	87	45 (52)	97	46 (47)
Receptive sharing	0	0 (0)	15	8 (53)	16	9 (56)
p value		--		0.908		0.513
2020						
No receptive sharing	4	0 (0)	73	36 (49)	78	36 (46)
Receptive sharing	0	0 (0)	15	9 (60)	17	11 (65)
p value		--		0.451		0.166
2021						
No receptive sharing	7	2 (29)	60	24 (40)	70	27 (39)
Receptive sharing	2	1 (50)	17	8 (47)	19	9 (47)
p value		1.000		0.602		0.488
2022						
No receptive sharing	7	0 (0)	70	24 (34)	80	25 (31)
Receptive sharing	0	0 (0)	15	8 (53)	15	8 (53)
p value		--		0.167		0.099
2023						
No receptive sharing	2	0 (0)	62	38 (61)	67	40 (60)
Receptive sharing	1	1 (100)	25	22 (88)	26	23 (88)
p value		0.333		0.020		0.007

Table 2.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

Aust. Capital Territory Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
Heroin	2	0 (0)	53	32 (60)	57	33 (58)
Methamphetamine	5	0 (0)	50	19 (38)	56	20 (36)
Other opioids	1	0 (0)	6	3 (50)	7	3 (43)
Other drugs	0	0 (0)	4	3 (75)	4	3 (75)
p value		--		0.104		0.076
2020						
Heroin	1	0 (0)	46	28 (61)	50	30 (60)
Methamphetamine	3	0 (0)	35	16 (46)	38	16 (42)
Other opioids	0	0 (0)	8	3 (38)	8	3 (38)
Other drugs	0	0 (0)	7	2 (29)	7	2 (29)
p value		--		0.243		0.193
2021						
Heroin	2	0 (0)	39	14 (36)	43	15 (35)
Methamphetamine	5	0 (0)	32	12 (38)	39	12 (31)
Other opioids	2	2 (100)	3	1 (33)	5	3 (60)
Other drugs	0	0 (0)	9	5 (56)	9	5 (56)
p value		0.011		0.738		0.361
2022						
Heroin	1	0 (0)	42	22 (52)	44	22 (50)
Methamphetamine	6	0 (0)	33	7 (21)	41	8 (20)
Other opioids	0	0 (0)	2	1 (50)	2	1 (50)
Other drugs	1	0 (0)	9	2 (22)	10	2 (20)
p value		--		0.033		0.019
2023						
Heroin	0	0 (0)	44	36 (82)	44	36 (82)
Methamphetamine	2	1 (50)	41	20 (49)	45	22 (49)
Other opioids	0	0 (0)	4	3 (75)	5	4 (80)
Other drugs	1	0 (0)	3	3 (100)	4	3 (75)
p value		0.386		0.007		0.010

Table 2.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Aust. Capital Territory Frequency of injection last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
Less than daily	6	0 (0)	42	22 (52)	50	24 (48)
Daily or more	2	0 (0)	61	31 (51)	64	31 (48)
Not last month	0	0 (0)	10	4 (40)	10	4 (40)
p value		--		0.850		0.926
2020						
Less than daily	1	0 (0)	36	11 (31)	37	11 (30)
Daily or more	3	0 (0)	53	35 (66)	59	37 (63)
Not last month	0	0 (0)	7	3 (43)	7	3 (43)
p value		--		0.003		0.005
2021						
Less than daily	4	1 (25)	27	5 (19)	32	6 (19)
Daily or more	5	2 (40)	51	27 (53)	58	30 (52)
Not last month	1	0 (0)	5	0 (0)	7	0 (0)
p value		1.000		0.001		0.001
2022						
Less than daily	4	0 (0)	35	15 (43)	41	16 (39)
Daily or more	3	0 (0)	50	17 (34)	54	17 (31)
Not last month	1	0 (0)	2	1 (50)	3	1 (33)
p value		--		0.627		0.782
2023						
Less than daily	2	1 (50)	36	18 (50)	39	19 (49)
Daily or more	1	0 (0)	51	42 (82)	54	44 (81)
Not last month	0	0 (0)	5	2 (40)	5	2 (40)
p value		1.000		0.002		0.001

Table 2.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Aust. Capital Territory Imprisonment last year	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
No imprisonment	6	0 (0)	95	50 (53)	102	51 (50)
Imprisonment	2	0 (0)	15	6 (40)	19	7 (37)
p value		--		0.363		0.292
2020						
No imprisonment	3	0 (0)	80	38 (48)	83	38 (46)
Imprisonment	1	0 (0)	12	7 (58)	15	9 (60)
p value		--		0.310		0.310
2021						
No imprisonment	8	3 (38)	68	25 (37)	80	29 (36)
Imprisonment	1	0 (0)	11	3 (27)	12	3 (25)
p value		1.000		0.738		0.532
2022						
No imprisonment	8	0 (0)	78	30 (38)	89	31 (35)
Imprisonment	0	0 (0)	9	3 (33)	9	3 (33)
p value		--		1.000		1.000
2023						
No imprisonment	3	1 (33)	85	56 (66)	90	59 (66)
Imprisonment	0	0 (0)	7	7 (100)	7	7 (100)
p value		--		0.093		0.093

Table 2.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aust. Capital Territory Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
Non Indigenous	73	34 (47)	31	16 (52)	104	50 (48)
Indigenous	10	4 (40)	11	7 (64)	21	11 (52)
p value		0.748		0.726		0.719
2020						
Non Indigenous	57	22 (39)	23	11 (48)	81	33 (41)
Indigenous	10	8 (80)	9	7 (78)	19	15 (79)
p value		0.034		0.235		0.004
2021						
Non Indigenous	49	18 (37)	19	5 (26)	68	23 (34)
Indigenous	16	9 (56)	12	3 (25)	28	12 (43)
p value		0.169		1.000		0.403
2022						
Non Indigenous	53	21 (40)	18	6 (33)	71	27 (38)
Indigenous	13	3 (23)	13	3 (23)	27	6 (22)
p value		0.345		0.696		0.139
2023						
Non Indigenous	52	33 (63)	22	13 (59)	74	46 (62)
Indigenous	11	10 (91)	12	9 (75)	25	20 (80)
p value		0.151		0.465		0.102

Table 2.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Aust. Capital Territory Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
English speaking	78	38 (49)	39	20 (51)	117	58 (50)
Non-English speaking	6	0 (0)	3	3 (100)	9	3 (33)
p value		0.030		0.102		0.494
2020						
English speaking	64	29 (45)	33	19 (58)	98	48 (49)
Non-English speaking	5	3 (60)	0	0 (0)	5	3 (60)
p value		0.657		--		0.678
2021						
English speaking	65	26 (40)	29	7 (24)	94	33 (35)
Non-English speaking	2	1 (50)	3	2 (67)	5	3 (60)
p value		1.000		0.184		0.350
2022						
English speaking	63	22 (35)	31	10 (32)	94	32 (34)
Non-English speaking	3	2 (67)	1	0 (0)	4	2 (50)
p value		0.548		1.000		0.608
2023						
English speaking	60	40 (67)	32	20 (63)	94	61 (65)
Non-English speaking	4	4 (100)	2	2 (100)	6	6 (100)
p value		0.300		0.529		0.174

Table 2.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

Aust. Capital Territory	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
Australia	72	33 (46)	39	21 (54)	111	54 (49)
Other Oceania	3	2 (67)	3	2 (67)	6	4 (67)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	4	2 (50)	0	0 (0)	4	2 (50)
Other	5	1 (20)	0	0 (0)	5	1 (20)
p value		0.618		1.000		0.520
2020						
Australia	60	27 (45)	31	18 (58)	92	45 (49)
Other Oceania	3	1 (33)	0	0 (0)	3	1 (33)
Asia	1	1 (100)	0	0 (0)	1	1 (100)
UK & Ireland	1	1 (100)	2	1 (50)	3	2 (67)
Other	2	2 (100)	0	0 (0)	2	2 (100)
p value		0.315		1.000		0.636
2021						
Australia	62	23 (37)	28	7 (25)	90	30 (33)
Other Oceania	2	2 (100)	0	0 (0)	2	2 (100)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	2	1 (50)	1	0 (0)	3	1 (33)
Other	1	1 (100)	3	2 (67)	4	3 (75)
p value		0.128		0.421		0.070
2022						
Australia	56	19 (34)	28	9 (32)	85	28 (33)
Other Oceania	5	3 (60)	0	0 (0)	5	3 (60)
Asia	1	0 (0)	1	0 (0)	2	0 (0)
UK & Ireland	2	0 (0)	2	0 (0)	4	0 (0)
Other	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.402		1.000		0.177
2023						
Australia	58	40 (69)	32	21 (66)	92	62 (67)
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)
Asia	1	1 (100)	1	0 (0)	2	1 (50)
UK & Ireland	1	1 (100)	0	0 (0)	1	1 (100)
Other	2	0 (0)	1	1 (100)	3	1 (33)
p value		0.312		0.588		0.713

HCV RNA prevalence

Table 2.4.1 HCV RNA prevalence by gender and survey year

Australian Capital Territory	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*	77	16 (21)	38	10 (26)	115	25 (22)
2020	60	13 (22)	30	5 (17)	91	18 (20)
2021	62	14 (23)	32	6 (19)	94	20 (21)
2022	65	7 (11)	31	3 (10)	97	10 (10)
2023	63	17 (27)	34	5 (15)	99	22 (22)
X ² p trend		0.946		0.130		0.478

* 2019: Weighted for gender and HCV antibody status

Totals include respondents where gender was reported as other or not reported

Table 2.4.2 HCV RNA prevalence by sexual identity, gender and survey year

Australian Capital Territory	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
Heterosexual	61	12 (20)	25	6 (24)	85	17 (20)
Bisexual	4	1 (25)	8	2 (25)	12	3 (25)
Homosexual	3	1 (33)	1	0 (0)	4	1 (25)
p value		0.823		0.856		0.924
2020						
Heterosexual	55	12 (22)	19	2 (11)	74	14 (19)
Bisexual	4	1 (25)	4	2 (50)	8	3 (38)
Homosexual	0	0 (0)	2	0 (0)	2	0 (0)
p value		0.882		0.120		0.356
2021						
Heterosexual	57	13 (23)	24	4 (17)	81	17 (21)
Bisexual	3	1 (33)	4	2 (50)	7	3 (43)
Homosexual	2	0 (0)	2	0 (0)	4	0 (0)
p value		0.676		0.233		0.226
2022						
Heterosexual	58	6 (10)	20	2 (10)	78	8 (10)
Bisexual	3	0 (0)	8	1 (13)	11	1 (9)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.394		1.000		0.533
2023						
Heterosexual	56	15 (27)	22	5 (23)	78	20 (26)
Bisexual	3	1 (33)	8	0 (0)	11	1 (9)
Homosexual	1	0 (0)	2	0 (0)	3	0 (0)
p value		0.780		0.635		0.657

Table 2.4.3 HCV RNA prevalence by age group, gender and survey year

Australian Capital Territory	Male		Female		Total	
Age group	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
<25 years	1	0 (0)	4	1 (25)	5	1 (20)
25-34 years	8	1 (13)	9	5 (56)	17	6 (35)
35-44 years	32	7 (22)	12	2 (17)	44	9 (20)
45+ years	35	8 (23)	13	2 (15)	49	10 (20)
p value		0.858		0.128		0.650
2020						
<25 years	0	0 (0)	1	0 (0)	1	0 (0)
25-34 years	9	0 (0)	5	2 (40)	15	2 (13)
35-44 years	19	3 (16)	12	3 (25)	31	6 (19)
45+ years	32	10 (31)	12	0 (0)	44	10 (23)
p value		0.100		0.160		0.829
2021						
<25 years	0	0 (0)	2	1 (50)	2	1 (50)
25-34 years	14	5 (36)	5	1 (20)	19	6 (32)
35-44 years	21	5 (24)	11	2 (18)	32	7 (22)
45+ years	27	4 (15)	14	2 (14)	41	6 (15)
p value		0.312		0.689		0.351
2022						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	8	0 (0)	8	1 (13)	17	1 (6)
35-44 years	22	3 (14)	8	1 (13)	30	4 (13)
45+ years	35	4 (11)	15	1 (7)	50	5 (10)
p value		0.861		1.000		0.820
2023						
<25 years	1	0 (0)	0	0 (0)	1	0 (0)
25-34 years	6	0 (0)	7	1 (14)	14	1 (7)
35-44 years	19	6 (32)	13	2 (15)	32	8 (25)
45+ years	37	11 (30)	14	2 (14)	51	13 (25)
p value		0.512		1.000		0.500

Table 2.4.4 HCV RNA prevalence by years since first injection, gender and survey year

Australian Capital Territory	Male		Female		Total	
Years of injection	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
<3 years	3	0 (0)	5	0 (0)	8	0 (0)
3 to 10 years	6	0 (0)	6	4 (67)	12	4 (33)
11+ years	65	15 (23)	28	6 (21)	93	20 (22)
p value		0.278		0.027		0.222
2020						
<3 years	3	0 (0)	1	0 (0)	4	0 (0)
3 to 10 years	6	0 (0)	2	1 (50)	8	1 (13)
11+ years	50	13 (26)	25	4 (16)	76	17 (22)
p value		0.223		0.431		0.470
2021						
<3 years	5	0 (0)	5	1 (20)	10	1 (10)
3 to 10 years	4	1 (25)	4	1 (25)	8	2 (25)
11+ years	52	12 (23)	20	4 (20)	72	16 (22)
p value		0.476		0.974		0.648
2022						
<3 years	4	0 (0)	4	0 (0)	8	0 (0)
3 to 10 years	6	0 (0)	6	1 (17)	12	1 (8)
11+ years	55	7 (13)	19	2 (11)	74	9 (12)
p value		1.000		1.000		0.840
2023						
<3 years	2	0 (0)	1	0 (0)	3	0 (0)
3 to 10 years	6	1 (17)	5	1 (20)	11	2 (18)
11+ years	54	16 (30)	28	4 (14)	82	20 (24)
p value		0.824		1.000		1.000

Table 2.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Australian Capital Territory	Male		Female		Total	
Receptively shared syringe last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
No receptive sharing	55	12 (22)	33	9 (27)	88	20 (23)
Receptive sharing	14	3 (21)	1	0 (0)	15	3 (20)
p value		0.951		0.557		0.732
2020						
No receptive sharing	45	11 (24)	22	3 (14)	68	14 (21)
Receptive sharing	10	1 (10)	6	2 (33)	16	3 (19)
p value		0.317		0.264		0.869
2021						
No receptive sharing	44	9 (20)	22	3 (14)	66	12 (18)
Receptive sharing	12	5 (42)	6	3 (50)	18	8 (44)
p value		0.133		0.054		0.020
2022						
No receptive sharing	50	5 (10)	26	2 (8)	77	7 (9)
Receptive sharing	11	1 (9)	4	1 (25)	15	2 (13)
p value		1.000		0.360		0.637
2023						
No receptive sharing	42	12 (29)	23	3 (13)	67	15 (22)
Receptive sharing	16	3 (19)	8	2 (25)	24	5 (21)
p value		0.522		0.583		0.875

Table 2.4.6 HCV RNA prevalence by last drug injected, gender and survey year

Australian Capital Territory	Male		Female		Total	
Last drug injected	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
Heroin	30	6 (20)	23	7 (30)	53	12 (23)
Methamphetamine	37	8 (22)	12	2 (17)	50	10 (20)
Other opioids	5	0 (0)	2	0 (0)	7	0 (0)
Other drugs	3	1 (33)	1	1 (100)	4	2 (50)
p value		0.655		0.215		0.266
2020						
Heroin	31	6 (19)	12	2 (17)	43	8 (19)
Methamphetamine	21	5 (24)	12	2 (17)	34	7 (21)
Other opioids	2	0 (0)	5	1 (20)	7	1 (14)
Other drugs	6	2 (33)	1	0 (0)	7	2 (29)
p value		0.756		0.971		0.913
2021						
Heroin	28	5 (18)	14	2 (14)	42	7 (17)
Methamphetamine	25	7 (28)	11	2 (18)	36	9 (25)
Other opioids	4	0 (0)	1	1 (100)	5	1 (20)
Other drugs	4	2 (50)	4	1 (25)	8	3 (38)
p value		0.306		0.224		0.569
2022						
Heroin	24	3 (13)	19	3 (16)	43	6 (14)
Methamphetamine	29	2 (7)	10	0 (0)	40	2 (5)
Other opioids	2	0 (0)	0	0 (0)	2	0 (0)
Other drugs	8	1 (13)	1	0 (0)	9	1 (11)
p value		0.856		0.381		0.541
2023						
Heroin	28	8 (29)	16	3 (19)	44	11 (25)
Methamphetamine	31	6 (19)	13	1 (8)	45	7 (16)
Other opioids	1	0 (0)	1	0 (0)	3	0 (0)
Other drugs	1	1 (100)	3	1 (33)	4	2 (50)
p value		0.252		0.643		0.253

Table 2.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year

Australian Capital Territory	Male		Female		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
Less than daily	29	10 (34)	17	3 (18)	47	13 (28)
Daily or more	40	5 (13)	17	6 (35)	57	11 (19)
Not last month	5	0 (0)	4	1 (25)	9	1 (11)
p value		0.049		0.524		0.391
2020						
Less than daily	21	2 (10)	8	0 (0)	30	2 (7)
Daily or more	35	10 (29)	20	5 (25)	55	15 (27)
Not last month	4	1 (25)	2	0 (0)	6	1 (17)
p value		0.242		0.223		0.073
2021						
Less than daily	19	3 (16)	12	0 (0)	31	3 (10)
Daily or more	37	11 (30)	17	6 (35)	54	17 (31)
Not last month	5	0 (0)	2	0 (0)	7	0 (0)
p value		0.223		0.047		0.022
2022						
Less than daily	26	3 (12)	15	1 (7)	41	4 (10)
Daily or more	35	3 (9)	15	2 (13)	51	5 (10)
Not last month	3	0 (0)	0	0 (0)	3	0 (0)
p value		1.000		1.000		1.000
2023						
Less than daily	24	4 (17)	14	3 (21)	39	7 (18)
Daily or more	34	11 (32)	17	2 (12)	52	13 (25)
Not last month	3	0 (0)	2	0 (0)	5	0 (0)
p value		0.339		0.739		0.497

Table 2.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year

Australian Capital Territory	Male		Female		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
No imprisonment	56	13 (23)	35	7 (20)	91	20 (22)
Imprisonment	17	2 (12)	2	2 (100)	19	4 (21)
p value		0.305		0.011		0.928
2020						
No imprisonment	49	9 (18)	24	2 (8)	74	11 (15)
Imprisonment	8	3 (38)	5	2 (40)	13	5 (38)
p value		0.218		0.062		0.043
2021						
No imprisonment	48	9 (19)	28	6 (21)	76	15 (20)
Imprisonment	8	1 (13)	3	0 (0)	11	1 (9)
p value		0.669		0.372		0.394
2022						
No imprisonment	56	7 (13)	29	2 (7)	86	9 (10)
Imprisonment	7	0 (0)	2	1 (50)	9	1 (11)
p value		1.000		0.187		1.000
2023						
No imprisonment	56	17 (30)	31	5 (16)	88	22 (25)
Imprisonment	5	0 (0)	2	0 (0)	7	0 (0)
p value		0.309		1.000		0.195

Table 2.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Australian Capital Territory	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
Non Indigenous	67	14 (21)	29	5 (17)	96	18 (19)
Indigenous	9	2 (22)	10	5 (50)	19	7 (37)
p value		0.961		0.044		0.113
2020						
Non Indigenous	49	10 (20)	20	1 (5)	70	11 (16)
Indigenous	9	2 (22)	9	4 (44)	18	6 (33)
p value		0.902		0.009		0.091
2021						
Non Indigenous	45	7 (16)	19	4 (21)	64	11 (17)
Indigenous	15	7 (47)	12	2 (17)	27	9 (33)
p value		0.017		0.763		0.089
2022						
Non Indigenous	51	6 (12)	17	1 (6)	68	7 (10)
Indigenous	13	1 (8)	13	1 (8)	27	2 (7)
p value		1.000		1.000		1.000
2023						
Non Indigenous	51	13 (25)	22	2 (9)	73	15 (21)
Indigenous	11	3 (27)	12	3 (25)	25	6 (24)
p value		1.000		0.319		0.717

Table 2.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year

Australian Capital Territory	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
English speaking	70	16 (23)	35	9 (26)	106	24 (23)
Non-English speaking	6	0 (0)	3	1 (33)	9	1 (11)
p value		0.186		0.730		0.368
2020						
English speaking	55	11 (20)	30	5 (17)	86	16 (19)
Non-English speaking	5	2 (40)	0	0 (0)	5	2 (40)
p value		0.299		--		0.243
2021						
English speaking	60	13 (22)	29	5 (17)	89	18 (20)
Non-English speaking	2	1 (50)	3	1 (33)	5	2 (40)
p value		0.346		0.497		0.293
2022						
English speaking	61	6 (10)	30	3 (10)	91	9 (10)
Non-English speaking	3	1 (33)	1	0 (0)	4	1 (25)
p value		0.298		1.000		0.364
2023						
English speaking	59	14 (24)	32	4 (13)	93	18 (19)
Non-English speaking	4	3 (75)	2	1 (50)	6	4 (67)
p value		0.057		0.276		0.021

Table 2.4.11 HCV RNA prevalence by region/country of birth, gender and survey year

Australian Capital Territory	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
Australia	66	15 (23)	35	9 (26)	102	23 (23)
Other Oceania	3	0 (0)	3	1 (33)	6	1 (17)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	2	1 (50)	0	0 (0)	2	1 (50)
Other	5	0 (0)	0	0 (0)	5	0 (0)
p value		0.352		0.733		0.465
2020						
Australia	51	11 (22)	29	5 (17)	81	16 (20)
Other Oceania	3	0 (0)	0	0 (0)	3	0 (0)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	1	1 (100)	1	0 (0)	2	1 (50)
Other	2	1 (50)	0	0 (0)	2	1 (50)
p value		0.285		0.649		0.581
2021						
Australia	57	14 (25)	28	5 (18)	85	19 (22)
Other Oceania	2	0 (0)	0	0 (0)	2	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	2	0 (0)	1	0 (0)	3	0 (0)
Other	1	0 (0)	3	1 (33)	4	1 (25)
p value		0.663		0.717		0.695
2022						
Australia	54	5 (9)	27	3 (11)	82	8 (10)
Other Oceania	5	1 (20)	0	0 (0)	5	1 (20)
Asia	1	0 (0)	1	0 (0)	2	0 (0)
UK & Ireland	2	0 (0)	2	0 (0)	4	0 (0)
Other	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.145		1.000		0.162
2023						
Australia	57	14 (25)	32	5 (16)	91	19 (21)
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)
Asia	1	1 (100)	1	0 (0)	2	1 (50)
UK & Ireland	1	1 (100)	0	0 (0)	1	1 (100)
Other	2	0 (0)	1	0 (0)	3	0 (0)
p value		0.059		1.000		0.063

New South Wales

Table 3.1.1 Number (percentage) of respondents by demographic characteristics and survey year

New South Wales	2019	2020*	2021*	2022	2023
Number of sites	18	12	3	18	19
N° surveyed	N=553	N=338	N=46	N=420	N=415
Response rate (%)	41%	25%	40%	23%	22%
Gender (%)					
Male	397 (72)	242 (72)	29 (63)	275 (65)	277 (67)
Female	146 (26)	91 (27)	16 (35)	133 (32)	131 (32)
Other	9 (2)	5 (1)	1 (2)	10 (2)	6 (1)
Not reported	1 (<1)	0 (0)	0 (0)	2 (<1)	1 (<1)
Sexual identity (%)					
Heterosexual	397 (72)	257 (76)	32 (70)	327 (78)	326 (79)
Bisexual	69 (12)	36 (11)	5 (11)	45 (11)	43 (10)
Gay/Lesbian	38 (7)	21 (6)	7 (15)	31 (7)	29 (7)
Other	-- --	9 (3)	2 (4)	15 (4)	12 (3)
Not reported	49 (9)	15 (4)	0 (0)	2 (<1)	5 (1)
Aboriginal and Torres Strait Islander origin (%)					
No	424 (77)	252 (75)	31 (67)	315 (75)	295 (71)
Yes	118 (21)	67 (20)	11 (24)	94 (22)	115 (28)
Not reported	11 (2)	19 (6)	4 (9)	11 (3)	5 (1)
Region/country of birth (%)					
Australia	471 (85)	276 (82)	36 (78)	358 (85)	365 (88)
Other Oceania	22 (4)	9 (3)	3 (7)	14 (3)	15 (4)
Asia	9 (2)	12 (4)	1 (2)	8 (2)	5 (1)
UK & Ireland	12 (2)	9 (3)	2 (4)	9 (2)	11 (3)
Other	29 (5)	25 (7)	2 (4)	26 (6)	17 (4)
Not reported	10 (2)	7 (2)	2 (4)	5 (1)	2 (<1)
Main language spoken at home by parents (%)					
English	510 (92)	303 (90)	43 (93)	391 (93)	397 (96)
Non-English	37 (7)	28 (8)	2 (4)	22 (5)	17 (4)
Not reported	6 (1)	7 (2)	1 (2)	7 (2)	1 (<1)
Age and time since first injection (years)					
<i>Median age</i>	44	42.5	49	45	45
<i>Age range</i>	18-73	18-67	27-66	17-71	20-71
Age group (%)					
<25 years	23 (4)	10 (3)	0 (0)	21 (5)	17 (4)
25+ years	530 (96)	328 (97)	46 (100)	397 (95)	396 (95)
Not reported	0 (0)	0 (0)	0 (0)	2 (<1)	2 (<1)
Median age first injection					
<i>Median age first injection</i>	19	20	20	20	20
<i>Age range</i>	10-63	10-60	13-45	10-55	10-56
<i>N° not reported</i>	22	15	1	28	24
Median yrs since first injection					
<i>Median yrs since first injection</i>	23	22	26	24	24
<i>Range</i>	<1-59	<1-52	4-49	<1-56	<1-56
Years since first injection					
<3 years	40 (7)	27 (8)	0 (0)	37 (9)	22 (5)
3+ years	491 (89)	296 (88)	45 (98)	355 (85)	368 (89)
Not reported	22 (4)	15 (4)	1 (2)	28 (7)	25 (6)
Imprisonment last year (%)					
No	454 (82)	265 (78)	41 (89)	367 (87)	336 (81)
Yes	67 (12)	41 (12)	4 (9)	37 (9)	39 (9)
Not reported	32 (6)	32 (9)	1 (2)	16 (4)	40 (10)
N° in prison					
<i>N° in prison</i>	N=67	N=41	N=4	N=37	N=39
Injected in prison	26 (39)	15 (37)	1 (25)	10 (27)	13 (33)

* Implementation of the 2020 and 2021 ANSPS was impacted by the COVID-19 pandemic, see page 1 for more information

Table 3.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

New South Wales	2019	2020	2021	2022	2023
N° surveyed	N=553	N=338	N=46	N=420	N=415
Drug last injected (%)					
Cocaine	11 (2)	2 (1)	1 (2)	9 (2)	5 (1)
Methamphetamine	213 (39)	118 (35)	25 (54)	143 (34)	177 (43)
Heroin	172 (31)	94 (28)	16 (35)	126 (30)	98 (24)
Pharm. opioids	15 (3)	8 (2)	1 (2)	6 (1)	10 (2)
Methadone	30 (5)	32 (9)	2 (4)	32 (8)	35 (8)
Buprenorphine	8 (1)	2 (1)	0 (0)	4 (1)	1 (<1)
Buprenorphine/naloxone	3 (1)	4 (1)	0 (0)	1 (<1)	1 (<1)
PIEDs	56 (10)	47 (14)	1 (2)	69 (16)	62 (15)
More than one	24 (4)	22 (7)	0 (0)	20 (5)	18 (4)
Other	13 (2)	2 (1)	0 (0)	3 (1)	5 (1)
Not reported	8 (1)	7 (2)	0 (0)	7 (2)	3 (1)
Ever injected opioids					
No	133 (24)	109 (32)	12 (26)	113 (27)	121 (29)
Yes	418 (76)	229 (68)	34 (74)	305 (73)	293 (71)
Not reported	2 (<1)	0 (0)	0 (0)	2 (<1)	1 (<1)
Frequency of injection last month (%)					
Not last month	80 (14)	42 (12)	11 (24)	66 (16)	51 (12)
Less than weekly	85 (15)	51 (15)	9 (20)	72 (17)	56 (13)
Weekly not daily	123 (22)	84 (25)	12 (26)	97 (23)	105 (25)
Daily or more	254 (46)	155 (46)	14 (30)	175 (42)	196 (47)
Not reported	11 (2)	6 (2)	0 (0)	10 (2)	7 (2)
Present when someone injected for the first time in the last 12 months (%)					
No	432 (78)	276 (82)	40 (87)	340 (81)	326 (79)
Yes	96 (17)	47 (14)	6 (13)	71 (17)	59 (14)
Not reported	25 (5)	15 (4)	0 (0)	9 (2)	30 (7)
Overdosed in last 12 months					
No	432 (78)	287 (85)	39 (85)	363 (86)	335 (81)
Yes	92 (17)	35 (10)	7 (15)	48 (11)	48 (12)
Not reported	29 (5)	16 (5)	0 (0)	9 (2)	32 (8)

Table 3.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

New South Wales	2019	2020	2021	2022	2023
N° injected last month	N=462	N=290	N=35	N=344	N=357
Places injected last month (%)					
All private	261 (56)	184 (63)	25 (71)	220 (64)	236 (66)
Any public	200 (43)	104 (36)	10 (29)	122 (35)	119 (33)
Not reported	1 (<1)	2 (1)	0 (0)	2 (1)	2 (1)
Use of new and sterile needles and syringes last month (%)					
All injections	355 (77)	230 (79)	29 (83)	273 (79)	279 (78)
Most of the time	83 (18)	44 (15)	4 (11)	55 (16)	59 (17)
Half of the time	8 (2)	3 (1)	1 (3)	5 (1)	5 (1)
Some of the time	9 (2)	3 (1)	1 (3)	4 (1)	7 (2)
Not last month	3 (1)	1 (<1)	0 (0)	1 (<1)	4 (1)
Not reported	4 (1)	9 (3)	0 (0)	6 (2)	3 (1)
Re-used someone else's used needle & syringe last month (%)					
None	388 (84)	257 (89)	31 (89)	288 (84)	305 (85)
Once	24 (5)	11 (4)	2 (6)	17 (5)	16 (4)
Twice	17 (4)	6 (2)	1 (3)	12 (3)	16 (4)
3-5 times	16 (3)	3 (1)	1 (3)	14 (4)	4 (1)
>5 times	10 (2)	8 (3)	0 (0)	9 (3)	7 (2)
Not reported	7 (2)	5 (2)	0 (0)	4 (1)	9 (3)
Number of people needle & syringe was re-used after last month (%)					
None	388 (84)	257 (89)	31 (89)	288 (84)	305 (85)
One	26 (6)	8 (3)	2 (6)	19 (6)	19 (5)
Two	7 (2)	3 (1)	0 (0)	2 (1)	5 (1)
Three to five	5 (1)	5 (2)	0 (0)	3 (1)	0 (0)
More than five	2 (<1)	3 (1)	0 (0)	5 (1)	3 (1)
Don't know	15 (3)	6 (2)	1 (3)	13 (4)	10 (3)
Not reported	19 (4)	8 (3)	1 (3)	14 (4)	15 (4)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	19 (4)	13 (4)	0 (0)	19 (6)	15 (4)
Casual sex partner	2 (<1)	3 (1)	0 (0)	3 (1)	1 (<1)
Close friend	16 (3)	6 (2)	0 (0)	9 (3)	10 (3)
Acquaintance	12 (3)	6 (2)	2 (6)	4 (1)	8 (2)
Other	8 (2)	4 (1)	1 (3)	9 (3)	4 (1)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	100 (22)	55 (19)	4 (11)	60 (17)	62 (17)
Water	78 (17)	39 (13)	3 (9)	50 (15)	60 (17)
Filter	37 (8)	21 (7)	1 (3)	23 (7)	33 (9)
Drug mix	51 (11)	23 (8)	2 (6)	36 (10)	33 (9)
None	317 (69)	209 (72)	32 (91)	245 (71)	260 (73)
Injected by someone after that person injected themselves or others last month (%)					
No	396 (86)	238 (82)	30 (86)	286 (83)	301 (84)
Yes	64 (14)	45 (16)	5 (14)	53 (15)	53 (15)
Not reported	2 (<1)	7 (2)	0 (0)	5 (1)	3 (1)
Source of needle acquisition					
Needle Syringe Program	398 (86)	240 (83)	32 (91)	296 (86)	288 (81)
Chemist/Pharmacy	79 (17)	55 (19)	3 (9)	49 (14)	36 (10)
Personal sources	76 (16)	35 (12)	3 (9)	34 (10)	37 (10)
Dispensing/Vending Machine	159 (34)	92 (32)	12 (34)	97 (28)	98 (27)
Other sources	14 (3)	14 (5)	2 (6)	12 (3)	1 (<1)

Table 3.1.4 Number (percentage) of respondents by treatment for drug use and survey year

New South Wales	2019	2020	2021	2022	2023
N° surveyed	N=553	N=338	N=46	N=420	N=415
Ever any treatment/therapy for drug use (%)					
No	168 (30)	102 (30)	11 (24)	127 (30)	135 (33)
Yes	381 (69)	235 (70)	35 (76)	293 (70)	280 (67)
Not reported	4 (1)	1 (<1)	0 (0)	0 (0)	0 (0)
History of methadone maintenance treatment (%)					
Currently	187 (34)	90 (27)	13 (28)	115 (27)	102 (25)
Previously	103 (19)	67 (20)	6 (13)	97 (23)	89 (21)
Never	252 (46)	158 (47)	24 (52)	195 (46)	192 (46)
Not reported	11 (2)	23 (7)	3 (7)	13 (3)	32 (8)
History of buprenorphine (Subutex®) treatment (%)					
Currently	33 (6)	24 (7)	2 (4)	29 (7)	18 (4)
Previously	148 (27)	74 (22)	10 (22)	98 (23)	105 (25)
Never	363 (66)	218 (65)	30 (65)	283 (67)	261 (63)
Not reported	9 (2)	22 (7)	4 (9)	10 (2)	31 (7)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	26 (5)	17 (5)	0 (0)	18 (4)	18 (4)
Previously	126 (23)	67 (20)	10 (22)	94 (22)	72 (17)
Never	389 (70)	251 (74)	33 (72)	304 (72)	324 (78)
Not reported	12 (2)	3 (1)	3 (7)	4 (1)	1 (<1)
History of depot buprenorphine treatment (%)					
Currently	-- --	18 (5)	2 (4)	33 (8)	30 (7)
Previously	-- --	24 (7)	4 (9)	37 (9)	34 (8)
Never	-- --	153 (45)	36 (78)	341 (81)	323 (78)
Not reported	-- --	143 (42)	4 (9)	9 (2)	28 (7)

Table 3.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

New South Wales	2019	2020	2021	2022	2023
N° surveyed	N=553	N=338	N=46	N=420	N=415
Previous HIV test (%)					
Yes, ever	463 (84)	255 (75)	38 (83)	336 (80)	305 (73)
Yes, last year	274 (50)	156 (46)	22 (48)	204 (49)	182 (44)
>1 year ago	189 (34)	99 (29)	16 (35)	132 (31)	123 (30)
Never tested	63 (11)	60 (18)	4 (9)	68 (16)	80 (19)
Not reported	27 (5)	23 (7)	4 (9)	16 (4)	30 (7)
Previous HCV test (%)					
Yes, ever	455 (82)	271 (80)	38 (83)	329 (78)	312 (75)
Yes, last year	309 (56)	167 (49)	29 (63)	204 (49)	195 (47)
>1 year ago	146 (26)	104 (31)	9 (20)	125 (30)	117 (28)
Never tested	54 (10)	31 (9)	2 (4)	49 (12)	49 (12)
Not reported	44 (8)	36 (11)	6 (13)	42 (10)	54 (13)
Lifetime treatment for HCV (%)#					
N° self-reported HCV diagnosis	N=147	N=64	N=9	N=78	N=91
Antiviral treatment	93 (63)	46 (72)	5 (56)	58 (74)	74 (81)
No antiviral treatment	53 (36)	18 (28)	4 (44)	19 (24)	16 (18)
Not reported	1 (1)	0 (0)	0 (0)	1 (1)	1 (1)
Treatment for HCV in past 12 months (%)**					
N° self-reported HCV diagnosis	N=114	N=47	N=8	N=43	N=40
Antiviral treatment	53 (46)	22 (47)	4 (50)	19 (44)	16 (40)
No antiviral treatment	60 (53)	25 (53)	4 (50)	23 (53)	23 (58)
Not reported	1 (1)	0 (0)	0 (0)	1 (2)	1 (3)

among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

Table 3.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

New South Wales	2019	2020	2021	2022	2023
N° surveyed	N=553	N=338	N=46	N=420	N=415
Sex with a regular partner last month (%)					
No	279 (50)	143 (42)	30 (65)	222 (53)	209 (50)
Yes	245 (44)	174 (51)	11 (24)	182 (43)	175 (42)
Not reported	29 (5)	21 (6)	5 (11)	16 (4)	31 (7)
Condom used with regular partner last month (%)					
N° surveyed	N=245	N=174	N=11	N=182	N=175
Never	171 (70)	127 (73)	9 (82)	134 (74)	130 (74)
Sometimes	35 (14)	21 (12)	2 (18)	18 (10)	20 (11)
Every time	26 (11)	20 (11)	0 (0)	21 (12)	16 (9)
Not reported	13 (5)	6 (3)	0 (0)	9 (5)	9 (5)
Sex with other partner(s) last month (%)					
No	421 (76)	252 (75)	37 (80)	317 (75)	304 (73)
Yes	91 (16)	61 (18)	5 (11)	85 (20)	77 (19)
Not reported	41 (7)	25 (7)	4 (9)	18 (4)	34 (8)
Condom used with other partner(s) last month (%)					
N° surveyed	N=91	N=61	N=5	N=85	N=77
Never	35 (38)	25 (41)	2 (40)	43 (51)	48 (62)
Sometimes	20 (22)	19 (31)	2 (40)	21 (25)	10 (13)
Every time	28 (31)	15 (25)	1 (20)	20 (24)	18 (23)
Not reported	8 (9)	2 (3)	0 (0)	1 (1)	1 (1)
Sex work last month (%)					
No	474 (86)	293 (87)	40 (87)	364 (87)	355 (86)
Yes	28 (5)	20 (6)	1 (2)	29 (7)	22 (5)
Not reported	51 (9)	25 (7)	5 (11)	27 (6)	38 (9)
Condom used at last sex work (%)					
Yes	19 (68)	10 (50)	1 (100)	20 (69)	13 (59)

Table 3.1.7 Number (percentage) of respondents by COVID-19 related impacts, 2020-2023

New South Wales	2020	2021	2022	2023
N° surveyed	N=338	N=46	N=420	N=415
COVID-19 test				
Yes	138 (41)	25 (54)	384 (91)	369 (89)
No	155 (46)	8 (17)	33 (8)	38 (9)
Don't know	9 (3)	0 (0)	-- --	-- --
Not reported	36 (11)	13 (28)	3 (1)	8 (2)
Self-reported positive COVID-19 test result				
Yes	2 (1)	0 (0)	167 (43)	172 (47)
Yes, last 12 months	-- --	-- --	132 (34)	71 (19)
Yes, more than a year ago	-- --	-- --	35 (9)	101 (27)
COVID-19 vaccine uptake				
≥1 dose	-- --	38 (83)	351 (84)	322 (78)
COVID-19 vaccine doses				
One dose	-- --	8 (17)	22 (5)	20 (5)
Two doses	-- --	30 (65)	136 (32)	102 (25)
Three or more doses	-- --	-- --	193 (46)	200 (48)
No doses	-- --	0 (0)	59 (14)	80 (19)
Not reported	-- --	8 (17)	10 (2)	13 (3)
Vaccine type *			N=351	
Astra Zeneca	-- --	12 (26)	150 (43)	-- --
Pfizer	-- --	21 (46)	231 (66)	-- --
Don't know	-- --	1 (2)	25 (7)	-- --
Other	-- --	-- --	24 (7)	-- --
Not reported	-- --	12 (26)	-- --	-- --
* 2021 only one response permitted, 2022 multiple responses permitted				
Last vaccine location			N=420	N=415
GP or medical centre	-- --	-- --	130 (31)	146 (35)
Pharmacy/ chemist	-- --	-- --	66 (16)	69 (17)
Vaccine hub	-- --	-- --	68 (16)	44 (11)
Opioid treatment/ methadone clinic	-- --	-- --	18 (4)	10 (2)
NSP	-- --	-- --	18 (4)	14 (3)
Prison	-- --	-- --	18 (4)	28 (7)
Multiple response	-- --	-- --	10 (2)	1 (<1)
Other	-- --	-- --	29 (7)	18 (4)
Not reported	-- --	-- --	63 (15)	85 (20)
Vaccine hesitancy - if not had three or more doses				
Haven't got around to it	-- --	-- --	73 (17)	42 (10)
Difficulty booking appointment	-- --	-- --	4 (1)	0 (0)
Concerns about side effects	-- --	-- --	29 (7)	28 (7)
Concerns about vaccine safety	-- --	-- --	20 (5)	34 (8)
Not at risk of serious illness	-- --	-- --	34 (8)	38 (9)
Other	-- --	-- --	45 (11)	45 (11)
Multiple response	-- --	-- --	23 (5)	20 (5)
Not reported	-- --	-- --	192 (46)	208 (50)

HIV antibody prevalence

Table 3.2.1 HIV antibody prevalence by gender and survey year

New South Wales Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019	387	22 (5.7)	143	1 (0.7)	540	24 (4.4)
2020	232	11 (4.7)	88	0 (0.0)	325	13 (4.0)
2021	27	2 (7.4)	16	1 (6.3)	44	3 (6.8)
2022	270	15 (5.6)	133	4 (3.0)	415	22 (5.3)
2023	247	10 (4.1)	127	1 (0.8)	380	11 (2.9)
X ² p trend		0.534		0.364		0.594

Table 3.2.2 HIV antibody prevalence by sexual identity, gender and survey year

New South Wales Sexual identity	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
Heterosexual	299	1 (0.3)	88	1 (1.1)	388	2 (0.5)
Bisexual	26	4 (15.3)	36	0 (0.0)	67	5 (7.5)
Homosexual	31	17 (54.8)	6	0 (0.0)	38	17 (44.7)
p value		<0.001		1.000		<0.001
2020						
Heterosexual	194	2 (1.0)	53	0 (0.0)	248	2 (0.8)
Bisexual	8	0 (0.0)	24	0 (0.0)	34	1 (2.9)
Homosexual	18	9 (50.0)	1	0 (0.0)	20	10 (50.0)
p value		<0.001		--		<0.001
2021						
Heterosexual	21	0 (0.0)	10	1 (10.0)	31	1 (3.2)
Bisexual	1	0 (0.0)	3	0 (0.0)	5	0 (0.0)
Homosexual	5	2 (40.0)	1	0 (0.0)	6	2 (33.3)
p value		0.043		1.000		0.204
2022						
Heterosexual	226	1 (0.4)	96	2 (2.1)	323	3 (0.9)
Bisexual	15	2 (13.3)	25	1 (4.0)	45	5 (11.1)
Homosexual	23	12 (52.2)	5	0 (0.0)	30	12 (40.0)
p value		<0.001		0.174		<0.001
2023						
Heterosexual	205	0 (0.0)	90	1 (1.1)	296	1 (0.3)
Bisexual	16	1 (6.3)	24	0 (0.0)	42	1 (2.4)
Homosexual	21	9 (42.9)	4	0 (0.0)	26	9 (34.6)
p value		<0.001		1.000		<0.001

Table 3.2.3 HIV antibody prevalence by age group, gender and survey year

New South Wales Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
<25 years	15	0 (0.0)	6	0 (0.0)	21	0 (0.0)
25-34 years	66	3 (4.6)	25	0 (0.0)	93	3 (3.2)
35-44 years	118	3 (2.5)	51	0 (0.0)	171	3 (1.8)
45+ years	188	16 (8.5)	61	1 (1.6)	255	18 (7.1)
p value		0.150		1.000		0.051
2020						
<25 years	8	0 (0.0)	1	0 (0.0)	10	0 (0.0)
25-34 years	49	1 (2.0)	16	0 (0.0)	65	1 (1.5)
35-44 years	70	1 (1.4)	37	0 (0.0)	107	1 (0.9)
45+ years	105	9 (8.6)	34	0 (0.0)	143	11 (7.7)
p value		0.154		--		0.039
2021						
<25 years	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
25-34 years	3	0 (0.0)	3	0 (0.0)	6	0 (0.0)
35-44 years	7	2 (28.6)	3	1 (33.3)	10	3 (30.0)
45+ years	17	0 (0.0)	10	0 (0.0)	28	0 (0.0)
p value		0.128		0.375		0.011
2022						
<25 years	15	0 (0.0)	5	0 (0.0)	21	0 (0.0)
25-34 years	45	1 (2.2)	17	0 (0.0)	63	1 (1.6)
35-44 years	69	3 (4.4)	44	2 (4.6)	116	6 (5.2)
45+ years	139	10 (7.2)	67	2 (3.0)	213	14 (6.6)
p value		0.570		0.831		0.406
2023						
<25 years	11	0 (0.0)	5	0 (0.0)	16	0 (0.0)
25-34 years	35	1 (2.9)	20	0 (0.0)	56	1 (1.8)
35-44 years	72	6 (8.3)	36	1 (2.8)	108	7 (6.5)
45+ years	128	3 (2.3)	66	0 (0.0)	198	3 (1.5)
p value		0.225		0.480		0.117

Table 3.2.4 HIV antibody prevalence by last drug injected, gender and survey year

New South Wales Last drug injected	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
Heroin	110	1 (0.9)	51	0 (0.0)	168	2 (1.2)
Methamphetamine	153	19 (12.4)	51	1 (2.0)	207	20 (9.7)
Other opioids	36	2 (5.6)	19	0 (0.0)	55	2 (3.6)
PIEDs	54	0 (0.0)	2	0 (0.0)	56	0 (0.0)
Other drugs	29	0 (0.0)	17	0 (0.0)	46	0 (0.0)
p value		<0.001		1.000		<0.001
2020						
Heroin	62	1 (1.6)	28	0 (0.0)	91	1 (1.1)
Methamphetamine	80	9 (11.3)	30	0 (0.0)	113	10 (8.9)
Other opioids	27	0 (0.0)	19	0 (0.0)	46	0 (0.0)
PIEDs	43	0 (0.0)	2	0 (0.0)	45	0 (0.0)
Other drugs	16	0 (0.0)	7	0 (0.0)	24	1 (4.2)
p value		0.019		--		0.012
2021						
Heroin	9	0 (0.0)	7	0 (0.0)	16	0 (0.0)
Methamphetamine	14	2 (14.3)	8	1 (12.5)	23	3 (13.0)
Other opioids	2	0 (0.0)	1	0 (0.0)	3	0 (0.0)
PIEDs	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)
Other drugs	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)
p value		0.641		1.000		0.486
2022						
Heroin	69	0 (0.0)	53	0 (0.0)	124	1 (0.8)
Methamphetamine	84	13 (15.5)	52	4 (7.7)	41	17 (12.1)
Other opioids	28	0 (0.0)	13	0 (0.0)	43	0 (0.0)
PIEDs	64	1 (1.6)	4	0 (0.0)	68	1 (1.5)
Other drugs	22	1 (4.6)	8	0 (0.0)	32	2 (6.3)
p value		<0.001		0.213		<0.001
2023						
Heroin	57	2 (3.5)	39	0 (0.0)	97	2 (2.1)
Methamphetamine	98	8 (8.2)	61	1 (1.6)	163	9 (5.5)
Other opioids	25	0 (0.0)	16	0 (0.0)	41	0 (0.0)
PIEDs	49	0 (0.0)	1	0 (0.0)	50	0 (0.0)
Other drugs	17	0 (0.0)	9	0 (0.0)	26	0 (0.0)
p value		0.149		1.000		0.206

Table 3.2.5 HIV antibody prevalence by years of injection, gender and survey year

New South Wales Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2019						
<3 years	31	1 (3.2)	8	0 (0.0)	39	1 (2.6)
3 to 10 years	63	7 (11.1)	11	0 (0.0)	75	7 (9.3)
11+ years	275	14 (5.1)	122	1 (0.8)	405	16 (4.0)
p value		0.144		1.000		0.121
2020						
<3 years	19	1 (5.3)	8	0 (0.0)	27	1 (3.7)
3 to 10 years	42	3 (7.1)	7	0 (0.0)	50	3 (6.0)
11+ years	161	7 (4.4)	70	0 (0.0)	235	9 (3.8)
p value		0.582		--		0.698
2021						
<3 years	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
3 to 10 years	3	0 (0.0)	2	0 (0.0)	5	0 (0.0)
11+ years	24	2 (8.3)	13	1 (7.7)	38	3 (7.9)
p value		1.000		1.000		1.000
2022						
<3 years	30	0 (0.0)	5	0 (0.0)	36	0 (0.0)
3 to 10 years	36	1 (2.8)	13	0 (0.0)	49	1 (2.0)
11+ years	183	12 (6.6)	109	4 (3.7)	302	19 (6.3)
p value		0.414		1.000		0.222
2023						
<3 years	15	0 (0.0)	3	0 (0.0)	19	0 (0.0)
3 to 10 years	41	1 (2.4)	17	0 (0.0)	58	1 (1.7)
11+ years	177	9 (5.1)	102	1 (1.0)	281	10 (3.6)
p value		0.844		1.000		0.835

Table 3.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

New South Wales Receptively shared syringe last month	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2019						
No receptive sharing	277	18 (6.5)	98	0 (0.0)	381	19 (5.0)
Receptive sharing	47	3 (6.4)	17	1 (5.9)	65	4 (6.2)
p value		1.000		0.148		0.760
2020						
No receptive sharing	174	7 (4.0)	69	0 (0.0)	247	9 (3.6)
Receptive sharing	16	0 (0.0)	11	0 (0.0)	27	0 (0.0)
p value		1.000		--		0.606
2021						
No receptive sharing	18	1 (5.6)	11	1 (9.1)	30	2 (6.7)
Receptive sharing	2	1 (50.0)	2	0 (0.0)	4	1 (25.0)
p value		0.195		1.000		0.322
2022						
No receptive sharing	188	12 (6.4)	88	1 (1.1)	285	15 (5.3)
Receptive sharing	33	2 (6.1)	17	1 (5.9)	52	3 (5.8)
p value		1.000		0.299		0.747
2023						
No receptive sharing	184	9 (4.9)	92	1 (1.1)	279	10 (3.6)
Receptive sharing	23	1 (4.4)	15	0 (0.0)	39	1 (2.6)
p value		1.000		1.000		1.000

Table 3.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

New South Wales		Male		Female		Total	
Frequency of injection	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	
2019							
Less than daily	155	13 (8.4)	49	0 (0.0)	205	13 (6.3)	
Daily or more	171	8 (4.7)	69	1 (1.5)	246	10 (4.1)	
Not last month	51	1 (2.0)	24	0 (0.0)	78	1 (1.3)	
p value		0.209		1.000		0.195	
2020							
Less than daily	95	3 (3.2)	33	0 (0.0)	129	3 (2.3)	
Daily or more	98	4 (4.1)	48	0 (0.0)	149	6 (4.0)	
Not last month	34	4 (11.8)	7	0 (0.0)	42	4 (9.5)	
p value		0.137		--		0.119	
2021							
Less than daily	13	1 (7.7)	7	0 (0.0)	20	1 (5.0)	
Daily or more	7	1 (14.3)	6	1 (16.7)	0	0 (0.0)	
Not last month	7	0 (0.0)	3	0 (0.0)	10	0 (0.0)	
p value		1.000		0.562		0.444	
2022							
Less than daily	117	8 (6.8)	47	1 (2.1)	168	9 (5.4)	
Daily or more	107	6 (5.6)	59	1 (1.7)	173	9 (5.2)	
Not last month	42	1 (2.4)	22	2 (9.1)	64	3 (4.7)	
p value		0.678		0.229		1.000	
2023							
Less than daily	106	8 (7.6)	39	1 (2.6)	147	9 (6.1)	
Daily or more	107	2 (1.9)	70	0 (0.0)	179	2 (1.1)	
Not last month	30	0 (0.0)	16	0 (0.0)	47	0 (0.0)	
p value		0.079		0.440		0.022	

Table 3.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

New South Wales		Male		Female		Total	
Imprisonment last year	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	
2019							
No imprisonment	315	21 (6.7)	123	1 (0.8)	445	23 (5.2)	
Imprisonment	48	0 (0.0)	14	0 (0.0)	64	0 (0.0)	
p value		0.091		1.000		0.098	
2020							
No imprisonment	180	11 (6.1)	72	0 (0.0)	257	13 (5.1)	
Imprisonment	28	0 (0.0)	12	0 (0.0)	40	0 (0.0)	
p value		0.367		--		0.228	
2021							
No imprisonment	24	1 (4.2)	14	1 (7.1)	39	2 (5.1)	
Imprisonment	2	0 (0.0)	2	0 (0.0)	4	0 (0.0)	
p value		1.000		1.000		1.000	
2022							
No imprisonment	236	15 (6.4)	116	2 (1.7)	363	20 (5.5)	
Imprisonment	24	0 (0.0)	12	2 (16.7)	37	2 (5.4)	
p value		0.374		0.044		1.000	
2023							
No imprisonment	203	10 (4.9)	102	1 (1.0)	311	11 (3.5)	
Imprisonment	23	0 (0.0)	13	0 (0.0)	36	0 (0.0)	
p value		0.604		1.000		0.613	

Table 3.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

New South Wales		Male		Female		Total	
Condom use at last sex	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2019							
No condom use	120	8 (6.7)	49	0 (0.0)	169	8 (4.7)	
Condom use	44	1 (2.3)	13	1 (7.7)	59	2 (3.4)	
p value		0.447		0.210		1.000	
2020							
No condom use	83	6 (7.2)	37	0 (0.0)	122	7 (5.7)	
Condom use	28	1 (3.6)	13	0 (0.0)	41	1 (2.4)	
p value		0.677		--		0.681	
2021							
No condom use	4	0 (0.0)	5	0 (0.0)	9	0 (0.0)	
Condom use	0	0 (0.0)	1	0 (0.0)	2	0 (0.0)	
p value		--		--		--	
2022							
No condom use	79	7 (8.9)	50	2 (4.0)	133	10 (7.5)	
Condom use	25	0 (0.0)	12	0 (0.0)	39	1 (2.6)	
p value		0.192		1.000		0.460	
2023							
No condom use	82	2 (2.4)	40	1 (2.5)	124	3 (2.4)	
Condom use	19	2 (10.5)	12	0 (0.0)	31	2 (6.5)	
p value		0.159		1.000		0.261	

Table 3.2.10 HIV antibody prevalence by sex work last month, gender and survey year

New South Wales		Male		Female		Total	
Sex work last month	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2019							
No sex work	338	18 (5.3)	121	1 (0.8)	465	20 (4.3)	
Sex work	12	2 (16.7)	12	0 (0.0)	27	2 (7.4)	
p value		0.145		1.000		0.343	
2020							
No sex work	210	10 (4.8)	72	0 (0.0)	285	11 (3.9)	
Sex work	7	1 (14.3)	10	0 (0.0)	19	2 (10.5)	
p value		0.309		--		0.191	
2021							
No sex work	23	1 (4.4)	14	1 (7.1)	38	2 (5.3)	
Sex work	0	0 (0.0)	1	0 (0.0)	1	0 (0.0)	
p value		--		1.000		1.000	
2022							
No sex work	238	9 (3.8)	112	4 (3.6)	360	16 (4.4)	
Sex work	11	5 (45.5)	16	0 (0.0)	29	5 (17.2)	
p value		<0.001		1.000		0.003	
2023							
No sex work	215	6 (2.8)	108	1 (0.9)	328	7 (2.1)	
Sex work	10	3 (30.0)	9	0 (0.0)	19	3 (15.8)	
p value		0.005		1.000		0.013	

Table 3.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

New South Wales Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
Non Indigenous	315	17 (5.4)	94	0 (0.0)	417	17 (4.1)
Indigenous	65	5 (7.7)	47	1 (2.1)	113	7 (6.2)
p value		0.557		0.333		0.337
2020						
Non Indigenous	184	10 (5.4)	56	0 (0.0)	243	11 (4.5)
Indigenous	35	1 (2.9)	29	0 (0.0)	66	2 (3.0)
p value		1.000		--		0.742
2021						
Non Indigenous	19	2 (10.5)	9	0 (0.0)	29	2 (6.9)
Indigenous	7	0 (0.0)	4	1 (25.0)	11	1 (9.1)
p value		1.000		0.308		1.000
2022						
Non Indigenous	213	12 (5.6)	90	2 (2.2)	311	15 (4.8)
Indigenous	49	3 (6.1)	40	2 (5.0)	93	7 (7.5)
p value		1.000		0.586		0.313
2023						
Non Indigenous	185	5 (2.7)	82	0 (0.0)	270	5 (1.9)
Indigenous	59	5 (8.5)	45	1 (2.2)	106	6 (5.7)
p value		0.052		0.354		0.049

Table 3.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

New South Wales Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
English speaking	354	21 (5.9)	136	0 (0.0)	498	22 (4.4)
Non-English speaking	29	1 (3.5)	7	1 (14.3)	37	2 (5.4)
p value		1.000		0.049		0.678
2020						
English speaking	206	10 (4.9)	81	0 (0.0)	292	12 (4.1)
Non-English speaking	24	1 (4.2)	4	0 (0.0)	28	1 (3.6)
p value		1.000		--		1.000
2021						
English speaking	25	2 (8.0)	15	1 (6.7)	41	3 (7.3)
Non-English speaking	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)
p value		1.000		--		1.000
2022						
English speaking	248	14 (5.7)	127	4 (3.2)	387	21 (5.4)
Non-English speaking	16	1 (6.3)	5	0 (0.0)	21	1 (4.8)
p value		1.000		1.000		1.000
2023						
English speaking	234	10 (4.3)	124	1 (0.8)	363	11 (3.0)
Non-English speaking	13	0 (0.0)	3	0 (0.0)	16	0 (0.0)
p value		1.000		1.000		1.000

Table 3.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

New South Wales		Male		Female		Total	
Region/country of birth	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2019							
Australia	329	18 (5.5)	127	1 (0.8)	461	20 (4.3)	
Other Oceania	14	1 (7.1)	5	0 (0.0)	22	1 (4.6)	
Asia	9	3 (33.3)	0	0 (0.0)	9	3 (33.3)	
UK & Ireland	7	0 (0.0)	4	0 (0.0)	11	0 (0.0)	
Other	20	0 (0.0)	7	0 (0.0)	28	0 (0.0)	
p value		0.044		1.000		0.024	
2020							
Australia	189	7 (3.7)	72	0 (0.0)	265	8 (3.0)	
Other Oceania	8	1 (12.5)	1	0 (0.0)	9	1 (11.1)	
Asia	10	1 (10.0)	2	0 (0.0)	12	1 (8.3)	
UK & Ireland	4	0 (0.0)	4	0 (0.0)	8	0 (0.0)	
Other	18	1 (5.6)	7	0 (0.0)	25	1 (4.0)	
p value		0.277		--		0.296	
2021							
Australia	21	1 (4.8)	14	1 (7.1)	35	2 (5.7)	
Other Oceania	1	0 (0.0)	1	0 (0.0)	3	0 (0.0)	
Asia	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)	
UK & Ireland	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)	
Other	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)	
p value		1.000		1.000		1.000	
2022							
Australia	224	10 (4.5)	121	4 (3.3)	355	16 (4.5)	
Other Oceania	12	2 (16.7)	1	0 (0.0)	14	2 (14.3)	
Asia	5	0 (0.0)	2	0 (0.0)	7	0 (0.0)	
UK & Ireland	7	1 (14.3)	2	0 (0.0)	9	1 (11.1)	
Other	19	2 (10.5)	6	0 (0.0)	25	2 (8.0)	
p value		0.115		1.000		0.196	
2023							
Australia	214	9 (4.2)	112	1 (0.9)	331	10 (3.0)	
Other Oceania	8	1 (12.5)	7	0 (0.0)	15	1 (6.7)	
Asia	4	0 (0.0)	0	0 (0.0)	4	0 (0.0)	
UK & Ireland	8	0 (0.0)	3	0 (0.0)	11	0 (0.0)	
Other	12	0 (0.0)	5	0 (0.0)	17	0 (0.0)	
p value		0.617		1.000		0.640	

HCV antibody prevalence

Table 3.3.1 HCV antibody prevalence by gender and survey year

New South Wales Survey year	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019	384	154 (40)	141	72 (51)	535	231 (43)
2020	233	79 (34)	88	34 (39)	326	115 (35)
2021	28	7 (25)	16	6 (38)	45	13 (29)
2022	257	68 (26)	125	50 (40)	393	121 (31)
2023*	247	96 (39)	127	61 (48)	380	159 (42)
X ² p trend		0.132		0.573		0.155

* Antibody testing assay changed in 2023. See Appendix B: Methodological Notes

Table 3.3.2 HCV antibody prevalence by sexual identity, gender and survey year

New South Wales Sexual identity	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019						
Heterosexual	297	126 (42)	85	46 (54)	383	173 (45)
Bisexual	25	8 (32)	37	18 (49)	67	29 (43)
Homosexual	31	4 (13)	6	2 (33)	38	6 (16)
p value		0.003		0.575		0.002
2020						
Heterosexual	194	69 (36)	53	18 (34)	248	88 (35)
Bisexual	8	3 (38)	24	15 (63)	34	18 (53)
Homosexual	19	2 (11)	1	0 (0)	21	2 (10)
p value		0.107		0.030		0.007
2021						
Heterosexual	21	6 (29)	10	5 (50)	31	11 (35)
Bisexual	1	0 (0)	3	1 (33)	5	1 (20)
Homosexual	6	1 (17)	1	0 (0)	7	1 (14)
p value		1.000		1.000		0.787
2022						
Heterosexual	212	61 (29)	89	41 (46)	302	103 (34)
Bisexual	15	3 (20)	24	6 (25)	44	9 (20)
Homosexual	24	1 (4)	5	0 (0)	31	2 (6)
p value		0.009		0.041		0.001
2023						
Heterosexual	205	83 (40)	90	42 (47)	296	125 (42)
Bisexual	16	4 (25)	24	11 (46)	42	15 (36)
Homosexual	21	6 (29)	4	2 (50)	26	8 (31)
p value		0.539		0.526		0.338

Table 3.3.3 HCV antibody prevalence by age group, gender and survey year

New South Wales Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
<25 years	15	3 (20)	7	1 (14)	22	4 (18)
25-34 years	66	13 (20)	25	16 (64)	93	29 (31)
35-44 years	116	52 (45)	51	26 (51)	169	80 (47)
45+ years	187	86 (46)	58	29 (50)	251	118 (47)
p value		<0.001		0.144		0.003
2020						
<25 years	8	0 (0)	1	0 (0)	10	0 (0)
25-34 years	49	10 (20)	16	3 (19)	65	13 (20)
35-44 years	70	22 (31)	37	15 (41)	107	37 (35)
45+ years	106	47 (44)	34	16 (47)	144	65 (45)
p value		0.003		0.202		<0.001
2021						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	3	0 (0)	3	0 (0)	6	0 (0)
35-44 years	8	2 (25)	3	1 (33)	11	3 (27)
45+ years	17	5 (29)	10	5 (50)	28	10 (36)
p value		0.831		0.494		0.253
2022						
<25 years	15	0 (0)	4	1 (25)	19	1 (5)
25-34 years	45	3 (7)	16	6 (38)	62	9 (15)
35-44 years	66	15 (23)	42	12 (29)	111	27 (24)
45+ years	129	48 (37)	63	31 (49)	199	82 (41)
p value		<0.001		0.169		<0.001
2023						
<25 years	11	0 (0)	5	1 (20)	16	1 (6)
25-34 years	35	3 (9)	20	3 (15)	56	6 (11)
35-44 years	72	24 (33)	36	17 (47)	108	41 (38)
45+ years	128	68 (53)	66	40 (61)	198	109 (55)
p value		<0.001		0.001		<0.001

Table 3.3.4 HCV antibody prevalence by years since first injection, gender and survey year

New South Wales Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019						
<3 years	30	2 (7)	9	0 (0)	39	2 (5)
3 to 10 years	63	11 (17)	11	3 (27)	75	15 (20)
11+ years	273	134 (49)	119	69 (58)	400	206 (52)
p value		<0.001		<0.001		<0.001
2020						
<3 years	19	2 (11)	8	0 (0)	27	2 (7)
3 to 10 years	42	7 (17)	7	3 (43)	50	10 (20)
11+ years	161	68 (42)	70	31 (44)	235	101 (43)
p value		<0.001		0.042		<0.001
2021						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	3	1 (33)	2	0 (0)	5	1 (20)
11+ years	25	6 (24)	13	6 (46)	39	12 (31)
p value		1.000		0.486		1.000
2022						
<3 years	30	0 (0)	4	0 (0)	34	0 (0)
3 to 10 years	36	2 (6)	12	2 (17)	48	4 (8)
11+ years	171	62 (36)	103	44 (43)	284	109 (38)
p value		<0.001		0.064		<0.001
2023						
<3 years	15	0 (0)	3	1 (33)	19	1 (5)
3 to 10 years	41	5 (12)	17	0 (0)	58	5 (9)
11+ years	177	88 (50)	102	57 (56)	281	145 (52)
p value		<0.001		<0.001		<0.001

Table 3.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

New South Wales Receptively shared syringe last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019						
No receptive sharing	28	1 (4)	340	156 (46)	378	163 (43)
Receptive sharing	4	1 (25)	56	34 (61)	63	37 (59)
p value		0.238		0.040		0.021
2020						
No receptive sharing	22	2 (9)	220	83 (38)	248	87 (35)
Receptive sharing	1	0 (0)	25	13 (52)	27	13 (48)
p value		1.000		0.166		0.180
2021						
No receptive sharing	--	-- --	29	9 (31)	30	9 (30)
Receptive sharing	--	-- --	4	2 (50)	4	2 (50)
p value		--		0.586		0.580
2022						
No receptive sharing	26	0 (0)	233	70 (30)	268	74 (28)
Receptive sharing	2	0 (0)	44	29 (66)	50	31 (62)
p value		--		<0.001		<0.001
2023						
No receptive sharing	15	0 (0)	251	110 (44)	279	117 (42)
Receptive sharing	1	1 (100)	35	20 (57)	39	21 (54)
p value		0.062		0.138		0.160

Table 3.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

New South Wales Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
Heroin	6	0 (0)	150	91 (61)	163	95 (58)
Methamphetamine	15	2 (13)	185	75 (41)	204	79 (39)
Other opioids	1	0 (0)	52	25 (48)	53	25 (47)
PIEDs	13	0 (0)	37	0 (0)	54	0 (0)
Other drugs	1	0 (0)	41	27 (66)	44	29 (66)
p value		0.564		<0.001		<0.001
2020						
Heroin	4	1 (25)	85	42 (49)	90	43 (48)
Methamphetamine	7	1 (14)	105	35 (33)	114	37 (32)
Other opioids	2	0 (0)	42	21 (50)	45	22 (49)
PIEDs	12	0 (0)	26	0 (0)	44	0 (0)
Other drugs	1	0 (0)	21	12 (57)	23	12 (52)
p value		0.499		<0.001		<0.001
2021						
Heroin	--	-- --	16	5 (31)	16	5 (31)
Methamphetamine	--	-- --	23	6 (26)	24	6 (26)
Other opioids	--	-- --	3	2 (67)	3	2 (67)
PIEDs	--	-- --	1	0 (0)	1	0 (0)
Other drugs	--	-- --	1	0 (0)	1	0 (0)
p value		--		0.561		0.538
2022						
Heroin	1	0 (0)	111	49 (44)	115	50 (43)
Methamphetamine	4	0 (0)	120	33 (28)	132	37 (28)
Other opioids	0	0 (0)	37	21 (57)	37	21 (57)
PIEDs	28	0 (0)	32	1 (3)	66	2 (3)
Other drugs	0	0 (0)	26	8 (31)	29	9 (31)
p value		--		<0.001		<0.001
2023						
Heroin	0	0 (0)	94	56 (60)	95	57 (60)
Methamphetamine	4	0 (0)	151	60 (40)	163	64 (39)
Other opioids	2	0 (0)	36	20 (56)	41	22 (54)
PIEDs	11	0 (0)	33	0 (0)	49	0 (0)
Other drugs	2	1 (50)	21	11 (52)	24	12 (50)
p value		0.030		<0.001		<0.001

Table 3.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

New South Wales Frequency of injection last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019						
Less than daily	15	1 (7)	181	70 (39)	201	75 (37)
Daily or more	17	1 (6)	220	123 (56)	245	128 (52)
Not last month	7	0 (0)	66	26 (39)	78	26 (33)
p value		1.000		0.001		0.001
2020						
Less than daily	11	2 (18)	116	38 (33)	130	40 (31)
Daily or more	12	0 (0)	133	60 (45)	149	62 (42)
Not last month	4	0 (0)	32	12 (38)	42	12 (29)
p value		0.436		0.135		0.101
2021						
Less than daily	--	-- --	19	6 (32)	20	6 (30)
Daily or more	--	-- --	14	5 (36)	14	5 (36)
Not last month	--	-- --	11	2 (18)	11	2 (18)
p value		--		0.645		0.644
2022						
Less than daily	21	0 (0)	130	39 (30)	159	41 (26)
Daily or more	7	0 (0)	149	60 (40)	163	64 (39)
Not last month	5	0 (0)	49	14 (29)	61	15 (25)
p value		--		0.127		0.016
2023						
Less than daily	10	0 (0)	130	55 (42)	147	58 (39)
Daily or more	6	1 (17)	164	80 (49)	179	85 (47)
Not last month	3	0 (0)	41	12 (29)	47	12 (26)
p value		0.474		0.071		0.020

Table 3.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

New South Wales Imprisonment last year	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019						
No imprisonment	36	2 (6)	389	175 (45)	440	181 (41)
Imprisonment	2	0 (0)	58	29 (50)	64	31 (48)
p value		1.000		0.475		0.269
2020						
No imprisonment	24	2 (8)	223	80 (36)	258	83 (32)
Imprisonment	3	0 (0)	34	17 (50)	40	18 (45)
p value		1.000		0.113		0.111
2021						
No imprisonment	0	0 (0)	39	12 (31)	40	12 (30)
Imprisonment	0	0 (0)	4	0 (0)	4	0 (0)
p value		--		0.563		0.562
2022						
No imprisonment	32	0 (0)	288	93 (32)	342	99 (29)
Imprisonment	1	0 (0)	31	14 (45)	36	15 (42)
p value		--		0.149		0.114
2023						
No imprisonment	17	1 (6)	279	119 (43)	311	124 (40)
Imprisonment	0	0 (0)	31	17 (55)	36	21 (58)
p value		--		0.195		0.033

Table 3.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

New South Wales Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
Non Indigenous	311	116 (37)	92	44 (48)	411	165 (40)
Indigenous	66	34 (52)	47	26 (55)	114	60 (53)
p value		0.032		0.403		0.017
2020						
Non Indigenous	185	60 (32)	56	20 (36)	244	82 (34)
Indigenous	35	15 (43)	29	12 (41)	66	27 (41)
p value		0.233		0.609		0.270
2021						
Non Indigenous	20	5 (25)	9	3 (33)	30	8 (27)
Indigenous	7	2 (29)	4	2 (50)	11	4 (36)
p value		1.000		1.000		0.701
2022						
Non Indigenous	203	51 (25)	82	31 (38)	292	84 (29)
Indigenous	46	15 (33)	40	17 (43)	90	33 (37)
p value		0.355		0.618		0.155
2023						
Non Indigenous	185	66 (36)	82	40 (49)	270	107 (40)
Indigenous	59	29 (49)	45	21 (47)	106	50 (47)
p value		0.065		0.820		0.182

Table 3.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

New South Wales Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
English speaking	352	140 (40)	134	69 (51)	494	213 (43)
Non-English speaking	28	13 (46)	7	3 (43)	36	17 (47)
p value		0.489		0.715		0.631
2020						
English speaking	207	69 (33)	81	32 (40)	293	103 (35)
Non-English speaking	24	10 (42)	4	2 (50)	28	12 (43)
p value		0.415		1.000		0.417
2021						
English speaking	26	6 (23)	15	5 (33)	42	11 (26)
Non-English speaking	2	1 (50)	0	0 (0)	2	1 (50)
p value		0.444		--		0.476
2022						
English speaking	236	61 (26)	119	49 (41)	366	113 (31)
Non-English speaking	16	5 (31)	5	1 (20)	21	6 (29)
p value		0.634		0.647		0.824
2023						
English speaking	234	95 (41)	124	59 (48)	363	155 (43)
Non-English speaking	13	1 (8)	3	2 (67)	16	3 (19)
p value		0.018		0.608		0.070

Table 3.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

New South Wales		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2019							
Australia	327	132 (40)	125	64 (51)	457	199 (44)	
Other Oceania	14	7 (50)	5	3 (60)	22	11 (50)	
Asia	9	3 (33)	0	0 (0)	9	3 (33)	
UK & Ireland	7	3 (43)	4	3 (75)	11	6 (55)	
Other	19	6 (32)	7	2 (29)	27	8 (30)	
p value		0.857		0.517		0.493	
2020							
Australia	190	65 (34)	72	26 (36)	266	93 (35)	
Other Oceania	8	1 (13)	1	0 (0)	9	1 (11)	
Asia	10	3 (30)	2	1 (50)	12	4 (33)	
UK & Ireland	4	0 (0)	4	2 (50)	8	2 (25)	
Other	18	10 (56)	7	4 (57)	25	14 (56)	
p value		0.136		0.709		0.130	
2021							
Australia	21	5 (24)	14	6 (43)	35	11 (31)	
Other Oceania	1	0 (0)	1	0 (0)	3	0 (0)	
Asia	1	0 (0)	0	0 (0)	1	0 (0)	
UK & Ireland	1	0 (0)	1	0 (0)	2	0 (0)	
Other	2	1 (50)	0	0 (0)	2	1 (50)	
p value		0.764		1.000		0.720	
2022							
Australia	210	60 (29)	114	46 (40)	333	108 (32)	
Other Oceania	12	3 (25)	1	0 (0)	14	4 (29)	
Asia	5	1 (20)	2	1 (50)	7	2 (29)	
UK & Ireland	7	0 (0)	2	1 (50)	9	1 (11)	
Other	20	4 (20)	5	1 (20)	25	5 (20)	
p value		0.557		0.950		0.544	
2023							
Australia	214	87 (41)	112	51 (46)	331	139 (42)	
Other Oceania	8	4 (50)	7	3 (43)	15	7 (47)	
Asia	4	1 (25)	0	0 (0)	4	1 (25)	
UK & Ireland	8	3 (38)	3	3 (100)	11	6 (55)	
Other	12	1 (8)	5	4 (80)	17	5 (29)	
p value		0.184		0.159		0.689	

HCV RNA prevalence

Table 3.4.1 HCV RNA prevalence by gender and survey year

New South Wales Survey year	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019*	320	46 (14)	118	26 (22)	446	72 (16)
2020	221	20 (9)	76	9 (12)	300	29 (10)
2021	26	2 (8)	14	2 (14)	41	4 (10)
2022	262	19 (7)	131	14 (11)	405	35 (9)
2023	240	16 (7)	126	7 (6)	372	23 (6)
X ² p trend		0.001		<0.001		<0.001

* 2019: Weighted for gender and HCV antibody status

Totals include respondents where gender was reported as other or not reported

Table 3.4.2 HCV RNA prevalence by sexual identity, gender and survey year

New South Wales Sexual identity	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019*						
Heterosexual	254	36 (14)	69	14 (20)	323	50 (15)
Bisexual	20	2 (10)	32	8 (25)	57	10 (18)
Homosexual	26	0 (0)	6	0 (0)	33	0 (0)
p value		0.112		0.416		0.036
2020						
Heterosexual	184	19 (10)	46	6 (13)	231	25 (11)
Bisexual	8	0 (0)	20	3 (15)	29	3 (10)
Homosexual	17	0 (0)	1	0 (0)	18	0 (0)
p value		0.242		0.903		0.339
2021						
Heterosexual	21	2 (10)	9	2 (22)	30	4 (13)
Bisexual	1	0 (0)	2	0 (0)	4	0 (0)
Homosexual	4	0 (0)	1	0 (0)	5	0 (0)
p value		0.773		0.670		0.512
2022						
Heterosexual	221	19 (9)	95	14 (15)	317	33 (10)
Bisexual	14	0 (0)	25	0 (0)	44	0 (0)
Homosexual	21	0 (0)	4	0 (0)	27	1 (3)
p value		0.591		0.347		0.165
2023						
Heterosexual	200	14 (7)	90	4 (4)	291	18 (6)
Bisexual	15	1 (7)	23	1 (4)	40	2 (5)
Homosexual	20	1 (5)	4	0 (0)	25	1 (4)
p value		1.000		0.051		0.171

Table 3.4.3 HCV RNA prevalence by age group, gender and survey year

New South Wales Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
<25 years	12	2 (17)	6	1 (17)	18	3 (17)
25-34 years	56	5 (9)	22	5 (23)	80	10 (13)
35-44 years	96	22 (23)	41	10 (24)	138	32 (23)
45+ years	156	17 (11)	49	10 (20)	210	27 (13)
p value		0.035		0.899		0.049
2020						
<25 years	7	0 (0)	1	0 (0)	9	0 (0)
25-34 years	46	4 (9)	16	1 (6)	62	5 (8)
35-44 years	69	8 (12)	30	5 (17)	99	13 (13)
45+ years	99	8 (8)	29	3 (10)	130	11 (8)
p value		0.715		0.719		0.436
2021						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	3	0 (0)	2	0 (0)	5	0 (0)
35-44 years	6	1 (17)	3	0 (0)	9	1 (11)
45+ years	17	1 (6)	9	2 (22)	27	3 (11)
p value		0.604		0.523		0.735
2022						
<25 years	14	0 (0)	5	0 (0)	20	0 (0)
25-34 years	45	2 (4)	17	2 (12)	63	4 (6)
35-44 years	67	3 (4)	42	3 (7)	112	6 (5)
45+ years	134	14 (10)	67	9 (13)	208	25 (12)
p value		0.323		0.786		0.103
2023						
<25 years	11	0 (0)	5	0 (0)	16	0 (0)
25-34 years	35	1 (3)	19	1 (5)	55	2 (4)
35-44 years	70	8 (11)	36	2 (6)	106	10 (9)
45+ years	123	7 (6)	66	4 (6)	193	11 (6)
p value		0.340		1.000		0.420

Table 3.4.4 HCV RNA prevalence by years since first injection, gender and survey year

New South Wales Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019*						
<3 years	25	2 (8)	7	0 (0)	32	2 (6)
3 to 10 years	49	3 (6)	11	2 (18)	60	6 (10)
11+ years	232	37 (16)	98	23 (23)	337	59 (18)
p value		0.139		0.331		0.085
2020						
<3 years	18	2 (11)	7	0 (0)	25	2 (8)
3 to 10 years	40	3 (8)	6	1 (17)	47	4 (9)
11+ years	152	14 (9)	61	8 (13)	215	22 (10)
p value		0.898		0.567		0.893
2021						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	3	1 (33)	1	0 (0)	4	1 (25)
11+ years	23	1 (4)	12	2 (17)	36	3 (8)
p value		0.076		0.657		0.292
2022						
<3 years	29	0 (0)	5	0 (0)	35	0 (0)
3 to 10 years	36	1 (3)	13	1 (8)	49	2 (4)
11+ years	177	18 (10)	107	13 (12)	294	33 (11)
p value		0.083		1.000		0.034
2023						
<3 years	15	0 (0)	3	0 (0)	19	0 (0)
3 to 10 years	40	2 (5)	17	0 (0)	57	2 (4)
11+ years	172	14 (8)	101	6 (6)	275	20 (7)
p value		0.717		0.650		0.429

Table 3.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

New South Wales Receptively shared syringe last month	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019*						
No receptive sharing	232	32 (14)	81	20 (25)	318	53 (17)
Receptive sharing	36	10 (28)	12	4 (33)	50	14 (28)
p value		0.037		0.643		0.056
2020						
No receptive sharing	166	16 (10)	60	9 (15)	228	25 (11)
Receptive sharing	15	4 (27)	10	0 (0)	25	4 (16)
p value		0.044		0.190		0.453
2021						
No receptive sharing	17	0 (0)	10	2 (20)	28	2 (7)
Receptive sharing	1	1 (100)	2	0 (0)	3	1 (33)
p value		<0.001		0.488		0.145
2022						
No receptive sharing	182	12 (7)	87	10 (11)	278	23 (8)
Receptive sharing	33	5 (15)	16	4 (25)	51	10 (20)
p value		0.094		0.225		0.013
2023						
No receptive sharing	179	13 (7)	91	5 (5)	273	18 (7)
Receptive sharing	22	3 (14)	15	1 (7)	38	4 (11)
p value		0.393		1.000		0.325

Table 3.4.6 HCV RNA prevalence by last drug injected, gender and survey year

New South Wales Last drug injected	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
Heroin	95	20 (21)	37	9 (24)	138	28 (20)
Methamphetamine	123	16 (13)	44	9 (20)	169	25 (15)
Other opioids	30	5 (17)	17	3 (18)	47	8 (17)
PIEDs	43	0 (0)	2	0 (0)	45	0 (0)
Other drugs	22	4 (18)	13	6 (46)	36	10 (28)
p value		0.024		0.350		0.007
2020						
Heroin	58	8 (14)	27	1 (3)	86	9 (11)
Methamphetamine	76	7 (9)	22	4 (18)	100	11 (11)
Other opioids	25	3 (12)	19	2 (11)	44	5 (11)
PIEDs	39	0 (0)	2	0 (0)	41	0 (0)
Other drugs	15	2 (13)	6	2 (33)	21	4 (19)
p value		0.211		0.238		0.151
2021						
Heroin	9	1 (11)	5	1 (20)	14	2 (14)
Methamphetamine	13	1 (8)	8	1 (13)	22	2 (9)
Other opioids	2	0 (0)	1	0 (0)	3	0 (0)
PIEDs	1	0 (0)	0	0 (0)	1	0 (0)
Other drugs	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.975		0.852		0.928
2022						
Heroin	66	9 (14)	51	7 (14)	119	16 (13)
Methamphetamine	80	5 (6)	50	3 (6)	135	8 (6)
Other opioids	27	3 (11)	13	4 (31)	42	9 (21)
PIEDs	62	0 (0)	3	0 (0)	65	0 (0)
Other drugs	22	2 (9)	7	0 (0)	30	2 (7)
p value		0.050		0.095		0.001
2023						
Heroin	56	8 (14)	38	0 (0)	95	8 (8)
Methamphetamine	93	7 (8)	61	4 (7)	158	11 (7)
Other opioids	25	1 (4)	16	2 (13)	41	3 (7)
PIEDs	48	0 (0)	1	0 (0)	49	0 (0)
Other drugs	15	0 (0)	7	0 (0)	22	0 (0)
p value		0.040		0.316		0.208

Table 3.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year

New South Wales		Male		Female		Total	
Frequency of injection last month	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	
2019*							
Less than daily	133	15 (11)	40	10 (25)	174	24 (14)	
Daily or more	136	27 (20)	55	14 (25)	197	42 (21)	
Not last month	46	3 (7)	21	2 (10)	69	5 (7)	
p value		0.036		0.263		0.013	
2020							
Less than daily	92	9 (10)	29	5 (17)	122	14 (11)	
Daily or more	92	11 (12)	42	4 (10)	135	15 (11)	
Not last month	32	0 (0)	5	0 (0)	38	0 (0)	
p value		0.129		0.428		0.092	
2021							
Less than daily	12	0 (0)	7	1 (14)	19	1 (5)	
Daily or more	6	1 (17)	5	1 (20)	12	2 (17)	
Not last month	8	1 (13)	2	0 (0)	10	1 (10)	
p value		0.379		0.792		0.581	
2022							
Less than daily	114	5 (4)	46	5 (11)	164	10 (6)	
Daily or more	104	12 (12)	58	9 (16)	169	23 (14)	
Not last month	40	2 (5)	22	0 (0)	62	2 (3)	
p value		0.139		0.137		0.016	
2023							
Less than daily	104	7 (7)	39	2 (5)	145	9 (6)	
Daily or more	103	9 (9)	69	4 (6)	174	13 (7)	
Not last month	30	0 (0)	16	0 (0)	47	0 (0)	
p value		0.300		1.000		0.144	

Table 3.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year

New South Wales		Male		Female		Total	
Imprisonment last year	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	
2019*							
No imprisonment	264	33 (13)	104	21 (20)	374	55 (15)	
Imprisonment	37	9 (24)	10	4 (40)	49	13 (27)	
p value		0.061		0.151		0.039	
2020							
No imprisonment	172	15 (9)	62	9 (15)	237	24 (10)	
Imprisonment	26	3 (12)	11	0 (0)	37	3 (8)	
p value		0.641		0.177		0.702	
2021							
No imprisonment	24	2 (8)	12	2 (17)	37	4 (11)	
Imprisonment	2	0 (0)	2	0 (0)	4	0 (0)	
p value		0.671		0.533		0.489	
2022							
No imprisonment	228	15 (7)	114	13 (11)	353	30 (9)	
Imprisonment	24	2 (8)	12	1 (8)	37	3 (8)	
p value		0.669		1.000		1.000	
2023							
No imprisonment	197	14 (7)	102	7 (7)	305	21 (7)	
Imprisonment	23	1 (4)	12	0 (0)	35	1 (3)	
p value		1.000		1.000		0.713	

Table 3.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

New South Wales		Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	
2019*							
Non Indigenous	263	31 (12)	78	13 (17)	348	45 (13)	
Indigenous	53	13 (25)	37	11 (30)	91	24 (26)	
p value		0.014		0.090		0.001	
2020							
Non Indigenous	174	14 (8)	47	6 (13)	223	20 (9)	
Indigenous	34	3 (9)	27	3 (11)	62	6 (10)	
p value		0.880		0.843		0.864	
2021							
Non Indigenous	18	0 (0)	7	2 (29)	26	2 (8)	
Indigenous	7	2 (29)	4	0 (0)	11	2 (18)	
p value		0.018		0.237		0.348	
2022							
Non Indigenous	205	15 (7)	88	12 (14)	301	28 (9)	
Indigenous	49	3 (6)	40	1 (3)	93	5 (5)	
p value		1.000		0.062		0.232	
2023							
Non Indigenous	180	12 (7)	81	5 (6)	264	17 (6)	
Indigenous	57	4 (7)	45	2 (4)	104	6 (6)	
p value		1.000		1.000		0.811	

Table 3.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year

New South Wales		Male		Female		Total	
Main language spoken at home by parents	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	
2019*							
English speaking	298	42 (14)	112	25 (22)	417	67 (16)	
Non-English speaking	21	4 (19)	6	1 (17)	28	5 (18)	
p value		0.558		0.750		0.835	
2020							
English speaking	196	17 (9)	71	8 (11)	270	25 (9)	
Non-English speaking	23	3 (13)	4	1 (25)	27	4 (15)	
p value		0.491		0.411		0.354	
2021							
English speaking	24	2 (8)	13	1 (8)	38	3 (8)	
Non-English speaking	2	0 (0)	0	0 (0)	2	0 (0)	
p value		0.671		--		0.679	
2022							
English speaking	240	18 (8)	125	14 (11)	377	34 (9)	
Non-English speaking	16	1 (6)	5	0 (0)	21	1 (5)	
p value		1.000		1.000		1.000	
2023							
English speaking	227	16 (7)	123	7 (6)	355	23 (6)	
Non-English speaking	13	0 (0)	3	0 (0)	16	0 (0)	
p value		1.000		1.000		0.612	

Table 3.4.11 HCV RNA prevalence by region/country of birth, gender and survey year

New South Wales						
Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
Australia	277	41 (15)	104	25 (24)	386	65 (17)
Other Oceania	11	0 (0)	4	1 (25)	17	2 (12)
Asia	6	2 (33)	0	0 (0)	6	2 (33)
UK & Ireland	3	0 (0)	4	0 (0)	7	0 (0)
Other	17	2 (12)	6	0 (0)	24	2 (8)
p value		0.385		0.380		0.367
2020						
Australia	181	16 (9)	62	7 (11)	246	23 (9)
Other Oceania	8	0 (0)	0	0 (0)	8	0 (0)
Asia	10	0 (0)	2	0 (0)	12	0 (0)
UK & Ireland	3	0 (0)	4	1 (25)	7	1 (14)
Other	16	4 (25)	7	1 (14)	23	5 (22)
p value		0.196		0.890		0.252
2021						
Australia	20	2 (10)	12	2 (17)	32	4 (13)
Other Oceania	1	0 (0)	1	0 (0)	3	0 (0)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	1	0 (0)	1	0 (0)	2	0 (0)
Other	2	0 (0)	0	0 (0)	2	0 (0)
p value		0.969		0.823		0.893
2022						
Australia	216	18 (8)	119	14 (12)	345	33 (10)
Other Oceania	11	0 (0)	1	0 (0)	13	1 (8)
Asia	5	1 (20)	2	0 (0)	7	1 (14)
UK & Ireland	7	0 (0)	2	0 (0)	9	0 (0)
Other	20	0 (0)	6	0 (0)	26	0 (0)
p value		0.416		1.000		0.383
2023						
Australia	208	15 (7)	111	7 (6)	324	22 (7)
Other Oceania	8	0 (0)	7	0 (0)	15	0 (0)
Asia	4	0 (0)	0	0 (0)	4	0 (0)
UK & Ireland	7	1 (14)	3	0 (0)	10	1 (10)
Other	12	0 (0)	5	0 (0)	17	0 (0)
p value		0.672		1.000		0.643

Northern Territory

Table 4.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Northern Territory	2019	2020*	2021*	2022	2023
Number of sites	3	3	3	3	3
N° surveyed	N=85	N=37	N=40	N=20	N=50
Response rate (%)	42%	23%	18%	15%	34%
Gender (%)					
Male	53 (62)	25 (68)	25 (63)	14 (70)	32 (64)
Female	31 (36)	12 (32)	15 (38)	4 (20)	16 (32)
Other	1 (1)	0 (0)	0 (0)	2 (10)	2 (4)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	68 (80)	30 (81)	29 (73)	15 (75)	38 (76)
Bisexual	8 (9)	4 (11)	7 (18)	3 (15)	10 (20)
Gay/Lesbian	2 (2)	0 (0)	2 (5)	0 (0)	0 (0)
Other	-- --	1 (3)	2 (5)	2 (10)	2 (4)
Not reported	7 (8)	2 (5)	0 (0)	0 (0)	0 (0)
Aboriginal and Torres Strait Islander origin (%)					
No	55 (65)	25 (68)	20 (50)	15 (75)	30 (60)
Yes	30 (35)	10 (27)	20 (50)	4 (20)	20 (40)
Not reported	0 (0)	2 (5)	0 (0)	1 (5)	0 (0)
Region/country of birth (%)					
Australia	79 (93)	35 (95)	39 (98)	19 (95)	46 (92)
Other Oceania	1 (1)	1 (3)	0 (0)	0 (0)	3 (6)
Asia	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
UK & Ireland	1 (1)	0 (0)	0 (0)	1 (5)	1 (2)
Other	3 (4)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	1 (1)	1 (3)	1 (3)	0 (0)	0 (0)
Main language spoken at home by parents (%)					
English	80 (94)	33 (89)	39 (98)	20 (100)	49 (98)
Non-English	4 (5)	2 (5)	1 (3)	0 (0)	0 (0)
Not reported	1 (1)	2 (5)	0 (0)	0 (0)	1 (2)
Age and time since first injection (years)					
<i>Median age</i>	43.5	45	50	47.5	47
<i>Age range</i>	30-70	21-64	31-65	34-68	26-71
Age group (%)					
<25 years	0 (0)	1 (3)	0 (0)	0 (0)	0 (0)
25+ years	84 (99)	36 (97)	40 (100)	20 (100)	50 (100)
Not reported	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Median age first injection</i>	18	19	17	18.5	19
<i>Age range</i>	11-65	10-42	10-42	10-38	13-45
<i>N° not reported</i>	3	0	1	2	0
<i>Median yrs since first injection</i>	22.5	24	29	27	27
<i>Range</i>	2-50	4-51	1-50	13-51	0-49
Years since first injection					
<3 years	1 (1)	0 (0)	1 (3)	0 (0)	1 (2)
3+ years	81 (95)	37 (100)	38 (95)	18 (90)	49 (98)
Not reported	3 (4)	0 (0)	1 (3)	2 (10)	0 (0)
Imprisonment last year (%)					
No	68 (80)	32 (86)	36 (90)	19 (95)	42 (84)
Yes	10 (12)	3 (8)	4 (10)	0 (0)	3 (6)
Not reported	7 (8)	2 (5)	0 (0)	1 (5)	5 (10)
N° in prison					
Injected in prison	1 (10)	0 (0)	0 (0)	0 (0)	1 (33)

* Implementation of the 2020 and 2021 ANSPS was impacted by the COVID-19 pandemic, see page 1 for more information

Table 4.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

Northern Territory	2019	2020	2021	2022	2023
N° surveyed	N=85	N=37	N=40	N=20	N=50
Drug last injected (%)					
Cocaine	2 (2)	0 (0)	1 (3)	0 (0)	0 (0)
Methamphetamine	46 (54)	25 (68)	27 (68)	11 (55)	36 (72)
Heroin	0 (0)	0 (0)	1 (3)	0 (0)	2 (4)
Pharm. opioids	23 (27)	7 (19)	4 (10)	6 (30)	6 (12)
Methadone	6 (7)	0 (0)	3 (8)	0 (0)	0 (0)
Buprenorphine	4 (5)	3 (8)	1 (3)	1 (5)	1 (2)
Buprenorphine/naloxone	0 (0)	1 (3)	0 (0)	0 (0)	1 (2)
PIEDs	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
More than one	2 (2)	1 (3)	1 (3)	2 (10)	3 (6)
Other	1 (1)	0 (0)	1 (3)	0 (0)	1 (2)
Not reported	1 (1)	0 (0)	1 (3)	0 (0)	0 (0)
Ever injected opioids					
No	19 (22)	10 (27)	11 (28)	3 (15)	17 (34)
Yes	65 (76)	27 (73)	29 (73)	17 (85)	33 (66)
Not reported	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Frequency of injection last month (%)					
Not last month	6 (7)	5 (14)	5 (13)	1 (5)	7 (14)
Less than weekly	8 (9)	8 (22)	10 (25)	6 (30)	10 (20)
Weekly not daily	12 (14)	7 (19)	7 (18)	5 (25)	9 (18)
Daily or more	59 (69)	17 (46)	16 (40)	8 (40)	22 (44)
Not reported	0 (0)	0 (0)	2 (5)	0 (0)	2 (4)
Present when someone injected for the first time in the last 12 months (%)					
No	63 (74)	33 (89)	31 (78)	17 (85)	43 (86)
Yes	17 (20)	2 (5)	9 (23)	3 (15)	3 (6)
Not reported	5 (6)	2 (5)	0 (0)	0 (0)	4 (8)
Overdosed in last 12 months					
No	72 (85)	33 (89)	35 (88)	18 (90)	43 (86)
Yes	8 (9)	1 (3)	4 (10)	1 (5)	4 (8)
Not reported	5 (6)	3 (8)	1 (3)	1 (5)	3 (6)

Table 4.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

Northern Territory	2019	2020	2021	2022	2023
N° injected last month	N=79	N=32	N=33	N=19	N=41
Places injected last month (%)					
All private	51 (65)	19 (59)	15 (45)	13 (68)	20 (49)
Any public	28 (35)	12 (38)	18 (55)	6 (32)	21 (51)
Not reported	0 (0)	1 (3)	0 (0)	0 (0)	0 (0)
Use of new and sterile needles and syringes last month (%)					
All injections	67 (85)	26 (81)	27 (82)	18 (95)	34 (83)
Most of the time	8 (10)	2 (6)	4 (12)	1 (5)	5 (12)
Half of the time	2 (3)	2 (6)	1 (3)	0 (0)	2 (5)
Some of the time	1 (1)	1 (3)	1 (3)	0 (0)	0 (0)
Not last month	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	1 (1)	1 (3)	0 (0)	0 (0)	0 (0)
Re-used someone else's used needle & syringe last month (%)					
None	70 (89)	27 (84)	28 (85)	19 (100)	35 (85)
Once	3 (4)	1 (3)	0 (0)	0 (0)	2 (5)
Twice	0 (0)	1 (3)	2 (6)	0 (0)	1 (2)
3-5 times	4 (5)	1 (3)	1 (3)	0 (0)	2 (5)
>5 times	1 (1)	1 (3)	2 (6)	0 (0)	1 (2)
Not reported	1 (1)	1 (3)	0 (0)	0 (0)	0 (0)
Number of people needle & syringe was re-used after last month (%)					
None	70 (89)	27 (84)	28 (85)	19 (100)	35 (85)
One	2 (3)	0 (0)	1 (3)	0 (0)	1 (2)
Two	1 (1)	1 (3)	2 (6)	0 (0)	1 (2)
Three to five	1 (1)	0 (0)	0 (0)	0 (0)	1 (2)
More than five	0 (0)	1 (3)	0 (0)	0 (0)	0 (0)
Don't know	2 (3)	2 (6)	2 (6)	0 (0)	3 (7)
Not reported	3 (4)	1 (3)	0 (0)	0 (0)	0 (0)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	3 (4)	2 (6)	0 (0)	0 (0)	4 (10)
Casual sex partner	1 (1)	0 (0)	0 (0)	0 (0)	1 (2)
Close friend	0 (0)	2 (6)	4 (12)	0 (0)	3 (7)
Acquaintance	3 (4)	0 (0)	1 (3)	0 (0)	0 (0)
Other	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	15 (19)	3 (9)	2 (6)	0 (0)	6 (15)
Water	10 (13)	5 (16)	6 (18)	1 (5)	9 (22)
Filter	7 (9)	3 (9)	3 (9)	0 (0)	3 (7)
Drug mix	4 (5)	0 (0)	1 (3)	0 (0)	3 (7)
None	55 (70)	25 (78)	22 (67)	18 (95)	30 (73)
Injected by someone after that person injected themselves or others last month (%)					
No	63 (80)	26 (81)	28 (85)	18 (95)	35 (85)
Yes	16 (20)	5 (16)	5 (15)	1 (5)	6 (15)
Not reported	0 (0)	1 (3)	0 (0)	0 (0)	0 (0)
Source of needle acquisition					
Needle Syringe Program	67 (85)	28 (88)	30 (91)	18 (95)	38 (93)
Chemist/Pharmacy	9 (11)	0 (0)	2 (6)	2 (11)	4 (10)
Personal sources	7 (9)	1 (3)	4 (12)	1 (5)	4 (10)
Dispensing/Vending Machine	17 (22)	5 (16)	3 (9)	3 (16)	7 (17)
Other sources	1 (1)	1 (3)	1 (3)	0 (0)	0 (0)

Table 4.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Northern Territory	2019	2020	2021	2022	2023
N° surveyed	N=85	N=37	N=40	N=20	N=50
Ever any treatment/therapy for drug use (%)					
No	39 (46)	16 (43)	20 (50)	6 (30)	22 (44)
Yes	46 (54)	21 (57)	20 (50)	14 (70)	28 (56)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
History of methadone maintenance treatment (%)					
Currently	10 (12)	1 (3)	6 (15)	1 (5)	3 (6)
Previously	17 (20)	7 (19)	4 (10)	4 (20)	9 (18)
Never	57 (67)	28 (76)	29 (73)	14 (70)	34 (68)
Not reported	1 (1)	1 (3)	1 (3)	1 (5)	4 (8)
History of buprenorphine (Subutex®) treatment (%)					
Currently	5 (6)	6 (16)	3 (8)	2 (10)	3 (6)
Previously	17 (20)	4 (11)	2 (5)	6 (30)	9 (18)
Never	62 (73)	26 (70)	35 (88)	10 (50)	33 (66)
Not reported	1 (1)	1 (3)	0 (0)	2 (10)	5 (10)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	3 (4)	4 (11)	1 (3)	1 (5)	1 (2)
Previously	18 (21)	6 (16)	4 (10)	7 (35)	11 (22)
Never	64 (75)	27 (73)	35 (88)	11 (55)	38 (76)
Not reported	0 (0)	0 (0)	0 (0)	1 (5)	0 (0)
History of depot buprenorphine treatment (%)					
Currently	-- --	2 (5)	3 (8)	0 (0)	1 (2)
Previously	-- --	3 (8)	0 (0)	0 (0)	3 (6)
Never	-- --	19 (51)	37 (93)	19 (95)	41 (82)
Not reported	-- --	13 (35)	0 (0)	1 (5)	5 (10)

Table 4.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

Northern Territory	2019	2020	2021	2022	2023
N° surveyed	N=85	N=37	N=40	N=20	N=50
Previous HIV test (%)					
Yes, ever	69 (81)	26 (70)	34 (85)	16 (80)	35 (70)
Yes, last year	43 (51)	14 (38)	18 (45)	6 (30)	16 (32)
>1 year ago	26 (31)	12 (32)	16 (40)	10 (50)	19 (38)
Never tested	11 (13)	9 (24)	6 (15)	2 (10)	10 (20)
Not reported	5 (6)	2 (5)	0 (0)	2 (10)	5 (10)
Previous HCV test (%)					
Yes, ever	66 (78)	27 (73)	34 (85)	17 (85)	34 (68)
Yes, last year	44 (52)	10 (27)	20 (50)	9 (45)	18 (36)
>1 year ago	22 (26)	17 (46)	14 (35)	8 (40)	16 (32)
Never tested	8 (9)	3 (8)	4 (10)	1 (5)	10 (20)
Not reported	11 (13)	7 (19)	2 (5)	2 (10)	6 (12)
Lifetime treatment for HCV (%)#					
N° self-reported HCV diagnosis	N=23	N=2	N=6	N=4	N=10
Antiviral treatment	16 (70)	2 (100)	3 (50)	1 (25)	9 (90)
No antiviral treatment	7 (30)	0 (0)	3 (50)	3 (75)	1 (10)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Treatment for HCV in past 12 months (%)**					
N° self-reported HCV diagnosis	N=16	N=1	N=4	N=4	N=5
Antiviral treatment	8 (50)	1 (100)	0 (0)	1 (25)	1 (20)
No antiviral treatment	8 (50)	0 (0)	4 (100)	3 (75)	4 (80)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

Table 4.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

Northern Territory	2019	2020	2021	2022	2023
N° surveyed	N=85	N=37	N=40	N=20	N=50
Sex with a regular partner last month (%)					
No	43 (51)	22 (59)	25 (63)	12 (60)	28 (56)
Yes	36 (42)	13 (35)	14 (35)	7 (35)	17 (34)
Not reported	6 (7)	2 (5)	1 (3)	1 (5)	5 (10)
Condom used with regular partner last month (%)					
N° surveyed	N=36	N=13	N=14	N=7	N=17
Never	28 (78)	11 (85)	8 (57)	6 (86)	14 (82)
Sometimes	5 (14)	1 (8)	1 (7)	0 (0)	3 (18)
Every time	3 (8)	1 (8)	5 (36)	1 (14)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sex with other partner(s) last month (%)					
No	58 (68)	31 (84)	29 (73)	15 (75)	38 (76)
Yes	20 (24)	4 (11)	10 (25)	5 (25)	7 (14)
Not reported	7 (8)	2 (5)	1 (3)	0 (0)	5 (10)
Condom used with other partner(s) last month (%)					
N° surveyed	N=20	N=4	N=10	N=5	N=7
Never	7 (35)	0 (0)	3 (30)	2 (40)	0 (0)
Sometimes	6 (30)	0 (0)	0 (0)	1 (20)	3 (43)
Every time	6 (30)	4 (100)	6 (60)	1 (20)	2 (29)
Not reported	1 (5)	0 (0)	1 (10)	1 (20)	2 (29)
Sex work last month (%)					
No	67 (79)	31 (84)	32 (80)	16 (80)	40 (80)
Yes	11 (13)	3 (8)	8 (20)	1 (5)	4 (8)
Not reported	7 (8)	3 (8)	0 (0)	3 (15)	6 (12)
Condom used at last sex work (%)					
Yes	7 (64)	3 (100)	7 (88)	1 (100)	4 (100)

Table 4.1.7 Number (percentage) of respondents by COVID-19 related impacts, 2020-2023

Northern Territory	2020	2021	2022	2023
N° surveyed	N=37	N=40	N=20	N=50
COVID-19 test				
Yes	8 (22)	9 (23)	17 (85)	42 (84)
No	25 (68)	21 (53)	2 (10)	8 (16)
Don't know	1 (3)	1 (3)	-- --	-- --
Not reported	3 (8)	9 (23)	1 (5)	0 (0)
Self-reported positive COVID-19 test result				
Yes	0 (0)	0 (0)	5 (29)	17 (40)
Yes, last 12 months	-- --	-- --	5 (29)	3 (7)
Yes, more than a year ago	-- --	-- --	0 (0)	14 (33)
COVID-19 vaccine uptake				
≥1 dose	-- --	23 (58)	15 (75)	38 (76)
COVID-19 vaccine doses				
One dose	-- --	5 (13)	0 (0)	2 (4)
Two doses	-- --	18 (45)	7 (35)	16 (32)
Three or more doses	-- --	-- --	8 (40)	20 (40)
No doses	-- --	13 (33)	5 (25)	12 (24)
Not reported	-- --	4 (10)	0 (0)	0 (0)
Vaccine type *			N=15	
Astra Zeneca	-- --	7 (18)	3 (20)	-- --
Pfizer	-- --	11 (28)	10 (67)	-- --
Don't know	-- --	1 (3)	2 (13)	-- --
Other	-- --	-- --	0 (0)	-- --
Not reported	-- --	21 (53)	-- --	-- --
* 2021 only one response permitted, 2022 multiple responses permitted				
Last vaccine location			N=20	N=50
GP or medical centre	-- --	-- --	7 (35)	18 (36)
Pharmacy/ chemist	-- --	-- --	0 (0)	2 (4)
Vaccine hub	-- --	-- --	5 (25)	15 (30)
Opioid treatment/ methadone clinic	-- --	-- --	0 (0)	0 (0)
NSP	-- --	-- --	0 (0)	0 (0)
Prison	-- --	-- --	0 (0)	4 (8)
Multiple response	-- --	-- --	1 (5)	0 (0)
Other	-- --	-- --	1 (5)	0 (0)
Not reported	-- --	-- --	6 (30)	11 (22)
Vaccine hesitancy - if not had three or more doses				
Haven't got around to it	-- --	-- --	3 (15)	12 (24)
Difficulty booking appointment	-- --	-- --	0 (0)	1 (2)
Concerns about side effects	-- --	-- --	2 (10)	3 (6)
Concerns about vaccine safety	-- --	-- --	2 (10)	2 (4)
Not at risk of serious illness	-- --	-- --	0 (0)	9 (18)
Other	-- --	-- --	4 (20)	1 (2)
Multiple response	-- --	-- --	1 (5)	4 (8)
Not reported	-- --	-- --	8 (40)	18 (36)

HIV antibody prevalence

Table 4.2.1 HIV antibody prevalence by gender and survey year

Northern Territory Survey year	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2019	52	1 (1.9)	29	1 (3.5)	82	2 (2.4)
2020	20	0 (0.0)	10	0 (0.0)	30	0 (0.0)
2021	25	1 (4.0)	14	1 (7.1)	39	2 (5.1)
2022	14	0 (0.0)	4	0 (0.0)	20	0 (0.0)
2023	27	1 (3.7)	13	0 (0.0)	41	1 (2.4)
X ² p trend		0.645		0.666		0.960

HCV antibody prevalence

Table 4.3.1 HCV antibody prevalence by gender and survey year

Northern Territory Survey year	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019	51	23 (45)	29	7 (24)	81	30 (37)
2020	20	5 (25)	10	0 (0)	30	5 (17)
2021	24	7 (29)	14	2 (14)	38	9 (24)
2022	14	5 (36)	4	0 (0)	20	5 (25)
2023*	27	11 (41)	13	5 (38)	41	16 (39)
X ² p trend		0.667		0.479		0.989

* Antibody testing assay changed in 2023. See Appendix B: Methodological Notes

Table 4.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Northern Territory Sexual identity	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019						
Heterosexual	43	20 (47)	21	4 (19)	65	24 (37)
Bisexual	4	2 (50)	3	1 (33)	7	3 (43)
Homosexual	1	0 (0)	1	1 (100)	2	1 (50)
p value		1.000		0.234		1.000
2020						
Heterosexual	19	5 (26)	5	0 (0)	24	5 (21)
Bisexual	1	0 (0)	2	0 (0)	3	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		1.000		--		1.000
2021						
Heterosexual	18	6 (33)	9	1 (11)	27	7 (26)
Bisexual	4	1 (25)	3	0 (0)	7	1 (14)
Homosexual	1	0 (0)	1	1 (100)	2	1 (50)
p value		1.000		0.308		0.790
2022						
Heterosexual	12	4 (33)	3	0 (0)	15	4 (27)
Bisexual	2	1 (50)	1	0 (0)	3	1 (33)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		1.000		--		1.000
2023						
Heterosexual	22	8 (36)	9	4 (44)	31	12 (39)
Bisexual	4	3 (75)	4	1 (25)	8	4 (50)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.273		1.000		0.888

Table 4.3.3 HCV antibody prevalence by age group, gender and survey year

Northern Territory Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	9	3 (33)	5	0 (0)	14	3 (21)
35-44 years	14	7 (50)	15	5 (33)	29	12 (41)
45+ years	27	13 (48)	9	2 (22)	37	15 (41)
p value		0.799		0.376		0.459
2020						
<25 years	1	0 (0)	0	0 (0)	1	0 (0)
25-34 years	3	0 (0)	0	0 (0)	3	0 (0)
35-44 years	4	1 (25)	3	0 (0)	7	1 (14)
45+ years	12	4 (33)	7	0 (0)	19	4 (21)
p value		0.830		--		1.000
2021						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	2	0 (0)	0	0 (0)	2	0 (0)
35-44 years	7	2 (29)	4	1 (4)	11	3 (27)
45+ years	15	5 (33)	10	1 (10)	25	6 (24)
p value		1.000		0.505		1.000
2022						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	1	0 (0)	0	0 (0)	1	0 (0)
35-44 years	4	1 (25)	1	0 (0)	5	1 (20)
45+ years	9	4 (44)	3	0 (0)	14	4 (29)
p value		1.000		--		1.000
2023						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	3	0 (0)	2	0 (0)	5	0 (0)
35-44 years	8	3 (38)	3	1 (33)	11	4 (36)
45+ years	16	8 (50)	8	4 (50)	25	12 (48)
p value		0.276		0.739		0.158

Table 4.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Northern Territory Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019						
<3 years	0	0 (0)	1	0 (0)	1	0 (0)
3 to 10 years	5	2 (40)	5	0 (0)	10	2 (20)
11+ years	43	20 (47)	23	7 (30)	67	27 (40)
p value		1.000		0.461		0.370
2020						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	3	0 (0)	0	0 (0)	3	0 (0)
11+ years	17	5 (29)	10	0 (0)	27	5 (19)
p value		0.539		--		1.000
2021						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	0	0 (0)	0	0 (0)	0	0 (0)
11+ years	22	7 (32)	14	2 (14)	36	9 (25)
p value		1.000		--		1.000
2022						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	0	0 (0)	0	0 (0)	0	0 (0)
11+ years	12	4 (33)	4	0 (0)	18	4 (22)
p value		--		--		--
2023						
<3 years	0	0 (0)	1	0 (0)	1	0 (0)
3 to 10 years	1	0 (0)	2	0 (0)	3	0 (0)
11+ years	26	11 (42)	10	5 (50)	37	16 (43)
p value		1.000		0.674		0.372

Table 4.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Northern Territory Receptively shared syringe last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019						
No receptive sharing	1	0 (0)	62	22 (35)	66	23 (35)
Receptive sharing	0	0 (0)	8	4 (50)	8	4 (50)
p value		--		0.458		0.452
2020						
No receptive sharing	0	0 (0)	22	3 (14)	22	3 (14)
Receptive sharing	0	0 (0)	3	0 (0)	3	0 (0)
p value		--		1.000		1.000
2021						
No receptive sharing	0	0 (0)	26	5 (19)	26	5 (19)
Receptive sharing	0	0 (0)	5	2 (40)	5	2 (40)
p value		--		0.562		0.562
2022						
No receptive sharing	0	0 (0)	18	4 (22)	19	5 (26)
Receptive sharing	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2023						
No receptive sharing	1	0 (0)	29	12 (41)	30	12 (40)
Receptive sharing	0	0 (0)	3	1 (33)	3	1 (33)
p value		--		1.000		1.000

Table 4.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

Northern Territory Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
Methamphetamine	1	0 (0)	39	12 (31)	42	13 (31)
Pharm. Opioids	0	0 (0)	23	11 (48)	23	11 (48)
OAT*	0	0 (0)	10	3 (30)	10	3 (30)
Other drugs	0	0 (0)	4	2 (50)	5	2 (40)
p value		--		0.511		0.563
2020						
Methamphetamine	0	0 (0)	19	2 (11)	19	2 (11)
Pharm. Opioids	0	0 (0)	6	2 (33)	6	2 (33)
OAT*	0	0 (0)	4	0 (0)	4	0 (0)
Other drugs	0	0 (0)	1	1 (100)	1	1 (100)
p value		--		0.057		0.057
2021						
Methamphetamine	1	0 (0)	23	3 (13)	24	3 (13)
Pharm. Opioids	0	0 (0)	4	1 (25)	4	1 (25)
OAT*	0	0 (0)	4	2 (50)	4	2 (50)
Other drugs	0	0 (0)	4	2 (50)	4	2 (50)
p value		--		0.203		0.179
2022						
Methamphetamine	0	0 (0)	9	2 (22)	11	3 (27)
Pharm. Opioids	0	0 (0)	6	1 (17)	6	1 (17)
OAT*	0	0 (0)	1	1 (100)	1	1 (100)
Other drugs	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.243		0.270
2023						
Methamphetamine	1	0 (0)	26	12 (46)	27	12 (44)
Pharm. Opioids	0	0 (0)	6	2 (33)	6	2 (33)
OAT*	0	0 (0)	2	1 (50)	2	1 (50)
Other drugs	0	0 (0)	4	0 (0)	4	0 (0)
p value		--		0.350		0.378

*OAT = methadone, buprenorphine or buprenorphine/naloxone

Table 4.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Northern Territory Frequency of injection last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019						
Less than daily	0	0 (0)	19	9 (47)	20	9 (45)
Daily or more	1	0 (0)	52	17 (33)	55	18 (33)
Not last month	0	0 (0)	6	3 (50)	6	3 (50)
p value		--		0.378		0.483
2020						
Less than daily	0	0 (0)	12	2 (17)	12	2 (17)
Daily or more	0	0 (0)	14	1 (7)	14	1 (7)
Not last month	0	0 (0)	4	2 (50)	4	2 (50)
p value		--		0.134		0.134
2021						
Less than daily	0	0 (0)	17	2 (12)	17	2 (12)
Daily or more	0	0 (0)	14	5 (36)	14	5 (36)
Not last month	1	0 (0)	4	1 (25)	5	1 (20)
p value		--		0.220		0.345
2022						
Less than daily	0	0 (0)	10	2 (20)	11	3 (27)
Daily or more	0	0 (0)	8	2 (25)	8	2 (25)
Not last month	0	0 (0)	0	0 (0)	1	0 (0)
p value		--		1.000		1.000
2023						
Less than daily	0	0 (0)	16	9 (56)	16	9 (56)
Daily or more	1	0 (0)	16	4 (25)	17	4 (24)
Not last month	0	0 (0)	6	2 (33)	6	2 (33)
p value		--		0.242		0.160

Table 4.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Northern Territory Imprisonment last year	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019						
No imprisonment	1	0 (0)	65	27 (42)	66	27 (41)
Imprisonment	0	0 (0)	7	2 (29)	8	2 (25)
p value		--		0.694		0.469
2020						
No imprisonment	0	0 (0)	25	5 (20)	25	5 (20)
Imprisonment	0	0 (0)	3	0 (0)	3	0 (0)
p value		--		1.000		1.000
2021						
No imprisonment	1	0 (0)	32	9 (28)	34	9 (26)
Imprisonment	0	0 (0)	4	0 (0)	4	0 (0)
p value		--		0.553		0.554
2022						
No imprisonment	0	0 (0)	17	4 (24)	19	5 (26)
Imprisonment	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2023						
No imprisonment	1	0 (0)	34	12 (35)	35	12 (34)
Imprisonment	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		1.000		1.000

Table 4.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Northern Territory Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
Non Indigenous	39	16 (41)	13	1 (8)	53	17 (32)
Indigenous	12	7 (58)	16	6 (38)	28	13 (46)
p value		0.292		0.093		0.203
2020						
Non Indigenous	12	3 (25)	9	0 (0)	21	3 (14)
Indigenous	6	1 (17)	1	0 (0)	7	1 (14)
p value		1.000		--		1.000
2021						
Non Indigenous	13	4 (31)	6	0 (0)	19	4 (21)
Indigenous	11	3 (27)	8	2 (25)	19	5 (26)
p value		0.605		0.473		1.000
2022						
Non Indigenous	10	4 (40)	4	0 (0)	15	4 (27)
Indigenous	3	1 (33)	0	0 (0)	4	1 (25)
p value		1.000		--		1.000
2023						
Non Indigenous	15	7 (47)	9	5 (56)	25	12 (48)
Indigenous	12	4 (33)	4	0 (0)	16	4 (25)
p value		0.696		0.105		0.195

Table 4.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Northern Territory Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
English speaking	48	22 (46)	28	7 (25)	77	29 (38)
Non-English speaking	3	1 (33)	1	0 (0)	4	1 (25)
p value		1.000		1.000		1.000
2020						
English speaking	18	4 (22)	9	0 (0)	27	4 (15)
Non-English speaking	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		--		1.000
2021						
English speaking	23	6 (26)	14	2 (14)	37	8 (22)
Non-English speaking	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.292		--		0.237
2022						
English speaking	14	5 (36)	4	0 (0)	20	5 (25)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2023						
English speaking	27	11 (41)	12	5 (42)	40	16 (40)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

Table 4.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

Northern Territory Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
Australia	47	21 (45)	28	7 (25)	76	28 (37)
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	1 (100)	0	0 (0)	1	1 (100)
Other	2	1 (50)	1	0 (0)	3	1 (33)
p value		0.849		1.000		0.824
2020						
Australia	18	5 (28)	10	0 (0)	28	5 (18)
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		1.000		--		1.000
2021						
Australia	23	7 (30)	14	2 (14)	37	9 (24)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2022						
Australia	13	5 (38)	4	0 (0)	19	5 (26)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	0 (0)	0	0 (0)	1	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		1.000		--		1.000
2023						
Australia	26	10 (38)	13	5 (38)	39	15 (38)
Other Oceania	0	0 (0)	0	0 (0)	1	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	1 (100)	0	0 (0)	1	1 (100)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.407		--		0.634

HCV RNA prevalence

Table 4.4.1 HCV RNA prevalence by gender and survey year

Northern Territory Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*	36	4 (11)	18	2 (11)	56	6 (11)
2019	13	0 (0)	5	0 (0)	18	0 (0)
2021	22	3 (14)	11	0 (0)	33	3 (9)
2022	14	3 (21)	4	0 (0)	20	3 (15)
2023	27	3 (11)	13	1 (8)	41	4 (10)
X ² p trend		0.577		0.615		0.782

* 2019: Weighted for gender and HCV antibody status

Totals include respondents where gender was reported as other or not reported

Table 4.4.2 HCV RNA prevalence by sexual identity, gender and survey year

Northern Territory Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
Heterosexual	28	4 (14)	15	1 (7)	43	5 (12)
Bisexual	3	0 (0)	1	0 (0)	4	0 (0)
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)
p value		0.731		0.935		0.698
2020						
Heterosexual	13	0 (0)	3	0 (0)	16	0 (0)
Bisexual	0	0 (0)	2	0 (0)	2	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2021						
Heterosexual	17	2 (12)	8	0 (0)	25	2 (8)
Bisexual	3	1 (33)	2	0 (0)	5	1 (20)
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)
p value		0.564		--		0.629
2022						
Heterosexual	12	3 (25)	3	0 (0)	15	3 (20)
Bisexual	2	0 (0)	1	0 (0)	3	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		1.000		--		1.000
2023						
Heterosexual	22	3 (14)	9	1 (11)	31	4 (13)
Bisexual	4	0 (0)	4	0 (0)	8	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		1.000		1.000		0.645

Table 4.4.3 HCV RNA prevalence by age group, gender and survey year

Northern Territory Age group	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019*						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	4	0 (0)	3	0 (0)	7	0 (0)
35-44 years	7	0 (0)	12	2 (17)	19	2 (11)
45+ years	24	4 (17)	6	0 (0)	30	4 (13)
p value		0.405		0.464		0.617
2020						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	2	0 (0)	0	0 (0)	2	0 (0)
35-44 years	1	0 (0)	2	0 (0)	3	0 (0)
45+ years	10	0 (0)	3	0 (0)	13	0 (0)
p value		--		--		--
2021						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	2	0 (0)	0	0 (0)	2	0 (0)
35-44 years	6	1 (17)	4	0 (0)	10	1 (10)
45+ years	14	2 (14)	7	0 (0)	21	2 (10)
p value		0.832		--		0.898
2022						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	1	0 (0)	0	0 (0)	1	0 (0)
35-44 years	4	0 (0)	1	0 (0)	5	0 (0)
45+ years	9	3 (33)	3	0 (0)	14	3 (21)
p value		0.604		--		0.601
2023						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	3	0 (0)	2	0 (0)	5	0 (0)
35-44 years	8	0 (0)	3	1 (33)	11	1 (9)
45+ years	16	3 (19)	8	0 (0)	25	3 (12)
p value		0.672		0.385		1.000

Table 4.4.4 HCV RNA prevalence by years since first injection, gender and survey year

Northern Territory Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
<3 years	0	0 (0)	1	0 (0)	1	0 (0)
3 to 10 years	2	0 (0)	4	0 (0)	6	0 (0)
11+ years	32	4 (13)	16	2 (13)	47	6 (13)
p value		0.566		0.720		0.606
2020						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	1	0 (0)	0	0 (0)	1	0 (0)
11+ years	12	0 (0)	5	0 (0)	17	0 (0)
p value		--		--		--
2021						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	0	0 (0)	0	0 (0)	0	0 (0)
11+ years	20	3 (15)	11	0 (0)	31	3 (10)
p value		0.676		--		0.744
2022						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	0	0 (0)	0	0 (0)	0	0 (0)
11+ years	12	3 (25)	4	0 (0)	18	3 (17)
p value		--		--		--
2023						
<3 years	0	0 (0)	1	0 (0)	1	0 (0)
3 to 10 years	1	0 (0)	2	1 (50)	3	1 (33)
11+ years	26	3 (12)	10	0 (0)	37	3 (8)
p value		1.000		0.231		0.348

Table 4.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Northern Territory Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
No receptive sharing	29	4 (14)	17	1 (6)	46	5 (11)
Receptive sharing	4	0 (0)	3	1 (33)	7	1 (14)
p value		0.496		0.153		0.805
2020						
No receptive sharing	9	0 (0)	5	0 (0)	14	0 (0)
Receptive sharing	1	0 (0)	0	0 (0)	1	0 (0)
p value		--		--		--
2021						
No receptive sharing	14	1 (7)	10	0 (0)	24	1 (4)
Receptive sharing	4	1 (25)	1	0 (0)	5	1 (20)
p value		0.316		--		0.204
2022						
No receptive sharing	13	3 (23)	4	0 (0)	19	3 (16)
Receptive sharing	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2023						
No receptive sharing	18	2 (11)	12	1 (8)	30	3 (10)
Receptive sharing	3	0 (0)	0	0 (0)	3	0 (0)
p value		1.000		--		1.000

Table 4.4.6 HCV RNA prevalence by last drug injected, gender and survey year

Northern Territory Last drug injected	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
Methamphetamine	15	2 (13)	11	1 (9)	26	3 (12)
Pharm. Opioids	12	2 (17)	6	0 (0)	18	2 (11)
OAT	6	0 (0)	1	0 (0)	7	0 (0)
Other drugs	3	0 (0)	2	0 (0)	5	0 (0)
p value		0.746		0.849		0.707
2020						
Methamphetamine	5	0 (0)	4	0 (0)	9	0 (0)
Pharm. Opioids	4	0 (0)	1	0 (0)	5	0 (0)
OAT	3	0 (0)	0	0 (0)	3	0 (0)
Other drugs	1	0 (0)	0	0 (0)	1	0 (0)
p value		--		--		--
2021						
Methamphetamine	11	1 (9)	10	0 (0)	21	1 (5)
Pharm. Opioids	3	0 (0)	0	0 (0)	3	0 (0)
OAT	4	1 (25)	0	0 (0)	4	1 (25)
Other drugs	2	0 (0)	1	0 (0)	3	0 (0)
p value		0.667		--		0.425
2022						
Methamphetamine	7	2 (29)	3	0 (0)	11	2 (18)
Pharm. Opioids	5	1 (20)	1	0 (0)	6	1 (17)
OAT	1	0 (0)	0	0 (0)	1	0 (0)
Other drugs	1	0 (0)	0	0 (0)	2	0 (0)
p value		0.858		--		0.890
2023						
Methamphetamine	16	2 (13)	10	1 (10)	27	3 (11)
Pharm. Opioids	5	1 (20)	1	0 (0)	6	1 (17)
OAT	1	0 (0)	1	0 (0)	2	0 (0)
Other drugs	3	0 (0)	1	0 (0)	4	0 (0)
p value		0.837		0.955		0.807

OAT: methadone, buprenorphine or buprenorphine/naloxone

Table 4.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year

Northern Territory Frequency of injection last month	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019*						
Less than daily	11	2 (18)	5	1 (20)	15	3 (20)
Daily or more	23	2 (9)	15	1 (7)	37	3 (8)
Not last month	2	0 (0)	1	0 (0)	3	0 (0)
p value		0.820		0.630		0.607
2020						
Less than daily	5	0 (0)	2	0 (0)	7	0 (0)
Daily or more	6	0 (0)	3	0 (0)	9	0 (0)
Not last month	2	0 (0)	0	0 (0)	2	0 (0)
p value		--		--		--
2021						
Less than daily	9	1 (11)	7	0 (0)	16	1 (6)
Daily or more	9	1 (11)	4	0 (0)	13	1 (8)
Not last month	2	0 (0)	0	0 (0)	2	0 (0)
p value		0.884		--		0.918
2022						
Less than daily	6	2 (33)	3	0 (0)	11	2 (18)
Daily or more	7	1 (14)	1	0 (0)	8	1 (13)
Not last month	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.654		--		1.000
2023						
Less than daily	10	2 (20)	6	1 (17)	16	3 (19)
Daily or more	11	0 (0)	6	0 (0)	17	0 (0)
Not last month	4	1 (25)	1	0 (0)	6	1 (17)
p value		0.259		1.000		0.147

Table 4.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year

Northern Territory Imprisonment last year	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019*						
No imprisonment	31	4 (13)	18	1 (6)	48	5 (10)
Imprisonment	2	0 (0)	2	1 (50)	4	1 (25)
p value		0.561		0.059		0.452
2020						
No imprisonment	11	0 (0)	4	0 (0)	15	0 (0)
Imprisonment	1	0 (0)	0	0 (0)	1	0 (0)
p value		--		--		--
2021						
No imprisonment	19	3 (16)	10	0 (0)	29	3 (10)
Imprisonment	3	0 (0)	1	0 (0)	4	0 (0)
p value		0.459		--		0.500
2022						
No imprisonment	14	3 (21)	3	0 (0)	19	3 (16)
Imprisonment	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2023						
No imprisonment	21	2 (10)	13	1 (8)	35	3 (9)
Imprisonment	2	0 (0)	0	0 (0)	2	0 (0)
p value		1.000		--		1.000

Table 4.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Northern Territory Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019*						
Non Indigenous	32	2 (6)	9	0 (0)	41	2 (5)
Indigenous	4	2 (50)	11	2 (18)	15	4 (27)
p value		0.108		0.183		0.102
2020						
Non Indigenous	9	0 (0)	5	0 (0)	14	0 (0)
Indigenous	3	0 (0)	0	0 (0)	3	0 (0)
p value		--		--		--
2021						
Non Indigenous	11	2 (18)	4	0 (0)	15	2 (13)
Indigenous	11	1 (9)	7	0 (0)	18	1 (6)
p value		0.534		--		0.439
2022						
Non Indigenous	10	3 (30)	4	0 (0)	15	3 (20)
Indigenous	3	0 (0)	0	0 (0)	4	0 (0)
p value		0.528		--		1.000
2023						
Non Indigenous	15	3 (20)	9	0 (0)	25	3 (12)
Indigenous	12	0 (0)	4	1 (25)	16	1 (6)
p value		0.231		0.308		1.000

Table 4.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year

Northern Territory Main language spoken at home by parents	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019*						
English speaking	34	4 (12)	19	2 (11)	53	6 (11)
Non-English speaking	2	0 (0)	1	0 (0)	3	0 (0)
p value		0.644		0.746		0.569
2020						
English speaking	12	0 (0)	5	0 (0)	17	0 (0)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2021						
English speaking	21	3 (14)	11	0 (0)	32	3 (9)
Non-English speaking	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.684		--		0.748
2022						
English speaking	14	3 (21)	4	0 (0)	20	3 (15)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2023						
English speaking	27	3 (11)	12	1 (8)	40	4 (10)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

Table 4.4.11 HCV RNA prevalence by region/country of birth, gender and survey year

Northern Territory		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2019*							
Australia	32	4 (13)	19	2 (11)	51	6 (12)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	2	0 (0)	0	0 (0)	2	0 (0)	
Other	2	0 (0)	1	0 (0)	3	0 (0)	
p value		0.859		0.746		0.823	
2020							
Australia	12	0 (0)	5	0 (0)	17	0 (0)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		--		--		--	
2021							
Australia	21	3 (14)	11	0 (0)	32	3 (9)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		--		--		--	
2022							
Australia	13	3 (23)	4	0 (0)	19	3 (16)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	1	0 (0)	0	0 (0)	1	0 (0)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		1.000		--		1.000	
2023							
Australia	26	2 (8)	13	1 (8)	39	3	
Other Oceania	0	0 (0)	0	0 (0)	1	0	
Asia	0	0 (0)	0	0 (0)	0	0	
UK & Ireland	1	1 (100)	0	0 (0)	1	1	
Other	0	0 (0)	0	0 (0)	0	0	
p value		0.111		--		0.188	

Queensland

Table 5.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Queensland	2019	2020*	2021*	2022	2023
Number of sites	10	7	11	10	10
N° surveyed	N=574	N=391	N=458	N=328	N=359
Response rate (%)	34%	33%	31%	26%	39%
Gender (%)					
Male	407 (71)	285 (73)	307 (67)	229 (70)	230 (64)
Female	160 (28)	104 (27)	145 (32)	92 (28)	124 (35)
Other	3 (1)	1 (<1)	6 (1)	6 (2)	4 (1)
Not reported	4 (1)	1 (<1)	0 (0)	1 (<1)	1 (<1)
Sexual identity (%)					
Heterosexual	427 (74)	315 (81)	382 (83)	254 (77)	276 (77)
Bisexual	63 (11)	38 (10)	42 (9)	34 (10)	47 (13)
Gay/Lesbian	27 (5)	12 (3)	24 (5)	20 (6)	22 (6)
Other	-- --	8 (2)	9 (2)	16 (5)	11 (3)
Not reported	57 (10)	18 (5)	1 (<1)	4 (1)	3 (1)
Aboriginal and Torres Strait Islander origin (%)					
No	452 (79)	317 (81)	365 (80)	268 (82)	288 (80)
Yes	116 (20)	64 (16)	79 (17)	55 (17)	69 (19)
Not reported	6 (1)	10 (3)	14 (3)	5 (2)	2 (1)
Region/country of birth (%)					
Australia	525 (91)	352 (90)	407 (89)	293 (89)	331 (92)
Other Oceania	12 (2)	15 (4)	11 (2)	11 (3)	10 (3)
Asia	4 (1)	1 (<1)	3 (1)	1 (<1)	1 (<1)
UK & Ireland	11 (2)	11 (3)	11 (2)	8 (2)	9 (3)
Other	17 (3)	8 (2)	14 (3)	8 (2)	5 (1)
Not reported	5 (1)	4 (1)	12 (3)	7 (2)	3 (1)
Main language spoken at home by parents (%)					
English	550 (96)	382 (98)	441 (96)	316 (96)	351 (98)
Non-English	22 (4)	9 (2)	11 (2)	12 (4)	7 (2)
Not reported	2 (<1)	0 (0)	6 (1)	0 (0)	1 (<1)
Age and time since first injection (years)					
<i>Median age</i>	42	42	42	43	43
<i>Age range</i>	16-70	19-69	16-72	16-71	18-72
Age group (%)					
<25 years	30 (5)	19 (5)	20 (4)	15 (5)	14 (4)
25+ years	543 (95)	372 (95)	438 (96)	310 (95)	345 (96)
Not reported	1 (<1)	0 (0)	0 (0)	3 (<1)	0 (0)
Median age first injection					
<i>Median age first injection</i>	19	19	19	19	20
<i>Age range</i>	10-60	11-59	12-52	10-55	10-65
<i>N° not reported</i>	26	4	14	17	5
Median yrs since first injection					
<i>Median yrs since first injection</i>	21	23	22	22	21
<i>Range</i>	<1-51	<1-53	<1-58	<1-51	<1-54
Years since first injection					
<3 years	51 (9)	32 (8)	27 (6)	21 (6)	24 (7)
3+ years	497 (87)	354 (91)	415 (91)	290 (88)	330 (92)
Not reported	26 (5)	5 (1)	16 (3)	17 (5)	5 (1)
Imprisonment last year (%)					
No	480 (84)	336 (86)	385 (84)	288 (88)	303 (84)
Yes	66 (12)	39 (10)	46 (10)	29 (9)	36 (10)
Not reported	28 (5)	16 (4)	27 (6)	11 (3)	20 (6)
N° in prison					
<i>N° in prison</i>	N=66	N=39	N=46	N=29	N=36
Injected in prison	30 (45)	18 (46)	27 (59)	12 (41)	14 (39)

* Implementation of the 2020 and 2021 ANSPS was impacted by the COVID-19 pandemic, see page 1 for more information

Table 5.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

Queensland	2019	2020	2021	2022	2023
N° surveyed	N=574	N=391	N=458	N=328	N=359
Drug last injected (%)					
Cocaine	3 (1)	2 (1)	2 (<1)	3 (1)	4 (1)
Methamphetamine	281 (49)	156 (40)	194 (42)	142 (43)	185 (52)
Heroin	93 (16)	63 (16)	72 (16)	61 (19)	50 (14)
Pharm. opioids	75 (13)	69 (18)	73 (16)	40 (12)	23 (6)
Methadone	29 (5)	22 (6)	20 (4)	13 (4)	21 (6)
Buprenorphine	22 (4)	23 (6)	25 (5)	12 (4)	18 (5)
Buprenorphine/naloxone	9 (2)	4 (1)	12 (3)	8 (2)	7 (2)
PIEDs	27 (5)	31 (8)	34 (7)	30 (9)	24 (7)
More than one	26 (5)	16 (4)	15 (3)	11 (3)	16 (4)
Other	8 (1)	2 (1)	4 (1)	3 (1)	6 (2)
Not reported	1 (<1)	3 (1)	7 (2)	5 (2)	5 (1)
Ever injected opioids					
No	143 (25)	101 (26)	120 (26)	99 (30)	114 (32)
Yes	428 (75)	290 (74)	333 (73)	227 (69)	241 (67)
Not reported	3 (1)	0 (0)	5 (1)	2 (1)	4 (1)
Frequency of injection last month (%)					
Not last month	47 (8)	46 (12)	73 (16)	35 (11)	40 (11)
Less than weekly	86 (15)	59 (15)	75 (16)	63 (19)	59 (16)
Weekly not daily	133 (23)	78 (20)	89 (19)	68 (21)	82 (23)
Daily or more	305 (53)	204 (52)	215 (47)	157 (48)	169 (47)
Not reported	3 (1)	4 (1)	6 (1)	5 (2)	9 (3)
Present when someone injected for the first time in the last 12 months (%)					
No	457 (80)	320 (82)	377 (82)	284 (87)	291 (81)
Yes	96 (17)	67 (17)	73 (16)	39 (12)	58 (16)
Not reported	21 (4)	4 (1)	8 (2)	5 (2)	10 (3)
Overdosed in last 12 months					
No	478 (83)	329 (84)	400 (87)	290 (88)	303 (84)
Yes	78 (14)	58 (15)	49 (11)	34 (10)	45 (13)
Not reported	18 (3)	4 (1)	9 (2)	4 (1)	11 (3)

Table 5.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

Queensland	2019	2020	2021	2022	2023
N° injected last month	N=524	N=341	N=379	N=288	N=310
Places injected last month (%)					
All private	327 (62)	225 (66)	249 (66)	187 (65)	183 (59)
Any public	194 (37)	116 (34)	128 (34)	101 (35)	126 (41)
Not reported	3 (1)	0 (0)	2 (1)	0 (0)	1 (<1)
Use of new and sterile needles and syringes last month (%)					
All injections	416 (79)	274 (80)	306 (81)	221 (77)	235 (76)
Most of the time	87 (17)	55 (16)	57 (15)	52 (18)	61 (20)
Half of the time	8 (2)	6 (2)	9 (2)	9 (3)	3 (1)
Some of the time	8 (2)	5 (1)	5 (1)	2 (1)	5 (2)
Not last month	2 (<1)	0 (0)	2 (1)	2 (1)	2 (1)
Not reported	3 (1)	1 (<1)	0 (0)	2 (1)	4 (1)
Re-used someone else's used needle & syringe last month (%)					
None	464 (89)	292 (86)	327 (86)	247 (86)	257 (83)
Once	13 (2)	16 (5)	12 (3)	18 (6)	21 (7)
Twice	17 (3)	10 (3)	13 (3)	12 (4)	16 (5)
3-5 times	15 (3)	13 (4)	14 (4)	5 (2)	7 (2)
>5 times	12 (2)	9 (3)	12 (3)	6 (2)	6 (2)
Not reported	3 (1)	1 (<1)	1 (<1)	0 (0)	3 (1)
Number of people needle & syringe was re-used after last month (%)					
None	464 (89)	292 (86)	327 (86)	247 (86)	257 (83)
One	19 (4)	18 (5)	22 (6)	13 (5)	17 (5)
Two	4 (1)	7 (2)	4 (1)	7 (2)	6 (2)
Three to five	6 (1)	3 (1)	2 (1)	1 (<1)	4 (1)
More than five	4 (1)	2 (1)	4 (1)	3 (1)	1 (<1)
Don't know	14 (3)	9 (3)	13 (3)	7 (2)	14 (5)
Not reported	13 (2)	10 (3)	7 (2)	10 (3)	11 (4)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	19 (4)	16 (5)	15 (4)	13 (5)	17 (5)
Casual sex partner	3 (1)	4 (1)	3 (1)	3 (1)	5 (2)
Close friend	19 (4)	15 (4)	14 (4)	11 (4)	9 (3)
Acquaintance	9 (2)	5 (1)	10 (3)	6 (2)	13 (4)
Other	6 (1)	4 (1)	7 (2)	1 (<1)	2 (1)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	102 (19)	43 (13)	74 (20)	50 (17)	50 (16)
Water	102 (19)	47 (14)	65 (17)	45 (16)	57 (18)
Filter	59 (11)	17 (5)	36 (10)	19 (7)	30 (10)
Drug mix	63 (12)	21 (6)	38 (10)	20 (7)	29 (9)
None	368 (70)	263 (77)	274 (72)	210 (73)	219 (71)
Injected by someone after that person injected themselves or others last month (%)					
No	442 (84)	305 (89)	325 (86)	237 (82)	266 (86)
Yes	78 (15)	35 (10)	53 (14)	47 (16)	42 (14)
Not reported	4 (1)	1 (<1)	1 (<1)	4 (1)	2 (1)
Source of needle acquisition					
Needle Syringe Program	473 (90)	309 (91)	339 (89)	242 (84)	263 (85)
Chemist/Pharmacy	161 (31)	89 (26)	96 (25)	69 (24)	75 (24)
Personal sources	55 (11)	24 (7)	37 (10)	20 (7)	41 (13)
Dispensing/Vending Machine	87 (17)	45 (13)	47 (12)	26 (9)	42 (14)
Other sources	12 (2)	9 (3)	9 (2)	11 (4)	2 (1)

Table 5.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Queensland	2019	2020	2021	2022	2023
N° surveyed	N=574	N=391	N=458	N=328	N=359
Ever any treatment/therapy for drug use (%)					
No	179 (31)	124 (32)	152 (33)	113 (34)	127 (35)
Yes	394 (69)	266 (68)	305 (67)	214 (65)	232 (65)
Not reported	1 (<1)	1 (<1)	1 (<1)	1 (<1)	0 (0)
History of methadone maintenance treatment (%)					
Currently	81 (14)	58 (15)	42 (9)	44 (13)	42 (12)
Previously	113 (20)	77 (20)	101 (22)	65 (20)	70 (20)
Never	369 (64)	247 (63)	297 (65)	210 (64)	236 (66)
Not reported	11 (2)	9 (2)	18 (4)	9 (3)	11 (3)
History of buprenorphine (Subutex®) treatment (%)					
Currently	52 (9)	45 (12)	52 (11)	31 (9)	40 (11)
Previously	131 (23)	99 (25)	93 (20)	67 (20)	61 (17)
Never	381 (66)	240 (61)	299 (65)	221 (67)	247 (69)
Not reported	10 (2)	7 (2)	14 (3)	9 (3)	11 (3)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	44 (8)	26 (7)	36 (8)	16 (5)	23 (6)
Previously	125 (22)	90 (23)	100 (22)	73 (22)	70 (20)
Never	395 (69)	273 (70)	317 (69)	234 (71)	265 (74)
Not reported	10 (2)	2 (1)	5 (1)	5 (2)	1 (<1)
History of depot buprenorphine treatment (%)					
Currently	-- --	20 (5)	22 (5)	10 (3)	11 (3)
Previously	-- --	18 (5)	18 (4)	27 (8)	25 (7)
Never	-- --	219 (56)	404 (88)	279 (85)	309 (86)
Not reported	-- --	134 (34)	14 (3)	12 (4)	14 (4)

Table 5.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

Queensland	2019	2020	2021	2022	2023
N° surveyed	N=574	N=391	N=458	N=328	N=359
Previous HIV test (%)					
Yes, ever	489 (85)	328 (84)	350 (76)	251 (77)	256 (71)
Yes, last year	287 (50)	180 (46)	146 (32)	118 (36)	147 (41)
>1 year ago	202 (35)	148 (38)	204 (45)	133 (41)	109 (30)
Never tested	69 (12)	56 (14)	95 (21)	68 (21)	86 (24)
Not reported	16 (3)	7 (2)	13 (3)	9 (3)	17 (5)
Previous HCV test (%)					
Yes, ever	482 (84)	341 (87)	367 (80)	267 (81)	286 (80)
Yes, last year	322 (56)	192 (49)	198 (43)	144 (44)	164 (46)
>1 year ago	160 (28)	149 (38)	169 (37)	123 (38)	122 (34)
Never tested	46 (8)	29 (7)	59 (13)	41 (13)	44 (12)
Not reported	46 (8)	21 (5)	32 (7)	20 (6)	29 (8)
Lifetime treatment for HCV (%)#					
N° self-reported HCV diagnosis	N=146	N=100	N=107	N=54	N=81
Antiviral treatment	92 (63)	65 (65)	80 (75)	33 (61)	57 (70)
No antiviral treatment	54 (37)	35 (35)	25 (23)	21 (39)	24 (30)
Not reported	0 (0)	0 (0)	2 (2)	0 (0)	0 (0)
Treatment for HCV in past 12 months (%)##					
N° self-reported HCV diagnosis	N=113	N=62	N=54	N=33	N=50
Antiviral treatment	48 (42)	23 (37)	20 (37)	11 (33)	18 (36)
No antiviral treatment	65 (58)	39 (63)	32 (59)	22 (67)	32 (64)
Not reported	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)

among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

Table 5.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

Queensland	2019	2020	2021	2022	2023
N° surveyed	N=574	N=391	N=458	N=328	N=359
Sex with a regular partner last month (%)					
No	301 (52)	217 (56)	234 (51)	172 (52)	166 (46)
Yes	256 (45)	168 (43)	210 (46)	149 (45)	175 (49)
Not reported	17 (3)	6 (2)	14 (3)	7 (2)	18 (5)
Condom used with regular partner last month (%)					
N° surveyed	N=256	N=168	N=210	N=149	N=175
Never	197 (77)	133 (79)	161 (77)	116 (78)	146 (83)
Sometimes	26 (10)	12 (7)	28 (13)	17 (11)	13 (7)
Every time	22 (9)	15 (9)	14 (7)	8 (5)	12 (7)
Not reported	11 (4)	8 (5)	7 (3)	8 (5)	4 (2)
Sex with other partner(s) last month (%)					
No	457 (80)	317 (81)	366 (80)	265 (81)	269 (75)
Yes	96 (17)	58 (15)	70 (15)	48 (15)	67 (19)
Not reported	21 (4)	16 (4)	22 (5)	15 (5)	23 (6)
Condom used with other partner(s) last month (%)					
N° surveyed	N=96	N=58	N=70	N=48	N=67
Never	43 (45)	28 (48)	31 (44)	26 (54)	40 (60)
Sometimes	25 (26)	15 (26)	22 (31)	14 (29)	10 (15)
Every time	21 (22)	14 (24)	12 (17)	6 (13)	16 (24)
Not reported	7 (7)	1 (2)	5 (7)	2 (4)	1 (1)
Sex work last month (%)					
No	528 (92)	363 (93)	422 (92)	304 (93)	317 (88)
Yes	21 (4)	14 (4)	14 (3)	9 (3)	18 (5)
Not reported	25 (4)	14 (4)	22 (5)	15 (5)	24 (7)
Condom used at last sex work (%)					
Yes	13 (62)	8 (57)	8 (57)	7 (78)	10 (56)

Table 5.1.7 Number (percentage) of respondents by COVID-19 related impacts, 2020-2023

Queensland	2020	2021	2022	2023
N° surveyed	N=391	N=458	N=328	N=359
COVID-19 test				
Yes	78 (20)	122 (27)	244 (74)	245 (68)
No	246 (63)	205 (45)	54 (16)	45 (13)
Don't know	16 (4)	12 (3)	-- --	-- --
Not reported	51 (13)	119 (26)	30 (9)	69 (19)
Self-reported positive COVID-19 test result				
Yes	0 (0)	0 (0)	86 (35)	104 (42)
Yes, last 12 months	-- --	-- --	80 (33)	50 (20)
Yes, more than a year ago	-- --	-- --	6 (2)	54 (22)
COVID-19 vaccine uptake				
≥1 dose	-- --	103 (22)	228 (70)	217 (60)
COVID-19 vaccine doses				
One dose	-- --	53 (12)	18 (5)	22 (6)
Two doses	-- --	50 (11)	93 (28)	79 (22)
Three or more doses	-- --	-- --	117 (36)	116 (32)
No doses	-- --	239 (52)	68 (21)	62 (17)
Not reported	-- --	116 (25)	32 (10)	80 (22)
Vaccine type *			N=228	
Astra Zeneca	-- --	48 (10)	60 (26)	-- --
Pfizer	-- --	37 (8)	149 (65)	-- --
Don't know	-- --	26 (6)	32 (14)	-- --
Other	-- --	-- --	27 (12)	-- --
Not reported	-- --	347 (76)	-- --	-- --
* 2021 only one response permitted, 2022 multiple responses permitted				
Last vaccine location			N=328	N=359
GP or medical centre	-- --	-- --	89 (27)	99 (28)
Pharmacy/ chemist	-- --	-- --	55 (17)	61 (17)
Vaccine hub	-- --	-- --	59 (18)	32 (9)
Opioid treatment/ methadone clinic	-- --	-- --	0 (0)	2 (1)
NSP	-- --	-- --	4 (1)	3 (1)
Prison	-- --	-- --	17 (5)	17 (5)
Multiple response	-- --	-- --	3 (1)	5 (1)
Other	-- --	-- --	12 (4)	10 (3)
Not reported	-- --	-- --	89 (27)	130 (36)
Vaccine hesitancy - if not had three or more doses				
Haven't got around to it	-- --	-- --	45 (14)	21 (6)
Difficulty booking appointment	-- --	-- --	4 (1)	2 (1)
Concerns about side effects	-- --	-- --	19 (6)	29 (8)
Concerns about vaccine safety	-- --	-- --	26 (8)	16 (4)
Not at risk of serious illness	-- --	-- --	21 (6)	37 (10)
Other	-- --	-- --	46 (14)	31 (9)
Multiple response	-- --	-- --	14 (4)	18 (5)
Not reported	-- --	-- --	153 (47)	205 (57)

HIV antibody prevalence

Table 5.2.1 HIV antibody prevalence by gender and survey year

Queensland Survey year	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2019	401	11 (2.7)	157	0 (0.0)	565	12 (2.1)
2020	284	13 (4.6)	102	1 (1.0)	388	14 (3.6)
2021	304	7 (2.3)	145	0 (0.0)	455	8 (1.8)
2022	227	7 (3.1)	91	0 (0.0)	325	7 (2.2)
2023	207	8 (3.9)	115	1 (0.9)	327	9 (2.8)
X ² p trend		0.799		0.519		0.993

Table 5.2.2 HIV antibody prevalence by sexual identity, gender and survey year

Queensland Sexual identity	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2019						
Heterosexual	322	1 (0.3)	95	0 (0.0)	419	1 (0.2)
Bisexual	24	4 (16.7)	36	0 (0.0)	62	4 (6.5)
Homosexual	21	6 (28.6)	5	0 (0.0)	27	7 (25.9)
p value		<0.001		--		<0.001
2020						
Heterosexual	245	2 (0.8)	69	1 (1.5)	314	3 (1.0)
Bisexual	13	3 (23.1)	21	0 (0.0)	36	3 (8.3)
Homosexual	9	7 (77.8)	3	0 (0.0)	12	7 (58.3)
p value		<0.001		1.000		<0.001
2021						
Heterosexual	267	1 (0.4)	110	0 (0.0)	379	1 (0.3)
Bisexual	18	0 (0.0)	24	0 (0.0)	42	0 (0.0)
Homosexual	15	5 (33.3)	6	0 (0.0)	24	6 (25.0)
p value		<0.001		--		<0.001
2022						
Heterosexual	192	0 (0.0)	59	0 (0.0)	252	0 (0.0)
Bisexual	13	0 (0.0)	19	0 (0.0)	34	0 (0.0)
Homosexual	15	7 (46.7)	5	0 (0.0)	20	7 (35.0)
p value		<0.001		--		<0.001
2023						
Heterosexual	170	1 (0.6)	82	0 (0.0)	253	1 (0.4)
Bisexual	17	3 (17.7)	26	1 (3.9)	44	4 (9.1)
Homosexual	15	4 (26.7)	4	0 (0.0)	19	4 (21.1)
p value		<0.001		0.287		<0.001

Table 5.2.3 HIV antibody prevalence by age group, gender and survey year

Queensland Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
<25 years	18	0 (0.0)	12	0 (0.0)	30	0 (0.0)
25-34 years	62	1 (1.6)	34	0 (0.0)	99	2 (2.0)
35-44 years	147	2 (1.4)	67	0 (0.0)	217	2 (0.9)
45+ years	173	8 (4.6)	44	0 (0.0)	218	8 (3.7)
p value		0.330		--		0.244
2020						
<25 years	11	0 (0.0)	7	1 (14.3)	18	1 (5.6)
25-34 years	42	3 (7.1)	20	0 (0.0)	62	3 (4.8)
35-44 years	103	4 (3.9)	40	0 (0.0)	144	4 (2.8)
45+ years	128	6 (4.7)	35	0 (0.0)	164	6 (3.7)
p value		0.814		0.069		0.621
2021						
<25 years	14	0 (0.0)	5	0 (0.0)	20	0 (0.0)
25-34 years	49	0 (0.0)	30	0 (0.0)	80	0 (0.0)
35-44 years	108	0 (0.0)	49	0 (0.0)	161	1 (0.6)
45+ years	133	7 (5.3)	61	0 (0.0)	194	7 (3.6)
p value		0.496		--		0.120
2022						
<25 years	9	0 (0.0)	3	0 (0.0)	15	0 (0.0)
25-34 years	36	0 (0.0)	17	0 (0.0)	55	0 (0.0)
35-44 years	71	3 (4.2)	39	0 (0.0)	111	3 (2.7)
45+ years	109	4 (3.7)	31	0 (0.0)	141	4 (2.8)
p value		0.761		--		0.775
2023						
<25 years	9	0 (0.0)	5	0 (0.0)	14	0 (0.0)
25-34 years	29	1 (3.5)	13	1 (7.7)	44	2 (4.6)
35-44 years	70	1 (1.4)	44	0 (0.0)	115	1 (0.9)
45+ years	99	6 (6.1)	53	0 (0.0)	154	6 (3.9)
p value		0.523		0.157		0.316

Table 5.2.4 HIV antibody prevalence by last drug injected, gender and survey year

Queensland Last drug injected	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
Heroin	58	2 (3.5)	31	0 (0.0)	90	2 (2.2)
Methamphetamine	189	9 (4.8)	85	0 (0.0)	277	10 (3.6)
Other opioids	101	0 (0.0)	31	0 (0.0)	134	0 (0.0)
PIEDs	24	0 (0.0)	3	0 (0.0)	27	0 (0.0)
Other drugs	29	0 (0.0)	7	0 (0.0)	36	0 (0.0)
p value		0.131		--		0.138
2020						
Heroin	45	0 (0.0)	17	0 (0.0)	62	0 (0.0)
Methamphetamine	110	11 (10.0)	44	1 (2.3)	155	12 (7.7)
Other opioids	85	2 (2.4)	32	0 (0.0)	118	2 (1.7)
PIEDs	29	0 (0.0)	1	0 (0.0)	30	0 (0.0)
Other drugs	14	0 (0.0)	8	0 (0.0)	22	0 (0.0)
p value		0.030		1.000		0.025
2021						
Heroin	48	0 (0.0)	22	0 (0.0)	71	0 (0.0)
Methamphetamine	108	5 (4.6)	82	0 (0.0)	193	6 (3.1)
Other opioids	94	2 (2.1)	33	0 (0.0)	129	2 (1.6)
PIEDs	34	0 (0.0)	0	0 (0.0)	34	0 (0.0)
Other drugs	16	0 (0.0)	5	0 (0.0)	21	0 (0.0)
p value		0.496		--		0.585
2022						
Heroin	40	0 (0.0)	21	0 (0.0)	61	0 (0.0)
Methamphetamine	87	5 (5.8)	46	0 (0.0)	140	5 (3.6)
Other opioids	58	1 (1.7)	15	0 (0.0)	73	1 (1.4)
PIEDs	30	0 (0.0)	0	0 (0.0)	30	0 (0.0)
Other drugs	11	1 (9.1)	6	0 (0.0)	17	1 (5.9)
p value		0.200		--		0.329
2023						
Heroin	25	0 (0.0)	23	0 (0.0)	48	0 (0.0)
Methamphetamine	105	7 (6.7)	62	1 (1.6)	170	8 (4.7)
Other opioids	44	1 (2.3)	21	0 (0.0)	66	1 (1.5)
PIEDs	18	0 (0.0)	1	0 (0.0)	20	0 (0.0)
Other drugs	13	0 (0.0)	8	0 (0.0)	21	0 (0.0)
p value		0.574		1.000		0.494

Table 5.2.5 HIV antibody prevalence by years of injection, gender and survey year

Queensland Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2019						
<3 years	36	2 (5.6)	14	0 (0.0)	50	2 (4.0)
3 to 10 years	59	2 (3.4)	29	0 (0.0)	90	3 (3.3)
11+ years	285	7 (2.5)	110	0 (0.0)	399	7 (1.8)
p value		0.369		--		0.302
2020						
<3 years	24	0 (0.0)	8	0 (0.0)	32	0 (0.0)
3 to 10 years	42	5 (11.9)	18	1 (5.6)	60	6 (10.0)
11+ years	213	8 (3.8)	76	0 (0.0)	291	8 (2.8)
p value		0.053		0.255		0.025
2021						
<3 years	20	0 (0.0)	6	0 (0.0)	27	0 (0.0)
3 to 10 years	47	2 (4.3)	20	0 (0.0)	67	2 (3.0)
11+ years	228	5 (2.2)	112	0 (0.0)	345	6 (1.7)
p value		0.600		--		0.773
2022						
<3 years	13	1 (7.7)	5	0 (0.0)	21	1 (4.8)
3 to 10 years	28	0 (0.0)	21	0 (0.0)	50	0 (0.0)
11+ years	172	6 (3.5)	62	0 (0.0)	237	6 (2.5)
p value		0.278		--		0.328
2023						
<3 years	16	1 (6.3)	6	0 (0.0)	22	1 (4.6)
3 to 10 years	38	2 (5.3)	18	0 (0.0)	58	2 (3.5)
11+ years	151	5 (3.3)	90	1 (1.1)	244	6 (2.5)
p value		0.536		1.000		0.551

Table 5.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Queensland Receptively shared syringe last month	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2019						
No receptive sharing	321	9 (2.8)	130	0 (0.0)	456	10 (2.2)
Receptive sharing	40	1 (2.5)	15	0 (0.0)	56	1 (1.8)
p value		1.000		--		1.000
2020						
No receptive sharing	217	11 (5.1)	71	1 (1.4)	290	12 (4.1)
Receptive sharing	32	1 (3.1)	15	0 (0.0)	47	1 (2.1)
p value		1.000		1.000		1.000
2021						
No receptive sharing	225	7 (3.1)	95	0 (0.0)	324	8 (2.5)
Receptive sharing	32	0 (0.0)	19	0 (0.0)	51	0 (0.0)
p value		0.602		--		0.605
2022						
No receptive sharing	180	4 (2.2)	59	0 (0.0)	245	4 (1.6)
Receptive sharing	25	1 (4.0)	16	0 (0.0)	41	1 (2.4)
p value		0.482		--		0.541
2023						
No receptive sharing	147	5 (3.4)	86	1 (1.2)	236	6 (2.5)
Receptive sharing	39	2 (5.1)	6	0 (0.0)	46	2 (4.4)
p value		0.638		1.000		0.621

Table 5.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

Queensland	Male		Female		Total	
Frequency of injection	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
Less than daily	163	7 (4.3)	53	0 (0.0)	218	7 (3.2)
Daily or more	200	3 (1.5)	93	0 (0.0)	297	4 (1.4)
Not last month	37	1 (2.7)	10	0 (0.0)	47	1 (2.1)
p value		0.221		--		0.267
2020						
Less than daily	93	7 (7.5)	41	1 (2.4)	136	8 (5.9)
Daily or more	156	5 (3.2)	46	0 (0.0)	202	5 (2.5)
Not last month	32	1 (3.1)	14	0 (0.0)	46	1 (2.2)
p value		0.238		0.545		0.235
2021						
Less than daily	121	4 (3.3)	40	0 (0.0)	162	4 (2.5)
Daily or more	136	3 (2.2)	75	0 (0.0)	214	4 (1.9)
Not last month	42	0 (0.0)	29	0 (0.0)	73	0 (0.0)
p value		0.670		--		0.498
2022						
Less than daily	100	3 (3.0)	25	0 (0.0)	131	3 (2.3)
Daily or more	105	2 (1.9)	50	0 (0.0)	155	2 (1.3)
Not last month	21	2 (9.5)	12	0 (0.0)	34	2 (5.9)
p value		0.195		--		0.214
2023						
Less than daily	82	2 (2.4)	45	1 (2.2)	129	3 (2.3)
Daily or more	107	5 (4.7)	47	0 (0.0)	156	5 (3.2)
Not last month	15	1 (6.7)	19	0 (0.0)	35	1 (2.9)
p value		0.433		0.577		0.894

Table 5.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

Queensland	Male		Female		Total	
Imprisonment last year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
No imprisonment	334	11 (3.3)	133	0 (0.0)	472	12 (2.5)
Imprisonment	48	0 (0.0)	15	0 (0.0)	65	0 (0.0)
p value		0.372		--		0.377
2020						
No imprisonment	240	10 (4.2)	91	1 (1.1)	333	11 (3.3)
Imprisonment	33	3 (9.1)	6	0 (0.0)	39	3 (7.7)
p value		0.198		1.000		0.172
2021						
No imprisonment	252	7 (2.8)	126	0 (0.0)	383	8 (2.1)
Imprisonment	36	0 (0.0)	9	0 (0.0)	45	0 (0.0)
p value		0.602		--		1.000
2022						
No imprisonment	197	7 (3.6)	82	0 (0.0)	285	7 (2.5)
Imprisonment	22	0 (0.0)	7	0 (0.0)	29	0 (0.0)
p value		1.000		--		1.000
2023						
No imprisonment	167	7 (4.2)	100	1 (1.0)	272	8 (2.9)
Imprisonment	28	0 (0.0)	7	0 (0.0)	35	0 (0.0)
p value		0.596		1.000		0.604

Table 5.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

Queensland	Male		Female		Total	
Condom use at last sex	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
No condom use	128	6 (4.7)	65	0 (0.0)	196	6 (3.1)
Condom use	32	0 (0.0)	14	0 (0.0)	47	0 (0.0)
p value		0.601		--		0.600
2020						
No condom use	88	6 (6.8)	43	0 (0.0)	131	6 (4.6)
Condom use	21	1 (4.8)	5	0 (0.0)	26	1 (3.9)
p value		1.000		--		1.000
2021						
No condom use	106	1 (0.9)	54	0 (0.0)	160	1 (0.6)
Condom use	26	0 (0.0)	15	0 (0.0)	42	1 (2.4)
p value		1.000		--		0.373
2022						
No condom use	73	1 (1.4)	41	0 (0.0)	115	1 (0.9)
Condom use	18	1 (5.6)	5	0 (0.0)	25	1 (4.0)
p value		0.358		--		0.326
2023						
No condom use	82	5 (6.1)	54	0 (0.0)	138	5 (3.6)
Condom use	11	0 (0.0)	7	0 (0.0)	19	0 (0.0)
p value		1.000		--		1.000

Table 5.2.10 HIV antibody prevalence by sex work last month, gender and survey year

Queensland	Male		Female		Total	
Sex work last month	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
No sex work	373	9 (2.4)	140	0 (0.0)	519	10 (1.9)
Sex work	13	2 (15.4)	7	0 (0.0)	21	2 (9.5)
p value		0.049		--		0.075
2020						
No sex work	268	10 (3.7)	91	1 (1.1)	361	11 (3.1)
Sex work	9	3 (33.3)	4	0 (0.0)	13	3 (23.1)
p value		0.006		1.000		0.010
2021						
No sex work	285	7 (2.5)	131	0 (0.0)	420	7 (1.7)
Sex work	8	0 (0.0)	5	0 (0.0)	14	1 (7.1)
p value		1.000		--		0.232
2022						
No sex work	209	7 (3.4)	85	0 (0.0)	301	7 (2.3)
Sex work	5	0 (0.0)	4	0 (0.0)	9	0 (0.0)
p value		1.000		--		1.000
2023						
No sex work	186	8 (4.3)	100	1 (1.0)	290	9 (3.1)
Sex work	10	0 (0.0)	4	0 (0.0)	15	0 (0.0)
p value		1.000		1.000		1.000

Table 5.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Queensland Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
Non Indigenous	314	8 (2.6)	129	0 (0.0)	448	9 (2.0)
Indigenous	83	3 (3.6)	27	0 (0.0)	112	3 (2.7)
p value		0.705		--		0.714
2020						
Non Indigenous	231	9 (3.9)	82	1 (1.2)	314	10 (3.2)
Indigenous	45	3 (6.7)	19	0 (0.0)	64	3 (4.7)
p value		0.421		1.000		0.468
2021						
Non Indigenous	247	6 (2.4)	114	0 (0.0)	364	6 (1.7)
Indigenous	49	1 (2.0)	26	0 (0.0)	78	2 (2.6)
p value		1.000		--		0.635
2022						
Non Indigenous	186	7 (3.8)	73	0 (0.0)	265	7 (2.6)
Indigenous	37	0 (0.0)	17	0 (0.0)	55	0 (0.0)
p value		0.604		--		0.608
2023						
Non Indigenous	174	6 (3.5)	84	1 (1.2)	263	7 (2.7)
Indigenous	32	2 (6.3)	30	0 (0.0)	62	2 (3.2)
p value		0.360		1.000		0.683

Table 5.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

Queensland Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
English speaking	383	11 (2.9)	153	0 (0.0)	542	12 (2.2)
Non-English speaking	17	0 (0.0)	4	0 (0.0)	22	0 (0.0)
p value		1.000		--		1.000
2020						
English speaking	276	13 (4.7)	101	1 (1.0)	379	14 (3.7)
Non-English speaking	8	0 (0.0)	1	0 (0.0)	9	0 (0.0)
p value		1.000		1.000		1.000
2021						
English speaking	292	7 (2.4)	143	0 (0.0)	439	8 (1.8)
Non-English speaking	8	0 (0.0)	1	0 (0.0)	11	0 (0.0)
p value		1.000		--		1.000
2022						
English speaking	216	7 (3.2)	90	0 (0.0)	313	7 (2.2)
Non-English speaking	11	0 (0.0)	1	0 (0.0)	12	0 (0.0)
p value		1.000		--		1.000
2023						
English speaking	204	8 (3.9)	113	1 (0.9)	322	9 (2.8)
Non-English speaking	3	0 (0.0)	2	0 (0.0)	5	0 (0.0)
p value		1.000		1.000		1.000

Table 5.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

Queensland	Male		Female		Total	
Region/country of birth	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
Australia	366	11 (3.0)	145	0 (0.0)	517	12 (2.3)
Other Oceania	9	0 (0.0)	2	0 (0.0)	12	0 (0.0)
Asia	2	0 (0.0)	2	0 (0.0)	4	0 (0.0)
UK & Ireland	8	0 (0.0)	3	0 (0.0)	11	0 (0.0)
Other	12	0 (0.0)	5	0 (0.0)	17	0 (0.0)
p value		1.000		--		1.000
2020						
Australia	252	12 (4.8)	95	1 (1.1)	349	13 (3.7)
Other Oceania	11	0 (0.0)	4	0 (0.0)	15	0 (0.0)
Asia	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)
UK & Ireland	9	1 (11.1)	2	0 (0.0)	11	1 (9.1)
Other	7	0 (0.0)	1	0 (0.0)	8	0 (0.0)
p value		0.607		1.000		0.584
2021						
Australia	273	6 (2.2)	127	0 (0.0)	405	7 (1.7)
Other Oceania	7	0 (0.0)	3	0 (0.0)	11	0 (0.0)
Asia	2	0 (0.0)	1	0 (0.0)	3	0 (0.0)
UK & Ireland	8	0 (0.0)	3	0 (0.0)	11	0 (0.0)
Other	10	1 (10.0)	4	0 (0.0)	14	1 (7.1)
p value		0.487		--		0.524
2022						
Australia	200	7 (3.5)	83	0 (0.0)	290	7 (2.4)
Other Oceania	7	0 (0.0)	4	0 (0.0)	11	0 (0.0)
Asia	0	0 (0.0)	1	0 (0.0)	1	0 (0.0)
UK & Ireland	7	0 (0.0)	1	0 (0.0)	8	0 (0.0)
Other	6	0 (0.0)	2	0 (0.0)	8	0 (0.0)
p value		1.000		--		1.000
2023						
Australia	187	8 (4.3)	111	1 (0.9)	303	9 (3.0)
Other Oceania	7	0 (0.0)	3	0 (0.0)	10	0 (0.0)
Asia	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)
UK & Ireland	6	0 (0.0)	1	0 (0.0)	7	0 (0.0)
Other	4	0 (0.0)	0	0 (0.0)	4	0 (0.0)
p value		1.000		1.000		1.000

HCV antibody prevalence

Table 5.3.1 HCV antibody prevalence by gender and survey year

Queensland	Male		Female		Total	
Survey year	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019	401	175 (44)	156	57 (37)	564	234 (41)
2020	283	104 (37)	102	42 (41)	387	146 (38)
2021	304	120 (39)	145	51 (35)	455	172 (38)
2022	227	53 (23)	91	30 (33)	325	84 (26)
2023*	208	81 (39)	115	41 (36)	328	122 (37)
X ² p trend		0.004		0.549		0.004

* Antibody testing assay changed in 2023. See Appendix B: Methodological Notes

Table 5.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Queensland	Male		Female		Total	
Sexual identity	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019						
Heterosexual	322	142 (44)	94	34 (36)	418	178 (43)
Bisexual	24	11 (46)	36	14 (39)	62	25 (40)
Homosexual	21	6 (29)	5	3 (60)	27	9 (33)
p value		0.414		0.531		0.620
2020						
Heterosexual	244	92 (38)	69	30 (43)	313	122 (39)
Bisexual	13	2 (15)	21	10 (48)	36	12 (33)
Homosexual	9	1 (11)	3	0 (0)	12	1 (8)
p value		0.027		0.559		0.064
2021						
Heterosexual	267	111 (42)	110	39 (35)	379	151 (40)
Bisexual	18	5 (28)	24	7 (29)	42	12 (29)
Homosexual	15	3 (20)	6	4 (67)	24	7 (29)
p value		0.238		0.466		0.333
2022						
Heterosexual	192	48 (25)	59	20 (34)	252	69 (27)
Bisexual	13	3 (23)	19	5 (26)	34	8 (24)
Homosexual	15	2 (13)	5	1 (20)	20	3 (15)
p value		0.891		0.303		0.144
2023						
Heterosexual	170	74 (44)	82	32 (39)	253	106 (42)
Bisexual	18	3 (17)	26	7 (27)	45	10 (22)
Homosexual	15	3 (20)	4	2 (50)	19	5 (26)
p value		0.046		0.601		0.055

Table 5.3.3 HCV antibody prevalence by age group, gender and survey year

Queensland Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
<25 years	18	5 (28)	12	2 (17)	30	7 (23)
25-34 years	62	16 (26)	34	11 (32)	99	28 (28)
35-44 years	147	66 (45)	67	26 (39)	217	93 (43)
45+ years	173	88 (51)	43	18 (42)	217	106 (49)
p value		0.003		0.412		0.001
2020						
<25 years	11	3 (27)	7	2 (29)	18	5 (28)
25-34 years	42	3 (7)	20	9 (45)	62	12 (19)
35-44 years	103	42 (41)	40	17 (43)	144	59 (41)
45+ years	127	56 (44)	35	14 (40)	163	70 (43)
p value		<0.001		0.921		0.005
2021						
<25 years	14	2 (14)	5	1 (20)	20	3 (15)
25-34 years	49	14 (29)	30	12 (40)	80	26 (33)
35-44 years	108	47 (44)	49	17 (35)	161	65 (40)
45+ years	133	57 (43)	61	21 (34)	194	78 (40)
p value		0.055		0.865		0.092
2022						
<25 years	9	1 (11)	3	1 (33)	15	2 (13)
25-34 years	36	5 (14)	17	4 (24)	55	9 (16)
35-44 years	71	16 (23)	39	12 (31)	111	29 (26)
45+ years	109	31 (28)	31	12 (39)	141	43 (31)
p value		0.285		0.756		0.154
2023						
<25 years	9	2 (22)	5	1 (20)	14	3 (21)
25-34 years	29	8 (28)	13	2 (15)	44	10 (23)
35-44 years	71	23 (32)	44	15 (34)	116	38 (33)
45+ years	99	48 (48)	53	23 (43)	154	71 (46)
p value		0.059		0.252		0.009

Table 5.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Queensland Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019						
<3 years	36	3 (8)	14	0 (0)	50	3 (6)
3 to 10 years	59	12 (20)	29	7 (24)	90	19 (21)
11+ years	285	151 (53)	109	50 (46)	398	203 (51)
p value		<0.001		<0.001		<0.001
2020						
<3 years	24	3 (13)	8	0 (0)	32	3 (9)
3 to 10 years	42	2 (5)	18	5 (28)	60	7 (12)
11+ years	212	96 (45)	76	37 (49)	290	133 (46)
p value		<0.001		0.008		<0.001
2021						
<3 years	20	0 (0)	6	0 (0)	27	0 (0)
3 to 10 years	47	4 (9)	20	4 (20)	67	8 (12)
11+ years	228	111 (49)	112	45 (40)	345	157 (46)
p value		<0.001		0.043		<0.001
2022						
<3 years	13	0 (0)	5	0 (0)	21	0 (0)
3 to 10 years	28	5 (18)	21	3 (14)	50	8 (16)
11+ years	172	44 (26)	62	26 (42)	237	71 (30)
p value		0.07		0.018		0.001
2023						
<3 years	16	1 (6)	6	0 (0)	22	1 (5)
3 to 10 years	38	5 (13)	18	3 (17)	58	8 (14)
11+ years	152	73 (48)	90	38 (42)	245	111 (45)
p value		<0.001		0.017		<0.001

Table 5.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Queensland Receptively shared syringe last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019						
No receptive sharing	41	2 (5)	401	175 (44)	455	183 (40)
Receptive sharing	3	0 (0)	48	31 (65)	56	33 (59)
p value		1.000		0.006		0.007
2020						
No receptive sharing	22	2 (9)	265	104 (39)	289	107 (37)
Receptive sharing	3	0 (0)	43	23 (53)	47	24 (51)
p value		0.770		0.078		0.067
2021						
No receptive sharing	19	0 (0)	295	113 (38)	324	118 (36)
Receptive sharing	1	0 (0)	49	26 (53)	51	26 (51)
p value		--		0.051		0.047
2022						
No receptive sharing	17	0 (0)	217	59 (27)	245	63 (26)
Receptive sharing	0	0 (0)	36	11 (31)	41	12 (29)
p value		--		0.676		0.632
2023						
No receptive sharing	18	0 (0)	218	86 (39)	237	87 (37)
Receptive sharing	1	1 (100)	44	24 (55)	46	26 (57)
p value		0.053		0.064		0.012

Table 5.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

Queensland Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
Heroin	1	0 (0)	87	55 (63)	90	57 (63)
Methamphetamine	31	1 (3)	230	71 (31)	275	75 (27)
Other opioids	4	1 (25)	125	78 (62)	133	82 (62)
PIEDs	11	0 (0)	15	0 (0)	27	0 (0)
Other drugs	3	1 (33)	29	16 (55)	36	18 (50)
p value		0.102		<0.001		<0.001
2020						
Heroin	0	0 (0)	61	37 (61)	61	37 (61)
Methamphetamine	14	3 (21)	138	29 (21)	155	34 (22)
Other opioids	3	0 (0)	112	57 (51)	116	58 (50)
PIEDs	11	0 (0)	18	1 (6)	30	1 (3)
Other drugs	3	0 (0)	17	13 (76)	20	13 (65)
p value		0.258		<0.001		<0.001
2021						
Heroin	0	0 (0)	71	41 (58)	71	41 (58)
Methamphetamine	17	0 (0)	168	46 (27)	190	49 (26)
Other opioids	2	0 (0)	120	64 (53)	127	65 (51)
PIEDs	6	0 (0)	27	3 (11)	34	3 (9)
Other drugs	1	0 (0)	15	7 (47)	20	9 (45)
p value		--		<0.001		<0.001
2022						
Heroin	1	0 (0)	57	26 (46)	60	27 (45)
Methamphetamine	8	0 (0)	121	21 (17)	137	24 (18)
Other opioids	2	0 (0)	67	25 (37)	73	26 (36)
PIEDs	8	0 (0)	21	1 (5)	30	1 (3)
Other drugs	1	0 (0)	14	6 (43)	16	6 (38)
p value		--		<0.001		<0.001
2023						
Heroin	1	0 (0)	46	24 (52)	47	24 (51)
Methamphetamine	12	1 (8)	153	48 (31)	166	50 (30)
Other opioids	1	0 (0)	64	36 (56)	65	36 (55)
PIEDs	6	0 (0)	14	0 (0)	20	0 (0)
Other drugs	2	0 (0)	18	10 (56)	21	11 (52)
p value		0.928		<0.001		<0.001

Table 5.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Queensland	<3 years		3+ years		Total	
Frequency of injection last month	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019						
Less than daily	25	1 (4)	185	74 (40)	217	77 (35)
Daily or more	19	1 (5)	267	133 (50)	297	140 (47)
Not last month	6	1 (17)	34	13 (38)	47	15 (32)
p value		0.491		0.083		0.012
2020						
Less than daily	16	0 (0)	119	41 (34)	136	41 (30)
Daily or more	9	2 (22)	190	86 (45)	201	90 (45)
Not last month	7	1 (14)	37	10 (27)	46	12 (26)
p value		0.113		0.043		0.006
2021						
Less than daily	15	0 (0)	143	38 (27)	162	40 (25)
Daily or more	5	0 (0)	202	102 (51)	214	105 (49)
Not last month	7	0 (0)	61	22 (36)	73	24 (33)
p value		--		<0.001		<0.001
2022						
Less than daily	13	0 (0)	113	28 (25)	131	30 (23)
Daily or more	4	0 (0)	140	42 (30)	155	45 (29)
Not last month	3	0 (0)	30	9 (30)	34	9 (26)
p value		--		0.631		0.502
2023						
Less than daily	9	0 (0)	121	37 (31)	130	37 (28)
Daily or more	10	1 (10)	144	74 (51)	156	77 (49)
Not last month	3	0 (0)	32	8 (25)	35	8 (23)
p value		1.000		<0.001		<0.001

Table 5.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Queensland	<3 years		3+ years		Total	
Imprisonment last year	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019						
No imprisonment	46	3 (7)	402	170 (42)	471	181 (38)
Imprisonment	3	0 (0)	60	41 (68)	65	41 (63)
p value		1.000		<0.001		<0.001
2020						
No imprisonment	31	2 (6)	297	112 (38)	333	117 (35)
Imprisonment	1	1 (100)	37	17 (46)	38	18 (47)
p value		0.094		0.372		0.138
2021						
No imprisonment	25	0 (0)	345	124 (36)	383	129 (34)
Imprisonment	0	0 (0)	44	31 (70)	45	32 (71)
p value		--		<0.001		<0.001
2022						
No imprisonment	17	0 (0)	254	70 (28)	285	74 (26)
Imprisonment	3	0 (0)	24	6 (25)	29	7 (24)
p value		--		0.788		0.830
2023						
No imprisonment	19	0 (0)	251	94 (37)	273	96 (35)
Imprisonment	2	1 (50)	33	14 (42)	35	15 (43)
p value		0.095		0.580		0.372

Table 5.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Queensland Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
Non Indigenous	314	128 (41)	128	42 (33)	447	170 (38)
Indigenous	83	45 (54)	27	15 (56)	112	62 (55)
p value		0.028		0.026		0.001
2020						
Non Indigenous	231	76 (33)	82	33 (40)	314	109 (35)
Indigenous	44	26 (59)	19	9 (47)	63	35 (56)
p value		0.001		0.570		0.002
2021						
Non Indigenous	247	84 (34)	114	37 (32)	364	122 (34)
Indigenous	49	33 (67)	26	12 (46)	78	45 (58)
p value		<0.001		0.186		<0.001
2022						
Non Indigenous	186	40 (22)	73	24 (33)	265	65 (25)
Indigenous	37	11 (30)	17	6 (35)	55	17 (31)
p value		0.277		0.849		0.324
2023						
Non Indigenous	175	62 (35)	84	31 (37)	264	93 (35)
Indigenous	32	18 (56)	30	10 (33)	62	28 (45)
p value		0.026		0.726		0.145

Table 5.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Queensland Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
English speaking	383	166 (43)	152	55 (36)	541	223 (41)
Non-English speaking	17	8 (47)	4	2 (50)	22	10 (45)
p value		0.762		0.623		0.693
2020						
English speaking	275	99 (36)	101	41 (41)	378	140 (37)
Non-English speaking	8	5 (63)	1	1 (100)	9	6 (67)
p value		0.148		0.412		0.087
2021						
English speaking	292	118 (40)	143	49 (34)	439	167 (38)
Non-English speaking	8	2 (25)	1	1 (100)	11	4 (36)
p value		0.483		0.347		1.000
2022						
English speaking	216	48 (22)	90	30 (33)	313	79 (25)
Non-English speaking	11	5 (45)	1	0 (0)	12	5 (42)
p value		0.076		1.000		0.202
2023						
English speaking	205	80 (39)	113	41 (36)	323	121 (37)
Non-English speaking	3	1 (33)	2	0 (0)	5	1 (20)
p value		1.000		0.537		0.622

Table 5.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

Queensland		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2019							
Australia	366	163 (45)	144	52 (36)	516	217 (42)	
Other Oceania	9	5 (56)	2	1 (50)	12	6 (50)	
Asia	2	0 (0)	2	0 (0)	4	0 (0)	
UK & Ireland	8	3 (38)	3	2 (67)	11	5 (45)	
Other	12	2 (17)	5	2 (40)	17	4 (24)	
p value		0.213		0.728		0.246	
2020							
Australia	251	94 (37)	95	41 (43)	348	135 (39)	
Other Oceania	11	4 (36)	4	1 (25)	15	5 (33)	
Asia	1	0 (0)	0	0 (0)	1	0 (0)	
UK & Ireland	9	1 (11)	2	0 (0)	11	1 (9)	
Other	7	4 (57)	1	0 (0)	8	4 (50)	
p value		0.347		0.586		0.230	
2021							
Australia	273	108 (40)	127	41 (32)	405	150 (37)	
Other Oceania	7	3 (43)	3	3 (100)	11	6 (55)	
Asia	2	0 (0)	1	1 (100)	3	1 (33)	
UK & Ireland	8	3 (38)	3	1 (33)	11	4 (36)	
Other	10	5 (50)	4	2 (50)	14	7 (50)	
p value		0.857		0.049		0.637	
2022							
Australia	200	44 (22)	83	29 (35)	290	74 (26)	
Other Oceania	7	2 (29)	4	1 (25)	11	3 (27)	
Asia	0	0 (0)	1	0 (0)	1	0 (0)	
UK & Ireland	7	1 (14)	1	0 (0)	8	1 (13)	
Other	6	1 (17)	2	0 (0)	8	1 (13)	
p value		0.953		0.919		0.894	
2023							
Australia	188	74 (39)	111	39 (35)	304	113 (37)	
Other Oceania	7	2 (29)	3	2 (67)	10	4 (40)	
Asia	1	0 (0)	0	0 (0)	1	0 (0)	
UK & Ireland	6	4 (67)	1	0 (0)	7	4 (57)	
Other	4	0 (0)	0	0 (0)	4	0 (0)	
p value		0.248		0.545		0.431	

HCV RNA prevalence

Table 5.4.1 HCV RNA prevalence by gender and survey year

Queensland Survey year	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019*	371	62 (17)	144	16 (11)	522	79 (15)
2020	267	41 (15)	101	10 (10)	370	51 (14)
2021	291	32 (11)	143	15 (10)	440	48 (11)
2022	223	22 (10)	91	9 (10)	321	32 (10)
2023	208	24 (12)	115	11 (10)	328	35 (11)
X ² p trend		0.010		0.705		0.011

* 2019: Weighted for gender and HCV antibody status

Totals include respondents where gender was reported as other or not reported

Table 5.4.2 HCV RNA prevalence by sexual identity, gender and survey year

Queensland Sexual identity	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019*						
Heterosexual	300	50 (17)	86	9 (10)	388	61 (16)
Bisexual	23	6 (26)	34	4 (12)	58	10 (17)
Homosexual	19	1 (5)	5	1 (20)	25	2 (8)
p value		0.203		0.801		0.554
2020						
Heterosexual	230	34 (15)	67	6 (9)	297	40 (13)
Bisexual	13	1 (8)	22	4 (18)	37	5 (14)
Homosexual	9	0 (0)	3	0 (0)	12	0 (0)
p value		0.364		0.400		0.395
2021						
Heterosexual	256	30 (12)	108	11 (10)	366	42 (11)
Bisexual	17	2 (12)	24	1 (4)	41	3 (7)
Homosexual	15	0 (0)	6	2 (33)	24	2 (8)
p value		0.372		0.106		0.661
2022						
Heterosexual	187	19 (10)	59	7 (12)	247	27 (11)
Bisexual	13	2 (15)	19	1 (5)	34	3 (9)
Homosexual	15	1 (7)	5	0 (0)	20	1 (5)
p value		0.863		0.628		0.833
2023						
Heterosexual	170	22 (13)	82	10 (12)	253	32 (13)
Bisexual	18	1 (6)	26	1 (4)	45	2 (4)
Homosexual	15	1 (7)	4	0 (0)	19	1 (5)
p value		0.862		0.656		0.600

Table 5.4.3 HCV RNA prevalence by age group, gender and survey year

Queensland Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
<25 years	17	2 (12)	11	3 (27)	28	5 (18)
25-34 years	55	5 (9)	29	2 (7)	87	8 (9)
35-44 years	136	28 (21)	65	11 (17)	204	38 (19)
45+ years	162	28 (17)	39	0 (0)	202	28 (14)
p value		0.288		0.019		0.178
2020						
<25 years	10	1 (10)	8	1 (13)	18	2 (11)
25-34 years	36	1 (3)	20	5 (25)	56	6 (11)
35-44 years	100	24 (24)	39	4 (10)	140	28 (20)
45+ years	121	15 (12)	34	0 (0)	156	15 (10)
p value		0.011		0.030		0.061
2021						
<25 years	14	0 (0)	5	0 (0)	20	0 (0)
25-34 years	47	9 (19)	29	3 (10)	77	12 (16)
35-44 years	102	16 (16)	49	6 (12)	155	23 (15)
45+ years	128	7 (5)	60	6 (10)	188	13 (7)
p value		0.011		0.858		0.021
2022						
<25 years	9	1 (11)	3	1 (33)	15	2 (13)
25-34 years	36	3 (8)	17	2 (12)	55	5 (9)
35-44 years	70	9 (13)	39	3 (8)	110	13 (12)
45+ years	106	9 (8)	31	3 (10)	138	12 (9)
p value		0.716		0.470		0.788
2023						
<25 years	9	1 (11)	5	1 (20)	14	2 (14)
25-34 years	29	3 (10)	13	0 (0)	44	3 (7)
35-44 years	71	6 (8)	44	3 (7)	116	9 (8)
45+ years	99	14 (14)	53	7 (13)	154	21 (14)
p value		0.718		0.269		0.326

Table 5.4.4 HCV RNA prevalence by years since first injection, gender and survey year

Queensland Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
<3 years	33	2 (6)	13	1 (8)	46	3 (7)
3 to 10 years	55	6 (11)	25	4 (16)	82	10 (12)
11+ years	264	52 (20)	102	11 (11)	370	64 (17)
p value		0.055		0.631		0.113
2020						
<3 years	22	0 (0)	8	0 (0)	30	0 (0)
3 to 10 years	40	1 (3)	19	4 (21)	59	5 (8)
11+ years	200	39 (20)	74	6 (8)	276	45 (16)
p value		0.003		0.150		0.021
2021						
<3 years	20	0 (0)	6	0 (0)	27	0 (0)
3 to 10 years	47	5 (11)	19	0 (0)	66	5 (8)
11+ years	215	27 (13)	111	15 (14)	331	43 (13)
p value		0.235		0.150		0.071
2022						
<3 years	13	0 (0)	5	0 (0)	21	0 (0)
3 to 10 years	29	5 (17)	21	3 (14)	51	8 (16)
11+ years	167	16 (10)	62	6 (10)	232	23 (10)
p value		0.255		0.819		0.125
2023						
<3 years	16	0 (0)	6	0 (0)	22	0 (0)
3 to 10 years	38	1 (3)	18	2 (11)	58	3 (5)
11+ years	152	22 (14)	90	9 (10)	245	31 (13)
p value		0.041		1.000		0.058

Table 5.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Queensland Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
No receptive sharing	296	50 (17)	118	13 (11)	418	64 (15)
Receptive sharing	37	8 (22)	14	2 (14)	52	10 (19)
p value		0.501		0.649		0.457
2020						
No receptive sharing	203	27 (13)	69	6 (9)	274	33 (12)
Receptive sharing	29	12 (41)	16	3 (19)	45	15 (33)
p value		<0.001		0.239		<0.001
2021						
No receptive sharing	214	24 (11)	94	10 (11)	312	35 (11)
Receptive sharing	30	6 (20)	19	1 (5)	49	7 (14)
p value		0.170		0.471		0.534
2022						
No receptive sharing	177	16 (9)	59	5 (8)	242	22 (9)
Receptive sharing	25	5 (20)	16	2 (13)	41	7 (17)
p value		0.093		0.637		0.119
2023						
No receptive sharing	148	20 (14)	86	11 (13)	237	31 (13)
Receptive sharing	39	4 (10)	6	0 (0)	46	4 (9)
p value		0.789		1.000		0.624

Table 5.4.6 HCV RNA prevalence by last drug injected, gender and survey year

Queensland Last drug injected	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
Heroin	55	10 (18)	28	2 (7)	83	12 (14)
Methamphetamine	175	28 (16)	76	7 (9)	254	35 (14)
Other opioids	92	19 (21)	30	3 (10)	124	23 (19)
PIEDs	21	0 (0)	3	0 (0)	24	0 (0)
Other drugs	27	6 (22)	7	2 (29)	34	8 (24)
p value		0.208		0.525		0.105
2020						
Heroin	44	7 (16)	18	1 (6)	62	8 (13)
Methamphetamine	103	15 (15)	43	3 (7)	147	18 (12)
Other opioids	78	15 (19)	30	1 (3)	109	16 (15)
PIEDs	27	0 (0)	1	0 (0)	28	0 (0)
Other drugs	11	3 (27)	8	5 (63)	19	8 (42)
p value		0.130		<0.001		0.001
2021						
Heroin	46	4 (9)	22	2 (9)	69	7 (10)
Methamphetamine	103	10 (10)	80	6 (8)	186	16 (9)
Other opioids	86	13 (15)	33	7 (21)	121	20 (17)
PIEDs	34	2 (6)	0	0 (0)	34	2 (6)
Other drugs	15	2 (13)	5	0 (0)	20	2 (10)
p value		0.571		0.149		0.208
2022						
Heroin	38	4 (11)	20	3 (15)	58	7 (12)
Methamphetamine	86	10 (12)	44	3 (7)	137	14 (10)
Other opioids	57	7 (12)	15	3 (20)	72	10 (14)
PIEDs	30	0 (0)	0	0 (0)	30	0 (0)
Other drugs	11	1 (9)	5	0 (0)	16	1 (6)
p value		0.410		0.386		0.291
2023						
Heroin	25	2 (8)	22	2 (9)	47	4 (9)
Methamphetamine	103	12 (12)	60	6 (10)	166	18 (11)
Other opioids	44	8 (18)	20	1 (5)	65	9 (14)
PIEDs	18	0 (0)	1	0 (0)	20	0 (0)
Other drugs	13	2 (15)	8	2 (25)	21	4 (19)
p value		0.327		0.608		0.318

Table 5.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year

Queensland Frequency of injection last month	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019*						
Less than daily	152	21 (14)	46	4 (9)	200	26 (13)
Daily or more	182	38 (21)	88	11 (13)	273	48 (18)
Not last month	36	4 (11)	10	0 (0)	46	4 (9)
p value		0.142		0.469		0.162
2020						
Less than daily	88	12 (14)	40	2 (5)	130	14 (11)
Daily or more	144	27 (19)	46	7 (15)	190	34 (18)
Not last month	32	1 (3)	14	1 (7)	46	2 (4)
p value		0.074		0.269		0.027
2021						
Less than daily	115	9 (8)	40	2 (5)	156	11 (7)
Daily or more	129	21 (16)	73	9 (12)	205	31 (15)
Not last month	42	1 (2)	29	4 (14)	73	5 (7)
p value		0.017		0.392		0.025
2022						
Less than daily	100	6 (6)	25	1 (4)	131	8 (6)
Daily or more	102	15 (15)	50	6 (12)	152	21 (14)
Not last month	21	1 (5)	12	2 (17)	34	3 (9)
p value		0.103		0.316		0.100
2023						
Less than daily	83	8 (10)	45	4 (9)	130	12 (9)
Daily or more	107	16 (15)	47	7 (15)	156	23 (15)
Not last month	15	0 (0)	19	0 (0)	35	0 (0)
p value		0.232		0.214		0.018

Table 5.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year

Queensland Imprisonment last year	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019*						
No imprisonment	310	43 (14)	121	11 (9)	435	55 (13)
Imprisonment	45	14 (31)	14	3 (21)	61	18 (30)
p value		0.004		0.164		<0.001
2020						
No imprisonment	228	30 (13)	90	9 (10)	320	39 (12)
Imprisonment	30	9 (30)	6	1 (17)	36	10 (28)
p value		0.015		0.605		0.010
2021						
No imprisonment	243	21 (9)	124	13 (10)	372	34 (9)
Imprisonment	34	10 (29)	9	2 (22)	43	12 (28)
p value		<0.001		0.282		<0.001
2022						
No imprisonment	194	16 (8)	82	6 (7)	282	23 (8)
Imprisonment	22	5 (23)	7	2 (29)	29	7 (24)
p value		0.030		0.119		0.006
2023						
No imprisonment	168	18 (11)	100	9 (9)	273	27 (10)
Imprisonment	28	3 (11)	7	1 (14)	35	4 (11)
p value		1.000		0.507		0.766

Table 5.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Queensland	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
Non Indigenous	290	39 (13)	118	9 (8)	412	48 (12)
Indigenous	78	23 (29)	26	6 (23)	105	30 (29)
p value		<0.001		0.018		<0.001
2020						
Non Indigenous	215	28 (13)	81	8 (10)	297	36 (12)
Indigenous	44	13 (30)	19	2 (11)	63	15 (24)
p value		0.006		0.932		0.016
2021						
Non Indigenous	236	18 (8)	112	12 (11)	351	31 (9)
Indigenous	47	14 (30)	26	3 (12)	76	17 (22)
p value		<0.001		0.903		0.001
2022						
Non Indigenous	182	15 (8)	73	6 (8)	261	22 (8)
Indigenous	37	6 (16)	17	3 (18)	55	9 (16)
p value		0.133		0.363		0.072
2023						
Non Indigenous	175	15 (9)	84	9 (11)	264	24 (9)
Indigenous	32	9 (28)	30	2 (7)	62	11 (18)
p value		0.001		0.725		0.048

Table 5.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year

Queensland	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
English speaking	354	59 (17)	141	15 (11)	501	75 (15)
Non-English speaking	16	3 (19)	3	1 (33)	20	4 (20)
p value		0.843		0.190		0.521
2020						
English speaking	259	39 (15)	100	10 (10)	361	49 (14)
Non-English speaking	8	2 (25)	1	0 (0)	9	2 (22)
p value		0.442		0.739		0.457
2021						
English speaking	279	31 (11)	142	15 (11)	425	46 (11)
Non-English speaking	8	1 (13)	1	0 (0)	11	2 (18)
p value		0.902		0.731		0.441
2022						
English speaking	212	19 (9)	90	9 (10)	309	29 (9)
Non-English speaking	11	3 (27)	1	0 (0)	12	3 (25)
p value		0.082		1.000		0.106
2023						
English speaking	205	24 (12)	113	11 (10)	323	35 (11)
Non-English speaking	3	0 (0)	2	0 (0)	5	0 (0)
p value		1.000		1.000		1.000

Table 5.4.11 HCV RNA prevalence by region/country of birth, gender and survey year

Queensland	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
Australia	338	61 (18)	132	15 (11)	476	77 (16)
Other Oceania	9	1 (11)	2	0 (0)	12	1 (8)
Asia	2	0 (0)	2	0 (0)	4	0 (0)
UK & Ireland	8	0 (0)	3	0 (0)	11	0 (0)
Other	10	0 (0)	5	1 (20)	15	1 (7)
p value		0.323		0.853		0.377
2020						
Australia	237	35 (15)	94	10 (11)	333	45 (14)
Other Oceania	10	3 (30)	4	0 (0)	14	3 (21)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	8	0 (0)	2	0 (0)	10	0 (0)
Other	7	3 (43)	1	0 (0)	8	3 (38)
p value		0.148		0.843		0.229
2021						
Australia	261	27 (10)	126	13 (10)	392	41 (10)
Other Oceania	6	1 (17)	3	1 (33)	10	2 (20)
Asia	2	0 (0)	1	0 (0)	3	0 (0)
UK & Ireland	8	1 (13)	3	0 (0)	11	1 (9)
Other	10	3 (30)	4	1 (25)	14	4 (29)
p value		0.379		0.576		0.224
2022						
Australia	197	16 (8)	83	9 (11)	287	26 (9)
Other Oceania	7	1 (14)	4	0 (0)	11	1 (9)
Asia	0	0 (0)	1	0 (0)	1	0 (0)
UK & Ireland	7	0 (0)	1	0 (0)	8	0 (0)
Other	6	1 (17)	2	0 (0)	8	1 (13)
p value		0.437		1.000		0.858
2023						
Australia	188	23 (12)	111	11 (10)	304	34 (11)
Other Oceania	7	0 (0)	3	0 (0)	10	0 (0)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	6	0 (0)	1	0 (0)	7	0 (0)
Other	4	0 (0)	0	0 (0)	4	0 (0)
p value		1.000		1.000		0.811

South Australia

Table 6.1.1 Number (percentage) of respondents by demographic characteristics and survey year

South Australia	2019	2020*	2021*	2022	2023
Number of sites	8	7	8	8	8
N° surveyed	N=326	N=20	N=210	N=279	N=283
Response rate (%)	57%	--	50%	49%	61%
Gender (%)					
Male	191 (59)	13 (65)	133 (63)	168 (60)	173 (61)
Female	134 (41)	7 (35)	70 (33)	102 (37)	102 (36)
Other	1 (<1)	0 (0)	7 (3)	9 (3)	8 (3)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	257 (79)	16 (80)	166 (79)	219 (78)	226 (80)
Bisexual	27 (8)	1 (5)	23 (11)	28 (10)	27 (10)
Gay/Lesbian	19 (6)	0 (0)	10 (5)	11 (4)	10 (4)
Other	-- --	1 (5)	9 (4)	17 (6)	18 (6)
Not reported	23 (7)	2 (10)	2 (1)	4 (1)	2 (1)
Aboriginal and Torres Strait Islander origin (%)					
No	251 (77)	17 (85)	138 (66)	200 (72)	189 (67)
Yes	67 (21)	3 (15)	55 (26)	75 (27)	87 (31)
Not reported	8 (2)	0 (0)	17 (8)	4 (1)	7 (2)
Region/country of birth (%)					
Australia	285 (87)	17 (85)	181 (86)	238 (85)	256 (90)
Other Oceania	5 (2)	0 (0)	3 (1)	4 (1)	9 (3)
Asia	6 (2)	0 (0)	3 (1)	10 (4)	2 (1)
UK & Ireland	20 (6)	3 (15)	12 (6)	13 (5)	9 (3)
Other	7 (2)	0 (0)	5 (2)	6 (2)	4 (1)
Not reported	3 (1)	0 (0)	6 (3)	8 (3)	3 (1)
Main language spoken at home by parents (%)					
English	312 (96)	20 (100)	200 (95)	259 (93)	269 (95)
Non-English	12 (4)	0 (0)	7 (3)	16 (6)	12 (4)
Not reported	2 (1)	0 (0)	3 (1)	4 (1)	2 (1)
Age and time since first injection (years)					
<i>Median age</i>	44	48	45	48	47
<i>Age range</i>	19-72	32-62	19-78	22-68	18-71
Age group (%)					
<25 years	8 (2)	0 (0)	3 (1)	4 (1)	10 (4)
25+ years	315 (97)	20 (100)	206 (98)	269 (96)	270 (95)
Not reported	3 (1)	0 (0)	1 (<1)	6 (2)	3 (1)
Median age first injection					
<i>Median age first injection</i>	18	21	19	20	19
<i>Age range</i>	12-67	12-42	12-46	10-54	11-55
<i>N° not reported</i>	23	0	10	15	14
Median yrs since first injection					
<i>Median yrs since first injection</i>	24	27	25	27	24
<i>Range</i>	<1-52	<1-45	<1-62	<1-51	<1-52
Years since first injection					
<3 years	8 (2)	2 (10)	3 (1)	11 (4)	11 (4)
3+ years	295 (90)	18 (90)	196 (93)	252 (90)	258 (91)
Not reported	23 (7)	0 (0)	11 (5)	16 (6)	14 (5)
Imprisonment last year (%)					
No	267 (82)	19 (95)	176 (84)	234 (84)	237 (84)
Yes	32 (10)	1 (5)	20 (10)	37 (13)	26 (9)
Not reported	27 (8)	0 (0)	14 (7)	8 (3)	20 (7)
N° in prison					
<i>N° in prison</i>	N=32	N=1	N=20	N=37	N=26
Injected in prison	6 (19)	0 (0)	2 (10)	10 (27)	5 (19)

* Implementation of the 2020 and 2021 ANSPS was impacted by the COVID-19 pandemic, see page 1 for more information

Table 6.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

South Australia	2019	2020	2021	2022	2023
N° surveyed	N=326	N=20	N=210	N=279	N=283
Drug last injected (%)					
Cocaine	0 (0)	0 (0)	2 (1)	0 (0)	4 (1)
Methamphetamine	175 (54)	12 (60)	115 (55)	134 (48)	169 (60)
Heroin	79 (24)	5 (25)	57 (27)	83 (30)	62 (22)
Pharm. opioids	10 (3)	1 (5)	5 (2)	8 (3)	8 (3)
Methadone	33 (10)	1 (5)	9 (4)	7 (3)	13 (5)
Buprenorphine	1 (<1)	0 (0)	1 (<1)	6 (2)	0 (0)
Buprenorphine/naloxone	0 (0)	0 (0)	0 (0)	4 (1)	4 (1)
PIEDs	2 (1)	0 (0)	5 (2)	2 (1)	8 (3)
More than one	17 (5)	1 (5)	16 (8)	30 (11)	14 (5)
Other	2 (1)	0 (0)	0 (0)	3 (1)	1 (<1)
Not reported	7 (2)	0 (0)	0 (0)	2 (1)	0 (0)
Ever injected opioids					
No	85 (26)	7 (35)	84 (40)	71 (25)	88 (31)
Yes	237 (73)	13 (65)	126 (60)	205 (73)	195 (69)
Not reported	4 (1)	0 (0)	0 (0)	3 (1)	0 (0)
Frequency of injection last month (%)					
Not last month	40 (12)	1 (5)	38 (18)	19 (7)	42 (15)
Less than weekly	49 (15)	5 (25)	43 (20)	29 (10)	46 (16)
Weekly not daily	83 (25)	4 (20)	40 (19)	68 (24)	52 (18)
Daily or more	143 (44)	10 (50)	83 (40)	157 (56)	140 (49)
Not reported	11 (3)	0 (0)	6 (3)	6 (2)	3 (1)
Present when someone injected for the first time in the last 12 months (%)					
No	255 (78)	19 (95)	175 (83)	229 (82)	228 (81)
Yes	53 (16)	1 (5)	26 (12)	44 (16)	44 (16)
Not reported	18 (6)	0 (0)	9 (4)	6 (2)	11 (4)
Overdosed in last 12 months					
No	282 (87)	18 (90)	185 (88)	254 (91)	253 (89)
Yes	26 (8)	2 (10)	15 (7)	20 (7)	20 (7)
Not reported	18 (6)	0 (0)	10 (5)	5 (2)	10 (4)

Table 6.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

South Australia	2019	2020	2021	2022	2023
N° injected last month	N=275	N=19	N=166	N=254	N=238
Places injected last month (%)					
All private	156 (57)	13 (68)	86 (52)	125 (49)	123 (52)
Any public	114 (41)	6 (32)	80 (48)	129 (51)	113 (47)
Not reported	5 (2)	0 (0)	0 (0)	0 (0)	2 (1)
Use of new and sterile needles and syringes last month (%)					
All injections	218 (79)	18 (95)	135 (81)	202 (80)	191 (80)
Most of the time	41 (15)	1 (5)	23 (14)	41 (16)	33 (14)
Half of the time	5 (2)	0 (0)	2 (1)	2 (1)	6 (3)
Some of the time	2 (1)	0 (0)	3 (2)	3 (1)	1 (<1)
Not last month	2 (1)	0 (0)	1 (1)	0 (0)	3 (1)
Not reported	7 (3)	0 (0)	2 (1)	6 (2)	4 (2)
Re-used someone else's used needle & syringe last month (%)					
None	224 (81)	19 (100)	141 (85)	210 (83)	198 (83)
Once	19 (7)	0 (0)	7 (4)	13 (5)	10 (4)
Twice	15 (5)	0 (0)	6 (4)	16 (6)	14 (6)
3-5 times	5 (2)	0 (0)	5 (3)	6 (2)	7 (3)
>5 times	5 (2)	0 (0)	4 (2)	7 (3)	7 (3)
Not reported	7 (3)	0 (0)	3 (2)	2 (1)	2 (1)
Number of people needle & syringe was re-used after last month (%)					
None	224 (81)	19 (100)	141 (85)	210 (83)	198 (83)
One	18 (7)	0 (0)	10 (6)	19 (7)	17 (7)
Two	5 (2)	0 (0)	3 (2)	8 (3)	5 (2)
Three to five	4 (1)	0 (0)	1 (1)	1 (<1)	1 (<1)
More than five	3 (1)	0 (0)	1 (1)	3 (1)	2 (1)
Don't know	8 (3)	0 (0)	5 (3)	9 (4)	12 (5)
Not reported	13 (5)	0 (0)	5 (3)	4 (2)	3 (1)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	24 (9)	0 (0)	9 (5)	17 (7)	12 (5)
Casual sex partner	1 (<1)	0 (0)	2 (1)	2 (1)	3 (1)
Close friend	8 (3)	0 (0)	9 (5)	15 (6)	12 (5)
Acquaintance	6 (2)	0 (0)	1 (1)	7 (3)	4 (2)
Other	4 (1)	0 (0)	1 (1)	2 (1)	0 (0)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	45 (16)	1 (5)	29 (17)	43 (17)	35 (15)
Water	56 (20)	1 (5)	36 (22)	56 (22)	49 (21)
Filter	24 (9)	0 (0)	11 (7)	21 (8)	20 (8)
Drug mix	22 (8)	1 (5)	11 (7)	18 (7)	24 (10)
None	184 (67)	16 (84)	107 (64)	167 (66)	163 (68)
Injected by someone after that person injected themselves or others last month (%)					
No	231 (84)	18 (95)	138 (83)	196 (77)	198 (83)
Yes	38 (14)	1 (5)	25 (15)	55 (22)	37 (16)
Not reported	6 (2)	0 (0)	3 (2)	3 (1)	3 (1)
Source of needle acquisition					
Needle Syringe Program	238 (87)	16 (84)	142 (86)	228 (90)	198 (83)
Chemist/Pharmacy	44 (16)	3 (16)	25 (15)	33 (13)	28 (12)
Personal sources	43 (16)	4 (21)	18 (11)	40 (16)	23 (10)
Dispensing/Vending Machine	55 (20)	3 (16)	36 (22)	35 (14)	31 (13)
Other sources	3 (1)	0 (0)	3 (2)	2 (1)	2 (1)

Table 6.1.4 Number (percentage) of respondents by treatment for drug use and survey year

South Australia	2019	2020	2021	2022	2023
N° surveyed	N=326	N=20	N=210	N=279	N=283
Ever any treatment/therapy for drug use (%)					
No	109 (33)	6 (30)	87 (41)	92 (33)	106 (37)
Yes	214 (66)	14 (70)	123 (59)	186 (67)	176 (62)
Not reported	3 (1)	0 (0)	0 (0)	1 (<1)	1 (<1)
History of methadone maintenance treatment (%)					
Currently	86 (26)	4 (20)	34 (16)	53 (19)	37 (13)
Previously	49 (15)	2 (10)	44 (21)	66 (24)	50 (18)
Never	181 (56)	13 (65)	120 (57)	149 (53)	183 (65)
Not reported	10 (3)	1 (5)	12 (6)	11 (4)	13 (5)
History of buprenorphine (Subutex®) treatment (%)					
Currently	10 (3)	2 (10)	8 (4)	17 (6)	18 (6)
Previously	70 (21)	6 (30)	56 (27)	76 (27)	66 (23)
Never	240 (74)	12 (60)	138 (66)	175 (63)	188 (66)
Not reported	6 (2)	0 (0)	8 (4)	11 (4)	11 (4)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	21 (6)	2 (10)	24 (11)	18 (6)	18 (6)
Previously	57 (17)	5 (25)	44 (21)	75 (27)	51 (18)
Never	240 (74)	13 (65)	142 (68)	185 (66)	210 (74)
Not reported	8 (2)	0 (0)	0 (0)	1 (<1)	4 (1)
History of depot buprenorphine treatment (%)					
Currently	-- --	1 (5)	4 (2)	16 (6)	13 (5)
Previously	-- --	2 (10)	18 (9)	32 (11)	14 (5)
Never	-- --	10 (50)	180 (86)	223 (80)	243 (86)
Not reported	-- --	7 (35)	8 (4)	8 (3)	13 (5)

Table 6.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

South Australia	2019	2020	2021	2022	2023
N° surveyed	N=326	N=20	N=210	N=279	N=283
Previous HIV test (%)					
Yes, ever	241 (74)	16 (80)	136 (65)	186 (67)	191 (67)
Yes, last year	124 (38)	8 (40)	59 (28)	94 (34)	78 (28)
>1 year ago	117 (36)	8 (40)	77 (37)	92 (33)	113 (40)
Never tested	60 (18)	4 (20)	63 (30)	79 (28)	80 (28)
Not reported	25 (8)	0 (0)	11 (5)	14 (5)	12 (4)
Previous HCV test (%)					
Yes, ever	241 (74)	17 (85)	139 (66)	203 (73)	215 (76)
Yes, last year	150 (46)	8 (40)	66 (31)	123 (44)	97 (34)
>1 year ago	91 (28)	9 (45)	73 (35)	80 (29)	118 (42)
Never tested	48 (15)	2 (10)	51 (24)	52 (19)	46 (16)
Not reported	37 (11)	1 (5)	20 (10)	24 (9)	22 (8)
Lifetime treatment for HCV (%)#					
N° self-reported HCV diagnosis	N=56	N=3	N=23	N=54	N=38
Antiviral treatment	41 (73)	3 (100)	18 (78)	40 (74)	31 (82)
No antiviral treatment	15 (27)	0 (0)	5 (22)	14 (26)	6 (16)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (3)
Treatment for HCV in past 12 months (%)##					
N° self-reported HCV diagnosis	N=38	N=1	N=11	N=21	N=13
Antiviral treatment	21 (55)	1 (100)	3 (27)	5 (24)	6 (46)
No antiviral treatment	17 (45)	0 (0)	8 (73)	16 (76)	6 (46)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (8)

among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

Table 6.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

South Australia	2019	2020	2021	2022	2023
N° surveyed	N=326	N=20	N=210	N=279	N=283
Sex with a regular partner last month (%)					
No	165 (51)	14 (70)	116 (55)	148 (53)	161 (57)
Yes	134 (41)	6 (30)	83 (40)	120 (43)	113 (40)
Not reported	27 (8)	0 (0)	11 (5)	11 (4)	9 (3)
Condom used with regular partner last month (%)					
N° surveyed	N=134	N=6	N=83	N=120	N=113
Never	89 (66)	4 (67)	58 (70)	103 (86)	84 (74)
Sometimes	18 (13)	0 (0)	17 (20)	9 (8)	10 (9)
Every time	19 (14)	0 (0)	5 (6)	4 (3)	7 (6)
Not reported	8 (6)	2 (33)	3 (4)	4 (3)	12 (11)
Sex with other partner(s) last month (%)					
No	254 (78)	18 (90)	165 (79)	231 (83)	233 (82)
Yes	43 (13)	2 (10)	33 (16)	35 (13)	32 (11)
Not reported	29 (9)	0 (0)	12 (6)	13 (5)	18 (6)
Condom used with other partner(s) last month (%)					
N° surveyed	N=43	N=2	N=33	N=35	N=32
Never	21 (49)	1 (50)	17 (52)	23 (66)	18 (56)
Sometimes	10 (23)	1 (50)	5 (15)	6 (17)	9 (28)
Every time	12 (28)	0 (0)	9 (27)	5 (14)	4 (13)
Not reported	0 (0)	0 (0)	2 (6)	1 (3)	1 (3)
Sex work last month (%)					
No	279 (86)	20 (100)	186 (89)	244 (87)	253 (89)
Yes	12 (4)	0 (0)	11 (5)	19 (7)	14 (5)
Not reported	35 (11)	0 (0)	13 (6)	16 (6)	16 (6)
Condom used at last sex work (%)					
Yes	7 (58)	0 (0)	8 (73)	14 (74)	11 (79)

Table 6.1.7 Number (percentage) of respondents by COVID-19 related impacts, 2020-2023

South Australia	2020	2021	2022	2023
N° surveyed	N=20	N=210	N=279	N=283
COVID-19 test				
Yes	4 (20)	70 (33)	227 (81)	232 (82)
No	15 (75)	93 (44)	51 (18)	45 (16)
Don't know	1 (5)	15 (7)	-- --	-- --
Not reported	0 (0)	32 (15)	1 (<1)	6 (2)
Self-reported positive COVID-19 test result				
Yes	0 (0)	1 (<1)	97 (43)	105 (45)
Yes, last 12 months	-- --	-- --	77 (34)	40 (17)
Yes, more than a year ago	-- --	-- --	20 (9)	65 (28)
COVID-19 vaccine uptake				
≥1 dose	-- --	93 (44)	206 (74)	206 (73)
COVID-19 vaccine doses				
One dose	-- --	44 (21)	26 (9)	16 (6)
Two doses	-- --	49 (23)	53 (19)	65 (23)
Three or more doses	-- --	-- --	127 (46)	125 (44)
No doses	-- --	94 (45)	69 (25)	67 (24)
Not reported	-- --	23 (11)	4 (1)	10 (4)
Vaccine type *			N=206	
Astra Zeneca	-- --	11 (5)	49 (24)	-- --
Pfizer	-- --	48 (23)	132 (64)	-- --
Don't know	-- --	20 (10)	27 (13)	-- --
Other	-- --	-- --	19 (9)	-- --
Not reported	-- --	131 (62)	-- --	-- --
* 2021 only one response permitted, 2022 multiple responses permitted				
Last vaccine location			N=279	N=283
GP or medical centre	-- --	-- --	83 (30)	97 (34)
Pharmacy/ chemist	-- --	-- --	47 (17)	43 (15)
Vaccine hub	-- --	-- --	34 (12)	44 (16)
Opioid treatment/ methadone clinic	-- --	-- --	4 (1)	1 (<1)
NSP	-- --	-- --	4 (1)	1 (<1)
Prison	-- --	-- --	17 (6)	18 (6)
Multiple response	-- --	-- --	7 (3)	2 (1)
Other	-- --	-- --	14 (5)	9 (3)
Not reported	-- --	-- --	69 (25)	68 (24)
Vaccine hesitancy - if not had three or more doses				
Haven't got around to it	-- --	-- --	66 (24)	43 (15)
Difficulty booking appointment	-- --	-- --	7 (3)	5 (2)
Concerns about side effects	-- --	-- --	17 (6)	24 (8)
Concerns about vaccine safety	-- --	-- --	18 (6)	24 (8)
Not at risk of serious illness	-- --	-- --	14 (5)	31 (11)
Other	-- --	-- --	26 (9)	27 (10)
Multiple response	-- --	-- --	15 (5)	15 (5)
Not reported	-- --	-- --	116 (42)	114 (40)

HIV antibody prevalence

Table 6.2.1 HIV antibody prevalence by gender and survey year

South Australia	Male		Female		Total	
Survey year	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2019	177	4 (2.3)	126	0 (0.0)	304	4 (1.3)
2020	13	0 (0.0)	7	0 (0.0)	20	0 (0.0)
2021	116	0 (0.0)	67	0 (0.0)	188	0 (0.0)
2022	163	1 (0.6)	102	0 (0.0)	273	1 (0.4)
2023	127	0 (0.0)	81	0 (0.0)	215	0 (0.0)
X ² p trend		0.029		--		0.032

HCV antibody prevalence

Table 6.3.1 HCV antibody prevalence by gender and survey year

South Australia	Male		Female		Total	
Survey year	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019	175	82 (47)	126	43 (34)	302	125 (41)
2020	13	2 (15)	7	2 (29)	20	4 (20)
2021	116	36 (31)	67	20 (30)	188	57 (30)
2022	162	54 (33)	102	36 (35)	272	93 (34)
2023*	127	42 (33)	81	30 (37)	215	75 (35)
X ² p trend		0.008		0.665		0.096

* Antibody testing assay changed in 2023. See Appendix B: Methodological Notes

Table 6.3.2 HCV antibody prevalence by sexual identity, gender and survey year

South Australia	Male		Female		Total	
Sexual identity	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019						
Heterosexual	147	73 (50)	92	33 (36)	239	106 (44)
Bisexual	6	2 (33)	17	5 (29)	24	7 (29)
Homosexual	8	0 (0)	10	1 (10)	18	1 (6)
p value		0.009		0.256		0.001
2020						
Heterosexual	11	2 (18)	5	1 (20)	16	3 (19)
Bisexual	0	0 (0)	1	1 (100)	1	1 (100)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		1.000		0.333		0.405
2021						
Heterosexual	100	31 (31)	49	13 (27)	149	44 (30)
Bisexual	7	4 (57)	14	4 (29)	22	8 (36)
Homosexual	7	1 (14)	0	0 (0)	8	1 (13)
p value		0.361		0.749		0.828
2022						
Heterosexual	135	50 (37)	75	26 (35)	213	78 (37)
Bisexual	11	4 (36)	16	7 (44)	28	11 (39)
Homosexual	7	0 (0)	4	1 (25)	11	1 (9)
p value		0.158		0.780		0.287
2023						
Heterosexual	110	41 (37)	55	17 (31)	165	58 (35)
Bisexual	5	0 (0)	17	8 (47)	24	9 (38)
Homosexual	5	0 (0)	3	1 (33)	9	1 (11)
p value		0.123		0.193		0.650

Table 6.3.3 HCV antibody prevalence by age group, gender and survey year

South Australia Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
<25 years	4	1 (25)	3	1 (33)	7	2 (29)
25-34 years	21	7 (33)	23	4 (17)	44	11 (25)
35-44 years	57	20 (35)	45	15 (33)	102	35 (34)
45+ years	91	54 (59)	55	23 (42)	147	77 (52)
p value		0.008		0.195		0.002
2020						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	1	0 (0)	0	0 (0)	1	0 (0)
35-44 years	4	0 (0)	2	0 (0)	6	0 (0)
45+ years	8	2 (25)	5	2 (40)	13	4 (31)
p value		0.590		1.000		0.404
2021						
<25 years	3	1 (33)	0	0 (0)	3	1 (33)
25-34 years	15	2 (13)	9	2 (22)	24	4 (17)
35-44 years	37	16 (43)	28	9 (32)	67	25 (37)
45+ years	61	17 (28)	30	9 (30)	94	27 (29)
p value		0.142		0.936		0.232
2022						
<25 years	4	0 (0)	0	0 (0)	4	0 (0)
25-34 years	14	1 (7)	10	2 (20)	24	3 (13)
35-44 years	42	11 (26)	27	8 (30)	69	19 (28)
45+ years	98	41 (42)	64	25 (39)	169	68 (40)
p value		0.014		0.409		0.008
2023						
<25 years	4	0 (0)	4	1 (25)	8	1 (13)
25-34 years	10	1 (10)	3	0 (0)	16	2 (13)
35-44 years	37	7 (19)	28	10 (36)	66	17 (26)
45+ years	75	33 (44)	44	17 (39)	122	52 (43)
p value		0.008		0.742		0.011

Table 6.3.4 HCV antibody prevalence by years since first injection, gender and survey year

South Australia Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
<3 years	3	0 (0)	4	0 (0)	7	0 (0)
3 to 10 years	16	2 (13)	20	7 (35)	36	9 (25)
11+ years	145	74 (51)	92	33 (36)	238	107 (45)
p value		0.002		0.466		0.005
2020						
<3 years	2	0 (0)	0	0 (0)	2	0 (0)
3 to 10 years	1	0 (0)	0	0 (0)	1	0 (0)
11+ years	10	2 (20)	7	2 (29)	17	4 (24)
p value		1.000		--		1.000
2021						
<3 years	1	1 (100)	1	0 (0)	2	1 (50)
3 to 10 years	10	3 (30)	9	0 (0)	19	3 (16)
11+ years	98	28 (29)	54	19 (35)	157	48 (31)
p value		0.405		0.064		0.256
2022						
<3 years	9	0 (0)	2	1 (50)	11	1 (9)
3 to 10 years	14	2 (14)	10	1 (10)	25	4 (16)
11+ years	128	49 (38)	86	33 (38)	220	83 (38)
p value		0.013		0.139		0.016
2023						
<3 years	4	0 (0)	4	1 (25)	8	1 (13)
3 to 10 years	11	0 (0)	12	0 (0)	25	0 (0)
11+ years	107	41 (38)	60	27 (45)	172	71 (41)
p value		0.006		0.004		<0.001

Table 6.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

South Australia Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
No receptive sharing	5	0 (0)	193	83 (43)	209	90 (43)
Receptive sharing	0	0 (0)	35	12 (34)	38	13 (34)
p value		--		0.336		0.309
2020						
No receptive sharing	2	0 (0)	17	4 (24)	19	4 (21)
Receptive sharing	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2021						
No receptive sharing	2	1 (50)	118	40 (34)	127	44 (35)
Receptive sharing	0	0 (0)	17	4 (24)	19	5 (26)
p value		--		0.581		0.473
2022						
No receptive sharing	9	1 (11)	190	65 (34)	205	69 (34)
Receptive sharing	1	0 (0)	36	14 (39)	41	14 (34)
p value		1.000		0.589		0.952
2023						
No receptive sharing	4	0 (0)	138	52 (38)	146	54 (37)
Receptive sharing	3	1 (33)	25	12 (48)	29	13 (45)
p value		0.429		0.331		0.428

Table 6.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

South Australia Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
Heroin	0	0 (0)	69	43 (62)	72	46 (64)
Methamphetamine	6	0 (0)	141	40 (28)	157	44 (28)
Other opioids	0	0 (0)	40	19 (48)	41	20 (49)
Other drugs	1	0 (0)	17	10 (59)	20	10 (50)
p value		--		<0.001		<0.001
2020						
Heroin	0	0 (0)	5	2 (40)	5	2 (40)
Methamphetamine	2	0 (0)	10	2 (20)	12	2 (17)
Other opioids	0	0 (0)	2	0 (0)	2	0 (0)
Other drugs	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		0.615		0.555
2021						
Heroin	0	0 (0)	47	20 (43)	51	22 (43)
Methamphetamine	2	1 (50)	92	20 (22)	99	23 (23)
Other opioids	0	0 (0)	13	4 (31)	14	5 (36)
Other drugs	0	0 (0)	19	5 (26)	19	5 (26)
p value		--		0.083		0.083
2022						
Heroin	0	0 (0)	75	37 (49)	79	40 (51)
Methamphetamine	7	1 (14)	120	31 (26)	131	32 (24)
Other opioids	1	0 (0)	19	9 (47)	22	9 (41)
Other drugs	2	0 (0)	27	8 (30)	32	8 (25)
p value		0.788		0.005		0.001
2023						
Heroin	0	0 (0)	38	20 (53)	41	23 (56)
Methamphetamine	7	1 (14)	123	37 (30)	133	38 (29)
Other opioids	0	0 (0)	18	8 (44)	19	8 (42)
Other drugs	1	0 (0)	15	5 (33)	19	5 (26)
p value		0.686		0.071		0.009

Table 6.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

South Australia	<3 years		3+ years		Total	
Frequency of injection last month	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019						
Less than daily	3	0 (0)	116	44 (38)	124	47 (38)
Daily or more	3	0 (0)	118	52 (44)	130	57 (44)
Not last month	1	0 (0)	33	16 (48)	38	16 (42)
p value		--		0.457		0.624
2020						
Less than daily	2	0 (0)	7	2 (29)	9	2 (22)
Daily or more	0	0 (0)	10	2 (20)	10	2 (20)
Not last month	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		1.000		1.000
2021						
Less than daily	1	0 (0)	72	17 (24)	75	18 (24)
Daily or more	1	1 (100)	66	29 (44)	74	33 (45)
Not last month	0	0 (0)	33	3 (9)	34	4 (12)
p value		1.000		0.001		0.001
2022						
Less than daily	8	1 (13)	84	27 (32)	94	28 (30)
Daily or more	2	0 (0)	143	53 (37)	154	56 (36)
Not last month	1	0 (0)	15	5 (33)	18	5 (28)
p value		1.000		0.747		0.493
2023						
Less than daily	6	1 (17)	68	28 (41)	76	29 (38)
Daily or more	1	0 (0)	97	37 (38)	101	39 (39)
Not last month	1	0 (0)	29	5 (17)	35	6 (17)
p value		1.000		0.067		0.054

Table 6.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

South Australia	<3 years		3+ years		Total	
Imprisonment last year	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019						
No imprisonment	5	0 (0)	222	92 (41)	246	101 (41)
Imprisonment	1	0 (0)	30	15 (50)	32	15 (47)
p value		--		0.373		0.530
2020						
No imprisonment	2	0 (0)	17	4 (24)	19	4 (21)
Imprisonment	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		1.000		1.000
2021						
No imprisonment	1	0 (0)	149	43 (29)	156	47 (30)
Imprisonment	0	0 (0)	16	1 (6)	19	1 (5)
p value		--		0.072		0.027
2022						
No imprisonment	10	1 (10)	207	76 (37)	228	80 (35)
Imprisonment	1	0 (0)	31	7 (23)	36	8 (22)
p value		1.000		0.124		0.128
2023						
No imprisonment	8	1 (13)	163	54 (33)	178	57 (32)
Imprisonment	0	0 (0)	19	8 (42)	21	8 (38)
p value		--		0.435		0.575

Table 6.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

South Australia	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
Non Indigenous	133	65 (49)	98	33 (34)	231	98 (42)
Indigenous	39	14 (36)	24	9 (38)	64	23 (36)
p value		0.153		0.724		0.351
2020						
Non Indigenous	10	2 (20)	7	2 (29)	17	4 (24)
Indigenous	3	0 (0)	0	0 (0)	3	0 (0)
p value		1.000		--		1.000
2021						
Non Indigenous	78	20 (26)	43	12 (28)	124	32 (26)
Indigenous	28	12 (43)	18	6 (33)	48	19 (40)
p value		0.089		0.672		0.076
2022						
Non Indigenous	115	40 (35)	73	27 (37)	194	70 (36)
Indigenous	45	13 (29)	28	9 (32)	74	22 (30)
p value		0.476		0.649		0.327
2023						
Non Indigenous	89	32 (36)	53	19 (36)	148	53 (36)
Indigenous	34	9 (26)	25	9 (36)	60	19 (32)
p value		0.318		0.990		0.569

Table 6.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

South Australia	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
English speaking	165	79 (48)	124	42 (34)	290	121 (42)
Non-English speaking	9	3 (33)	2	1 (50)	11	4 (36)
p value		0.503		1.000		1.000
2020						
English speaking	13	2 (15)	7	2 (29)	20	4 (20)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2021						
English speaking	110	35 (32)	63	19 (30)	178	55 (31)
Non-English speaking	3	1 (33)	4	1 (25)	7	2 (29)
p value		1.000		1.000		1.000
2022						
English speaking	150	49 (33)	95	34 (36)	252	86 (34)
Non-English speaking	10	5 (50)	5	1 (20)	16	6 (38)
p value		0.262		0.655		0.783
2023						
English speaking	117	39 (33)	79	29 (37)	203	71 (35)
Non-English speaking	9	2 (22)	1	0 (0)	10	2 (20)
p value		0.717		1.000		0.500

Table 6.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

South Australia		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2019							
Australia	152	69 (45)	113	38 (34)	266	107 (40)	
Other Oceania	2	1 (50)	2	0 (0)	4	1 (25)	
Asia	5	1 (20)	1	1 (100)	6	2 (33)	
UK & Ireland	10	7 (70)	8	3 (38)	18	10 (56)	
Other	4	2 (50)	2	1 (50)	6	3 (50)	
p value		0.426		0.600		0.656	
2020							
Australia	12	2 (17)	5	1 (20)	17	3 (18)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	1	0 (0)	2	1 (50)	3	1 (33)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		1.000		1.000		0.509	
2021							
Australia	99	29 (29)	58	14 (24)	162	44 (27)	
Other Oceania	1	1 (100)	2	2 (100)	3	3 (100)	
Asia	2	1 (50)	1	1 (100)	3	2 (67)	
UK & Ireland	7	2 (29)	3	2 (67)	10	4 (40)	
Other	3	0 (0)	2	1 (50)	5	1 (20)	
p value		0.419		0.013		0.029	
2022							
Australia	140	44 (31)	86	29 (34)	233	76 (33)	
Other Oceania	2	2 (100)	2	1 (50)	4	3 (75)	
Asia	5	1 (20)	3	1 (33)	8	2 (25)	
UK & Ireland	5	2 (40)	8	5 (63)	13	7 (54)	
Other	3	1 (33)	2	0 (0)	6	1 (17)	
p value		0.340		0.412		0.161	
2023							
Australia	109	35 (32)	75	26 (35)	191	64 (34)	
Other Oceania	5	3 (60)	3	1 (33)	8	4 (50)	
Asia	2	0 (0)	0	0 (0)	2	0 (0)	
UK & Ireland	5	2 (40)	3	3 (100)	8	5 (63)	
Other	3	0 (0)	0	0 (0)	3	0 (0)	
p value		0.435		0.093		0.209	

HCV RNA prevalence

Table 6.4.1 HCV RNA prevalence by gender and survey year

South Australia	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*	117	18 (15)	85	5 (6)	203	23 (11)
2020	9	1 (11)	5	0 (0)	14	1 (7)
2021	87	16 (18)	54	5 (9)	146	22 (15)
2022	149	19 (13)	87	13 (15)	243	32 (13)
2023	128	9 (7)	80	1 (1)	215	11 (5)
X ² p trend		0.059		0.939		0.127

* 2019: Weighted for gender and HCV antibody status

Totals include respondents where gender was reported as other or not reported

Table 6.4.2 HCV RNA prevalence by sexual identity, gender and survey year

South Australia	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
Heterosexual	96	15 (16)	58	4 (7)	155	19 (12)
Bisexual	5	1 (20)	12	0 (0)	18	1 (6)
Homosexual	8	0 (0)	9	0 (0)	17	0 (0)
p value		0.492		0.444		0.221
2020						
Heterosexual	7	1 (14)	4	0 (0)	11	1 (9)
Bisexual	0	0 (0)	1	0 (0)	1	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		0.753
2021						
Heterosexual	76	14 (18)	38	3 (8)	114	17 (15)
Bisexual	4	2 (50)	13	1 (8)	18	3 (17)
Homosexual	5	0 (0)	0	0 (0)	6	0 (0)
p value		0.156		0.981		0.576
2022						
Heterosexual	122	17 (14)	63	10 (16)	188	27 (14)
Bisexual	11	2 (18)	14	2 (14)	25	4 (16)
Homosexual	7	0 (0)	3	0 (0)	10	0 (0)
p value		0.859		1.000		0.865
2023						
Heterosexual	110	9 (8)	55	1 (2)	165	10 (6)
Bisexual	5	0 (0)	17	0 (0)	24	1 (4)
Homosexual	5	0 (0)	2	0 (0)	8	0 (0)
p value		1.000		1.000		1.000

Table 6.4.3 HCV RNA prevalence by age group, gender and survey year

South Australia Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
<25 years	2	0 (0)	3	0 (0)	5	0 (0)
25-34 years	17	2 (12)	16	2 (13)	33	4 (12)
35-44 years	37	3 (8)	27	1 (4)	63	4 (6)
45+ years	60	13 (22)	39	2 (5)	100	15 (15)
p value		0.307		0.680		0.322
2020						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	0	0 (0)	0	0 (0)	0	0 (0)
35-44 years	3	0 (0)	1	0 (0)	4	0 (0)
45+ years	6	1 (17)	4	0 (0)	10	1 (10)
p value		0.501		--		0.525
2021						
<25 years	3	1 (33)	0	0 (0)	3	1 (33)
25-34 years	11	2 (18)	9	1 (11)	20	3 (15)
35-44 years	28	5 (18)	20	1 (5)	50	6 (12)
45+ years	45	8 (18)	25	3 (12)	73	12 (16)
p value		0.927		0.707		0.739
2022						
<25 years	4	0 (0)	0	0 (0)	4	0 (0)
25-34 years	14	0 (0)	9	1 (11)	23	1 (4)
35-44 years	41	4 (10)	24	3 (13)	65	7 (11)
45+ years	86	14 (16)	53	9 (17)	145	23 (16)
p value		0.358		0.903		0.428
2023						
<25 years	4	0 (0)	4	0 (0)	8	0 (0)
25-34 years	10	0 (0)	3	0 (0)	16	1 (6)
35-44 years	37	2 (5)	27	1 (4)	65	3 (5)
45+ years	76	7 (9)	44	0 (0)	123	7 (6)
p value		0.904		0.436		1.000

Table 6.4.4 HCV RNA prevalence by years since first injection, gender and survey year

South Australia Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019*						
<3 years	2	0 (0)	3	0 (0)	5	0 (0)
3 to 10 years	10	0 (0)	15	3 (20)	25	3 (12)
11+ years	97	18 (19)	62	1 (2)	160	19 (12)
p value		0.291		0.016		0.719
2020						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	0	0 (0)	0	0 (0)	0	0 (0)
11+ years	8	1 (13)	5	0 (0)	13	1 (8)
p value		0.708		--		0.773
2021						
<3 years	1	1 (100)	1	0 (0)	2	1 (50)
3 to 10 years	8	3 (38)	8	1 (13)	16	4 (25)
11+ years	73	11 (15)	42	4 (10)	120	16 (13)
p value		0.031		0.915		0.183
2022						
<3 years	9	0 (0)	2	0 (0)	11	0 (0)
3 to 10 years	14	1 (7)	10	1 (10)	25	2 (8)
11+ years	116	17 (15)	71	12 (17)	192	29 (15)
p value		0.675		1.000		0.415
2023						
<3 years	4	0 (0)	4	0 (0)	8	0 (0)
3 to 10 years	11	0 (0)	12	0 (0)	25	0 (0)
11+ years	108	9 (8)	59	1 (2)	172	11 (6)
p value		1.000		1.000		0.595

Table 6.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

South Australia Receptively shared syringe last month	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019*						
No receptive sharing	88	15 (17)	58	4 (7)	147	19 (13)
Receptive sharing	12	2 (17)	12	0 (0)	23	2 (9)
p value		0.983		0.347		0.552
2020						
No receptive sharing	8	1 (13)	5	0 (0)	13	1 (8)
Receptive sharing	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2021						
No receptive sharing	62	16 (26)	33	4 (12)	98	20 (20)
Receptive sharing	7	0 (0)	4	0 (0)	13	1 (8)
p value		0.125		0.461		0.271
2022						
No receptive sharing	112	17 (15)	64	6 (9)	181	23 (13)
Receptive sharing	20	1 (5)	16	5 (31)	37	6 (16)
p value		0.307		0.023		0.567
2023						
No receptive sharing	81	2 (2)	60	1 (2)	147	3 (2)
Receptive sharing	17	4 (24)	10	0 (0)	28	5 (18)
p value		0.008		1.000		0.003

Table 6.4.6 HCV RNA prevalence by last drug injected, gender and survey year

South Australia		Male		Female		Total	
Last drug injected	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2019*							
Heroin	24	5 (21)	23	2 (9)	48	7 (15)	
Methamphetamine	65	8 (12)	43	2 (5)	109	10 (9)	
Other opioids	18	3 (17)	10	1 (10)	29	4 (14)	
Other drugs	6	2 (33)	5	0 (0)	11	2 (18)	
p value		0.529		0.826		0.671	
2020							
Heroin	3	0 (0)	1	0 (0)	4	0 (0)	
Methamphetamine	4	1 (25)	3	0 (0)	7	1 (14)	
Other opioids	1	0 (0)	1	0 (0)	2	0 (0)	
Other drugs	1	0 (0)	0	0 (0)	1	0 (0)	
p value		0.704		--		0.783	
2021							
Heroin	21	5 (24)	14	2 (14)	37	7 (19)	
Methamphetamine	51	9 (18)	29	1 (3)	82	10 (12)	
Other opioids	8	1 (13)	3	0 (0)	12	2 (17)	
Other drugs	7	1 (14)	4	1 (25)	11	2 (18)	
p value		0.875		0.334		0.784	
2022							
Heroin	37	5 (14)	30	7 (23)	69	12 (17)	
Methamphetamine	70	10 (14)	47	4 (9)	121	14 (12)	
Other opioids	16	0 (0)	4	0 (0)	21	0 (0)	
Other drugs	19	3 (16)	5	2 (40)	24	5 (21)	
p value		0.444		0.098		0.124	
2023							
Heroin	16	1 (6)	21	0 (0)	41	1 (2)	
Methamphetamine	81	7 (9)	51	1 (2)	134	9 (7)	
Other opioids	14	1 (7)	4	0 (0)	19	1 (5)	
Other drugs	14	0 (0)	4	0 (0)	18	0 (0)	
p value		0.715		0.902		0.522	

Table 6.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year

South Australia	Male		Female		Total	
Frequency of injection last month	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019*						
Less than daily	51	5 (10)	43	1 (2)	95	6 (6)
Daily or more	51	12 (24)	29	3 (10)	80	15 (19)
Not last month	12	1 (8)	10	1 (10)	23	2 (9)
p value		0.128		0.330		0.033
2020						
Less than daily	3	0 (0)	2	0 (0)	5	0 (0)
Daily or more	5	1 (20)	3	0 (0)	8	1 (13)
Not last month	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.638		--		0.668
2021						
Less than daily	37	6 (16)	25	2 (8)	65	8 (12)
Daily or more	32	10 (31)	14	2 (14)	48	13 (27)
Not last month	18	0 (0)	11	0 (0)	29	0 (0)
p value		0.021		0.426		0.004
2022						
Less than daily	56	7 (13)	33	4 (12)	90	11 (12)
Daily or more	78	11 (14)	47	7 (15)	130	18 (14)
Not last month	10	0 (0)	6	2 (33)	17	2 (12)
p value		0.678		0.347		0.953
2023						
Less than daily	45	2 (4)	31	0 (0)	77	2 (3)
Daily or more	55	5 (9)	39	1 (3)	100	7 (7)
Not last month	25	2 (8)	10	0 (0)	35	2 (6)
p value		0.665		1.000		0.450

Table 6.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year

South Australia	Male		Female		Total	
Imprisonment last year	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019*						
No imprisonment	86	13 (15)	71	5 (7)	158	18 (11)
Imprisonment	17	2 (12)	8	0 (0)	24	2 (8)
p value		0.750		0.440		0.639
2020						
No imprisonment	9	1 (11)	5	0 (0)	14	1 (7)
Imprisonment	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2021						
No imprisonment	71	11 (15)	46	2 (4)	122	14 (11)
Imprisonment	9	0 (0)	5	0 (0)	14	0 (0)
p value		0.204		0.634		0.181
2022						
No imprisonment	119	15 (13)	80	13 (16)	203	28 (14)
Imprisonment	26	3 (12)	6	0 (0)	33	3 (9)
p value		1.000		0.585		0.586
2023						
No imprisonment	99	7 (7)	74	1 (1)	178	8 (4)
Imprisonment	17	1 (6)	2	0 (0)	20	2 (10)
p value		1.000		1.000		0.267

Table 6.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

South Australia		Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	
2019*							
Non Indigenous	89	14 (16)	67	4 (6)	157	18 (11)	
Indigenous	26	4 (15)	15	1 (7)	42	5 (12)	
p value		0.956		0.981		0.962	
2020							
Non Indigenous	7	1 (14)	5	0 (0)	12	1 (8)	
Indigenous	2	0 (0)	0	0 (0)	2	0 (0)	
p value		0.571		--		0.672	
2021							
Non Indigenous	55	9 (16)	34	4 (12)	92	13 (14)	
Indigenous	25	5 (20)	17	0 (0)	44	6 (14)	
p value		0.692		0.141		0.938	
2022							
Non Indigenous	106	15 (14)	63	11 (17)	174	26 (15)	
Indigenous	42	4 (10)	23	2 (9)	66	6 (9)	
p value		0.590		0.499		0.234	
2023							
Non Indigenous	89	7 (8)	53	1 (2)	148	8 (5)	
Indigenous	35	2 (6)	25	0 (0)	61	3 (5)	
p value		1.000		1.000		1.000	

Table 6.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year

South Australia		Male		Female		Total	
Main language spoken at home by parents	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	
2019*							
English speaking	112	18 (16)	84	5 (6)	197	23 (12)	
Non-English speaking	4	0 (0)	1	0 (0)	5	0 (0)	
p value		0.383		0.803		0.416	
2020							
English speaking	9	1 (11)	5	0 (0)	14	1 (7)	
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)	
p value		--		--		--	
2021							
English speaking	84	15 (18)	51	4 (8)	140	20 (14)	
Non-English speaking	2	1 (50)	3	1 (33)	5	2 (40)	
p value		0.248		0.139		0.115	
2022							
English speaking	138	16 (12)	81	13 (16)	226	29 (13)	
Non-English speaking	9	3 (33)	4	0 (0)	13	3 (23)	
p value		0.093		1.000		0.391	
2023							
English speaking	118	9 (8)	78	1 (1)	203	11 (5)	
Non-English speaking	9	0 (0)	1	0 (0)	10	0 (0)	
p value		1.000		1.000		1.000	

Table 6.4.11 HCV RNA prevalence by region/country of birth, gender and survey year

South Australia		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2019*							
Australia	104	16 (15)	74	4 (5)	179	20 (11)	
Other Oceania	1	0 (0)	1	0 (0)	2	0 (0)	
Asia	1	0 (0)	1	0 (0)	2	0 (0)	
UK & Ireland	8	2 (25)	7	1 (14)	15	3 (20)	
Other	2	0 (0)	2	0 (0)	4	0 (0)	
p value		0.868		0.846		0.688	
2020							
Australia	8	1 (13)	4	0 (0)	12	1 (8)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	1	0 (0)	1	0 (0)	2	0 (0)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		0.708		--		0.672	
2021							
Australia	76	13 (17)	45	2 (4)	126	16 (13)	
Other Oceania	0	0 (0)	2	1 (50)	2	1 (50)	
Asia	1	1 (100)	1	1 (100)	2	2 (100)	
UK & Ireland	5	2 (40)	3	1 (33)	8	3 (38)	
Other	1	0 (0)	2	0 (0)	3	0 (0)	
p value		0.110		0.002		0.002	
2022							
Australia	127	14 (11)	72	11 (15)	206	25 (12)	
Other Oceania	2	0 (0)	2	1 (50)	4	1 (25)	
Asia	5	1 (20)	2	0 (0)	7	1 (14)	
UK & Ireland	5	1 (20)	8	1 (13)	13	2 (15)	
Other	3	1 (33)	2	0 (0)	5	1 (20)	
p value		0.288		0.680		0.560	
2023							
Australia	110	7 (6)	74	0 (0)	191	8 (4)	
Other Oceania	5	1 (20)	3	1 (33)	8	2 (25)	
Asia	2	0 (0)	0	0 (0)	2	0 (0)	
UK & Ireland	5	1 (20)	3	0 (0)	8	1 (13)	
Other	3	0 (0)	0	0 (0)	3	0 (0)	
p value		0.294		0.075		0.093	

Tasmania

Table 7.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Tasmania	2019	2020*	2021*	2022	2023
Number of sites	4	4	4	4	4
N° surveyed	N=40	N=35	N=95	N=91	N=78
Response rate (%)	17%	17%	62%	38%	30%
Gender (%)					
Male	21 (53)	21 (60)	51 (54)	60 (66)	49 (63)
Female	19 (48)	14 (40)	44 (46)	29 (32)	28 (36)
Other	0 (0)	0 (0)	0 (0)	2 (2)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Sexual identity (%)					
Heterosexual	35 (88)	32 (91)	81 (85)	77 (85)	60 (77)
Bisexual	4 (10)	1 (3)	9 (9)	9 (10)	12 (15)
Gay/Lesbian	0 (0)	2 (6)	1 (1)	3 (3)	2 (3)
Other	-- --	0 (0)	2 (2)	2 (2)	2 (3)
Not reported	1 (3)	0 (0)	2 (2)	0 (0)	2 (3)
Aboriginal and Torres Strait Islander origin (%)					
No	36 (90)	31 (89)	72 (76)	63 (69)	61 (78)
Yes	4 (10)	4 (11)	20 (21)	25 (27)	17 (22)
Not reported	0 (0)	0 (0)	3 (3)	3 (3)	0 (0)
Region/country of birth (%)					
Australia	39 (98)	33 (94)	86 (91)	87 (96)	73 (94)
Other Oceania	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)
Asia	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
UK & Ireland	1 (3)	2 (6)	0 (0)	1 (1)	1 (1)
Other	0 (0)	0 (0)	6 (6)	1 (1)	3 (4)
Not reported	0 (0)	0 (0)	2 (2)	1 (1)	0 (0)
Main language spoken at home by parents (%)					
English	40 (100)	35 (100)	90 (95)	90 (99)	75 (96)
Non-English	0 (0)	0 (0)	4 (4)	1 (1)	2 (3)
Not reported	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)
Age and time since first injection (years)					
<i>Median age</i>	42	43	45	44	43
<i>Age range</i>	24-59	28-66	20-67	24-62	26-67
Age group (%)					
<25 years	1 (3)	0 (0)	2 (2)	1 (1)	0 (0)
25+ years	39 (98)	35 (100)	91 (96)	90 (99)	77 (99)
Not reported	0 (0)	0 (0)	2 (2)	0 (0)	1 (1)
Median age first injection					
<i>Median age first injection</i>	20	20	20	19	20
<i>Age range</i>	13-38	13-36	12-55	10-56	11-49
<i>N° not reported</i>	0	0	2	2	3
Median yrs since first injection					
<i>Median yrs since first injection</i>	22	23	21.5	25	22
<i>Range</i>	5-45	1-46	1-48	2-46	<1-47
Years since first injection					
<3 years	0 (0)	1 (3)	5 (5)	2 (2)	7 (9)
3+ years	40 (100)	34 (97)	87 (92)	87 (96)	68 (87)
Not reported	0 (0)	0 (0)	3 (3)	2 (2)	3 (4)
Imprisonment last year (%)					
No	36 (90)	30 (86)	82 (86)	75 (82)	67 (86)
Yes	4 (10)	5 (14)	8 (8)	14 (15)	9 (12)
Not reported	0 (0)	0 (0)	5 (5)	2 (2)	2 (3)
N° in prison					
<i>N° in prison</i>	N=4	N=5	N=8	N=14	N=9
Injected in prison	0 (0)	0 (0)	2 (25)	4 (29)	2 (22)

* Implementation of the 2020 and 2021 ANSPS was impacted by the COVID-19 pandemic, see page 1 for more information

Table 7.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

Tasmania	2019	2020	2021	2022	2023
N° surveyed	N=40	N=35	N=95	N=91	N=78
Drug last injected (%)					
Cocaine	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Methamphetamine	18 (45)	15 (43)	49 (52)	50 (55)	47 (60)
Heroin	2 (5)	1 (3)	7 (7)	3 (3)	2 (3)
Pharm. opioids	3 (8)	9 (26)	14 (15)	21 (23)	9 (12)
Methadone	11 (28)	7 (20)	9 (9)	6 (7)	6 (8)
Buprenorphine	2 (5)	0 (0)	4 (4)	6 (7)	6 (8)
Buprenorphine/naloxone	1 (3)	0 (0)	4 (4)	1 (1)	0 (0)
PIEDs	1 (3)	1 (3)	2 (2)	0 (0)	3 (4)
More than one	0 (0)	1 (3)	3 (3)	3 (3)	2 (3)
Other	2 (5)	0 (0)	2 (2)	1 (1)	2 (3)
Not reported	0 (0)	1 (3)	1 (1)	0 (0)	1 (1)
Ever injected opioids					
No	3 (8)	2 (6)	32 (34)	16 (18)	23 (29)
Yes	37 (93)	33 (94)	63 (66)	75 (82)	54 (69)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Frequency of injection last month (%)					
Not last month	3 (8)	5 (14)	10 (11)	2 (2)	6 (8)
Less than weekly	8 (20)	7 (20)	32 (34)	14 (15)	20 (26)
Weekly not daily	17 (43)	12 (34)	20 (21)	26 (29)	25 (32)
Daily or more	11 (28)	11 (31)	31 (33)	49 (54)	23 (29)
Not reported	1 (3)	0 (0)	2 (2)	0 (0)	4 (5)
Present when someone injected for the first time in the last 12 months (%)					
No	38 (95)	34 (97)	78 (82)	75 (82)	69 (88)
Yes	2 (5)	1 (3)	14 (15)	16 (18)	7 (9)
Not reported	0 (0)	0 (0)	3 (3)	0 (0)	2 (3)
Overdosed in last 12 months					
No	31 (78)	30 (86)	85 (89)	83 (91)	69 (88)
Yes	9 (23)	5 (14)	5 (5)	8 (9)	7 (9)
Not reported	0 (0)	0 (0)	5 (5)	0 (0)	2 (3)

Table 7.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

Tasmania	2019	2020	2021	2022	2023
N° injected last month	N=36	N=30	N=83	N=89	N=68
Places injected last month (%)					
All private	24 (67)	24 (80)	62 (75)	49 (55)	45 (66)
Any public	12 (33)	6 (20)	21 (25)	40 (45)	23 (34)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Use of new and sterile needles and syringes last month (%)					
All injections	30 (83)	26 (87)	71 (86)	75 (84)	54 (79)
Most of the time	3 (8)	4 (13)	8 (10)	12 (13)	10 (15)
Half of the time	1 (3)	0 (0)	0 (0)	1 (1)	3 (4)
Some of the time	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Not last month	2 (6)	0 (0)	2 (2)	0 (0)	1 (1)
Not reported	0 (0)	0 (0)	2 (2)	0 (0)	0 (0)
Re-used someone else's used needle & syringe last month (%)					
None	34 (94)	30 (100)	76 (92)	76 (85)	65 (96)
Once	1 (3)	0 (0)	2 (2)	3 (3)	1 (1)
Twice	0 (0)	0 (0)	4 (5)	6 (7)	1 (1)
3-5 times	1 (3)	0 (0)	0 (0)	1 (1)	1 (1)
>5 times	0 (0)	0 (0)	1 (1)	3 (3)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Number of people needle & syringe was re-used after last month (%)					
None	34 (94)	30 (100)	76 (92)	76 (85)	65 (96)
One	0 (0)	0 (0)	2 (2)	3 (3)	2 (3)
Two	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)
Three to five	0 (0)	0 (0)	0 (0)	2 (2)	0 (0)
More than five	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Don't know	0 (0)	0 (0)	3 (4)	4 (4)	1 (1)
Not reported	2 (6)	0 (0)	1 (1)	2 (2)	0 (0)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	0 (0)	0 (0)	2 (2)	2 (2)	0 (0)
Casual sex partner	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Close friend	0 (0)	0 (0)	2 (2)	3 (3)	2 (3)
Acquaintance	0 (0)	0 (0)	0 (0)	2 (2)	1 (1)
Other	0 (0)	0 (0)	1 (1)	3 (3)	0 (0)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	3 (8)	0 (0)	11 (13)	20 (22)	3 (4)
Water	3 (8)	1 (3)	19 (23)	13 (15)	15 (22)
Filter	4 (11)	0 (0)	9 (11)	5 (6)	6 (9)
Drug mix	1 (3)	0 (0)	5 (6)	4 (4)	1 (1)
None	26 (72)	28 (93)	58 (70)	54 (61)	48 (71)
Injected by someone after that person injected themselves or others last month (%)					
No	35 (97)	28 (93)	73 (88)	71 (80)	65 (96)
Yes	1 (3)	2 (7)	9 (11)	18 (20)	3 (4)
Not reported	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
Source of needle acquisition					
Needle Syringe Program	36 (100)	29 (97)	72 (87)	86 (97)	61 (90)
Chemist/Pharmacy	6 (17)	8 (27)	19 (23)	27 (30)	17 (25)
Personal sources	2 (6)	0 (0)	5 (6)	12 (13)	4 (6)
Dispensing/Vending Machine	8 (22)	7 (23)	7 (8)	19 (21)	5 (7)
Other sources	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)

Table 7.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Tasmania	2019	2020	2021	2022	2023
N° surveyed	N=40	N=35	N=95	N=91	N=78
Ever any treatment/therapy for drug use (%)					
No	10 (25)	11 (31)	33 (35)	23 (25)	22 (28)
Yes	30 (75)	24 (69)	62 (65)	68 (75)	56 (72)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
History of methadone maintenance treatment (%)					
Currently	10 (25)	7 (20)	10 (11)	12 (13)	7 (9)
Previously	11 (28)	5 (14)	18 (19)	24 (26)	19 (24)
Never	19 (48)	23 (66)	62 (65)	55 (60)	49 (63)
Not reported	0 (0)	0 (0)	5 (5)	0 (0)	3 (4)
History of buprenorphine (Subutex®) treatment (%)					
Currently	5 (13)	2 (6)	12 (13)	14 (15)	10 (13)
Previously	6 (15)	9 (26)	16 (17)	16 (18)	14 (18)
Never	29 (73)	24 (69)	64 (67)	59 (65)	51 (65)
Not reported	0 (0)	0 (0)	3 (3)	2 (2)	3 (4)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	2 (5)	1 (3)	6 (6)	9 (10)	6 (8)
Previously	6 (15)	9 (26)	16 (17)	16 (18)	11 (14)
Never	32 (80)	24 (69)	71 (75)	66 (73)	61 (78)
Not reported	0 (0)	1 (3)	2 (2)	0 (0)	0 (0)
History of depot buprenorphine treatment (%)					
Currently	-- --	0 (0)	1 (1)	3 (2)	2 (3)
Previously	-- --	2 (6)	7 (7)	10 (9)	5 (6)
Never	-- --	17 (49)	84 (88)	78 (81)	69 (88)
Not reported	-- --	16 (46)	3 (3)	0 (9)	2 (3)

Table 7.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

Tasmania	2019	2020	2021	2022	2023
N° surveyed	N=40	N=35	N=95	N=91	N=78
Previous HIV test (%)					
Yes, ever	33 (83)	29 (83)	71 (75)	77 (85)	64 (82)
Yes, last year	14 (35)	15 (43)	40 (42)	50 (55)	30 (38)
>1 year ago	19 (48)	14 (40)	31 (33)	27 (30)	34 (44)
Never tested	6 (15)	6 (17)	19 (20)	12 (13)	11 (14)
Not reported	1 (3)	0 (0)	5 (5)	2 (2)	3 (4)
Previous HCV test (%)					
Yes, ever	36 (90)	29 (83)	79 (83)	75 (82)	62 (79)
Yes, last year	22 (55)	18 (51)	52 (55)	52 (57)	37 (47)
>1 year ago	14 (35)	11 (31)	27 (28)	23 (25)	25 (32)
Never tested	1 (3)	3 (9)	7 (7)	6 (7)	8 (10)
Not reported	3 (8)	3 (9)	9 (9)	10 (11)	8 (10)
Lifetime treatment for HCV (%)#					
N° self-reported HCV diagnosis	N=11	N=4	N=19	N=17	N=12
Antiviral treatment	6 (55)	3 (75)	11 (42)	15 (88)	11 (92)
No antiviral treatment	5 (45)	1 (25)	8 (58)	2 (12)	1 (8)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Treatment for HCV in past 12 months (%)##					
N° self-reported HCV diagnosis	N=8	N=3	N=9	N=7	N=3
Antiviral treatment	2 (25)	1 (33)	1 (11)	4 (57)	2 (67)
No antiviral treatment	6 (75)	2 (67)	8 (89)	3 (43)	1 (33)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

Table 7.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

Tasmania	2019	2020	2021	2022	2023
N° surveyed	N=40	N=35	N=95	N=91	N=78
Sex with a regular partner last month (%)					
No	15 (38)	10 (29)	34 (36)	43 (47)	33 (42)
Yes	11 (28)	11 (31)	30 (32)	36 (40)	36 (46)
Not reported	14 (35)	14 (40)	31 (33)	12 (13)	9 (12)
Condom used with regular partner last month (%)					
N° surveyed	N=11	N=11	N=30	N=36	N=36
Never	9 (82)	9 (82)	23 (77)	30 (83)	29 (81)
Sometimes	1 (9)	1 (9)	3 (10)	2 (6)	1 (3)
Every time	1 (9)	1 (9)	1 (3)	4 (11)	3 (8)
Not reported	0 (0)	0 (0)	3 (10)	0 (0)	3 (8)
Sex with other partner(s) last month (%)					
No	24 (60)	21 (60)	57 (60)	69 (76)	59 (76)
Yes	2 (5)	1 (3)	5 (5)	9 (10)	9 (12)
Not reported	14 (35)	13 (37)	33 (35)	13 (14)	10 (13)
Condom used with other partner(s) last month (%)					
N° surveyed	N=2	N=1	N=5	N=9	N=9
Never	2 (100)	1 (100)	3 (60)	4 (44)	4 (44)
Sometimes	0 (0)	0 (0)	1 (20)	3 (33)	3 (33)
Every time	0 (0)	0 (0)	0 (0)	2 (22)	1 (11)
Not reported	0 (0)	0 (0)	1 (20)	0 (0)	1 (11)
Sex work last month (%)					
No	26 (65)	22 (63)	57 (60)	72 (79)	69 (88)
Yes	0 (0)	0 (0)	6 (6)	6 (7)	1 (1)
Not reported	14 (35)	13 (37)	32 (34)	13 (14)	8 (10)
Condom used at last sex work (%)					
Yes	0 (0)	0 (0)	3 (50)	4 (67)	1 (100)

Table 7.1.7 Number (percentage) of respondents by COVID-19 related impacts, 2020-2023

Tasmania	2020	2021	2022	2023
N° surveyed	N=35	N=95	N=91	N=78
COVID-19 test				
Yes	5 (14)	22 (23)	83 (91)	70 (90)
No	25 (71)	54 (57)	6 (7)	2 (3)
Don't know	2 (6)	2 (2)	-- --	-- --
Not reported	3 (9)	17 (18)	2 (2)	6 (8)
Self-reported positive COVID-19 test result				
Yes	0 (0)	0 (0)	44 (53)	38 (54)
Yes, last 12 months	-- --	-- --	39 (47)	17 (24)
Yes, more than a year ago	-- --	-- --	5 (6)	21 (30)
COVID-19 vaccine uptake				
≥1 dose	-- --	47 (49)	76 (84)	61 (78)
COVID-19 vaccine doses				
One dose	-- --	16 (17)	7 (8)	5 (6)
Two doses	-- --	31 (33)	32 (35)	26 (33)
Three or more doses	-- --	-- --	37 (41)	30 (38)
No doses	-- --	34 (36)	13 (14)	10 (13)
Not reported	-- --	14 (15)	2 (2)	7 (9)
Vaccine type *			N=76	
Astra Zeneca	-- --	5 (5)	16 (21)	-- --
Pfizer	-- --	22 (23)	44 (58)	-- --
Don't know	-- --	5 (5)	9 (12)	-- --
Other	-- --	-- --	13 (17)	-- --
Not reported	-- --	63 (66)	-- --	-- --
* 2021 only one response permitted, 2022 multiple responses permitted				
Last vaccine location			N=91	N=78
GP or medical centre	-- --	-- --	22 (24)	19 (24)
Pharmacy/ chemist	-- --	-- --	26 (29)	26 (33)
Vaccine hub	-- --	-- --	13 (14)	11 (14)
Opioid treatment/ methadone clinic	-- --	-- --	3 (3)	1 (1)
NSP	-- --	-- --	0 (0)	0 (0)
Prison	-- --	-- --	8 (9)	5 (6)
Multiple response	-- --	-- --	2 (2)	2 (3)
Other	-- --	-- --	3 (3)	1 (1)
Not reported	-- --	-- --	14 (15)	13 (17)
Vaccine hesitancy - if not had three or more doses				
Haven't got around to it	-- --	-- --	21 (23)	10 (13)
Difficulty booking appointment	-- --	-- --	3 (3)	0 (0)
Concerns about side effects	-- --	-- --	8 (9)	10 (13)
Concerns about vaccine safety	-- --	-- --	6 (7)	6 (8)
Not at risk of serious illness	-- --	-- --	4 (4)	8 (10)
Other	-- --	-- --	5 (5)	2 (3)
Multiple response	-- --	-- --	2 (2)	0 (0)
Not reported	-- --	-- --	42 (46)	42 (54)

HIV antibody prevalence

Table 7.2.1 HIV antibody prevalence by gender and survey year

Tasmania Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019	20	1 (5.0)	18	0 (0.0)	38	1 (2.6)
2020	20	0 (0.0)	14	0 (0.0)	34	0 (0.0)
2021	49	0 (0.0)	42	0 (0.0)	91	0 (0.0)
2022	59	0 (0.0)	29	0 (0.0)	90	0 (0.0)
2023	37	1 (2.7)	25	0 (0.0)	63	1 (1.6)
X ² p trend		0.647		--		0.703

HCV antibody prevalence

Table 7.3.1 HCV antibody prevalence by gender and survey year

Tasmania Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019	19	7 (37)	18	6 (33)	37	13 (35)
2020	20	6 (30)	14	3 (21)	34	9 (26)
2021	49	18 (37)	42	9 (21)	91	27 (30)
2022	59	21 (36)	29	6 (21)	90	28 (31)
2023*	37	11 (30)	25	11 (44)	63	22 (35)
X ² p trend		0.732		0.431		0.765

* Antibody testing assay changed in 2023. See Appendix B: Methodological Notes

Table 7.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Tasmania Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
Heterosexual	18	7 (39)	14	6 (43)	32	13 (41)
Bisexual	1	0 (0)	3	0 (0)	4	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		1.000		0.515		0.274
2020						
Heterosexual	19	6 (32)	12	3 (25)	31	9 (29)
Bisexual	0	0 (0)	1	0 (0)	1	0 (0)
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)
p value		1.000		1.000		1.000
2021						
Heterosexual	44	16 (36)	33	6 (18)	77	22 (29)
Bisexual	3	0 (0)	6	2 (33)	9	2 (22)
Homosexual	0	0 (0)	1	0 (0)	1	0 (0)
p value		0.219		0.260		0.147
2022						
Heterosexual	56	20 (36)	19	2 (11)	76	23 (30)
Bisexual	2	1 (50)	7	2 (29)	9	3 (33)
Homosexual	1	0 (0)	2	1 (50)	3	1 (33)
p value		1.000		0.085		0.733
2023						
Heterosexual	33	11 (33)	17	8 (47)	50	19 (38)
Bisexual	3	0 (0)	6	2 (33)	9	2 (22)
Homosexual	0	0 (0)	2	1 (50)	2	1 (50)
p value		0.675		0.825		0.699

Table 7.3.3 HCV antibody prevalence by age group, gender and survey year

Tasmania Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	1	0 (0)	4	2 (50)	5	2 (40)
35-44 years	12	3 (25)	7	1 (14)	19	4 (21)
45+ years	6	4 (67)	7	3 (43)	13	7 (54)
p value		0.129		0.541		0.178
2020						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	4	0 (0)	5	1 (20)	9	1 (11)
35-44 years	5	2 (40)	3	1 (33)	8	3 (38)
45+ years	11	4 (36)	6	1 (17)	17	5 (29)
p value		0.532		1.000		0.475
2021						
<25 years	0	0 (0)	2	0 (0)	2	0 (0)
25-34 years	7	2 (29)	7	1 (14)	14	3 (21)
35-44 years	15	5 (33)	12	1 (8)	27	6 (22)
45+ years	27	11 (41)	19	6 (32)	46	17 (37)
p value		0.847		0.489		0.437
2022						
<25 years	0	0 (0)	1	0 (0)	1	0 (0)
25-34 years	11	2 (18)	6	0 (0)	17	2 (12)
35-44 years	17	7 (41)	10	2 (20)	28	10 (36)
45+ years	31	12 (39)	12	4 (33)	44	16 (36)
p value		0.418		0.494		0.200
2023						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	6	0 (0)	4	2 (50)	10	2 (20)
35-44 years	12	2 (17)	10	5 (50)	22	7 (32)
45+ years	19	9 (47)	11	4 (36)	30	13 (43)
p value		0.044		0.869		0.400

Table 7.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Tasmania Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	2	0 (0)	4	1 (25)	6	1 (17)
11+ years	17	7 (41)	14	5 (36)	31	12 (39)
p value		0.509		1.000		0.394
2020						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	2	0 (0)	4	1 (25)	6	1 (17)
11+ years	17	6 (35)	10	2 (20)	27	8 (30)
p value		1.000		1.000		1.000
2021						
<3 years	2	0 (0)	3	0 (0)	5	0 (0)
3 to 10 years	2	0 (0)	5	0 (0)	7	0 (0)
11+ years	45	18 (40)	31	8 (26)	76	26 (34)
p value		0.394		0.607		0.067
2022						
<3 years	0	0 (0)	2	0 (0)	2	0 (0)
3 to 10 years	3	0 (0)	7	0 (0)	10	0 (0)
11+ years	55	20 (36)	19	6 (32)	76	27 (36)
p value		0.544		0.226		0.029
2023						
<3 years	1	0 (0)	3	0 (0)	4	0 (0)
3 to 10 years	5	0 (0)	3	1 (33)	8	1 (13)
11+ years	29	10 (34)	19	10 (53)	48	20 (42)
p value		0.377		0.407		0.091

Table 7.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Tasmania Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
No receptive sharing	0	0 (0)	32	13 (41)	32	13 (41)
Receptive sharing	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		1.000		1.000
2020						
No receptive sharing	1	0 (0)	28	9 (32)	29	9 (31)
Receptive sharing	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2021						
No receptive sharing	5	0 (0)	68	22 (32)	75	22 (29)
Receptive sharing	0	0 (0)	5	2 (40)	5	2 (40)
p value		--		1.000		0.633
2022						
No receptive sharing	2	0 (0)	71	21 (30)	75	22 (29)
Receptive sharing	0	0 (0)	13	5 (38)	13	5 (38)
p value		--		0.524		0.510
2023						
No receptive sharing	4	0 (0)	49	19 (39)	55	20 (36)
Receptive sharing	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.523		0.536

Table 7.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

Tasmania Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
Methamphetamine	0	0 (0)	16	6 (38)	16	6 (38)
Pharmaceutical opioids	0	0 (0)	3	0 (0)	3	0 (0)
OAT*	0	0 (0)	14	6 (43)	14	6 (43)
Other drugs	0	0 (0)	3	1 (33)	3	1 (33)
p value		--		0.573		0.573
2020						
Methamphetamine	1	0 (0)	13	2 (15)	14	2 (14)
Pharmaceutical opioids	0	0 (0)	9	3 (33)	9	3 (33)
OAT*	0	0 (0)	7	3 (43)	7	3 (43)
Other drugs	0	0 (0)	4	1 (25)	4	1 (25)
p value		--		0.581		0.521
2021						
Methamphetamine	4	0 (0)	40	8 (20)	44	8 (18)
Pharmaceutical opioids	1	0 (0)	13	5 (38)	14	5 (36)
OAT*	0	0 (0)	15	6 (40)	16	6 (38)
Other drugs	0	0 (0)	13	6 (46)	14	6 (43)
p value		--		0.206		0.194
2022						
Methamphetamine	0	0 (0)	48	14 (29)	49	15 (31)
Pharmaceutical opioids	1	0 (0)	20	5 (25)	21	5 (24)
OAT*	1	0 (0)	11	6 (55)	13	6 (46)
Other drugs	0	0 (0)	7	2 (29)	7	2 (29)
p value		--		0.354		0.589
2023						
Methamphetamine	4	0 (0)	30	9 (30)	35	9 (26)
Pharmaceutical opioids	0	0 (0)	8	5 (63)	9	6 (67)
OAT*	0	0 (0)	11	5 (45)	11	5 (45)
Other drugs	0	0 (0)	4	1 (25)	4	1 (25)
p value		--		0.333		0.114

*OAT = methadone, buprenorphine or buprenorphine/naloxone

Table 7.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Tasmania	<3 years		3+ years		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
Less than daily	0	0 (0)	24	7 (29)	24	7 (29)
Daily or more	0	0 (0)	9	6 (67)	9	6 (67)
Not last month	0	0 (0)	3	0 (0)	3	0 (0)
p value		--		0.081		0.081
2020						
Less than daily	1	0 (0)	18	6 (33)	19	6 (32)
Daily or more	0	0 (0)	10	3 (30)	10	3 (30)
Not last month	0	0 (0)	5	0 (0)	5	0 (0)
p value		--		0.480		0.485
2021						
Less than daily	3	0 (0)	47	11 (23)	51	11 (22)
Daily or more	2	0 (0)	26	13 (50)	29	13 (45)
Not last month	0	0 (0)	9	1 (11)	9	1 (11)
p value		--		0.032		0.048
2022						
Less than daily	0	0 (0)	39	11 (28)	40	11 (28)
Daily or more	2	0 (0)	45	15 (33)	48	16 (33)
Not last month	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		0.676		0.608
2023						
Less than daily	3	0 (0)	32	12 (38)	37	13 (35)
Daily or more	1	0 (0)	19	7 (37)	20	7 (35)
Not last month	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		1.000		1.000

Table 7.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Tasmania	<3 years		3+ years		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
No imprisonment	0	0 (0)	33	10 (30)	33	10 (30)
Imprisonment	0	0 (0)	4	3 (75)	4	3 (75)
p value		--		0.115		0.115
2020						
No imprisonment	1	0 (0)	28	8 (29)	29	8 (28)
Imprisonment	0	0 (0)	5	1 (20)	5	1 (20)
p value		--		0.582		1.000
2021						
No imprisonment	3	0 (0)	73	23 (32)	79	24 (30)
Imprisonment	1	0 (0)	6	3 (50)	7	3 (43)
p value		--		0.389		0.673
2022						
No imprisonment	2	0 (0)	70	19 (27)	74	20 (27)
Imprisonment	0	0 (0)	14	7 (50)	14	7 (50)
p value		--		0.091		0.087
2023						
No imprisonment	4	0 (0)	49	19 (39)	56	20 (36)
Imprisonment	0	0 (0)	5	1 (20)	5	1 (20)
p value		--		0.640		0.651

Table 7.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Tasmania	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
Non Indigenous	16	5 (31)	17	6 (35)	33	11 (33)
Indigenous	3	2 (67)	1	0 (0)	4	2 (50)
p value		0.523		1.000		0.602
2020						
Non Indigenous	16	5 (31)	14	3 (21)	30	8 (27)
Indigenous	4	1 (25)	0	0 (0)	4	1 (25)
p value		1.000		--		1.000
2021						
Non Indigenous	39	13 (33)	31	7 (23)	70	20 (29)
Indigenous	10	5 (50)	8	2 (25)	18	7 (39)
p value		0.329		1.000		0.397
2022						
Non Indigenous	41	12 (29)	20	3 (15)	62	15 (24)
Indigenous	17	9 (53)	8	2 (25)	25	11 (44)
p value		0.088		0.606		0.068
2023						
Non Indigenous	29	8 (28)	18	9 (50)	48	17 (35)
Indigenous	8	3 (38)	7	2 (29)	15	5 (33)
p value		0.672		0.407		0.883

Table 7.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Tasmania	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
English speaking	19	7 (37)	18	6 (33)	37	13 (35)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2020						
English speaking	20	6 (30)	14	3 (21)	34	9 (26)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2021						
English speaking	45	16 (36)	41	9 (22)	86	25 (29)
Non-English speaking	4	2 (50)	0	0 (0)	4	2 (50)
p value		0.618		--		0.580
2022						
English speaking	58	20 (34)	29	6 (21)	89	27 (30)
Non-English speaking	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.356		--		0.311
2023						
English speaking	36	11 (31)	24	11 (46)	61	22 (36)
Non-English speaking	1	0 (0)	1	0 (0)	2	0 (0)
p value		1.000		1.000		0.538

Table 7.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

Tasmania		Male		Female		Total	
Region/Country of birth	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	
2019							
Australia	19	7 (37)	17	6 (35)	36	13 (36)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	0	0 (0)	1	0 (0)	1	0 (0)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		--		1.000		1.000	
2020							
Australia	19	6 (32)	13	3 (23)	32	9 (28)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	1	0 (0)	1	0 (0)	2	0 (0)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		1.000		1.000		1.000	
2021							
Australia	42	15 (36)	40	8 (20)	82	23 (28)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	1	1 (100)	1	1 (100)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	5	2 (40)	1	0 (0)	6	2 (33)	
p value		1.000		0.387		0.415	
2022							
Australia	56	19 (34)	28	6 (21)	86	26 (30)	
Other Oceania	0	0 (0)	1	0 (0)	1	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	1	0 (0)	0	0 (0)	1	0 (0)	
Other	1	1 (100)	0	0 (0)	1	1 (100)	
p value		0.575		1.000		0.667	
2023							
Australia	34	10 (29)	24	11 (46)	59	21 (36)	
Other Oceania	0	0 (0)	1	0 (0)	1	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	1	0 (0)	0	0 (0)	1	0 (0)	
Other	2	1 (50)	0	0 (0)	2	1 (50)	
p value		0.665		1.000		1.000	

HCV RNA prevalence

Table 7.4.1 HCV RNA prevalence by gender and survey year

Tasmania	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*	16	3 (19)	16	3 (19)	32	5 (16)
2020	19	2 (11)	12	2 (17)	31	4 (13)
2021	42	6 (14)	35	3 (9)	77	9 (12)
2022	55	5 (9)	29	0 (0)	86	6 (7)
2023	37	0 (0)	25	2 (8)	63	2 (3)
X ² p trend		0.025		0.073		0.017

* 2019: Weighted for gender and HCV antibody status

Totals include respondents where gender was reported as other or not reported

Table 7.4.2 HCV RNA prevalence by sexual identity, gender and survey year

Tasmania	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
Heterosexual	15	3 (20)	12	2 (17)	27	4 (15)
Bisexual	1	0 (0)	3	1 (33)	4	1 (25)
Homosexual	0	3 (0)	0	0 (0)	0	0 (0)
p value		0.637		0.457		0.789
2020						
Heterosexual	18	2 (11)	10	2 (20)	28	4 (14)
Bisexual	0	0 (0)	1	0 (0)	1	0 (0)
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)
p value		0.725		0.787		0.782
2021						
Heterosexual	38	5 (13)	27	2 (7)	65	7 (11)
Bisexual	2	0 (0)	6	0 (0)	8	0 (0)
Homosexual	0	0 (0)	1	0 (0)	1	0 (0)
p value		0.583		0.759		0.586
2022						
Heterosexual	52	4 (8)	19	0 (0)	72	5 (7)
Bisexual	2	1 (50)	7	0 (0)	9	1 (11)
Homosexual	1	0 (0)	2	0 (0)	3	0 (0)
p value		0.253		--		0.668
2023						
Heterosexual	33	0 (0)	17	1 (6)	50	1 (2)
Bisexual	3	0 (0)	6	1 (17)	9	1 (11)
Homosexual	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.547		0.352

Table 7.4.3 HCV RNA prevalence by age group, gender and survey year

Tasmania Age group	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019*						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	0	0 (0)	3	1 (33)	3	1 (33)
35-44 years	10	1 (10)	6	1 (17)	16	2 (13)
45+ years	6	2 (33)	6	1 (17)	12	3 (25)
p value		0.340		0.886		0.669
2020						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	4	0 (0)	5	1 (20)	9	1 (11)
35-44 years	5	1 (20)	2	0 (0)	7	1 (14)
45+ years	10	1 (10)	5	1 (20)	15	2 (13)
p value		0.622		0.787		0.980
2021						
<25 years	0	0 (0)	2	0 (0)	2	0 (0)
25-34 years	6	0 (0)	6	0 (0)	12	0 (0)
35-44 years	13	0 (0)	9	0 (0)	22	0 (0)
45+ years	23	6 (26)	16	2 (13)	39	8 (21)
p value		0.056		0.520		0.041
2022						
<25 years	0	0 (0)	1	0 (0)	1	0 (0)
25-34 years	10	1 (10)	6	0 (0)	16	1 (6)
35-44 years	16	0 (0)	10	0 (0)	27	1 (4)
45+ years	29	4 (14)	12	0 (0)	42	4 (10)
p value		0.373		--		0.863
2023						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	6	0 (0)	4	1 (25)	10	1 (10)
35-44 years	12	0 (0)	10	0 (0)	22	0 (0)
45+ years	19	0 (0)	11	1 (9)	30	1 (3)
p value		--		0.300		0.421

Table 7.4.4 HCV RNA prevalence by years since first injection, gender and survey year

Tasmania Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	0	0 (0)	3	2 (67)	3	2 (67)
11+ years	16	3 (19)	12	1 (8)	29	3 (10)
p value		--		0.065		0.066
2020						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	2	0 (0)	4	1 (25)	6	1 (17)
11+ years	16	2 (13)	8	1 (13)	24	3 (13)
p value		0.811		0.584		0.893
2021						
<3 years	1	0 (0)	2	0 (0)	3	0 (0)
3 to 10 years	2	0 (0)	3	0 (0)	5	0 (0)
11+ years	39	6 (15)	27	2 (7)	66	8 (12)
p value		0.764		0.821		0.581
2022						
<3 years	0	0 (0)	2	0 (0)	2	0 (0)
3 to 10 years	3	0 (0)	7	0 (0)	10	0 (0)
11+ years	51	5 (10)	19	0 (0)	72	6 (8)
p value		1.000		--		1.000
2023						
<3 years	1	0 (0)	3	0 (0)	4	0 (0)
3 to 10 years	5	0 (0)	3	1 (33)	8	1 (13)
11+ years	29	0 (0)	19	1 (5)	48	1 (2)
p value		--		0.430		0.363

Table 7.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Tasmania Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
No receptive sharing	16	3 (19)	13	3 (23)	29	5 (17)
Receptive sharing	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2020						
No receptive sharing	18	2 (11)	8	2 (25)	26	4 (15)
Receptive sharing	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2021						
No receptive sharing	37	5 (14)	25	1 (4)	62	6 (10)
Receptive sharing	2	0 (0)	3	1 (33)	5	1 (20)
p value		0.578		0.062		0.468
2022						
No receptive sharing	45	5 (11)	26	0 (0)	72	5 (7)
Receptive sharing	8	0 (0)	3	0 (0)	12	1 (8)
p value		1.000		--		1.000
2023						
No receptive sharing	33	0 (0)	22	2 (9)	55	2 (4)
Receptive sharing	1	0 (0)	1	0 (0)	2	0 (0)
p value		--		1.000		1.000

Table 7.4.6 HCV RNA prevalence by last drug injected, gender and survey year

Tasmania Last drug injected	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
Methamphetamine	8	2 (25)	6	2 (33)	14	3 (21)
Pharm. Opioids	1	0 (0)	2	0 (0)	3	0 (0)
OAT	6	0 (0)	8	1 (13)	14	1 (7)
Other drugs	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.161		0.534		0.067
2020						
Methamphetamine	8	1 (13)	6	1 (17)	14	2 (14)
Pharm. Opioids	6	1 (17)	1	0 (0)	7	1 (14)
OAT	3	0 (0)	3	1 (33)	6	1 (17)
Other drugs	2	0 (0)	2	0 (0)	4	0 (0)
p value		0.835		0.753		0.872
2021						
Methamphetamine	12	0 (0)	21	2 (10)	33	2 (6)
Pharm. Opioids	11	3 (27)	3	0 (0)	14	3 (21)
OAT	11	1 (9)	3	0 (0)	14	1 (7)
Other drugs	7	2 (29)	6	0 (0)	13	2 (15)
p value		0.185		0.749		0.409
2022						
Methamphetamine	28	4 (14)	17	0 (0)	46	4 (9)
Pharm. Opioids	16	1 (6)	3	0 (0)	20	2 (10)
OAT	6	0 (0)	7	0 (0)	13	0 (0)
Other drugs	5	0 (0)	2	0 (0)	7	0 (0)
p value		0.538		--		0.574
2023						
Methamphetamine	15	0 (0)	20	2 (10)	35	2 (6)
Pharm. Opioids	7	0 (0)	2	0 (0)	9	0 (0)
OAT	9	0 (0)	2	0 (0)	11	0 (0)
Other drugs	4	0 (0)	0	0 (0)	4	0 (0)
p value		--		0.804		0.701

OAT: methadone, buprenorphine or buprenorphine/naloxone

Table 7.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year

Tasmania Frequency of injection last month	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019*						
Less than daily	12	2 (17)	9	2 (22)	21	3 (14)
Daily or more	4	1 (25)	4	1 (25)	8	2 (25)
Not last month	0	0 (0)	3	0 (0)	3	0 (0)
p value		0.735		0.705		0.714
2020						
Less than daily	12	1 (8)	6	2 (33)	18	3 (17)
Daily or more	6	1 (17)	2	0 (0)	8	1 (13)
Not last month	1	0 (0)	4	0 (0)	5	0 (0)
p value		0.811		0.301		0.616
2021						
Less than daily	20	1 (5)	21	2 (10)	41	3 (7)
Daily or more	19	4 (21)	7	0 (0)	26	4 (15)
Not last month	3	1 (33)	5	0 (0)	8	1 (13)
p value		0.222		0.544		0.572
2022						
Less than daily	25	2 (8)	14	0 (0)	40	2 (5)
Daily or more	28	3 (11)	15	0 (0)	44	4 (9)
Not last month	2	0 (0)	0	0 (0)	2	0 (0)
p value		1.000		--		0.722
2023						
Less than daily	21	0 (0)	16	2 (13)	37	2 (5)
Daily or more	13	0 (0)	7	0 (0)	20	0 (0)
Not last month	1	0 (0)	1	0 (0)	2	0 (0)
p value		--		1.000		0.568

Table 7.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year

Tasmania Imprisonment last year	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019*						
No imprisonment	14	1 (7)	15	3 (20)	29	3 (10)
Imprisonment	3	2 (67)	1	0 (0)	3	2 (67)
p value		0.026		0.654		0.066
2020						
No imprisonment	15	1 (7)	11	2 (18)	26	3 (12)
Imprisonment	4	1 (25)	1	0 (0)	5	1 (20)
p value		0.288		0.640		0.605
2021						
No imprisonment	36	6 (17)	32	3 (9)	68	9 (13)
Imprisonment	4	0 (0)	2	0 (0)	6	0 (0)
p value		0.376		0.650		0.342
2022						
No imprisonment	44	4 (9)	24	0 (0)	70	5 (7)
Imprisonment	10	1 (10)	4	0 (0)	14	1 (7)
p value		1.000		--		1.000
2023						
No imprisonment	31	0 (0)	24	2 (8)	56	2 (4)
Imprisonment	5	0 (0)	0	0 (0)	5	0 (0)
p value		--		--		1.000

Table 7.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Tasmania	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
Non Indigenous	15	2 (13)	15	3 (20)	29	4 (14)
Indigenous	2	1 (50)	1	0 (0)	3	1 (33)
p value		0.203		0.654		0.417
2020						
Non Indigenous	15	2 (13)	12	2 (17)	27	4 (15)
Indigenous	4	0 (0)	0	0 (0)	4	0 (0)
p value		0.440		--		0.409
2021						
Non Indigenous	35	6 (17)	24	3 (13)	59	9 (15)
Indigenous	7	0 (0)	8	0 (0)	15	0 (0)
p value		0.237		0.294		0.107
2022						
Non Indigenous	38	3 (8)	20	0 (0)	59	3 (5)
Indigenous	16	2 (13)	8	0 (0)	24	2 (8)
p value		0.627		--		0.624
2023						
Non Indigenous	29	0 (0)	18	2 (11)	48	2 (4)
Indigenous	8	0 (0)	7	0 (0)	15	0 (0)
p value		--		1.000		1.000

Table 7.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year

Tasmania	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
English speaking	16	3 (19)	16	3 (19)	32	5 (16)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2020						
English speaking	19	2 (11)	12	2 (17)	31	4 (13)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2021						
English speaking	39	6 (15)	35	3 (9)	74	9 (12)
Non-English speaking	3	0 (0)	0	0 (0)	3	0 (0)
p value		0.463		--		0.520
2022						
English speaking	54	5 (9)	29	0 (0)	85	6 (7)
Non-English speaking	1	0 (0)	0	0 (0)	1	0 (0)
p value		1.000		--		1.000
2023						
English speaking	36	0 (0)	24	2 (8)	61	2 (3)
Non-English speaking	1	0 (0)	1	0 (0)	2	0 (0)
p value		--		1.000		1.000

Table 7.4.11 HCV RNA prevalence by region/country of birth, gender and survey year

Tasmania Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
Australia	14	3 (21)	15	3 (20)	31	5 (16)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	1	0 (0)	1	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		0.654		0.664
2020						
Australia	18	2 (11)	11	2 (18)	29	4 (14)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	0 (0)	1	0 (0)	2	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.725		0.640		0.574
2021						
Australia	35	6 (17)	34	3 (9)	69	9 (13)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	1	0 (0)	1	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	5	0 (0)	0	0 (0)	5	0 (0)
p value		0.315		0.756		0.641
2022						
Australia	52	5 (10)	28	0 (0)	82	6 (7)
Other Oceania	0	0 (0)	1	0 (0)	1	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	0 (0)	0	0 (0)	1	0 (0)
Other	1	0 (0)	0	0 (0)	1	0 (0)
p value		1.000		--		1.000
2023						
Australia	34	0 (0)	24	2 (8)	59	2 (3)
Other Oceania	0	0 (0)	1	0 (0)	1	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	0 (0)	0	0 (0)	1	0 (0)
Other	2	0 (0)	0	0 (0)	2	0 (0)
p value		--		1.000		1.000

Victoria

Table 8.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Victoria	2019	2020*	2021*	2022	2023
Number of sites	6	--	3	5	6
N° surveyed	N=375	--	N=40	N=122	N=228
Response rate (%)	52%	--	44%	43%	59%
Gender (%)					
Male	240 (64)	-- --	28 (70)	78 (64)	156 (68)
Female	130 (35)	-- --	11 (28)	43 (35)	68 (30)
Other	3 (1)	-- --	1 (3)	1 (1)	3 (1)
Not reported	2 (1)	-- --	0 (0)	0 (0)	1 (<1)
Sexual identity (%)					
Heterosexual	277 (74)	-- --	30 (75)	92 (75)	184 (81)
Bisexual	39 (10)	-- --	7 (18)	14 (11)	19 (8)
Gay/Lesbian	17 (5)	-- --	1 (3)	9 (7)	11 (5)
Other	-- --	-- --	2 (5)	7 (6)	14 (6)
Not reported	42 (11)	-- --	0 (0)	0 (0)	0 (0)
Aboriginal and Torres Strait Islander origin (%)					
No	296 (79)	-- --	31 (78)	101 (83)	157 (69)
Yes	66 (18)	-- --	9 (23)	19 (16)	69 (30)
Not reported	13 (3)	-- --	0 (0)	2 (2)	2 (1)
Region/country of birth (%)					
Australia	333 (89)	-- --	33 (83)	96 (79)	199 (87)
Other Oceania	7 (2)	-- --	2 (5)	3 (2)	6 (3)
Asia	3 (1)	-- --	0 (0)	0 (0)	4 (2)
UK & Ireland	7 (2)	-- --	2 (5)	6 (5)	6 (3)
Other	20 (5)	-- --	3 (8)	12 (10)	11 (5)
Not reported	5 (1)	-- --	0 (0)	5 (4)	2 (1)
Main language spoken at home by parents (%)					
English	345 (92)	-- --	36 (90)	103 (84)	201 (88)
Non-English	27 (7)	-- --	4 (10)	16 (13)	26 (11)
Not reported	3 (1)	-- --	0 (0)	3 (2)	1 (<1)
Age and time since first injection (years)					
<i>Median age</i>	42	-- --	46	46	44.5
<i>Age range</i>	20-70	-- --	29-62	25-66	20-77
<i>Age group (%)</i>					
<25 years	6 (2)	-- --	0 (0)	0 (0)	2 (1)
25+ years	363 (97)	-- --	40 (100)	121 (99)	222 (97)
Not reported	6 (2)	-- --	0 (0)	1 (1)	4 (2)
<i>Median age first injection</i>	18	-- --	18	18	18
<i>Age range</i>	10-51	-- --	13-50	11-50	11-71
<i>N° not reported</i>	27	-- --	0	5	7
<i>Median yrs since first injection</i>	22	-- --	27.5	27	26
<i>Range</i>	<1-52	-- --	<1-41	<1-52	<1-49
<i>Years since first injection</i>					
<3 years	13 (3)	-- --	2 (5)	2 (2)	6 (3)
3+ years	333 (89)	-- --	38 (95)	115 (94)	213 (93)
Not reported	29 (8)	-- --	0 (0)	5 (4)	9 (4)
Imprisonment last year (%)					
No	268 (71)	-- --	34 (85)	93 (76)	185 (81)
Yes	83 (22)	-- --	2 (5)	15 (12)	32 (14)
Not reported	24 (6)	-- --	4 (10)	14 (11)	11 (5)
N° in prison	N=83	-- --	N=2	N=15	N=32
Injected in prison	20 (24)	-- --	0 (0)	5 (33)	8 (25)

* Implementation of the 2020 and 2021 ANSPS was impacted by the COVID-19 pandemic, see page 1 for more information

Table 8.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

Victoria	2019	2020	2021	2022	2023
N° surveyed	N=375	--	N=40	N=122	N=228
Drug last injected (%)					
Cocaine	4 (1)	-- --	0 (0)	1 (1)	1 (<1)
Methamphetamine	126 (34)	-- --	18 (45)	35 (29)	62 (27)
Heroin	198 (53)	-- --	16 (40)	70 (57)	144 (63)
Pharm. opioids	8 (2)	-- --	1 (3)	0 (0)	3 (1)
Methadone	3 (1)	-- --	0 (0)	1 (1)	1 (<1)
Buprenorphine	1 (<1)	-- --	1 (3)	3 (2)	0 (0)
Buprenorphine/naloxone	2 (1)	-- --	0 (0)	0 (0)	1 (<1)
PIEDs	0 (0)	-- --	0 (0)	0 (0)	0 (0)
More than one	25 (7)	-- --	3 (8)	9 (7)	13 (6)
Other	5 (1)	-- --	1 (3)	2 (2)	2 (1)
Not reported	3 (1)	-- --	0 (0)	1 (1)	1 (<1)
Ever injected opioids					
No	31 (8)	-- --	6 (15)	5 (4)	12 (5)
Yes	343 (91)	-- --	34 (85)	117 (96)	215 (94)
Not reported	1 (<1)	-- --	0 (0)	0 (0)	1 (<1)
Frequency of injection last month (%)					
Not last month	23 (6)	-- --	2 (5)	10 (8)	20 (9)
Less than weekly	47 (13)	-- --	10 (25)	16 (13)	24 (11)
Weekly not daily	62 (17)	-- --	6 (15)	20 (16)	36 (16)
Daily or more	240 (64)	-- --	22 (55)	73 (60)	148 (65)
Not reported	3 (1)	-- --	0 (0)	3 (2)	0 (0)
Present when someone injected for the first time in the last 12 months (%)					
No	299 (80)	-- --	28 (70)	90 (74)	199 (87)
Yes	65 (17)	-- --	7 (18)	25 (20)	21 (9)
Not reported	11 (3)	-- --	5 (13)	7 (6)	8 (4)
Overdosed in last 12 months					
No	255 (68)	-- --	30 (75)	85 (70)	163 (71)
Yes	103 (27)	-- --	4 (10)	28 (23)	54 (24)
Not reported	17 (5)	-- --	6 (15)	9 (7)	11 (5)

Table 8.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

Victoria	2019	2020	2021	2022	2023
N° injected last month	N=349	--	N=38	N=109	N=208
Places injected last month (%)					
All private	125 (36)	-- --	18 (47)	42 (39)	67 (32)
Any public	222 (64)	-- --	20 (53)	65 (60)	141 (68)
Not reported	2 (1)	-- --	0 (0)	2 (2)	0 (0)
Use of new and sterile needles and syringes last month (%)					
All injections	252 (72)	-- --	34 (89)	82 (75)	163 (78)
Most of the time	78 (22)	-- --	2 (5)	21 (19)	35 (17)
Half of the time	3 (1)	-- --	0 (0)	3 (3)	6 (3)
Some of the time	3 (1)	-- --	0 (0)	1 (1)	3 (1)
Not last month	2 (1)	-- --	2 (5)	1 (1)	0 (0)
Not reported	11 (3)	-- --	0 (0)	1 (1)	1 (<1)
Re-used someone else's used needle & syringe last month (%)					
None	291 (83)	-- --	35 (92)	84 (77)	175 (84)
Once	20 (6)	-- --	0 (0)	7 (6)	9 (4)
Twice	13 (4)	-- --	2 (5)	8 (7)	12 (6)
3-5 times	15 (4)	-- --	0 (0)	3 (3)	6 (3)
>5 times	6 (2)	-- --	1 (3)	6 (6)	4 (2)
Not reported	4 (1)	-- --	0 (0)	1 (1)	2 (1)
Number of people needle & syringe was re-used after last month (%)					
None	291 (83)	-- --	34 (89)	84 (77)	175 (84)
One	27 (8)	-- --	1 (3)	4 (4)	15 (7)
Two	4 (1)	-- --	0 (0)	3 (3)	2 (1)
Three to five	3 (1)	-- --	0 (0)	4 (4)	2 (1)
More than five	0 (0)	-- --	0 (0)	2 (2)	1 (<1)
Don't know	15 (4)	-- --	2 (5)	4 (4)	4 (2)
Not reported	9 (3)	-- --	1 (3)	8 (7)	9 (4)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	21 (6)	-- --	0 (0)	4 (4)	4 (2)
Casual sex partner	3 (1)	-- --	0 (0)	1 (1)	1 (<1)
Close friend	10 (3)	-- --	1 (3)	4 (4)	7 (3)
Acquaintance	11 (3)	-- --	0 (0)	4 (4)	9 (4)
Other	11 (3)	-- --	0 (0)	2 (2)	0 (0)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	96 (28)	-- --	9 (24)	30 (28)	57 (27)
Water	73 (21)	-- --	4 (11)	22 (20)	44 (21)
Filter	51 (15)	-- --	5 (13)	12 (11)	19 (9)
Drug mix	37 (11)	-- --	3 (8)	9 (8)	26 (13)
None	222 (64)	-- --	28 (74)	71 (65)	137 (66)
Injected by someone after that person injected themselves or others last month (%)					
No	291 (83)	-- --	35 (92)	85 (78)	169 (81)
Yes	54 (15)	-- --	3 (8)	19 (17)	39 (19)
Not reported	4 (1)	-- --	0 (0)	5 (5)	0 (0)
Source of needle acquisition					
Needle Syringe Program	314 (90)	-- --	31 (82)	92 (84)	199 (96)
Chemist/Pharmacy	63 (18)	-- --	4 (11)	10 (9)	11 (5)
Personal sources	53 (15)	-- --	5 (13)	10 (9)	12 (6)
Dispensing/Vending Machine	68 (19)	-- --	16 (42)	28 (26)	59 (28)
Other sources	13 (4)	-- --	0 (0)	5 (5)	1 (<1)

Table 8.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Victoria	2019	2020	2021	2022	2023
N° surveyed	N=375	--	N=40	N=122	N=228
Ever any treatment/therapy for drug use (%)					
No	53 (14)	-- --	6 (15)	13 (11)	23 (10)
Yes	320 (85)	-- --	34 (85)	108 (89)	205 (90)
Not reported	2 (1)	-- --	0 (0)	1 (1)	0 (0)
History of methadone maintenance treatment (%)					
Currently	143 (38)	-- --	16 (40)	37 (30)	61 (27)
Previously	114 (30)	-- --	12 (30)	51 (42)	101 (44)
Never	109 (29)	-- --	11 (28)	30 (25)	62 (27)
Not reported	9 (2)	-- --	1 (3)	4 (3)	4 (2)
History of buprenorphine (Subutex®) treatment (%)					
Currently	25 (7)	-- --	4 (10)	16 (13)	12 (5)
Previously	146 (39)	-- --	14 (35)	53 (43)	83 (36)
Never	194 (52)	-- --	21 (53)	49 (40)	125 (55)
Not reported	10 (3)	-- --	1 (3)	4 (3)	8 (4)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	27 (7)	-- --	3 (8)	8 (7)	13 (6)
Previously	149 (40)	-- --	14 (35)	56 (46)	93 (41)
Never	193 (51)	-- --	23 (58)	56 (46)	119 (52)
Not reported	6 (2)	-- --	0 (0)	2 (2)	3 (1)
History of depot buprenorphine treatment (%)					
Currently	-- --	-- --	2 (5)	16 (13)	28 (12)
Previously	-- --	-- --	5 (13)	26 (21)	48 (21)
Never	-- --	-- --	32 (80)	75 (61)	144 (63)
Not reported	-- --	-- --	1 (3)	5 (4)	8 (4)

Table 8.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

Victoria	2019	2020	2021	2022	2023
N° surveyed	N=375	--	N=40	N=122	N=228
Previous HIV test (%)					
Yes, ever	306 (82)	-- --	35 (88)	100 (82)	198 (87)
Yes, last year	206 (55)	-- --	12 (30)	58 (48)	122 (54)
>1 year ago	100 (27)	-- --	23 (58)	42 (34)	76 (33)
Never tested	54 (14)	-- --	1 (3)	13 (11)	24 (11)
Not reported	15 (4)	-- --	4 (10)	9 (7)	6 (3)
Previous HCV test (%)					
Yes, ever	309 (82)	-- --	33 (83)	104 (85)	200 (88)
Yes, last year	218 (58)	-- --	17 (43)	66 (54)	146 (64)
>1 year ago	91 (24)	-- --	17 (43)	38 (31)	54 (24)
Never tested	23 (6)	-- --	1 (3)	8 (7)	15 (7)
Not reported	43 (11)	-- --	5 (13)	10 (8)	13 (6)
Lifetime treatment for HCV (%)#					
N° self-reported HCV diagnosis	N=131	--	N=11	N=21	N=42
Antiviral treatment	87 (66)	-- --	5 (45)	15 (71)	32 (76)
No antiviral treatment	44 (34)	-- --	6 (55)	6 (29)	10 (24)
Not reported	0 (0)	-- --	0 (0)	0 (0)	0 (0)
Treatment for HCV in past 12 months (%)##					
N° self-reported HCV diagnosis	N=100	--	N=10	N=14	N=29
Antiviral treatment	48 (48)	-- --	2 (20)	5 (36)	15 (52)
No antiviral treatment	52 (52)	-- --	8 (80)	9 (64)	14 (48)
Not reported	0 (0)	-- --	0 (0)	0 (0)	0 (0)

among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

Table 8.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

Victoria	2019	2020	2021	2022	2023
N° surveyed	N=375	--	N=40	N=122	N=228
Sex with a regular partner last month (%)					
No	212 (57)	-- --	31 (78)	74 (61)	147 (64)
Yes	147 (39)	-- --	6 (15)	39 (32)	75 (33)
Not reported	16 (4)	-- --	3 (8)	9 (7)	6 (3)
Condom used with regular partner last month (%)					
N° surveyed	N=147	--	N=6	N=39	N=75
Never	102 (69)	-- --	5 (83)	29 (74)	61 (81)
Sometimes	20 (14)	-- --	0 (0)	4 (10)	7 (9)
Every time	13 (9)	-- --	1 (17)	4 (10)	4 (5)
Not reported	12 (8)	-- --	0 (0)	2 (5)	3 (4)
Sex with other partner(s) last month (%)					
No	297 (79)	-- --	25 (63)	94 (77)	179 (79)
Yes	54 (14)	-- --	8 (20)	19 (16)	31 (14)
Not reported	24 (6)	-- --	7 (18)	9 (7)	18 (8)
Condom used with other partner(s) last month (%)					
N° surveyed	N=54	--	N=8	N=19	N=31
Never	25 (46)	-- --	2 (25)	9 (47)	13 (42)
Sometimes	14 (26)	-- --	1 (13)	6 (32)	11 (35)
Every time	11 (20)	-- --	4 (50)	4 (21)	7 (23)
Not reported	4 (7)	-- --	1 (13)	0 (0)	0 (0)
Sex work last month (%)					
No	325 (87)	-- --	30 (75)	102 (84)	204 (89)
Yes	30 (8)	-- --	5 (13)	8 (7)	15 (7)
Not reported	20 (5)	-- --	5 (13)	12 (10)	9 (4)
Condom used at last sex work (%)					
Yes	17 (57)	-- --	4 (80)	6 (75)	8 (53)

Table 8.1.7 Number (percentage) of respondents by COVID-19 related impacts, 2020-2023

Victoria	2020	2021	2022	2023
N° surveyed	--	N=40	N=122	N=228
COVID-19 test				
Yes	-- --	27 (68)	109 (89)	207 (91)
No	-- --	9 (23)	10 (8)	20 (9)
Don't know	-- --	0 (0)	-- --	-- --
Not reported	-- --	4 (10)	3 (2)	1 (<1)
Self-reported positive COVID-19 test result				
Yes	-- --	2 (5)	38 (35)	72 (35)
Yes, last 12 months	-- --	-- --	28 (26)	27 (13)
Yes, more than a year ago	-- --	-- --	10 (9)	45 (22)
COVID-19 vaccine uptake				
≥1 dose	-- --	31 (78)	102 (84)	181 (79)
COVID-19 vaccine doses				
One dose	-- --	9 (23)	16 (13)	14 (6)
Two doses	-- --	22 (55)	27 (22)	62 (27)
Three or more doses	-- --	-- --	59 (48)	105 (46)
No doses	-- --	7 (18)	15 (12)	44 (19)
Not reported	-- --	2 (5)	5 (4)	3 (1)
Vaccine type *			N=102	
Astra Zeneca	-- --	6 (15)	25 (25)	-- --
Pfizer	-- --	19 (48)	73 (72)	-- --
Don't know	-- --	4 (10)	13 (13)	-- --
Other	-- --	-- --	5 (5)	-- --
Not reported	-- --	11 (28)	-- --	-- --
* 2021 only one response permitted, 2022 multiple responses permitted				
Last vaccine location			N=122	N=228
GP or medical centre	-- --	-- --	43 (35)	64 (28)
Pharmacy/ chemist	-- --	-- --	16 (13)	27 (12)
Vaccine hub	-- --	-- --	21 (17)	20 (9)
Opioid treatment/ methadone clinic	-- --	-- --	3 (2)	1 (<1)
NSP	-- --	-- --	9 (7)	7 (3)
Prison	-- --	-- --	4 (3)	16 (7)
Multiple response	-- --	-- --	3 (2)	8 (4)
Other	-- --	-- --	9 (7)	43 (19)
Not reported	-- --	-- --	14 (11)	42 (18)
Vaccine hesitancy - if not had three or more doses				
Haven't got around to it	-- --	-- --	20 (16)	43 (19)
Difficulty booking appointment	-- --	-- --	4 (3)	1 (<1)
Concerns about side effects	-- --	-- --	5 (4)	17 (7)
Concerns about vaccine safety	-- --	-- --	5 (4)	9 (4)
Not at risk of serious illness	-- --	-- --	6 (5)	16 (7)
Other	-- --	-- --	11 (9)	32 (14)
Multiple response	-- --	-- --	10 (8)	10 (4)
Not reported	-- --	-- --	61 (50)	100 (44)

HIV antibody prevalence

Table 8.2.1 HIV antibody prevalence by gender and survey year

Victoria Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019	234	8 (3.4)	128	1 (0.8)	367	9 (2.5)
2020	--	-- --	--	-- --	--	-- --
2021	25	1 (4.0)	11	0 (0.0)	37	2 (5.4)
2022	68	1 (1.5)	41	1 (2.4)	109	2 (1.8)
2023	80	3 (3.8)	38	1 (2.6)	120	4 (3.3)
X ² p trend		0.825		0.314		0.735

Table 8.2.2 HIV antibody prevalence by sexual identity, gender and survey year

Victoria Sexual identity	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
Heterosexual	194	7 (3.6)	78	1 (1.3)	272	8 (2.9)
Bisexual	11	0 (0.0)	22	0 (0.0)	37	0 (0.0)
Homosexual	6	1 (16.7)	10	0 (0.0)	16	1 (6.3)
p value		0.258		1.000		0.299
2020						
Heterosexual	--	-- --	--	-- --	--	-- --
Bisexual	--	-- --	--	-- --	--	-- --
Homosexual	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
Heterosexual	22	0 (0.0)	4	0 (0.0)	27	1 (3.7)
Bisexual	1	0 (0.0)	6	0 (0.0)	7	0 (0.0)
Homosexual	1	1 (100.0)	1	0 (0.0)	1	1 (100.0)
p value		0.120		--		0.108
2022						
Heterosexual	59	0 (0.0)	24	1 (4.2)	83	1 (1.2)
Bisexual	3	0 (0.0)	10	0 (0.0)	13	0 (0.0)
Homosexual	4	1 (25.0)	3	0 (0.0)	7	1 (14.3)
p value		0.132		1.000		0.239
2023						
Heterosexual	69	3 (4.4)	30	1 (3.3)	99	4 (4.0)
Bisexual	4	0 (0.0)	5	0 (0.0)	9	0 (0.0)
Homosexual	4	0 (0.0)	0	0 (0.0)	5	0 (0.0)
p value		1.000		1.000		1.000

Table 8.2.3 HIV antibody prevalence by age group, gender and survey year

Victoria Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
<25 years	3	0 (0.0)	3	0 (0.0)	6	0 (0.0)
25-34 years	32	3 (9.4)	25	0 (0.0)	59	3 (5.1)
35-44 years	97	3 (3.1)	54	0 (0.0)	152	3 (2.0)
45+ years	99	1 (1.0)	45	1 (2.2)	145	2 (1.4)
p value		0.139		0.575		0.387
2020						
<25 years	--	-- --	--	-- --	--	-- --
25-34 years	--	-- --	--	-- --	--	-- --
35-44 years	--	-- --	--	-- --	--	-- --
45+ years	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
<25 years	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
25-34 years	0	0 (0.0)	1	0 (0.0)	2	1 (50.0)
35-44 years	6	1 (16.7)	4	0 (0.0)	10	1 (10.0)
45+ years	19	0 (0.0)	6	0 (0.0)	25	0 (0.0)
p value		0.240		--		0.032
2022						
<25 years	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
25-34 years	5	0 (0.0)	6	0 (0.0)	11	0 (0.0)
35-44 years	17	0 (0.0)	18	1 (5.6)	35	1 (2.9)
45+ years	46	1 (2.2)	16	0 (0.0)	62	1 (1.6)
p value		1.000		1.000		1.000
2023						
<25 years	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)
25-34 years	3	0 (0.0)	3	0 (0.0)	6	0 (0.0)
35-44 years	35	1 (2.9)	15	0 (0.0)	52	1 (1.9)
45+ years	39	2 (5.1)	19	1 (5.3)	58	3 (5.2)
p value		1.000		1.000		0.704

Table 8.2.4 HIV antibody prevalence by last drug injected, gender and survey year

Victoria Last drug injected	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
Heroin	120	5 (4.2)	72	1 (1.4)	194	6 (3.1)
Methamphetamine	78	2 (2.6)	44	0 (0.0)	124	2 (1.6)
Other opioids	11	1 (9.1)	2	0 (0.0)	13	1 (7.7)
Other drugs	22	0 (0.0)	10	0 (0.0)	33	0 (0.0)
p value		0.555		1.000		0.318
2020						
Heroin	--	-- --	--	-- --	--	-- --
Methamphetamine	--	-- --	--	-- --	--	-- --
Other opioids	--	-- --	--	-- --	--	-- --
Other drugs	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
Heroin	10	0 (0.0)	4	0 (0.0)	15	1 (6.7)
Methamphetamine	10	1 (10.0)	6	0 (0.0)	16	1 (6.3)
Other opioids	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)
Other drugs	3	0 (0.0)	1	0 (0.0)	4	0 (0.0)
p value		1.000		--		1.000
2022						
Heroin	43	0 (0.0)	23	1 (4.4)	66	1 (1.5)
Methamphetamine	16	1 (6.3)	13	0 (0.0)	29	1 (3.5)
Other opioids	2	0 (0.0)	1	0 (0.0)	3	0 (0.0)
Other drugs	7	0 (0.0)	4	0 (0.0)	11	0 (0.0)
p value		0.368		1.000		0.636
2023						
Heroin	51	3 (5.9)	22	1 (4.6)	74	4 (5.4)
Methamphetamine	17	0 (0.0)	16	0 (0.0)	34	0 (0.0)
Other opioids	4	0 (0.0)	0	0 (0.0)	4	0 (0.0)
Other drugs	8	0 (0.0)	0	0 (0.0)	8	0 (0.0)
p value		0.736		1.000		0.547

Table 8.2.5 HIV antibody prevalence by years of injection, gender and survey year

Victoria Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2019						
<3 years	6	0 (0.0)	7	0 (0.0)	13	0 (0.0)
3 to 10 years	23	2 (8.7)	20	0 (0.0)	45	2 (4.4)
11+ years	188	5 (2.7)	93	1 (1.1)	282	6 (2.1)
p value		0.320		1.000		0.492
2020						
<3 years	--	-- --	--	-- --	--	-- --
3 to 10 years	--	-- --	--	-- --	--	-- --
11+ years	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
<3 years	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)
3 to 10 years	4	1 (25.0)	1	0 (0.0)	6	2 (33.3)
11+ years	20	0 (0.0)	9	0 (0.0)	29	0 (0.0)
p value		0.200		--		0.042
2022						
<3 years	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)
3 to 10 years	3	0 (0.0)	3	0 (0.0)	6	0 (0.0)
11+ years	60	1 (1.7)	36	1 (2.8)	96	2 (2.1)
p value		1.000		1.000		1.000
2023						
<3 years	2	0 (0.0)	2	0 (0.0)	4	0 (0.0)
3 to 10 years	8	0 (0.0)	2	0 (0.0)	10	0 (0.0)
11+ years	68	3 (4.4)	32	1 (3.1)	102	4 (3.9)
p value		1.000		1.000		1.000

Table 8.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Victoria Receptively shared syringe last month	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2019						
No receptive sharing	185	6 (3.2)	98	1 (1.0)	286	7 (2.5)
Receptive sharing	29	1 (3.5)	21	0 (0.0)	52	1 (1.9)
p value		1.000		1.000		1.000
2020						
No receptive sharing	--	-- --	--	-- --	--	-- --
Receptive sharing	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
No receptive sharing	22	1 (4.6)	9	0 (0.0)	32	2 (6.3)
Receptive sharing	2	0 (0.0)	1	0 (0.0)	3	0 (0.0)
p value		1.000		--		1.000
2022						
No receptive sharing	45	1 (2.2)	30	1 (3.3)	75	2 (2.7)
Receptive sharing	15	0 (0.0)	8	0 (0.0)	23	0 (0.0)
p value		1.000		1.000		1.000
2023						
No receptive sharing	59	3 (5.1)	26	1 (3.9)	87	4 (4.6)
Receptive sharing	12	0 (0.0)	6	0 (0.0)	18	0 (0.0)
p value		1.000		1.000		1.000

Table 8.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

Victoria	Male		Female		Total	
Frequency of injection	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
Less than daily	70	1 (1.4)	36	0 (0.0)	107	1 (0.9)
Daily or more	145	6 (4.1)	86	1 (1.2)	235	7 (3.0)
Not last month	17	1 (5.9)	5	0 (0.0)	22	1 (4.6)
p value		0.324		1.000		0.328
2020						
Less than daily	--	-- --	--	-- --	--	-- --
Daily or more	--	-- --	--	-- --	--	-- --
Not last month	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
Less than daily	12	1 (8.3)	3	0 (0.0)	15	1 (6.7)
Daily or more	12	0 (0.0)	7	0 (0.0)	20	1 (5.0)
Not last month	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)
p value		1.000		--		1.000
2022						
Less than daily	15	1 (6.7)	15	0 (0.0)	30	1 (3.3)
Daily or more	45	0 (0.0)	24	1 (4.2)	69	1 (1.5)
Not last month	5	0 (0.0)	2	0 (0.0)	7	0 (0.0)
p value		0.308		1.000		0.578
2023						
Less than daily	22	0 (0.0)	9	0 (0.0)	32	0 (0.0)
Daily or more	50	3 (6.0)	23	1 (4.4)	74	4 (5.4)
Not last month	8	0 (0.0)	6	0 (0.0)	14	0 (0.0)
p value		0.672		1.000		0.437

Table 8.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

Victoria	Male		Female		Total	
Imprisonment last year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
No imprisonment	162	5 (3.1)	95	1 (1.1)	261	6 (2.3)
Imprisonment	55	2 (3.6)	26	0 (0.0)	82	2 (2.4)
p value		1.000		1.000		1.000
2020						
No imprisonment	--	-- --	--	-- --	--	-- --
Imprisonment	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
No imprisonment	24	1 (4.2)	7	0 (0.0)	32	2 (6.3)
Imprisonment	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)
p value		1.000		--		1.000
2022						
No imprisonment	54	1 (1.9)	30	0 (0.0)	84	1 (1.2)
Imprisonment	8	0 (0.0)	6	0 (0.0)	14	0 (0.0)
p value		1.000		--		1.000
2023						
No imprisonment	63	3 (4.8)	33	1 (3.0)	98	4 (4.1)
Imprisonment	12	0 (0.0)	3	0 (0.0)	15	0 (0.0)
p value		1.000		1.000		1.000

Table 8.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

Victoria	Male		Female		Total	
Condom use at last sex	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
No condom use	57	1 (1.8)	42	0 (0.0)	100	1 (1.0)
Condom use	18	0 (0.0)	12	0 (0.0)	32	0 (0.0)
p value		1.000		--		1.000
2020						
No condom use	--	-- --	--	-- --	--	-- --
Condom use	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
No condom use	2	0 (0.0)	3	0 (0.0)	5	0 (0.0)
Condom use	0	0 (0.0)	1	0 (0.0)	1	0 (0.0)
p value		--		--		--
2022						
No condom use	14	1 (7.1)	12	0 (0.0)	26	1 (3.9)
Condom use	3	0 (0.0)	4	1 (25.0)	7	1 (14.3)
p value		1.000		0.250		0.384
2023						
No condom use	17	0 (0.0)	19	0 (0.0)	36	0 (0.0)
Condom use	5	1 (20.0)	0	0 (0.0)	5	1 (20.0)
p value		0.227		--		0.122

Table 8.2.10 HIV antibody prevalence by sex work last month, gender and survey year

Victoria	Male		Female		Total	
Sex work last month	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
No sex work	210	8 (3.8)	107	1 (0.9)	321	9 (2.8)
Sex work	14	0 (0.0)	14	0 (0.0)	29	0 (0.0)
p value		1.000		1.000		1.000
2020						
No sex work	--	-- --	--	-- --	--	-- --
Sex work	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
No sex work	23	1 (4.4)	4	0 (0.0)	27	1 (3.7)
Sex work	0	0 (0.0)	4	0 (0.0)	5	1 (20.0)
p value		--		--		0.292
2022						
No sex work	58	1 (1.7)	32	1 (3.1)	90	2 (2.2)
Sex work	4	0 (0.0)	4	0 (0.0)	8	0 (0.0)
p value		1.000		1.000		1.000
2023						
No sex work	73	3 (4.1)	36	1 (2.8)	111	4 (3.6)
Sex work	4	0 (0.0)	1	0 (0.0)	5	0 (0.0)
p value		1.000		1.000		1.000

Table 8.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Victoria	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
Non Indigenous	183	4 (2.2)	102	0 (0.0)	289	4 (1.4)
Indigenous	42	4 (9.5)	23	1 (4.4)	65	5 (7.7)
p value		0.042		0.184		0.012
2020						
Non Indigenous	--	-- --	--	-- --	--	-- --
Indigenous	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
Non Indigenous	19	1 (5.3)	10	0 (0.0)	30	2 (6.7)
Indigenous	6	0 (0.0)	1	0 (0.0)	7	0 (0.0)
p value		1.000		--		1.000
2022						
Non Indigenous	55	1 (1.8)	34	1 (2.9)	89	2 (2.3)
Indigenous	12	0 (0.0)	6	0 (0.0)	18	0 (0.0)
p value		1.000		1.000		1.000
2023						
Non Indigenous	62	0 (0.0)	26	0 (0.0)	90	0 (0.0)
Indigenous	17	3 (17.7)	12	1 (8.3)	29	4 (13.8)
p value		0.009		0.316		0.003

Table 8.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

Victoria	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
English speaking	209	7 (3.4)	125	1 (0.8)	338	8 (2.4)
Non-English speaking	23	1 (4.4)	2	0 (0.0)	26	1 (3.9)
p value		0.572		1.000		0.491
2020						
English speaking	--	-- --	--	-- --	--	-- --
Non-English speaking	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
English speaking	21	1 (4.8)	11	0 (0.0)	33	2 (6.1)
Non-English speaking	4	0 (0.0)	0	0 (0.0)	4	0 (0.0)
p value		1.000		--		1.000
2022						
English speaking	55	1 (1.8)	37	1 (2.7)	92	2 (2.2)
Non-English speaking	11	0 (0.0)	4	0 (0.0)	15	0 (0.0)
p value		1.000		1.000		1.000
2023						
English speaking	71	3 (4.2)	36	1 (2.8)	109	4 (3.7)
Non-English speaking	9	0 (0.0)	2	0 (0.0)	11	0 (0.0)
p value		1.000		1.000		1.000

Table 8.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

Victoria	Male		Female		Total	
Region/country of birth	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
Australia	206	6 (2.9)	119	1 (0.8)	328	7 (2.1)
Other Oceania	2	0 (0.0)	4	0 (0.0)	7	0 (0.0)
Asia	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)
UK & Ireland	6	0 (0.0)	1	0 (0.0)	7	0 (0.0)
Other	16	2 (12.5)	3	0 (0.0)	19	2 (10.5)
p value		0.283		1.000		0.234
2020						
Australia	--	-- --	--	-- --	--	-- --
Other Oceania	--	-- --	--	-- --	--	-- --
Asia	--	-- --	--	-- --	--	-- --
UK & Ireland	--	-- --	--	-- --	--	-- --
Other	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
Australia	20	1 (0.0)	10	0 (0.0)	30	1 (3.3)
Other Oceania	0	0 (0.0)	1	0 (0.0)	2	1 (50.0)
Asia	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
UK & Ireland	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)
Other	3	0 (0.0)	0	0 (0.0)	3	0 (0.0)
p value		1.000		--		0.212
2022						
Australia	51	1 (2.0)	34	1 (2.9)	85	2 (2.4)
Other Oceania	1	0 (0.0)	2	0 (0.0)	3	0 (0.0)
Asia	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
UK & Ireland	4	0 (0.0)	2	0 (0.0)	6	0 (0.0)
Other	9	0 (0.0)	1	0 (0.0)	10	0 (0.0)
p value		1.000		1.000		1.000
2023						
Australia	73	3 (4.1)	34	1 (2.9)	109	4 (3.7)
Other Oceania	0	0 (0.0)	1	0 (0.0)	1	0 (0.0)
Asia	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)
UK & Ireland	0	0 (0.0)	1	0 (0.0)	1	0 (0.0)
Other	5	0 (0.0)	2	0 (0.0)	7	0 (0.0)
p value		1.000		1.000		1.000

HCV antibody prevalence

Table 8.3.1 HCV antibody prevalence by gender and survey year

Victoria Survey year	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019	236	153 (65)	126	76 (60)	367	232 (63)
2020	--	-- --	--	-- --	--	-- --
2021	25	8 (32)	11	8 (73)	37	16 (43)
2022	64	19 (30)	39	18 (46)	103	37 (36)
2023*	80	46 (58)	38	23 (61)	120	70 (58)
X ² p trend		<0.001		0.511		0.002

* Antibody testing assay changed in 2023. See Appendix B: Methodological Notes

Table 8.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Victoria Sexual identity	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019						
Heterosexual	196	129 (66)	77	46 (60)	273	175 (64)
Bisexual	11	6 (55)	22	12 (55)	37	20 (54)
Homosexual	6	1 (17)	10	7 (70)	16	8 (50)
p value		0.041		0.737		0.290
2020						
Heterosexual	--	-- --	--	-- --	--	-- --
Bisexual	--	-- --	--	-- --	--	-- --
Homosexual	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
Heterosexual	22	8 (36.4)	4	4 (100.0)	27	12 (44.4)
Bisexual	1	0 (0.0)	6	3 (50.0)	7	3 (42.9)
Homosexual	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)
p value		1.000		0.273		1.000
2022						
Heterosexual	56	16 (29)	22	9 (41)	78	25 (32)
Bisexual	2	1 (50)	10	2 (20)	12	3 (25)
Homosexual	4	1 (25)	3	3 (100)	7	4 (57)
p value		0.723		0.018		0.076
2023						
Heterosexual	69	44 (64)	30	17 (57)	99	61 (62)
Bisexual	4	1 (25)	5	4 (80)	9	5 (56)
Homosexual	4	1 (25)	0	0 (0)	5	1 (20)
p value		0.029		0.888		0.334

Table 8.3.3 HCV antibody prevalence by age group, gender and survey year

Victoria Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
<25 years	3	2 (67)	3	0 (0)	6	2 (33)
25-34 years	32	13 (41)	25	17 (68)	59	30 (51)
35-44 years	98	56 (57)	54	30 (56)	153	87 (57)
45+ years	100	79 (79)	43	29 (67)	144	109 (76)
p value		<0.001		0.090		<0.001
2020						
<25 years	--	-- --	--	-- --	--	-- --
25-34 years	--	-- --	--	-- --	--	-- --
35-44 years	--	-- --	--	-- --	--	-- --
45+ years	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
<25 years	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
25-34 years	0	0 (0.0)	1	0 (0.0)	2	0 (0.0)
35-44 years	6	2 (33.3)	4	2 (50.0)	10	4 (40.0)
45+ years	19	6 (31.6)	6	6 (100.0)	25	12 (48.0)
p value		1.000		0.061		0.542
2022						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	5	2 (40)	6	2 (33)	11	4 (36)
35-44 years	16	7 (44)	17	8 (47)	33	15 (45)
45+ years	43	10 (23)	15	8 (53)	58	18 (31)
p value		0.248		0.760		0.361
2023						
<25 years	1	0 (0)	0	0 (0)	1	0 (0)
25-34 years	3	1 (33)	3	2 (67)	6	3 (50)
35-44 years	35	19 (54)	15	10 (67)	52	30 (58)
45+ years	39	25 (64)	19	10 (53)	58	35 (60)
p value		0.412		0.775		0.710

Table 8.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Victoria Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019						
<3 years	6	1 (17)	7	0 (0)	13	1 (8)
3 to 10 years	23	10 (43)	20	8 (40)	45	19 (42)
11+ years	189	129 (68)	91	62 (68)	281	191 (68)
p value		0.003		<0.001		<0.001
2020						
<3 years	--	-- --	--	-- --	--	-- --
3 to 10 years	--	-- --	--	-- --	--	-- --
11+ years	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
<3 years	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)
3 to 10 years	4	1 (25.0)	1	1 (100.0)	6	2 (33.3)
11+ years	20	7 (35.0)	9	7 (77.8)	29	14 (48.3)
p value		1.000		0.491		0.575
2022						
<3 years	2	1 (50)	0	0 (0)	2	1 (50)
3 to 10 years	3	0 (0)	3	0 (0)	6	0 (0)
11+ years	56	18 (32)	34	17 (50)	90	35 (39)
p value		0.588		0.234		0.095
2023						
<3 years	2	0 (0)	2	0 (0)	4	0 (0)
3 to 10 years	8	2 (25)	2	1 (50)	10	3 (30)
11+ years	68	43 (63)	32	20 (63)	102	64 (63)
p value		0.025		0.310		0.006

Table 8.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Victoria Receptively shared syringe last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019						
No receptive sharing	11	1 (9)	259	169 (65)	285	184 (65)
Receptive sharing	0	0 (0)	44	30 (68)	52	35 (67)
p value		--		0.705		0.703
2020						
No receptive sharing	--	-- --	--	-- --	--	-- --
Receptive sharing	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
No receptive sharing	2	0 (0.0)	30	14 (46.7)	32	14 (43.8)
Receptive sharing	0	0 (0.0)	3	2 (66.7)	3	2 (66.7)
p value		--		0.601		0.582
2022						
No receptive sharing	2	1 (50.0)	66	26 (39.3)	71	27 (38.0)
Receptive sharing	0	0 (0.0)	19	3 (15.8)	21	4 (19.1)
p value		--		0.970		0.123
2023						
No receptive sharing	4	0 (0.0)	81	50 (61.7)	87	52 (59.8)
Receptive sharing	0	0 (0.0)	16	9 (56.3)	18	10 (55.6)
p value		--		0.682		0.741

Table 8.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

Victoria Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
Heroin	4	1 (25)	177	126 (71)	194	138 (71)
Methamphetamine	9	0 (0)	104	63 (61)	121	69 (57)
Other opioids	0	0 (0)	12	6 (50)	13	7 (54)
Other drugs	0	0 (0)	29	13 (45)	33	16 (48)
p value		0.118		0.017		0.013
2020						
Heroin	--	-- --	--	-- --	--	-- --
Methamphetamine	--	-- --	--	-- --	--	-- --
Other opioids	--	-- --	--	-- --	--	-- --
Other drugs	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
Heroin	0	0 (0.0)	15	6 (40.0)	15	6 (40.0)
Methamphetamine	2	0 (0.0)	14	7 (50.0)	16	7 (43.8)
Other opioids	0	0 (0.0)	2	1 (50.0)	2	1 (50.0)
Other drugs	0	0 (0.0)	4	2 (50.0)	4	2 (50.0)
p value		--		0.951		0.981
2022						
Heroin	0	0 (0.0)	57	26 (45.6)	60	26 (43.3)
Methamphetamine	1	0 (0.0)	25	6 (24.0)	28	7 (25.0)
Other opioids	1	1 (100.0)	2	1 (50.0)	3	2 (66.7)
Other drugs	0	0 (0.0)	9	2 (22.2)	9	2 (22.2)
p value		0.157		0.206		0.192
2023						
Heroin	1	0 (0.0)	71	46 (64.8)	74	48 (64.9)
Methamphetamine	3	0 (0.0)	30	16 (53.3)	34	17 (50.0)
Other opioids	0	0 (0.0)	3	1 (33.3)	4	1 (25.0)
Other drugs	0	0 (0.0)	8	4 (50.0)	8	4 (50.0)
p value		--		0.484		0.228

Table 8.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Victoria	<3 years		3+ years		Total	
Frequency of injection last month	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019						
Less than daily	3	0 (0)	98	58 (59)	107	62 (58)
Daily or more	9	1 (11)	208	142 (68)	234	158 (68)
Not last month	1	0 (0)	17	9 (53)	23	11 (48)
p value		1.000		0.174		0.064
2020						
Less than daily	--	-- --	--	-- --	--	-- --
Daily or more	--	-- --	--	-- --	--	-- --
Not last month	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
Less than daily	0	0 (0.0)	15	7 (46.7)	15	7 (46.7)
Daily or more	2	0 (0.0)	18	9 (50.0)	20	9 (45.0)
Not last month	0	0 (0.0)	2	0 (0.0)	2	0 (0.0)
p value		--		0.641		0.657
2022						
Less than daily	1	0 (0.0)	24	9 (37.5)	27	9 (33.3)
Daily or more	1	1 (100.0)	62	21 (33.9)	66	23 (34.9)
Not last month	0	0 (0.0)	7	5 (71.4)	7	5 (71.4)
p value		1.000		0.179		0.183
2023						
Less than daily	2	0 (0.0)	29	21 (72.4)	32	21 (65.6)
Daily or more	2	0 (0.0)	69	39 (56.5)	74	42 (56.8)
Not last month	0	0 (0.0)	14	7 (50.0)	14	7 (50.0)
p value		--		0.248		0.556

Table 8.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Victoria	<3 years		3+ years		Total	
Imprisonment last year	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019						
No imprisonment	11	1 (9)	236	140 (59)	263	152 (58)
Imprisonment	1	0 (0)	69	52 (75)	81	61 (75)
p value		1.000		0.015		0.005
2020						
No imprisonment	--	-- --	--	-- --	--	-- --
Imprisonment	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
No imprisonment	2	0 (0.0)	30	12 (40.0)	32	12 (37.5)
Imprisonment	0	0 (0.0)	2	1 (50.0)	2	1 (50.0)
p value		--		1.000		1.000
2022						
No imprisonment	1	0 (0.0)	74	26 (35.1)	79	26 (32.9)
Imprisonment	1	1 (100.0)	12	3 (25.0)	14	5 (35.7)
p value		1.000		0.743		1.000
2023						
No imprisonment	4	0 (0.0)	90	55 (61.1)	98	58 (59.2)
Imprisonment	0	0 (0.0)	15	9 (60.0)	15	9 (60.0)
p value		--		0.935		0.952

Table 8.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Victoria	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
Non Indigenous	185	113 (61)	100	62 (62)	289	177 (61)
Indigenous	42	34 (81)	23	12 (52)	65	46 (71)
p value		0.015		0.385		0.151
2020						
Non Indigenous	--	-- --	--	-- --	--	-- --
Indigenous	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
Non Indigenous	19	7 (36.8)	10	7 (70.0)	30	14 (46.7)
Indigenous	6	1 (16.7)	1	1 (100.0)	7	2 (28.6)
p value		0.624		1.000		0.674
2022						
Non Indigenous	51	13 (25.5)	33	14 (42.4)	84	27 (32.1)
Indigenous	12	6 (50.0)	5	3 (60.0)	17	9 (52.9)
p value		0.096		0.640		0.103
2023						
Non Indigenous	62	34 (54.8)	26	12 (46.2)	90	47 (52.2)
Indigenous	17	12 (70.6)	12	11 (91.7)	29	23 (79.3)
p value		0.243		0.012		0.010

Table 8.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Victoria	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
English speaking	210	134 (64)	123	73 (59)	337	209 (62)
Non-English speaking	24	19 (79)	2	2 (100)	27	22 (81)
p value		0.134		0.516		0.043
2020						
English speaking	--	-- --	--	-- --	--	-- --
Non-English speaking	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
English speaking	21	6 (28.6)	11	8 (72.7)	33	14 (42.4)
Non-English speaking	4	2 (50.0)	0	0 (0.0)	4	2 (50.0)
p value		0.570		--		1.000
2022						
English speaking	53	17 (32.1)	36	17 (42.2)	89	34 (38.2)
Non-English speaking	9	2 (22.2)	3	1 (33.3)	12	3 (25.0)
p value		0.709		1.000		0.373
2023						
English speaking	71	40 (56.3)	36	21 (58.3)	109	62 (56.9)
Non-English speaking	9	6 (66.7)	2	2 (100.0)	11	8 (72.7)
p value		0.726		0.509		0.357

Table 8.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

Victoria	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
Australia	207	133 (64)	117	71 (61)	327	205 (63)
Other Oceania	2	2 (100)	4	1 (25)	7	4 (57)
Asia	3	2 (67)	0	0 (0)	3	2 (67)
UK & Ireland	6	5 (83)	1	1 (100)	7	6 (86)
Other	16	11 (69)	3	2 (67)	19	13 (68)
p value		0.855		0.485		0.802
2020						
Australia	--	-- --	--	-- --	--	-- --
Other Oceania	--	-- --	--	-- --	--	-- --
Asia	--	-- --	--	-- --	--	-- --
UK & Ireland	--	-- --	--	-- --	--	-- --
Other	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
Australia	20	7 (35.0)	10	8 (80.0)	30	15 (50.0)
Other Oceania	0	0 (0.0)	1	0 (0.0)	2	0 (0.0)
Asia	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
UK & Ireland	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)
Other	3	1 (33.3)	0	0 (0.0)	3	1 (33.3)
p value		1.000		0.273		0.435
2022						
Australia	48	17 (35.4)	32	15 (46.9)	80	32 (40.0)
Other Oceania	1	0 (0.0)	2	1 (50.0)	3	1 (33.3)
Asia	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
UK & Ireland	4	1 (25.0)	2	0 (0.0)	6	1 (16.7)
Other	8	1 (12.5)	1	0 (0.0)	9	1 (11.1)
p value		0.716		0.746		0.270
2023						
Australia	73	42 (57.5)	34	20 (58.8)	109	63 (57.8)
Other Oceania	0	0 (0.0)	1	1 (100.0)	1	1 (100.0)
Asia	2	1 (50.0)	0	0 (0.0)	2	1 (50.0)
UK & Ireland	0	0 (0.0)	1	1 (100.0)	1	1 (100.0)
Other	5	3 (60.0)	2	1 (50.0)	7	4 (57.1)
p value		1.000		1.000		1.000

HCV RNA prevalence

Table 8.4.1 HCV RNA prevalence by gender and survey year

Victoria	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*	219	49 (22)	117	23 (20)	341	73 (21)
2020	--	-- --	--	-- --	--	-- --
2021	19	0 (0)	8	4 (50)	28	5 (18)
2022	37	6 (16)	29	2 (7)	66	8 (12)
2023	76	8 (11)	35	8 (23)	113	16 (14)
X ² p trend (4 year)		0.114		0.865		0.032

* 2019: Weighted for gender and HCV antibody status

Totals include respondents where gender was reported as other or not reported

Table 8.4.2 HCV RNA prevalence by sexual identity, gender and survey year

Victoria	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
Heterosexual	183	42 (23)	71	15 (21)	254	57 (22)
Bisexual	9	2 (22)	20	2 (10)	33	6 (18)
Homosexual	6	0 (0)	10	5 (50)	16	5 (31)
p value		0.394		0.045		0.604
2020						
Heterosexual	--	-- --	--	-- --	--	-- --
Bisexual	--	-- --	--	-- --	--	-- --
Homosexual	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
Heterosexual	16	0 (0)	3	1 (33)	20	2 (10)
Bisexual	1	0 (0)	4	2 (50)	5	2 (40)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
p value		--		0.659		0.228
2022						
Heterosexual	34	6 (18)	18	1 (6)	52	7 (13)
Bisexual	1	0 (0)	5	0 (0)	6	0 (0)
Homosexual	2	0 (0)	2	1 (50)	4	1 (25)
p value		1.000		0.401		0.729
2023						
Heterosexual	65	8 (12)	27	7 (26)	92	15 (16)
Bisexual	4	0 (0)	5	1 (20)	9	1 (11)
Homosexual	4	0 (0)	0	0 (0)	5	0 (0)
p value		1.000		1.000		1.000

Table 8.4.3 HCV RNA prevalence by age group, gender and survey year

Victoria Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
<25 years	2	0 (0)	3	0 (0)	5	0 (0)
25-34 years	30	6 (20)	22	3 (14)	53	9 (17)
35-44 years	92	20 (22)	51	12 (24)	144	31 (22)
45+ years	92	22 (24)	40	8 (20)	134	31 (23)
p value		0.814		0.656		0.493
2020						
<25 years	--	-- --	--	-- --	--	-- --
25-34 years	--	-- --	--	-- --	--	-- --
35-44 years	--	-- --	--	-- --	--	-- --
45+ years	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	0	0 (0)	1	0 (0)	2	1 (50)
35-44 years	4	0 (0)	2	1 (50)	6	1 (17)
45+ years	15	0 (0)	5	3 (60)	20	3 (15)
p value		--		0.549		0.466
2022						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	2	1 (50)	3	1 (33)	5	2 (40)
35-44 years	10	1 (10)	11	1 (9)	21	2 (10)
45+ years	25	4 (16)	14	0 (0)	39	4 (10)
p value		0.408		0.095		0.164
2023						
<25 years	1	0 (0)	0	0 (0)	1	0 (0)
25-34 years	3	1 (33)	3	1 (33)	6	2 (33)
35-44 years	33	4 (12)	14	3 (21)	49	7 (14)
45+ years	37	2 (5)	17	3 (18)	54	5 (9)
p value		0.279		0.839		0.298

Table 8.4.4 HCV RNA prevalence by years since first injection, gender and survey year

Victoria Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
<3 years	6	1 (17)	7	0 (0)	13	1 (8)
3 to 10 years	20	6 (30)	19	3 (16)	40	10 (25)
11+ years	175	37 (21)	85	20 (24)	261	57 (22)
p value		0.639		0.290		0.398
2020						
<3 years	--	-- --	--	-- --	--	-- --
3 to 10 years	--	-- --	--	-- --	--	-- --
11+ years	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	3	0 (0)	1	1 (100)	5	2 (40)
11+ years	15	0 (0)	7	3 (43)	22	3 (14)
p value		--		0.285		0.340
2022						
<3 years	1	1 (100)	0	0 (0)	1	1 (100)
3 to 10 years	2	0 (0)	2	0 (0)	4	0 (0)
11+ years	34	5 (15)	25	1 (4)	59	6 (10)
p value		0.182		1.000		0.161
2023						
<3 years	2	0 (0)	2	0 (0)	4	0 (0)
3 to 10 years	8	0 (0)	2	2 (100)	10	2 (20)
11+ years	64	7 (11)	29	5 (17)	95	12 (13)
p value		1.000		0.079		0.782

Table 8.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Victoria Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
No receptive sharing	174	38 (22)	91	16 (18)	269	55 (20)
Receptive sharing	25	7 (28)	19	5 (26)	45	13 (29)
p value		0.549		0.358		0.225
2020						
No receptive sharing	--	-- --	--	-- --	--	-- --
Receptive sharing	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
No receptive sharing	18	0 (0)	6	3 (50)	25	4 (16)
Receptive sharing	1	0 (0)	1	1 (100)	2	1 (50)
p value		--		0.350		0.234
2022						
No receptive sharing	27	5 (19)	22	0 (0)	49	5 (10)
Receptive sharing	7	0 (0)	5	1 (20)	12	1 (8)
p value		0.559		0.185		1.000
2023						
No receptive sharing	55	6 (11)	24	4 (17)	81	10 (12)
Receptive sharing	12	1 (8)	6	3 (50)	18	4 (22)
p value		1.000		0.120		0.277

Table 8.4.6 HCV RNA prevalence by last drug injected, gender and survey year

Victoria Last drug injected	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
Heroin	115	19 (17)	67	12 (18)	183	30 (16)
Methamphetamine	69	19 (28)	38	9 (24)	109	29 (27)
Other opioids	11	11 (100)	2	0 (0)	13	5 (38)
Other drugs	19	5 (26)	10	2 (20)	31	7 (23)
p value		0.088		0.814		0.092
2020						
Heroin	--	-- --	--	-- --	--	-- --
Methamphetamine	--	-- --	--	-- --	--	-- --
Other opioids	--	-- --	--	-- --	--	-- --
Other drugs	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
Heroin	9	0 (0)	3	0 (0)	13	1 (8)
Methamphetamine	8	0 (0)	4	3 (75)	12	3 (25)
Other opioids	1	0 (0)	0	0 (0)	1	0 (0)
Other drugs	1	0 (0)	1	1 (100)	2	1 (50)
p value		--		0.082		0.398
2022						
Heroin	22	3 (14)	15	0 (0)	37	3 (8)
Methamphetamine	10	1 (10)	11	2 (18)	21	3 (14)
Other opioids	2	1 (50)	1	0 (0)	3	1 (33)
Other drugs	2	1 (50)	2	0 (0)	4	1 (25)
p value		0.300		0.319		0.474
2023						
Heroin	47	6 (13)	21	5 (24)	69	11 (16)
Methamphetamine	17	1 (6)	14	3 (21)	32	4 (13)
Other opioids	4	0 (0)	0	0 (0)	4	0 (0)
Other drugs	8	1 (13)	0	0 (0)	8	1 (13)
p value		0.767		0.869		0.818

Table 8.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year

Victoria	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
Frequency of injection last month						
2019*						
Less than daily	65	13 (20)	32	6 (19)	96	19 (20)
Daily or more	135	33 (24)	91	15 (16)	220	50 (23)
Not last month	17	2 (12)	5	2 (40)	22	4 (18)
p value		0.409		0.490		0.742
2020						
Less than daily	--	-- --	--	-- --	--	-- --
Daily or more	--	-- --	--	-- --	--	-- --
Not last month	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
Less than daily	9	0 (0)	2	2 (100)	11	2 (18)
Daily or more	10	0 (0)	5	2 (40)	16	3 (19)
Not last month	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		0.202		0.893
2022						
Less than daily	6	1 (17)	10	0 (0)	16	1 (6)
Daily or more	28	4 (14)	17	1 (6)	45	5 (11)
Not last month	2	1 (50)	2	1 (50)	4	2 (50)
p value		0.346		0.135		0.109
2023						
Less than daily	21	2 (10)	9	3 (33)	31	5 (16)
Daily or more	47	5 (11)	21	4 (19)	69	9 (13)
Not last month	8	1 (13)	5	1 (20)	13	2 (15)
p value		1.000		0.844		0.925

Table 8.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year

Victoria	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
Imprisonment last year						
2019*						
No imprisonment	156	27 (17)	90	18 (20)	250	46 (18)
Imprisonment	48	16 (33)	22	4 (18)	71	20 (28)
p value		0.030		0.865		0.058
2020						
No imprisonment	--	-- --	--	-- --	--	-- --
Imprisonment	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
No imprisonment	19	0 (0)	4	3 (75)	24	4 (17)
Imprisonment	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		0.171		0.656
2022						
No imprisonment	28	5 (18)	20	1 (5)	48	6 (13)
Imprisonment	6	1 (17)	5	1 (20)	11	2 (18)
p value		1.000		0.367		0.635
2023						
No imprisonment	59	7 (12)	31	8 (26)	92	15 (16)
Imprisonment	12	1 (8)	2	0 (0)	14	1 (7)
p value		1.000		1.000		0.689

Table 8.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Victoria	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019*						
Non Indigenous	175	34 (19)	91	18 (20)	270	53 (20)
Indigenous	39	14 (36)	23	5 (22)	61	19 (31)
p value		0.035		0.801		0.066
2020						
Non Indigenous	--	-- --	--	-- --	--	-- --
Indigenous	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
Non Indigenous	14	0 (0)	7	3 (43)	22	4 (18)
Indigenous	5	0 (0)	1	1 (100)	6	1 (17)
p value		--		0.285		0.932
2022						
Non Indigenous	30	4 (13)	24	1 (4)	54	5 (9)
Indigenous	7	2 (29)	4	1 (25)	11	3 (27)
p value		0.315		0.270		0.126
2023						
Non Indigenous	60	6 (10)	24	4 (17)	86	10 (12)
Indigenous	15	2 (13)	11	4 (36)	26	6 (23)
p value		0.657		0.226		0.144

Table 8.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year

Victoria	Male		Female		Total	
Main language spoken at home by parents	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019*						
English speaking	195	44 (23)	114	21 (18)	313	66 (21)
Non-English speaking	23	5 (22)	2	2 (100)	26	8 (31)
p value		0.891		0.004		0.274
2020						
English speaking	--	-- --	--	-- --	--	-- --
Non-English speaking	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
English speaking	16	0 (0)	8	4 (50)	25	5 (20)
Non-English speaking	3	0 (0)	0	0 (0)	3	0 (0)
p value		--		--		0.393
2022						
English speaking	31	5 (16)	26	1 (4)	57	6 (11)
Non-English speaking	5	1 (20)	3	1 (33)	8	2 (25)
p value		1.000		0.200		0.254
2023						
English speaking	67	8 (12)	33	8 (24)	102	16 (16)
Non-English speaking	9	0 (0)	2	0 (0)	11	0 (0)
p value		0.585		1.000		0.359

Table 8.4.11 HCV RNA prevalence by region/country of birth, gender and survey year

Victoria	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
Australia	192	42 (22)	109	21 (19)	304	64 (21)
Other Oceania	2	1 (50)	3	1 (33)	6	3 (50)
Asia	3	0 (0)	0	0 (0)	3	0 (0)
UK & Ireland	6	2 (33)	1	1 (100)	7	3 (43)
Other	15	4 (27)	3	0 (0)	18	4 (22)
p value		0.690		0.155		0.248
2020						
Australia	--	-- --	--	-- --	--	-- --
Other Oceania	--	-- --	--	-- --	--	-- --
Asia	--	-- --	--	-- --	--	-- --
UK & Ireland	--	-- --	--	-- --	--	-- --
Other	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
Australia	14	0 (0)	8	4 (50)	22	4 (18)
Other Oceania	0	0 (0)	0	0 (0)	1	1 (100)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	2	0 (0)	0	0 (0)	2	0 (0)
Other	3	0 (0)	0	0 (0)	3	0 (0)
p value		--		--		0.128
2022						
Australia	30	6 (20)	24	1 (4)	54	7 (13)
Other Oceania	0	0 (0)	1	0 (0)	1	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	0 (0)	2	0 (0)	3	0 (0)
Other	5	0 (0)	0	0 (0)	5	0 (0)
p value		0.634		1.000		1.000
2023						
Australia	69	8 (12)	31	8 (26)	102	16 (16)
Other Oceania	0	0 (0)	1	0 (0)	1	0 (0)
Asia	2	0 (0)	0	0 (0)	2	0 (0)
UK & Ireland	0	0 (0)	1	0 (0)	1	0 (0)
Other	5	0 (0)	2	0 (0)	7	0 (0)
p value		1.000		1.000		0.780

Western Australia

Table 9.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Western Australia	2019	2020*	2021*	2022	2023
Number of sites	4	4	4	4	4
N° surveyed	N=528	N=399	N=485	N=421	N=469
Response rate (%)	78%	57%	68%	62%	75%
Gender (%)					
Male	327 (62)	246 (62)	292 (60)	265 (63)	291 (62)
Female	199 (38)	152 (38)	187 (39)	151 (36)	172 (37)
Other*	1 (<1)	1 (<1)	4 (1)	4 (1)	4 (1)
Not reported	1 (<1)	0 (0)	2 (<1)	1 (<1)	2 (<1)
Sexual identity (%)					
Heterosexual	415 (79)	311 (78)	397 (82)	344 (82)	384 (82)
Bisexual	39 (7)	37 (9)	49 (10)	34 (8)	38 (8)
Gay/Lesbian	12 (2)	13 (3)	16 (3)	12 (3)	8 (2)
Other	-- --	13 (3)	18 (4)	27 (6)	31 (7)
Not reported	62 (12)	25 (6)	5 (1)	4 (1)	8 (2)
Aboriginal and Torres Strait Islander origin (%)					
No	374 (71)	258 (65)	306 (63)	279 (66)	286 (61)
Yes	146 (28)	123 (31)	150 (31)	139 (33)	174 (37)
Not reported	8 (2)	18 (5)	29 (6)	3 (1)	9 (2)
Region/country of birth (%)					
Australia	457 (87)	336 (84)	401 (83)	365 (87)	406 (87)
Other Oceania	14 (3)	14 (4)	22 (5)	12 (3)	17 (4)
Asia	4 (1)	4 (1)	4 (1)	5 (1)	4 (1)
UK & Ireland	31 (6)	24 (6)	27 (6)	16 (4)	17 (4)
Other	21 (4)	14 (4)	14 (3)	18 (4)	14 (3)
Not reported	1 (<1)	7 (2)	17 (4)	5 (1)	11 (2)
Main language spoken at home by parents (%)					
English	509 (96)	381 (95)	462 (95)	396 (94)	432 (92)
Non-English	17 (3)	15 (4)	17 (4)	22 (5)	30 (6)
Not reported	2 (<1)	3 (1)	6 (1)	3 (1)	7 (1)
Age and time since first injection (years)					
<i>Median age</i>	41	43	44	43	45
<i>Age range</i>	15-70	18-74	23-66	18-73	20-74
Age group (%)					
<25 years	22 (4)	13 (3)	7 (1)	11 (3)	4 (1)
25+ years	505 (96)	385 (96)	472 (97)	404 (96)	459 (98)
Not reported	1 (<1)	1 (<1)	6 (1)	6 (1)	6 (1)
Median age first injection					
<i>Median age first injection</i>	19	19	19	19	18
<i>Age range</i>	10-66	10-57	10-85	10-72	10-72
<i>N° not reported</i>	31	11	17	27	16
<i>Median yrs since first injection</i>	21	22	23	22	25
<i>Range</i>	<1-55	<1-52	<1-49	<1-51	<1-49
Years since first injection					
<3 years	28 (5)	16 (4)	17 (4)	16 (4)	28 (6)
3+ years	467 (88)	372 (93)	448 (92)	378 (90)	425 (91)
Not reported	33 (6)	11 (3)	20 (4)	27 (6)	16 (3)
Imprisonment last year (%)					
No	429 (81)	329 (82)	395 (81)	343 (81)	371 (79)
Yes	69 (13)	54 (14)	61 (13)	57 (14)	60 (13)
Not reported	30 (6)	16 (4)	29 (6)	21 (5)	38 (8)
N° in prison					
<i>N° in prison</i>	N=69	N=54	N=61	N=57	N=60
<i>Injected in prison</i>	23 (33)	12 (22)	14 (23)	22 (39)	19 (32)

* Implementation of the 2020 and 2021 ANSPS was impacted by the COVID-19 pandemic, see page 1 for more information

Table 9.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

Western Australia	2019	2020	2021	2022	2023
N° surveyed	N=528	N=399	N=485	N=421	N=469
Drug last injected (%)					
Cocaine	0 (0)	1 (<1)	1 (<1)	1 (<1)	0 (0)
Methamphetamine	352 (67)	254 (64)	282 (58)	283 (67)	320 (68)
Heroin	104 (20)	73 (18)	86 (18)	64 (15)	72 (15)
Pharm. opioids	17 (3)	12 (3)	12 (2)	6 (1)	5 (1)
Methadone	7 (1)	11 (3)	21 (4)	14 (3)	13 (3)
Buprenorphine	5 (1)	10 (3)	21 (4)	8 (2)	6 (1)
Buprenorphine/naloxone	8 (2)	8 (2)	17 (4)	9 (2)	7 (1)
PIEDs	7 (1)	4 (1)	9 (2)	16 (4)	3 (1)
More than one	21 (4)	20 (5)	32 (7)	16 (4)	37 (8)
Other	6 (1)	1 (<1)	3 (1)	2 (<1)	2 (<1)
Not reported	1 (<1)	5 (1)	1 (<1)	2 (<1)	4 (1)
Ever injected opioids					
No	181 (34)	137 (34)	154 (32)	151 (36)	168 (36)
Yes	341 (65)	261 (65)	327 (67)	270 (64)	300 (64)
Not reported	6 (1)	1 (<1)	4 (1)	0 (0)	1 (<1)
Frequency of injection last month (%)					
Not last month	26 (5)	32 (8)	40 (8)	29 (7)	30 (6)
Less than weekly	70 (13)	84 (21)	98 (20)	69 (16)	72 (15)
Weekly not daily	124 (23)	91 (23)	121 (25)	85 (20)	89 (19)
Daily or more	298 (56)	189 (47)	215 (44)	229 (54)	265 (57)
Not reported	10 (2)	3 (1)	11 (2)	9 (2)	13 (3)
Present when someone injected for the first time in the last 12 months (%)					
No	401 (76)	317 (79)	395 (81)	334 (79)	354 (75)
Yes	104 (20)	77 (19)	83 (17)	79 (19)	92 (20)
Not reported	23 (4)	5 (1)	7 (1)	8 (2)	23 (5)
Overdosed in last 12 months					
No	409 (77)	346 (87)	412 (85)	352 (84)	377 (80)
Yes	96 (18)	47 (12)	63 (13)	63 (15)	68 (15)
Not reported	23 (4)	6 (2)	10 (2)	6 (1)	24 (5)

Table 9.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

Western Australia	2019	2020	2021	2022	2023
N° injected last month	N=492	N=364	N=434	N=383	N=426
Places injected last month (%)					
All private	217 (44)	169 (46)	183 (42)	153 (40)	169 (40)
Any public	274 (56)	194 (53)	247 (57)	228 (60)	253 (59)
Not reported	1 (<1)	1 (<1)	4 (1)	2 (1)	4 (1)
Use of new and sterile needles and syringes last month (%)					
All injections	322 (65)	244 (67)	269 (62)	234 (61)	254 (60)
Most of the time	124 (25)	96 (26)	126 (29)	113 (30)	122 (29)
Half of the time	24 (5)	9 (2)	14 (3)	16 (4)	27 (6)
Some of the time	16 (3)	10 (3)	17 (4)	11 (3)	13 (3)
Not last month	1 (<1)	2 (1)	3 (1)	5 (1)	3 (1)
Not reported	5 (1)	3 (1)	5 (1)	4 (1)	7 (2)
Re-used someone else's used needle & syringe last month (%)					
None	354 (72)	276 (76)	321 (74)	265 (69)	287 (67)
Once	39 (8)	30 (8)	34 (8)	34 (9)	32 (8)
Twice	48 (10)	22 (6)	27 (6)	37 (10)	38 (9)
3-5 times	22 (4)	27 (7)	22 (5)	27 (7)	40 (9)
>5 times	21 (4)	9 (2)	26 (6)	20 (5)	25 (6)
Not reported	8 (2)	0 (0)	4 (1)	0 (0)	4 (1)
Number of people needle & syringe was re-used after last month (%)					
None	354 (72)	276 (76)	321 (74)	265 (69)	287 (67)
One	72 (15)	39 (11)	49 (11)	62 (16)	56 (13)
Two	14 (3)	8 (2)	17 (4)	14 (4)	14 (3)
Three to five	7 (1)	6 (2)	11 (3)	8 (2)	13 (3)
More than five	8 (2)	4 (1)	7 (2)	5 (1)	7 (2)
Don't know	20 (4)	21 (6)	18 (4)	14 (4)	23 (5)
Not reported	17 (3)	10 (3)	11 (3)	15 (4)	26 (6)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	56 (11)	39 (11)	43 (10)	49 (13)	42 (10)
Casual sex partner	7 (1)	6 (2)	6 (1)	4 (1)	8 (2)
Close friend	25 (5)	16 (4)	33 (8)	43 (11)	40 (9)
Acquaintance	15 (3)	15 (4)	26 (6)	15 (4)	16 (4)
Other	15 (3)	11 (3)	6 (1)	8 (2)	9 (2)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	94 (19)	56 (15)	94 (22)	60 (16)	98 (23)
Water	115 (23)	86 (24)	130 (30)	87 (23)	152 (36)
Filter	32 (7)	21 (6)	46 (11)	33 (9)	55 (13)
Drug mix	47 (10)	36 (10)	56 (13)	46 (12)	73 (17)
None	304 (62)	230 (63)	255 (59)	243 (63)	222 (52)
Injected by someone after that person injected themselves or others last month (%)					
No	379 (77)	304 (84)	327 (75)	301 (79)	313 (73)
Yes	105 (21)	60 (16)	103 (24)	82 (21)	108 (25)
Not reported	8 (2)	0 (0)	4 (1)	0 (0)	5 (1)
Source of needle acquisition					
Needle Syringe Program	398 (81)	293 (80)	350 (81)	295 (77)	319 (75)
Chemist/Pharmacy	177 (36)	138 (38)	153 (35)	126 (33)	142 (33)
Personal sources	72 (15)	49 (13)	57 (13)	54 (14)	61 (14)
Dispensing/Vending Machine	15 (3)	3 (1)	4 (1)	10 (3)	8 (2)
Other sources	23 (5)	10 (3)	8 (2)	11 (3)	7 (2)

Table 9.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Western Australia	2019	2020	2021	2022	2023
N° surveyed	N=528	N=399	N=485	N=421	N=469
Ever any treatment/therapy for drug use (%)					
No	225 (43)	174 (44)	205 (42)	174 (41)	202 (43)
Yes	303 (57)	225 (56)	280 (58)	247 (59)	267 (57)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
History of methadone maintenance treatment (%)					
Currently	68 (13)	42 (11)	59 (12)	46 (11)	39 (8)
Previously	83 (16)	55 (14)	70 (14)	74 (18)	86 (18)
Never	365 (69)	295 (74)	345 (71)	293 (70)	317 (68)
Not reported	12 (2)	7 (2)	11 (2)	8 (2)	27 (6)
History of buprenorphine (Subutex®) treatment (%)					
Currently	34 (6)	19 (5)	33 (7)	21 (5)	34 (7)
Previously	93 (18)	51 (13)	81 (17)	78 (19)	91 (19)
Never	399 (76)	323 (81)	358 (74)	315 (75)	322 (69)
Not reported	2 (<1)	6 (2)	13 (3)	7 (2)	22 (5)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	41 (8)	17 (4)	30 (6)	26 (6)	32 (7)
Previously	87 (16)	52 (13)	76 (16)	70 (17)	91 (19)
Never	394 (75)	327 (82)	372 (77)	323 (77)	341 (73)
Not reported	6 (1)	3 (1)	7 (1)	2 (<1)	5 (1)
History of depot buprenorphine treatment (%)					
Currently	-- --	11 (3)	16 (3)	22 (5)	29 (6)
Previously	-- --	23 (6)	30 (6)	36 (9)	37 (8)
Never	-- --	223 (56)	427 (88)	353 (84)	380 (81)
Not reported	-- --	142 (36)	12 (2)	10 (2)	23 (5)

Table 9.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

Western Australia	2019	2020	2021	2022	2023
N° surveyed	N=528	N=399	N=485	N=421	N=469
Previous HIV test (%)					
Yes, ever	391 (74)	303 (76)	370 (76)	311 (74)	342 (73)
Yes, last year	253 (48)	179 (45)	216 (45)	187 (44)	212 (45)
>1 year ago	138 (26)	124 (31)	154 (32)	124 (29)	130 (28)
Never tested	106 (20)	83 (21)	92 (19)	98 (23)	95 (20)
Not reported	31 (6)	13 (3)	23 (5)	12 (3)	32 (7)
Previous HCV test (%)					
Yes, ever	396 (75)	315 (79)	377 (78)	337 (80)	357 (76)
Yes, last year	264 (50)	188 (47)	258 (53)	219 (52)	226 (48)
>1 year ago	132 (25)	127 (32)	119 (25)	118 (28)	131 (28)
Never tested	73 (14)	52 (13)	63 (13)	44 (10)	58 (12)
Not reported	59 (11)	32 (8)	45 (9)	40 (10)	54 (12)
Lifetime treatment for HCV (%)#					
N° self-reported HCV diagnosis	N=103	N=87	N=110	N=83	N=93
Antiviral treatment	60 (58)	45 (52)	58 (53)	48 (58)	60 (65)
No antiviral treatment	42 (41)	41 (47)	52 (47)	35 (42)	33 (35)
Not reported	1 (1)	1 (1)	0 (0)	0 (0)	0 (0)
Treatment for HCV in past 12 months (%)##					
N° self-reported HCV diagnosis	N=76	N=64	N=86	N=62	N=67
Antiviral treatment	25 (33)	12 (19)	22 (26)	17 (27)	23 (34)
No antiviral treatment	50 (66)	51 (80)	64 (74)	45 (73)	44 (66)
Not reported	1 (1)	1 (2)	0 (0)	0 (0)	0 (0)

among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

Table 9.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

Western Australia	2019	2020	2021	2022	2023
N° surveyed	N=528	N=399	N=485	N=421	N=469
Sex with a regular partner last month (%)					
No	252 (48)	209 (52)	226 (47)	203 (48)	219 (47)
Yes	249 (47)	181 (45)	242 (50)	200 (48)	219 (47)
Not reported	27 (5)	9 (2)	17 (4)	18 (4)	31 (7)
Condom used with regular partner last month (%)					
N° surveyed	N=249	N=181	N=242	N=200	N=219
Never	174 (70)	141 (78)	192 (79)	154 (77)	160 (73)
Sometimes	42 (17)	16 (9)	16 (7)	19 (10)	30 (14)
Every time	23 (9)	13 (7)	20 (8)	16 (8)	16 (7)
Not reported	10 (4)	11 (6)	14 (6)	11 (6)	13 (6)
Sex with other partner(s) last month (%)					
No	414 (78)	329 (82)	389 (80)	327 (78)	359 (77)
Yes	82 (16)	59 (15)	72 (15)	77 (18)	78 (17)
Not reported	32 (6)	11 (3)	24 (5)	17 (4)	32 (7)
Condom used with other partner(s) last month (%)					
N° surveyed	N=82	N=59	N=72	N=77	N=78
Never	44 (54)	33 (56)	41 (57)	42 (55)	46 (59)
Sometimes	24 (29)	16 (27)	14 (19)	19 (25)	16 (21)
Every time	9 (11)	8 (14)	13 (18)	12 (16)	16 (21)
Not reported	5 (6)	2 (3)	4 (6)	4 (5)	0 (0)
Sex work last month (%)					
No	460 (87)	364 (91)	432 (89)	379 (90)	405 (86)
Yes	27 (5)	20 (5)	26 (5)	26 (6)	30 (6)
Not reported	41 (8)	15 (4)	27 (6)	16 (4)	34 (7)
Condom used at last sex work (%)					
Yes	11 (41)	5 (25)	11 (42)	16 (62)	16 (53)

Table 9.1.7 Number (percentage) of respondents by COVID-19 related impacts, 2020-2023

Western Australia	2020	2021	2022	2023
N° surveyed	N=399	N=485	N=421	N=469
COVID-19 test				
Yes	77 (19)	119 (25)	368 (87)	397 (85)
No	265 (66)	267 (55)	47 (11)	63 (13)
Don't know	26 (7)	28 (6)	-- --	-- --
Not reported	31 (8)	71 (15)	6 (1)	9 (2)
Self-reported positive COVID-19 test result				
Yes	2 (3)	3 (1)	172 (47)	194 (49)
Yes, last 12 months	-- --	-- --	157 (43)	91 (23)
Yes, more than a year ago	-- --	-- --	15 (4)	103 (26)
COVID-19 vaccine uptake				
≥1 dose	-- --	182 (38)	346 (82)	375 (80)
COVID-19 vaccine doses				
One dose	-- --	86 (18)	32 (8)	34 (7)
Two doses	-- --	96 (20)	121 (29)	103 (22)
Three or more doses	-- --	-- --	193 (46)	238 (51)
No doses	-- --	236 (49)	61 (14)	84 (18)
Not reported	-- --	67 (14)	14 (3)	10 (2)
Vaccine type *			N=346	
Astra Zeneca	-- --	33 (7)	82 (24)	-- --
Pfizer	-- --	106 (22)	228 (66)	-- --
Don't know	-- --	43 (9)	73 (21)	-- --
Other	-- --	-- --	19 (5)	-- --
Not reported	-- --	303 (62)	-- --	-- --
* 2021 only one response permitted, 2022 multiple responses permitted				
Last vaccine location			N=421	N=469
GP or medical centre	-- --	-- --	145 (34)	172 (37)
Pharmacy/ chemist	-- --	-- --	80 (19)	80 (17)
Vaccine hub	-- --	-- --	49 (12)	36 (8)
Opioid treatment/ methadone clinic	-- --	-- --	2 (<1)	5 (1)
NSP	-- --	-- --	12 (3)	21 (4)
Prison	-- --	-- --	23 (5)	42 (9)
Multiple response	-- --	-- --	10 (2)	12 (3)
Other	-- --	-- --	37 (9)	33 (7)
Not reported	-- --	-- --	63 (15)	68 (15)
Vaccine hesitancy - if not had three or more doses				
Haven't got around to it	-- --	-- --	97 (23)	79 (17)
Difficulty booking appointment	-- --	-- --	13 (3)	8 (2)
Concerns about side effects	-- --	-- --	13 (3)	26 (6)
Concerns about vaccine safety	-- --	-- --	12 (3)	25 (5)
Not at risk of serious illness	-- --	-- --	39 (9)	55 (12)
Other	-- --	-- --	40 (10)	63 (13)
Multiple response	-- --	-- --	16 (4)	11 (2)
Not reported	-- --	-- --	191 (45)	202 (43)

HIV antibody prevalence

Table 9.2.1 HIV antibody prevalence by gender and survey year

Western Australia	Male		Female		Total	
Survey year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019	320	4 (1.3)	198	3 (1.5)	520	7 (1.4)
2020	239	3 (1.3)	152	2 (1.3)	392	5 (1.3)
2021	289	5 (1.7)	187	1 (0.5)	482	6 (1.2)
2022	265	3 (1.1)	151	1 (0.7)	421	4 (1.0)
2023	259	3 (1.2)	150	1 (0.7)	415	4 (1.0)
X ² p trend		0.902		0.307		0.499

Table 9.2.2 HIV antibody prevalence by sexual identity, gender and survey year

Western Australia	Male		Female		Total	
Sexual identity	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
Heterosexual	264	2 (0.8)	145	2 (1.4)	409	4 (1.0)
Bisexual	15	2 (13.3)	23	0 (0.0)	39	2 (5.1)
Homosexual	9	0 (0.0)	3	0 (0.0)	12	0 (0.0)
p value		0.019		1.000		0.135
2020						
Heterosexual	195	1 (0.5)	111	2 (1.8)	306	3 (1.0)
Bisexual	16	1 (6.3)	18	0 (0.0)	35	1 (2.9)
Homosexual	10	1 (10.0)	3	0 (0.0)	13	1 (7.7)
p value		0.058		1.000		0.142
2021						
Heterosexual	258	3 (1.2)	136	1 (0.7)	395	4 (1.0)
Bisexual	12	0 (0.0)	36	0 (0.0)	49	0 (0.0)
Homosexual	9	2 (22.2)	5	0 (0.0)	15	2 (13.3)
p value		0.038		1.000		0.067
2022						
Heterosexual	233	1 (0.4)	110	1 (0.9)	344	2 (0.6)
Bisexual	12	0 (0.0)	21	0 (0.0)	34	0 (0.0)
Homosexual	7	1 (14.3)	5	0 (0.0)	12	1 (8.3)
p value		0.018		1.000		0.058
2023						
Heterosexual	231	1 (0.4)	108	1 (0.9)	341	2 (0.6)
Bisexual	8	0 (0.0)	26	0 (0.0)	34	0 (0.0)
Homosexual	5	1 (20.0)	0	0 (0.0)	5	1 (20.0)
p value		0.016		1.000		0.032

Table 9.2.3 HIV antibody prevalence by age group, gender and survey year

Western Australia Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
<25 years	10	0 (0.0)	11	0 (0.0)	22	0 (0.0)
25-34 years	54	1 (1.9)	49	0 (0.0)	103	1 (1.0)
35-44 years	124	1 (0.8)	79	1 (1.3)	203	2 (1.0)
45+ years	131	2 (1.5)	59	2 (3.4)	191	4 (2.1)
p value		0.847		0.560		0.718
2020						
<25 years	3	0 (0.0)	9	0 (0.0)	12	0 (0.0)
25-34 years	37	0 (0.0)	32	1 (3.1)	70	1 (1.4)
35-44 years	80	1 (1.3)	60	0 (0.0)	140	1 (0.7)
45+ years	118	2 (1.7)	51	1 (2.0)	169	3 (1.8)
p value		1.000		0.412		0.870
2021						
<25 years	4	1 (25.0)	3	0 (0.0)	7	1 (14.3)
25-34 years	31	1 (3.2)	28	0 (0.0)	61	1 (1.6)
35-44 years	103	0 (0.0)	83	0 (0.0)	189	0 (0.0)
45+ years	147	3 (2.0)	71	1 (1.4)	219	4 (1.8)
p value		0.018		0.551		0.016
2022						
<25 years	8	0 (0.0)	3	0 (0.0)	11	0 (0.0)
25-34 years	42	1 (2.4)	19	0 (0.0)	62	1 (1.6)
35-44 years	98	1 (1.0)	66	0 (0.0)	166	1 (0.6)
45+ years	114	1 (0.9)	60	1 (1.7)	176	2 (1.1)
p value		0.604		0.604		0.604
2023						
<25 years	1	0 (0.0)	2	0 (0.0)	3	0 (0.0)
25-34 years	40	0 (0.0)	27	0 (0.0)	67	0 (0.0)
35-44 years	70	0 (0.0)	48	0 (0.0)	120	0 (0.0)
45+ years	146	3 (2.1)	71	1 (1.4)	220	4 (1.8)
p value		0.735		1.000		0.312

Table 9.2.4 HIV antibody prevalence by last drug injected, gender and survey year

Western Australia Last drug injected	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2019						
Heroin	66	1 (1.5)	38	1 (2.6)	104	2 (1.9)
Methamphetamine	201	2 (1.0)	142	2 (1.4)	344	4 (1.2)
Other opioids	29	0 (0.0)	8	0 (0.0)	37	0 (0.0)
Other drugs	24	1 (4.2)	10	0 (0.0)	34	1 (2.9)
p value		0.286		0.633		0.511
2020						
Heroin	44	1 (2.3)	27	1 (3.7)	71	2 (2.8)
Methamphetamine	150	1 (0.7)	100	1 (1.0)	250	2 (0.8)
Other opioids	26	0 (0.0)	14	0 (0.0)	41	0 (0.0)
Other drugs	17	1 (5.9)	10	0 (0.0)	27	1 (3.7)
p value		0.161		0.563		0.180
2021						
Heroin	48	2 (4.2)	36	1 (2.8)	86	3 (3.5)
Methamphetamine	168	3 (1.8)	112	0 (0.0)	281	3 (1.1)
Other opioids	44	0 (0.0)	24	0 (0.0)	69	0 (0.0)
Other drugs	29	0 (0.0)	15	0 (0.0)	45	0 (0.0)
p value		0.468		0.401		0.259
2022						
Heroin	41	0 (0.0)	22	1 (4.6)	64	1 (1.6)
Methamphetamine	167	2 (1.2)	114	0 (0.0)	283	2 (0.7)
Other opioids	27	0 (0.0)	8	0 (0.0)	37	0 (0.0)
Other drugs	30	1 (3.3)	5	0 (0.0)	35	1 (2.9)
p value		0.566		0.235		0.317
2023						
Heroin	41	0 (0.0)	19	1 (5.3)	61	1 (1.6)
Methamphetamine	167	0 (0.0)	110	0 (0.0)	279	0 (0.0)
Other opioids	22	3 (13.6)	7	0 (0.0)	30	3 (10.0)
Other drugs	26	0 (0.0)	14	0 (0.0)	41	0 (0.0)
p value		0.001		0.267		<0.001

Table 9.2.5 HIV antibody prevalence by years of injection, gender and survey year

Western Australia Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2019						
<3 years	18	0 (0.0)	10	0 (0.0)	28	0 (0.0)
3 to 10 years	36	0 (0.0)	50	1 (2.0)	87	1 (1.2)
11 + years	248	4 (1.6)	124	2 (1.6)	372	6 (1.6)
p value		1.000		1.000		1.000
2020						
<3 years	7	0 (0.0)	9	0 (0.0)	16	0 (0.0)
3 to 10 years	39	0 (0.0)	30	1 (3.3)	70	1 (1.4)
11 + years	187	3 (1.6)	108	1 (0.9)	295	4 (1.4)
p value		1.000		0.462		1.000
2021						
<3 years	13	0 (0.0)	3	0 (0.0)	17	0 (0.0)
3 to 10 years	38	3 (7.9)	35	0 (0.0)	73	3 (4.1)
11 + years	224	2 (0.9)	144	1 (0.7)	372	3 (0.8)
p value		0.039		1.000		0.099
2022						
<3 years	11	0 (0.0)	5	0 (0.0)	16	0 (0.0)
3 to 10 years	37	1 (2.7)	17	0 (0.0)	55	1 (1.8)
11 + years	199	2 (1.0)	120	1 (0.8)	323	3 (0.9)
p value		0.479		1.000		0.550
2023						
<3 years	16	0 (0.0)	9	0 (0.0)	25	0 (0.0)
3 to 10 years	28	0 (0.0)	27	0 (0.0)	56	0 (0.0)
11 + years	204	3 (1.5)	112	1 (0.9)	319	4 (1.3)
p value		1.000		1.000		1.000

Table 9.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Western Australia Receptively shared syringe last month	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2019						
No receptive sharing	208	3 (1.4)	139	2 (1.4)	348	5 (1.4)
Receptive sharing	85	1 (1.2)	43	0 (0.0)	128	1 (0.8)
p value		1.000		1.000		1.000
2020						
No receptive sharing	175	2 (1.1)	94	2 (2.1)	270	4 (1.5)
Receptive sharing	46	1 (2.2)	42	0 (0.0)	88	1 (1.1)
p value		0.505		1.000		1.000
2021						
No receptive sharing	184	5 (2.7)	133	1 (0.8)	318	6 (1.9)
Receptive sharing	68	0 (0.0)	38	0 (0.0)	109	0 (0.0)
p value		0.328		1.000		0.345
2022						
No receptive sharing	165	3 (1.8)	98	0 (0.0)	265	3 (1.1)
Receptive sharing	74	0 (0.0)	41	0 (0.0)	118	0 (0.0)
p value		0.554		--		0.556
2023						
No receptive sharing	151	2 (1.3)	93	0 (0.0)	249	2 (0.8)
Receptive sharing	83	1 (1.2)	40	0 (0.0)	123	1 (0.8)
p value		1.000		--		1.000

Table 9.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

Western Australia		Male		Female		Total	
Frequency of injection	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2019							
Less than daily	130	2 (1.5)	61	2 (3.3)	192	4 (2.1)	
Daily or more	169	2 (1.2)	123	1 (0.8)	292	3 (1.0)	
Not last month	15	0 (0.0)	11	0 (0.0)	26	0 (0.0)	
p value		1.000		0.375		0.615	
2020							
Less than daily	111	1 (0.9)	61	1 (1.6)	173	2 (1.2)	
Daily or more	110	2 (1.8)	75	1 (1.3)	185	3 (1.6)	
Not last month	17	0 (0.0)	14	0 (0.0)	31	0 (0.0)	
p value		0.697		1.000		1.000	
2021							
Less than daily	130	4 (3.1)	84	0 (0.0)	216	4 (1.9)	
Daily or more	124	1 (0.8)	89	1 (1.1)	215	2 (0.9)	
Not last month	28	0 (0.0)	12	0 (0.0)	40	0 (0.0)	
p value		0.504		1.000		0.816	
2022							
Less than daily	91	2 (2.2)	60	0 (0.0)	154	2 (1.3)	
Daily or more	148	1 (0.7)	79	0 (0.0)	229	1 (0.4)	
Not last month	21	0 (0.0)	8	1 (12.5)	29	1 (3.5)	
p value		0.658		0.054		0.259	
2023							
Less than daily	99	0 (0.0)	45	0 (0.0)	145	0 (0.0)	
Daily or more	137	3 (2.2)	90	0 (0.0)	231	3 (1.3)	
Not last month	17	0 (0.0)	11	1 (9.1)	28	1 (3.6)	
p value		0.405		0.075		0.106	

Table 9.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

Western Australia		Male		Female		Total	
Imprisonment last year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2019							
No imprisonment	252	1 (0.4)	168	3 (1.8)	421	4 (1.0)	
Imprisonment	50	1 (2.0)	19	0 (0.0)	69	1 (1.5)	
p value		0.304		1.000		0.533	
2020							
No imprisonment	191	2 (1.1)	131	2 (1.5)	323	4 (1.2)	
Imprisonment	40	1 (2.5)	13	0 (0.0)	53	1 (1.9)	
p value		0.436		1.000		0.534	
2021							
No imprisonment	222	3 (1.4)	166	1 (0.6)	392	4 (1.0)	
Imprisonment	47	1 (2.1)	13	0 (0.0)	61	1 (1.6)	
p value		0.538		1.000		0.516	
2022							
No imprisonment	203	3 (1.5)	135	1 (0.7)	343	4 (1.2)	
Imprisonment	47	0 (0.0)	10	0 (0.0)	57	0 (0.0)	
p value		1.000		1.000		1.000	
2023							
No imprisonment	203	1 (0.5)	121	1 (0.8)	329	2 (0.6)	
Imprisonment	40	2 (5.0)	16	0 (0.0)	56	2 (3.6)	
p value		0.071		1.000		0.103	

Table 9.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

Western Australia		Male		Female		Total	
Condom use at last sex	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	
2019							
No condom use	86	1 (1.2)	86	0 (0.0)	172	1 (0.6)	
Condom use	40	0 (0.0)	24	1 (4.2)	64	1 (1.6)	
p value		1.000		0.218		0.470	
2020							
No condom use	75	1 (1.3)	63	1 (1.6)	138	2 (1.5)	
Condom use	20	1 (5.0)	8	0 (0.0)	28	1 (3.6)	
p value		0.378		1.000		0.428	
2021							
No condom use	99	3 (3.0)	90	0 (0.0)	192	3 (1.6)	
Condom use	19	0 (0.0)	16	0 (0.0)	36	0 (0.0)	
p value		1.000		--		1.000	
2022							
No condom use	88	1 (1.1)	64	0 (0.0)	154	1 (0.7)	
Condom use	22	0 (0.0)	42	0 (0.0)	35	0 (0.0)	
p value		1.000		--		1.000	
2023							
No condom use	79	1 (1.3)	62	0 (0.0)	143	1 (0.7)	
Condom use	19	0 (0.0)	20	0 (0.0)	39	0 (0.0)	
p value		1.000		--		1.000	

Table 9.2.10 HIV antibody prevalence by sex work last month, gender and survey year

Western Australia		Male		Female		Total	
Sex work last month	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	
2019							
No sex work	279	4 (1.4)	174	3 (1.7)	454	7 (1.5)	
Sex work	14	0 (0.0)	12	0 (0.0)	26	0 (0.0)	
p value		1.000		1.000		1.000	
2020							
No sex work	223	3 (1.4)	133	1 (0.8)	357	4 (1.1)	
Sex work	10	0 (0.0)	10	1 (10.0)	20	1 (5.0)	
p value		1.000		0.135		0.240	
2021							
No sex work	263	3 (1.1)	162	1 (0.6)	430	4 (0.9)	
Sex work	11	1 (9.1)	15	0 (0.0)	26	1 (3.9)	
p value		0.152		1.000		0.255	
2022							
No sex work	243	3 (1.2)	132	1 (0.8)	379	4 (1.1)	
Sex work	12	0 (0.0)	13	0 (0.0)	26	0 (0.0)	
p value		1.000		1.000		1.000	
2023							
No sex work	229	3 (1.3)	128	1 (0.8)	360	4 (1.1)	
Sex work	13	0 (0.0)	12	0 (0.0)	27	0 (0.0)	
p value		1.000		1.000		1.000	

Table 9.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Western Australia		Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2019							
Non Indigenous	238	2 (0.8)	131	1 (0.8)	369	3 (0.8)	
Indigenous	76	2 (2.6)	66	2 (3.0)	144	4 (2.8)	
p value		0.248		0.260		0.101	
2020							
Non Indigenous	165	1 (0.6)	87	1 (1.2)	252	2 (0.8)	
Indigenous	65	2 (3.1)	57	1 (1.8)	122	3 (2.5)	
p value		0.193		1.000		0.335	
2021							
Non Indigenous	185	4 (2.2)	115	1 (0.9)	303	5 (1.7)	
Indigenous	80	1 (1.3)	68	0 (0.0)	150	1 (0.7)	
p value		1.000		1.000		0.669	
2022							
Non Indigenous	190	2 (1.1)	87	1 (1.2)	279	3 (1.1)	
Indigenous	73	1 (1.4)	63	0 (0.0)	139	1 (0.7)	
p value		1.000		1.000		1.000	
2023							
Non Indigenous	153	0 (0.0)	86	1 (1.2)	243	1 (0.4)	
Indigenous	100	3 (3.0)	61	0 (0.0)	163	3 (1.8)	
p value		0.061		1.000		0.307	

Table 9.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

Western Australia		Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2019							
English speaking	306	4 (1.3)	194	3 (1.6)	502	7 (1.4)	
Non-English speaking	13	0 (0.0)	3	0 (0.0)	16	0 (0.0)	
p value		1.000		1.000		1.000	
2020							
English speaking	227	3 (1.3)	147	2 (1.4)	375	5 (1.3)	
Non-English speaking	11	0 (0.0)	4	0 (0.0)	15	0 (0.0)	
p value		1.000		1.000		1.000	
2021							
English speaking	274	4 (1.5)	179	1 (0.6)	459	5 (1.1)	
Non-English speaking	11	1 (9.1)	6	0 (0.0)	17	1 (5.9)	
p value		0.180		1.000		0.197	
2022							
English speaking	248	2 (0.8)	143	1 (0.7)	396	3 (0.8)	
Non-English speaking	16	1 (6.3)	6	0 (0.0)	22	1 (4.6)	
p value		0.172		1.000		0.195	
2023							
English speaking	238	3 (1.3)	138	1 (0.7)	381	4 (1.1)	
Non-English speaking	17	0 (0.0)	10	0 (0.0)	28	0 (0.0)	
p value		1.000		1.000		1.000	

Table 9.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

Western Australia		Male		Female		Total	
Region/country of birth	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2019							
Australia	273	4 (1.5)	175	3 (1.7)	450	7 (1.6)	
Other Oceania	7	0 (0.0)	7	0 (0.0)	14	0 (0.0)	
Asia	4	0 (0.0)	0	0 (0.0)	4	0 (0.0)	
UK & Ireland	19	0 (0.0)	11	0 (0.0)	30	0 (0.0)	
Other	17	0 (0.0)	4	0 (0.0)	21	0 (0.0)	
p value		1.000		1.000		1.000	
2020							
Australia	190	3 (1.6)	139	2 (1.4)	330	5 (1.5)	
Other Oceania	10	0 (0.0)	4	0 (0.0)	14	0 (0.0)	
Asia	4	0 (0.0)	0	0 (0.0)	4	0 (0.0)	
UK & Ireland	18	0 (0.0)	6	0 (0.0)	24	0 (0.0)	
Other	12	0 (0.0)	2	0 (0.0)	14	0 (0.0)	
p value		1.000		1.000		1.000	
2021							
Australia	235	3 (1.3)	158	1 (0.6)	399	4 (1.0)	
Other Oceania	11	0 (0.0)	11	0 (0.0)	22	0 (0.0)	
Asia	2	0 (0.0)	2	0 (0.0)	4	0 (0.0)	
UK & Ireland	19	0 (0.0)	7	0 (0.0)	26	0 (0.0)	
Other	9	2 (22.2)	5	0 (0.0)	14	2 (14.3)	
p value		0.037		1.000		0.058	
2022							
Australia	228	2 (0.9)	133	1 (0.8)	365	3 (0.8)	
Other Oceania	9	0 (0.0)	3	0 (0.0)	12	0 (0.0)	
Asia	1	0 (0.0)	4	0 (0.0)	5	0 (0.0)	
UK & Ireland	8	0 (0.0)	7	0 (0.0)	16	0 (0.0)	
Other	15	1 (6.7)	3	0 (0.0)	18	1 (5.6)	
p value		0.334		1.000		0.409	
2023							
Australia	225	3 (1.3)	132	1 (0.8)	362	4 (1.1)	
Other Oceania	7	0 (0.0)	8	0 (0.0)	15	0 (0.0)	
Asia	2	0 (0.0)	1	0 (0.0)	3	0 (0.0)	
UK & Ireland	11	0 (0.0)	2	0 (0.0)	14	0 (0.0)	
Other	9	0 (0.0)	3	0 (0.0)	12	0 (0.0)	
p value		1.000		1.000		1.000	

HCV antibody prevalence

Table 9.3.1 HCV antibody prevalence by gender and survey year

Western Australia	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019	320	149 (47)	197	76 (39)	519	225 (43)
2020	239	114 (48)	151	63 (42)	391	177 (45)
2021	289	120 (42)	187	68 (36)	482	192 (40)
2022	265	105 (40)	151	44 (29)	421	151 (36)
2023*	259	141 (54)	150	71 (47)	415	213 (51)
X ² p trend		0.472		0.718		0.426

* Antibody testing assay changed in 2023. See Appendix B: Methodological Notes

Table 9.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Western Australia	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
Heterosexual	264	120 (45)	144	55 (38)	408	175 (43)
Bisexual	15	6 (40)	23	6 (26)	39	12 (31)
Homosexual	9	1 (11)	3	1 (33)	12	2 (17)
p value		0.113		0.665		0.078
2020						
Heterosexual	196	95 (48)	110	42 (38)	306	137 (45)
Bisexual	16	8 (50)	18	11 (61)	35	19 (54)
Homosexual	9	3 (33)	3	2 (67)	12	5 (42)
p value		0.193		0.227		0.283
2021						
Heterosexual	257	113 (44)	136	43 (32)	394	157 (40)
Bisexual	12	4 (33)	36	19 (53)	49	23 (47)
Homosexual	10	1 (10)	5	2 (40)	16	3 (19)
p value		0.089		0.050		0.378
2022						
Heterosexual	233	94 (40)	110	36 (33)	344	131 (38)
Bisexual	12	4 (33)	21	2 (10)	34	6 (18)
Homosexual	7	2 (29)	5	0 (0)	12	2 (17)
p value		0.987		0.079		0.164
2023						
Heterosexual	231	124 (54)	108	54 (50)	341	178 (52)
Bisexual	8	6 (75)	26	9 (35)	34	15 (44)
Homosexual	5	1 (20)	0	0 (0)	5	1 (20)
p value		0.097		0.698		0.323

Table 9.3.3 HCV antibody prevalence by age group, gender and survey year

Western Australia Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
<25 years	10	2 (20)	11	2 (18)	22	4 (18)
25-34 years	54	13 (24)	49	18 (37)	103	31 (30)
35-44 years	124	55 (44)	78	28 (36)	202	83 (41)
45+ years	131	79 (60)	59	28 (47)	191	107 (56)
p value		<0.001		0.258		<0.001
2020						
<25 years	3	0 (0)	9	4 (44)	12	4 (33)
25-34 years	37	15 (41)	32	9 (28)	70	24 (34)
35-44 years	80	43 (54)	59	29 (49)	139	72 (52)
45+ years	118	55 (47)	51	21 (41)	169	76 (45)
p value		0.220		0.281		0.089
2021						
<25 years	4	1 (25)	3	1 (33)	7	2 (29)
25-34 years	31	7 (23)	28	9 (32)	61	17 (28)
35-44 years	103	41 (40)	83	25 (30)	189	68 (36)
45+ years	147	71 (48)	71	32 (45)	219	104 (47)
p value		0.039		0.236		0.013
2022						
<25 years	8	4 (50)	3	0 (0)	11	4 (36)
25-34 years	42	13 (31)	19	4 (21)	62	17 (27)
35-44 years	98	34 (35)	66	23 (35)	166	58 (35)
45+ years	114	53 (46)	60	17 (28)	176	71 (40)
p value		0.173		0.533		0.328
2023						
<25 years	1	1 (100)	2	1 (50)	3	2 (67)
25-34 years	40	13 (33)	27	11 (41)	67	24 (36)
35-44 years	70	34 (49)	48	25 (52)	120	59 (49)
45+ years	146	91 (62)	71	33 (46)	220	124 (56)
p value		0.002		0.826		0.018

Table 9.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Western Australia Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019						
<3 years	18	2 (11)	10	0 (0)	28	2 (7)
3 to 10 years	36	8 (22)	50	17 (34)	87	25 (29)
11+ years	248	132 (53)	123	51 (41)	371	183 (49)
p value		<0.001		0.021		<0.001
2020						
<3 years	7	0 (0)	9	0 (0)	16	0 (0)
3 to 10 years	39	11 (28)	30	11 (37)	70	22 (31)
11+ years	187	97 (52)	107	49 (46)	294	146 (50)
p value		0.001		0.014		<0.001
2021						
<3 years	13	0 (0)	3	1 (33)	17	1 (6)
3 to 10 years	38	9 (24)	35	10 (29)	73	19 (26)
11+ years	224	107 (48)	144	54 (38)	372	164 (44)
p value		<0.001		0.746		<0.001
2022						
<3 years	11	2 (18)	5	0 (0)	16	2 (13)
3 to 10 years	37	7 (19)	17	3 (18)	55	10 (18)
11+ years	199	88 (44)	120	38 (32)	323	128 (40)
p value		0.004		0.265		0.001
2023						
<3 years	16	1 (6)	9	2 (22)	25	3 (12)
3 to 10 years	28	8 (29)	27	9 (33)	56	17 (30)
11+ years	204	125 (61)	112	59 (53)	319	184 (58)
p value		<0.001		0.056		<0.001

Table 9.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Western Australia Receptively shared syringe last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019						
No receptive sharing	19	1 (5)	309	140 (45)	348	151 (43)
Receptive sharing	8	0 (0)	111	51 (46)	128	54 (42)
p value		1.000		0.908		0.814
2020						
No receptive sharing	14	0 (0)	247	113 (46)	268	118 (44)
Receptive sharing	1	0 (0)	85	43 (51)	88	45 (51)
p value		--		0.441		0.246
2021						
No receptive sharing	9	0 (0)	298	116 (39)	319	119 (37)
Receptive sharing	2	1 (50)	102	54 (53)	108	58 (54)
p value		0.182		0.013		0.003
2022						
No receptive sharing	10	0 (0)	235	78 (33)	265	85 (32)
Receptive sharing	3	2 (67)	110	51 (46)	118	56 (47)
p value		0.038		0.018		0.004
2023						
No receptive sharing	18	2 (11)	222	115 (52)	249	121 (49)
Receptive sharing	6	1 (17)	113	68 (60)	123	72 (59)
p value		1.000		0.145		0.071

Table 9.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

Western Australia Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
Heroin	1	1 (100)	95	67 (71)	100	71 (71)
Methamphetamine	23	1 (4)	293	99 (34)	339	109 (32)
Other opioids	1	0 (0)	34	20 (59)	37	21 (57)
Other drugs	3	0 (0)	29	19 (66)	34	20 (59)
p value		0.004		<0.001		<0.001
2020						
Heroin	1	0 (0)	69	51 (74)	71	52 (73)
Methamphetamine	15	0 (0)	226	76 (34)	247	80 (32)
Other opioids	0	0 (0)	40	27 (68)	41	28 (68)
Other drugs	0	0 (0)	24	12 (50)	26	14 (54)
p value		--		<0.001		<0.001
2021						
Heroin	2	1 (50)	82	45 (55)	85	47 (55)
Methamphetamine	8	0 (0)	257	82 (32)	274	85 (31)
Other opioids	3	0 (0)	62	33 (53)	68	35 (51)
Other drugs	3	0 (0)	36	19 (53)	44	20 (45)
p value		0.058		<0.000		<0.000
2022						
Heroin	1	0 (0)	61	25 (41)	63	26 (41)
Methamphetamine	9	2 (22)	249	81 (33)	277	90 (32)
Other opioids	1	0 (0)	31	22 (71)	36	25 (69)
Other drugs	5	0 (0)	26	7 (27)	34	7 (21)
p value		0.620		<0.001		<0.001
2023						
Heroin	1	0 (0)	55	41 (75)	58	42 (72)
Methamphetamine	19	2 (11)	248	114 (46)	275	120 (44)
Other opioids	0	0 (0)	30	22 (73)	30	22 (73)
Other drugs	4	1 (25)	31	20 (65)	38	23 (61)
p value		0.676		<0.001		<0.001

Table 9.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Western Australia	<3 years		3+ years		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
Less than daily	13	2 (15)	170	81 (48)	192	88 (46)
Daily or more	15	0 (0)	255	113 (44)	292	122 (42)
Not last month	0	0 (0)	26	11 (42)	26	11 (42)
p value		0.206		0.753		0.675
2020						
Less than daily	7	0 (0)	161	70 (43)	173	74 (43)
Daily or more	8	0 (0)	171	86 (50)	183	89 (49)
Not last month	1	0 (0)	30	11 (37)	32	12 (38)
p value		--		0.256		0.359
2021						
Less than daily	9	0 (0)	201	74 (37)	217	77 (35)
Daily or more	3	1 (33)	201	96 (48)	214	101 (47)
Not last month	4	0 (0)	35	9 (26)	40	9 (23)
p value		0.187		0.013		0.003
2022						
Less than daily	8	0 (0)	140	46 (33)	154	49 (32)
Daily or more	5	2 (40)	205	83 (40)	229	92 (40)
Not last month	3	0 (0)	24	7 (29)	29	8 (28)
p value		0.108		0.255		0.151
2023						
Less than daily	13	1 (8)	130	67 (52)	145	70 (48)
Daily or more	11	2 (18)	209	117 (56)	231	124 (54)
Not last month	0	0 (0)	28	14 (50)	28	14 (50)
p value		0.576		0.661		0.586

Table 9.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Western Australia	<3 years		3+ years		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
No imprisonment	24	1 (4)	373	163 (44)	420	175 (42)
Imprisonment	3	0 (0)	58	30 (52)	69	34 (49)
p value		1.000		0.253		0.236
2020						
No imprisonment	14	0 (0)	299	134 (45)	321	140 (44)
Imprisonment	2	0 (0)	49	26 (53)	54	29 (54)
p value		--		0.283		0.168
2021						
No imprisonment	15	1 (7)	364	147 (40)	392	151 (39)
Imprisonment	2	0 (0)	55	27 (49)	61	30 (49)
p value		1.000		0.242		0.114
2022						
No imprisonment	15	1 (7)	310	106 (34)	343	115 (34)
Imprisonment	1	1 (100)	50	25 (50)	57	29 (51)
p value		0.125		0.031		0.012
2023						
No imprisonment	15	2 (13)	303	155 (51)	329	163 (50)
Imprisonment	7	0 (0)	47	35 (74)	56	36 (64)
p value		1.000		0.003		0.041

Table 9.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Western Australia Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
Non Indigenous	238	107 (45)	131	49 (37)	369	156 (42)
Indigenous	76	40 (53)	65	27 (42)	143	67 (47)
p value		0.243		0.576		0.349
2020						
Non Indigenous	165	66 (40)	86	32 (37)	251	98 (39)
Indigenous	65	40 (62)	57	26 (46)	122	66 (54)
p value		0.003		0.316		0.006
2021						
Non Indigenous	185	63 (34)	115	37 (32)	303	101 (33)
Indigenous	80	43 (54)	68	30 (44)	150	75 (50)
p value		0.003		0.105		0.001
2022						
Non Indigenous	190	70 (37)	87	25 (29)	279	95 (34)
Indigenous	73	34 (47)	63	19 (30)	139	55 (40)
p value		0.148		0.850		0.268
2023						
Non Indigenous	153	79 (52)	86	35 (41)	243	114 (47)
Indigenous	100	60 (60)	61	34 (56)	163	95 (58)
p value		0.191		0.072		0.025

Table 9.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Western Australia Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019						
English speaking	306	140 (46)	193	75 (39)	501	215 (43)
Non-English speaking	13	9 (69)	3	1 (33)	16	10 (63)
p value		0.154		1.000		0.120
2020						
English speaking	227	110 (48)	146	60 (41)	374	170 (45)
Non-English speaking	11	4 (36)	4	3 (75)	15	7 (47)
p value		0.543		0.310		0.926
2021						
English speaking	274	113 (41)	179	64 (36)	459	181 (39)
Non-English speaking	11	4 (36)	6	3 (50)	17	7 (41)
p value		1.000		0.669		0.885
2022						
English speaking	248	96 (39)	143	42 (29)	396	140 (35)
Non-English speaking	16	8 (50)	6	2 (33)	22	10 (45)
p value		0.370		1.000		0.336
2023						
English speaking	238	134 (56)	138	64 (46)	381	199 (52)
Non-English speaking	17	5 (29)	10	6 (60)	28	11 (39)
p value		0.031		0.518		0.186

Table 9.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

Western Australia		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2019							
Australia	273	126 (46)	174	66 (38)	449	192 (43)	
Other Oceania	7	2 (29)	7	4 (57)	14	6 (43)	
Asia	4	1 (25)	0	0 (0)	4	1 (25)	
UK & Ireland	19	10 (53)	11	5 (45)	30	15 (50)	
Other	17	10 (59)	4	0 (0)	21	10 (48)	
p value		0.587		0.318		0.878	
2020							
Australia	190	93 (49)	139	60 (43)	330	153 (46)	
Other Oceania	10	4 (40)	4	1 (25)	14	5 (36)	
Asia	4	1 (25)	0	0 (0)	4	1 (25)	
UK & Ireland	18	8 (44)	5	1 (20)	23	9 (39)	
Other	12	6 (50)	2	1 (50)	14	7 (50)	
p value		0.909		0.711		0.809	
2021							
Australia	235	98 (42)	158	61 (39)	399	163 (41)	
Other Oceania	11	6 (55)	11	3 (27)	22	9 (41)	
Asia	2	0 (0)	2	0 (0)	4	0 (0)	
UK & Ireland	19	6 (32)	7	0 (0)	26	6 (23)	
Other	9	4 (44)	5	2 (40)	14	6 (43)	
p value		0.654		0.194		0.219	
2022							
Australia	228	85 (37)	133	39 (29)	365	126 (35)	
Other Oceania	9	6 (67)	3	1 (33)	12	7 (58)	
Asia	1	0 (0)	4	1 (25)	5	1 (20)	
UK & Ireland	8	3 (38)	7	1 (14)	16	4 (25)	
Other	15	10 (67)	3	1 (33)	18	11 (61)	
p value		0.059		0.973		0.054	
2023							
Australia	225	125 (56)	132	59 (45)	362	185 (51)	
Other Oceania	7	1 (14)	8	5 (63)	15	6 (40)	
Asia	2	1 (50)	1	0 (0)	3	1 (33)	
UK & Ireland	11	7 (64)	2	1 (50)	14	8 (57)	
Other	9	5 (56)	3	2 (67)	12	7 (58)	
p value		0.242		0.763		0.821	

HCV RNA prevalence

Table 9.4.1 HCV RNA prevalence by gender and survey year

Western Australia	Male		Female		Total	
Survey year	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019*	313	63 (20)	138	23 (17)	453	86 (19)
2020	219	59 (27)	132	31 (23)	351	90 (26)
2021	286	75 (26)	177	27 (15)	469	103 (22)
2022	260	56 (22)	150	17 (11)	415	74 (18)
2023	259	63 (24)	150	21 (14)	415	84 (20)
X ² p trend		0.566		0.075		0.508

* 2019: Weighted for gender and HCV antibody status

Totals include respondents where gender was reported as other or not reported

Table 9.4.2 HCV RNA prevalence by sexual identity, gender and survey year

Western Australia	Male		Female		Total	
Sexual identity	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2019*						
Heterosexual	261	50 (19)	102	16 (16)	363	65 (18)
Bisexual	15	2 (13)	18	3 (17)	34	4 (12)
Homosexual	11	1 (9)	1	0 (0)	12	1 (8)
p value		0.479		0.909		0.443
2020						
Heterosexual	177	49 (28)	95	27 (28)	272	76 (28)
Bisexual	16	5 (31)	15	1 (7)	31	6 (19)
Homosexual	9	2 (22)	3	0 (0)	12	2 (17)
p value		0.889		0.116		0.430
2021						
Heterosexual	255	70 (27)	128	18 (14)	384	88 (23)
Bisexual	12	2 (17)	35	5 (14)	48	7 (15)
Homosexual	9	1 (11)	5	2 (40)	15	3 (20)
p value		0.404		0.277		0.414
2022						
Heterosexual	228	48 (21)	109	13 (12)	338	61 (18)
Bisexual	12	2 (17)	21	1 (5)	34	3 (9)
Homosexual	7	2 (29)	5	0 (0)	12	2 (17)
p value		0.720		0.227		0.183
2023						
Heterosexual	231	57 (25)	108	15 (14)	341	72 (21)
Bisexual	8	5 (63)	26	3 (12)	34	8 (24)
Homosexual	5	1 (20)	0	0 (0)	5	1 (20)
p value		0.100		0.548		0.913

Table 9.4.3 HCV RNA prevalence by age group, gender and survey year

Western Australia Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
<25 years	13	1 (8)	10	2 (20)	24	3 (13)
25-34 years	65	8 (12)	35	5 (14)	99	13 (13)
35-44 years	117	21 (18)	51	7 (14)	168	27 (16)
45+ years	117	33 (28)	42	10 (24)	160	43 (27)
p value		0.017		0.617		0.009
2020						
<25 years	3	0 (0)	9	3 (33)	12	3 (25)
25-34 years	32	7 (22)	25	3 (12)	57	10 (18)
35-44 years	74	27 (36)	53	15 (28)	127	42 (33)
45+ years	109	25 (23)	45	10 (22)	154	35 (23)
p value		0.121		0.385		0.097
2021						
<25 years	4	1 (25)	3	1 (33)	7	2 (29)
25-34 years	30	5 (17)	26	5 (19)	58	11 (19)
35-44 years	101	27 (27)	76	8 (11)	180	35 (19)
45+ years	147	42 (29)	70	13 (19)	218	55 (25)
p value		0.612		0.399		0.482
2022						
<25 years	8	2 (25)	3	0 (0)	11	2 (18)
25-34 years	42	7 (17)	19	1 (5)	62	8 (13)
35-44 years	96	19 (20)	66	7 (11)	164	26 (16)
45+ years	111	28 (25)	59	9 (15)	172	38 (22)
p value		0.641		0.694		0.311
2023						
<25 years	1	0 (0)	2	0 (0)	3	0 (0)
25-34 years	40	8 (20)	27	6 (22)	67	14 (21)
35-44 years	70	14 (20)	48	5 (10)	120	19 (16)
45+ years	146	40 (27)	71	10 (14)	220	50 (23)
p value		0.583		0.545		0.426

Table 9.4.4 HCV RNA prevalence by years since first injection, gender and survey year

Western Australia Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
<3 years	24	1 (4)	6	0 (0)	30	2 (7)
3 to 10 years	42	7 (17)	36	9 (25)	80	16 (20)
11+ years	229	50 (22)	86	11 (13)	315	61 (19)
p value		0.219		0.140		0.156
2020						
<3 years	6	0 (0)	6	0 (0)	12	0 (0)
3 to 10 years	36	8 (22)	26	5 (19)	62	13 (21)
11+ years	172	48 (28)	95	25 (26)	267	73 (27)
p value		0.261		0.284		0.071
2021						
<3 years	13	0 (0)	3	0 (0)	17	0 (0)
3 to 10 years	36	11 (31)	31	6 (19)	67	17 (25)
11+ years	223	62 (28)	138	18 (13)	365	80 (22)
p value		0.077		0.513		0.072
2022						
<3 years	11	1 (9)	5	0 (0)	16	1 (6)
3 to 10 years	36	5 (14)	16	2 (13)	53	7 (13)
11+ years	195	44 (23)	120	14 (12)	319	59 (19)
p value		0.421		1.000		0.377
2023						
<3 years	16	0 (0)	9	2 (22)	25	2 (8)
3 to 10 years	28	6 (21)	27	5 (19)	56	11 (20)
11+ years	204	54 (26)	112	14 (13)	319	68 (21)
p value		0.029		0.429		0.302

Table 9.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Western Australia Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
No receptive sharing	199	48 (24)	94	14 (15)	294	62 (21)
Receptive sharing	89	12 (13)	33	8 (24)	122	20 (16)
p value		0.040		0.207		0.261
2020						
No receptive sharing	161	40 (25)	77	19 (25)	238	59 (25)
Receptive sharing	39	16 (41)	40	9 (23)	79	25 (32)
p value		0.043		0.794		0.232
2021						
No receptive sharing	182	46 (25)	125	16 (13)	308	62 (20)
Receptive sharing	67	23 (34)	36	9 (25)	106	32 (30)
p value		0.157		0.075		0.033
2022						
No receptive sharing	163	32 (20)	97	7 (7)	262	39 (15)
Receptive sharing	71	22 (31)	41	9 (22)	115	32 (28)
p value		0.058		0.013		0.003
2023						
No receptive sharing	151	38 (25)	93	13 (14)	249	51 (20)
Receptive sharing	83	22 (27)	40	5 (13)	123	27 (22)
p value		0.822		0.819		0.743

Table 9.4.6 HCV RNA prevalence by last drug injected, gender and survey year

Western Australia Last drug injected	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2019*						
Heroin	50	19 (38)	22	8 (36)	71	27 (38)
Methamphetamine	209	37 (18)	100	13 (13)	311	50 (16)
Other opioids	27	6 (22)	7	1 (14)	34	7 (21)
Other drugs	23	1 (4)	8	2 (25)	30	3 (10)
p value		0.002		0.048		<0.001
2020						
Heroin	41	13 (32)	26	10 (38)	67	23 (34)
Methamphetamine	137	27 (20)	81	14 (17)	218	41 (19)
Other opioids	23	12 (52)	14	3 (21)	37	15 (41)
Other drugs	15	5 (33)	9	4 (44)	24	9 (38)
p value		0.007		0.068		0.003
2021						
Heroin	48	14 (29)	33	7 (21)	83	21 (25)
Methamphetamine	159	44 (28)	104	13 (13)	264	57 (22)
Other opioids	43	13 (30)	23	3 (13)	67	16 (24)
Other drugs	29	1 (3)	15	4 (27)	44	5 (11)
p value		0.035		0.379		0.308
2022						
Heroin	40	4 (10)	21	2 (10)	62	6 (10)
Methamphetamine	160	39 (24)	110	13 (12)	272	53 (19)
Other opioids	26	8 (31)	8	1 (13)	36	9 (25)
Other drugs	29	4 (14)	5	0 (0)	34	4 (12)
p value		0.100		0.861		0.142
2023						
Heroin	39	8 (21)	18	6 (33)	58	14 (24)
Methamphetamine	165	41 (25)	108	12 (11)	275	53 (19)
Other opioids	22	7 (32)	7	0 (0)	30	7 (23)
Other drugs	24	6 (25)	13	3 (23)	38	9 (24)
p value		0.809		0.043		0.779

Table 9.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year

Western Australia		Male		Female		Total	
Frequency of injection last month	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	
2019*							
Less than daily	130	25 (19)	44	11 (25)	175	36 (21)	
Daily or more	164	36 (22)	85	11 (13)	249	47 (19)	
Not last month	14	2 (14)	8	1 (13)	22	3 (14)	
p value		0.591		0.155		0.571	
2020							
Less than daily	105	25 (24)	54	13 (24)	159	38 (24)	
Daily or more	95	31 (33)	63	15 (24)	158	46 (29)	
Not last month	18	2 (11)	13	3 (23)	31	5 (16)	
p value		0.111		0.997		0.256	
2021							
Less than daily	131	36 (27)	82	11 (13)	215	47 (22)	
Daily or more	120	33 (28)	81	15 (19)	203	48 (24)	
Not last month	28	3 (11)	12	1 (8)	40	4 (10)	
p value		0.157		0.519		0.158	
2022							
Less than daily	91	21 (23)	60	7 (12)	154	29 (19)	
Daily or more	143	33 (23)	78	9 (12)	223	42 (19)	
Not last month	21	1 (5)	8	0 (0)	29	1 (3)	
p value		0.134		0.832		0.093	
2023							
Less than daily	99	22 (22)	45	4 (9)	145	26 (18)	
Daily or more	137	39 (28)	90	14 (16)	231	53 (23)	
Not last month	17	1 (6)	11	3 (27)	28	4 (14)	
p value		0.098		0.224		0.381	

Table 9.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year

Western Australia		Male		Female		Total	
Imprisonment last year	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	
2019*							
No imprisonment	236	47 (20)	114	19 (17)	351	66 (19)	
Imprisonment	55	12 (22)	16	3 (19)	71	14 (20)	
p value		0.816		1.000		0.765	
2020							
No imprisonment	174	46 (26)	113	26 (23)	287	72 (25)	
Imprisonment	38	10 (26)	12	4 (33)	50	14 (28)	
p value		0.988		0.426		0.663	
2021							
No imprisonment	220	58 (26)	156	21 (13)	380	80 (21)	
Imprisonment	47	12 (26)	13	4 (31)	61	16 (26)	
p value		0.906		0.091		0.363	
2022							
No imprisonment	199	40 (20)	134	15 (11)	338	56 (17)	
Imprisonment	46	12 (26)	10	2 (20)	56	14 (25)	
p value		0.371		0.335		0.126	
2023							
No imprisonment	203	50 (25)	121	16 (13)	329	66 (20)	
Imprisonment	40	7 (18)	16	1 (6)	56	8 (14)	
p value		0.331		0.692		0.311	

Table 9.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Western Australia		Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	
2019*							
Non Indigenous	234	46 (20)	86	16 (19)	319	62 (19)	
Indigenous	73	16 (22)	51	7 (14)	126	23 (18)	
p value		0.610		0.366		0.794	
2020							
Non Indigenous	148	35 (24)	71	18 (25)	219	53 (24)	
Indigenous	62	20 (32)	53	11 (21)	115	31 (27)	
p value		0.196		0.550		0.581	
2021							
Non Indigenous	182	39 (21)	108	12 (11)	293	51 (17)	
Indigenous	80	26 (33)	65	15 (23)	147	42 (29)	
p value		0.056		0.036		0.007	
2022							
Non Indigenous	187	40 (21)	86	10 (12)	275	50 (18)	
Indigenous	71	16 (23)	63	7 (11)	137	24 (18)	
p value		0.842		0.922		0.869	
2023							
Non Indigenous	153	35 (23)	86	13 (15)	243	48 (20)	
Indigenous	100	28 (28)	61	8 (13)	163	36 (22)	
p value		0.357		0.733		0.569	

Table 9.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year

Western Australia		Male		Female		Total	
Main language spoken at home by parents	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	
2019*							
English speaking	299	58 (19)	134	22 (16)	434	81 (19)	
Non-English speaking	14	4 (29)	3	1 (33)	16	5 (31)	
p value		0.280		0.453		0.178	
2020							
English speaking	208	57 (27)	128	29 (23)	336	86 (26)	
Non-English speaking	10	2 (20)	4	2 (50)	14	4 (29)	
p value		0.607		0.204		0.803	
2021							
English speaking	271	70 (26)	170	24 (14)	447	95 (21)	
Non-English speaking	11	4 (36)	6	2 (33)	17	6 (35)	
p value		0.436		0.192		0.169	
2022							
English speaking	243	52 (21)	142	15 (11)	390	68 (17)	
Non-English speaking	16	3 (19)	6	1 (17)	22	4 (18)	
p value		1.000		0.503		1.000	
2023							
English speaking	238	62 (26)	138	16 (12)	381	78 (20)	
Non-English speaking	17	1 (6)	10	5 (50)	28	6 (21)	
p value		0.080		0.001		0.904	

Table 9.4.11 HCV RNA prevalence by region/country of birth, gender and survey year

Western Australia		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2019*							
Australia	266	53 (20)	119	20 (17)	388	73 (19)	
Other Oceania	8	2 (25)	5	1 (20)	13	3 (23)	
Asia	5	1 (20)	0	0 (0)	5	1 (20)	
UK & Ireland	19	3 (16)	9	2 (22)	27	5 (19)	
Other	15	3 (20)	3	0 (0)	18	3 (17)	
p value		0.995		0.829		1.000	
2020							
Australia	174	44 (25)	123	29 (24)	297	73 (25)	
Other Oceania	10	2 (20)	4	1 (25)	14	3 (21)	
Asia	4	0 (0)	0	0 (0)	4	0 (0)	
UK & Ireland	15	6 (40)	4	1 (25)	19	7 (37)	
Other	12	5 (42)	1	0 (0)	13	5 (38)	
p value		0.340		0.957		0.380	
2021							
Australia	234	61 (26)	152	23 (15)	392	85 (22)	
Other Oceania	11	6 (55)	9	2 (22)	20	8 (40)	
Asia	2	0 (0)	2	1 (50)	4	1 (25)	
UK & Ireland	18	3 (17)	6	0 (0)	24	3 (13)	
Other	8	2 (25)	5	0 (0)	13	2 (15)	
p value		0.196		0.374		0.250	
2022							
Australia	223	44 (20)	132	14 (11)	359	59 (16)	
Other Oceania	9	4 (44)	3	0 (0)	12	4 (33)	
Asia	1	0 (0)	4	1 (25)	5	1 (20)	
UK & Ireland	8	2 (25)	7	1 (14)	16	3 (19)	
Other	15	6 (40)	3	1 (33)	18	7 (39)	
p value		0.112		0.349		0.072	
2023							
Australia	225	55 (24)	132	18 (14)	362	73 (20)	
Other Oceania	7	0 (0)	8	0 (0)	15	0 (0)	
Asia	2	0 (0)	1	0 (0)	3	0 (0)	
UK & Ireland	11	5 (45)	2	0 (0)	14	5 (36)	
Other	9	2 (22)	3	1 (33)	12	3 (25)	
p value		0.272		0.526		0.109	

Appendix A: Participating NSP services

Year	'19	'20	'21	'22	'23
Number of NSP sites	54	38	37	53	55
Australian Capital Territory	1	1	1	1	1
Directions Health, Canberra	✓	✓	✓	✓	✓
New South Wales	18	12	3	18	19
ACON Hunter	✓	✓		✓	✓
Ballina Harm Reduction Services	✓			✓	✓
Blacktown HIV/Hepatitis C Prevention Service	✓	✓		✓	✓
Byron/Tweed Harm Reduction Services	✓			✓	✓
Canterbury Harm Minimisation Program	✓	✓		✓	✓
Central Coast NSP				✓	✓
Clinic 180 (formerly K2), Kings Cross	✓				
Coffs Harbour/ Grafton/ Kempsey Harm Reduction Services	✓			✓	✓
First Step Program, Port Kembla	✓				✓
Health ConneXions, Liverpool		✓		✓	✓
Hunter Harm Reduction Services	✓	✓		✓	✓
Kelly Close Needle Syringe Program, Mt Druitt	✓	✓		✓	✓
Kirketon Road Centre	✓	✓	✓	✓	✓
KRC Kellett St				✓	✓
KRC South, Sutherland	✓	✓	✓	✓	✓
Nimbin/Lismore Harm Reduction Services	✓			✓	✓
NSW Users and AIDS Association (NUAA)	✓	✓	✓	✓	✓
Parramatta HIV/Hepatitis C Prevention Service	✓	✓		✓	✓
Redfern Harm Minimisation Program	✓	✓		✓	✓
Royal Prince Alfred Hospital, Camperdown	✓				
South Court Primary Care NSP	✓	✓		✓	✓
Northern Territory	3	3	3	3	3
Northern Territory AIDS & Hepatitis Council, Alice Springs	✓	✓	✓	✓	✓
Northern Territory AIDS & Hepatitis Council, Darwin	✓	✓	✓	✓	✓
Northern Territory AIDS & Hepatitis Council, Palmerston	✓	✓	✓	✓	✓
Queensland	10	7	11	10	10
Biala Community Alcohol and Drug Services, Brisbane	✓	✓	✓	✓	✓
Cairns ATODS NSP	✓		✓	✓	✓
Inala Alcohol and Drugs Service			✓	✓	
Kobi Place (formerly Kobi House), Toowoomba	✓	✓	✓		✓
Queensland Injectors Health Network, Brisbane	✓	✓	✓	✓	✓
Queensland Injectors Health Network, Gold Coast	✓	✓	✓	✓	✓
Queensland Injectors Health Network, Sunshine Coast	✓	✓	✓	✓	✓
Rockhampton AODS NSP	✓		✓	✓	✓
Townsville ATODS NSP	✓	✓	✓	✓	✓
West Moreton Sexual Health Service	✓		✓	✓	✓
Youth Link, Cairns	✓	✓	✓	✓	✓

Year	'19	'20	'21	'22	'23
Number of NSP sites	54	38	37	53	55
South Australia	8	7	8	8	8
Community Access & Services SA (CASSA)	✓	✓	✓	✓	✓
Drug Arm Australasia	✓				
Kurlana Tampawardli, Hendon	✓	✓	✓	✓	✓
Noarlunga Primary Health (formerly SAVIVE Noarlunga)	✓	✓	✓	✓	✓
Northern DASSA Elizabeth			✓	✓	✓
Nunkuwarriin Yunti Community Health Centre	✓	✓	✓	✓	✓
Streetlink Youth Services	✓	✓	✓	✓	✓
Watto Purrinna, Port Adelaide (formerly SAVIVE Port Adelaide)	✓	✓	✓	✓	✓
West Coast Youth, Port Lincoln	✓	✓	✓	✓	✓
Tasmania	4	4	4	4	4
Clarence Integrated Care Centre	✓	✓	✓	✓	✓
Glenorchy NSP Service	✓	✓	✓	✓	✓
Hobart NSP Service	✓	✓	✓	✓	✓
Salvation Army Launceston	✓	✓	✓	✓	✓
Victoria	6	0	3	5	6
Barwon Health Drug and Alcohol Services	✓		✓	✓	✓
Health Information Exchange, St Kilda	✓		✓	✓	✓
Health Works, Footscray	✓		✓	✓	✓
Innerspace, Collingwood	✓			✓	✓
North Richmond NSP Services	✓			✓	✓
SHARPS, Frankston	✓				✓
Western Australia	4	4	4	4	4
HepatitisWA	✓	✓	✓	✓	✓
Peer Based Harm Reduction WA (formerly WASUA) - Perth	✓	✓	✓	✓	✓
Peer Based Harm Reduction WA (formerly WASUA) - Bunbury	✓	✓	✓	✓	✓
WAAC	✓	✓	✓	✓	✓

Appendix B: Methodological notes

Laboratory assays

Up until 2023 ANSPS samples were tested for HIV antibodies using the Murex HIV-1.2.0 ELISA (Diasorin, Italy) and the HIV confirmatory western blot (New-Lav Blot-1, Bio-rad France). The assay used for HCV antibody detection was the Monolisa anti-HCV Plus Version 3 (Bio-rad, France) and for HCV RNA the Aptima HCV Quant Dx assay (Hologic, USA).

For the 2023 ANSPS samples the serological testing platform changed to the Abbott Alinity i [Abbott Diagnostics, Chicago USA] using the HIV antigen/antibody combo and HCV antibody assays. The required dried blood spot (DBS) size for this assay is 12mm versus 6mm from the previous year's assays, which increased the number of 2023 DBS samples graded as insufficient to 16.34% compared to 1.45% from the previous year.

Utilising the HIV and HCV screening platform (Alinity i) available at SydPath, St Vincent's Hospital, Sydney, there was an increase in HCV antibody prevalence (from 32% in 2022 to 45% in 2023), likely due to the augmented quantity of sample volume and template introduced into the test via the larger 12mm spot size, alongside the enhanced assay sensitivity characteristics of the latest generation HCV antibody analyser and assay. It should be noted, however, that HCV Ab prevalence remains lower compared to ANSPS results in the pre-DAA era.

Laboratory testing methods prior to 2023

Capillary blood was obtained by finger-prick using disposable, single-use lancets [BD] and a Whatman 903 protein-saver card [Interpath]. Dried blood spot (DBS) samples were kept at room temperature at the survey sites and couriered to St Vincent's Centre for Applied Medical Research, Sydney every second or third day. When received, the DBS cards were stored in gas impermeable bags [ThermoFisher] containing two grams of desiccant packs [Desicco] and stored at minus 80 degrees Celsius until processing.

Prior to processing 6mm DBS discs were excised using an automated DBS puncher (BSD Electronics, Australia) with a blank spot punched in between each patient sample. Spots were punched into an unbound 96-well plate and eluted in 200uL of PBS, 5% Tween20 and 5% skim milk powder solution overnight at 2-8 degrees Celsius.

HIV antibodies was detected using the Murex HIV-1.2.0 ELISA (Diasorin, Italy) and repeatedly reactive specimens were subjected to Western blot confirmatory testing (New LAV Blot-1, Bio-rad, France). A modified third generation enzyme immunoassay (Monolisa anti-HCV Plus Version 3 EIA, Bio-rad, France) was used to test for HCV antibody. A modified cut off value for optical density was calculated to capture greater than 95% of the seronegative population. Specimens were considered positive for HCV antibody if the optical density to cut off ratio was greater than or equal to one on initial and subsequent testing.

Between 2019 and 2023, HCV RNA was detected and quantified on the Hologic Panther™ using the Aptima™ HCV Quant Dx assay (Hologic, Inc. San Diego, Calif) which has a limit of quantitation (LOQ) 10 IU/mL and an upper limit of quantitation of 108 IU/mL in plasma. A 12mm spot was excised with a stainless steel hole puncher and flame sterilised between each sample. Spots were placed into an aliquot containing 1mL Hologic Specimen Transfer Media and eluted for 30 minutes at room temperature on an orbital rocker [Ratek]. Samples were centrifuged at 3000g for 2 mins then placed onboard the analyser.

To correct for haematocrit, all post run DBS viral load results on the Aptima assay were multiplied by a plasma conversion factor of 36.36. This calculation was based on the following assumptions: 45% haematocrit average per DBS, 50uL DBS volume and 1000ul Aptima transport media volume. A qualitative result of <10IU/mL detected (trace/equivocal) was applied to samples <400IU/mL (plasma equivalency).

Laboratory 2023 testing methods

Capillary blood was obtained by finger-prick using disposable, single-use lancets [BD] and a Whatman 903 protein-saver card [Interpath]. DBS samples were kept at room temperature at the survey sites and couriered to St Vincent's Centre for Applied Medical Research, Sydney every second or third day. When received, the DBS cards were stored in gas impermeable bags [ThermoFisher] containing two grams of desiccant packs [Desicco] and stored at minus 80 degrees Celsius until processing.

DBS were excised using a 12mm stainless steel hole puncher and flame sterilised between each sample. Spots were placed into an aliquot containing 750uL of a PBS and 5% Tween20 solution. Samples were eluted at 1000rpm for 30 minutes at room temperature [PoCD] then centrifuged at 10,000g and 4 degrees Celsius [ThermoFisher] for 10 minutes prior to testing.

The serology analysis was completed on the Abbott Alinity i, HIV antigen/antibody combo and HCV antibody assays simultaneously. Specimens with an HIV and/or HCV sample to cutoff ratio (S/CO) >1.0 were repeated in duplicate. A western blot was performed to confirm HIV reactive screening results (New LAV blot 1, Bio-Rad). Specimens were considered HCV antibody positive with a S/CO of >1.0 from at least 2 out of the 3 results.

Other notes

Data presented in this report were analysed using Stata, Version 14 (Stata Corporation, College Station TX). Temporal changes in HIV/HCV antibody and HCV RNA prevalence were assessed using the χ^2 test for linear trend. Associations between demographic and behavioural variables and HIV/HCV antibody and HCV RNA prevalence were assessed using the χ^2 test or Fisher's exact test where frequencies were less than five. It should be noted that in 2019 the sub-sample of respondents with sufficient DBS sample for HCV RNA testing was <90% and HCV RNA tables were weighted to account for potential sample bias with respect to HCV antibody status and gender. Weights were applied to national data and to each individual jurisdiction, such that jurisdictional HCV RNA results will not necessarily add to data presented at the national level. Results with small sample size, particularly at the jurisdictional level, should be interpreted with caution.

Percentage values in tables may not add to 100 due to rounding. Totals in HIV and HCV antibody prevalence tables stratified by gender include people whose gender was not reported or reported as other. Time since first injection was calculated by subtracting age at first injection from age at survey completion. Totals in HIV and HCV antibody prevalence tables stratified by time since first injection include people who did not report age at survey completion or age at first injection. Tables reporting HIV antibody prevalence stratified by demographic and drug use characteristics are not included in this report for states and territories or survey years where the number of HIV antibody positive participants was less than 5 in all years.

Where data were collected but no participants endorsed a particular response, results are presented as "0 (0)". The symbol "--" shown in some tables denotes missing data; and is used to identify circumstances where data were not collected in the reported format. The vast majority of survey questions were consistent over all survey years.

NSP staff recorded sex, age group and survey participation for all clients at the NSP during the survey period and this data was used to assess response rates. Some clients visited the site more than once during the survey week, and only one attendance per person was included in the response rate denominator. Ethical approvals for the study were obtained from Human Research Ethics Committees associated with the investigators and participating sites. Verbal rather than written informed consent was obtained to assure the anonymity of participants.

Appendix C: List of tables

1. Demographic characteristics and drug use

Table 1.1.1	Number (percentage) of respondents by demographic characteristics and survey year
Table 1.1.2	Number (percentage) of respondents by last drug injected, frequency of injecting and survey year
Table 1.1.3	Number (percentage) of respondents by injecting behaviour in the last month and survey year
Table 1.1.4	Number (percentage) of respondents by treatment for drug use and survey year
Table 1.1.5	Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year
Table 1.1.6	Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year
Table 1.1.7	Number (percentage) of respondents by COVID-19 related behaviours in 2023

2. HIV antibody prevalence

Table 1.2.1	HIV antibody prevalence by gender and survey year
Table 1.2.2	HIV antibody prevalence by sexual identity, gender and survey year
Table 1.2.3	HIV antibody prevalence by age group, gender and survey year
Table 1.2.4	HIV antibody prevalence by last drug injected, gender and survey year
Table 1.2.5	HIV antibody prevalence by years of injection, gender and survey year
Table 1.2.6	HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year
Table 1.2.7	HIV antibody prevalence by frequency of drug injection last month, gender and survey year
Table 1.2.8	HIV antibody prevalence by imprisonment last year, gender and survey year
Table 1.2.9	HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year
Table 1.2.10	HIV antibody prevalence by sex work last month, gender and survey year
Table 1.2.11	HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year
Table 1.2.12	HIV antibody prevalence by main language spoken at home by parents, gender and survey year
Table 1.2.13	HIV antibody prevalence by region/country of birth, gender and survey year

3. HCV antibody prevalence

Table 1.3.1	HCV antibody prevalence by gender and survey year
Table 1.3.2	HCV antibody prevalence by sexual identity, gender and survey year
Table 1.3.3	HCV antibody prevalence by age group, gender and survey year
Table 1.3.4	HCV antibody prevalence by years since first injection, gender and survey year
Table 1.3.5	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year
Table 1.3.6	HCV antibody prevalence by last drug injected, years since first injection and survey year
Table 1.3.7	HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year
Table 1.3.8	HCV antibody prevalence by imprisonment last year, years since first injection and survey year
Table 1.3.9	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year
Table 1.3.10	HCV antibody prevalence by main language spoken at home by parents, gender and survey year
Table 1.3.11	HCV antibody prevalence by region/country of birth, gender and survey year

4. HCV RNA prevalence

- Table 1.4.1 HCV RNA prevalence by gender and survey year
- Table 1.4.2 HCV RNA prevalence by sexual identity, gender and survey year
- Table 1.4.3 HCV RNA prevalence by age group, gender and survey year
- Table 1.4.4 HCV RNA prevalence by years since first injection, gender and survey year
- Table 1.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year
- Table 1.4.6 HCV RNA prevalence by last drug injected, gender and survey year
- Table 1.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year
- Table 1.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year
- Table 1.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year
- Table 1.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year
- Table 1.4.11 HCV RNA prevalence by region/country of birth, gender and survey year

